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Abstract 
Macrophages are the predominant immune effector cell found in one of the most severe 
causes of renal failure in humans, crescentic glomerulonephritis (Crgn). The Wistar Kyoto 
(WLY) rat is uniquely susceptible among rat strains to Crgn and susceptibility genes have 
previously been mapped to seven quantitative trait loci (Crgn1-7). The AP-1 transcription 
factor JunD is markedly overexpressed in WKY macrophages and was identified as a major 
determinant of macrophage activation associated with Crgn susceptibility at Crgn2. 
 
The work presented in this thesis aimed to investigate mechanisms underlying the regulation 
of macrophage activation and glomerular inflammation by JunD in the NTN-susceptible 
WKY rat strain and in patients with Crgn. Genomic-based approaches, including microarray 
analysis of bone marrow-derived macrophage transcriptomes, RNA interference and cistrome 
analysis using ChIP-Seq, along with histological techniques and genotyping studies, were 
used to identify key genes and pathways underlying JunD-mediated activation of 
macrophages. 
 
Transcriptome analyses showed that the Crgn2 locus regulates expression of over 800 genes 
in WKY macrophage responses to lipopolysaccharide (LPS). Acute changes in Jund 
expression by RNA interference also modulated gene expression in WKY macrophages, 
including effector genes for the macrophage LPS response. Cistrome analysis revealed that 
genetically determined differences in Jund expression alter its genome binding pattern and 
the increased numbers of JunD-bound genes in WKY macrophages were functionally linked 
with signalling pathways and cell activation. Integration of the data identified 47 genes, that 
were associated with JunD binding peaks and whose expression was both regulated by Crgn2 
and altered by siRNA knockdown of Jund, as the key candidates through which JunD 
determines macrophage activation. 
 
Overall, this work provides the basis for understanding genes and pathways through which 
JunD regulates macrophage activation and has identified novel gene targets for modulation of 
macrophage phenotypes in WKY rat and human macrophages. 
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Chapter 1. Introduction 
 
1.1 Crescentic GN is a rapidly progressive form of renal failure 
Crescentic glomerulonephritis (Crgn) is a histological term describing one of the severest 
forms of glomerular inflammation that presents clinically as rapidly progressive 
glomerulonephritis (RPGN). Crgn is characterised by the disruption of the glomerular 
basement membrane leading to the infiltration and proliferation of inflammatory cells such as 
macrophages and T cells along with plasma proteins in Bowman’s space (Little and Pusey, 
2005; Tarzi et al., 2011).  
 
In clinical terms, Crgn is the most aggressive form of glomerulonephritis and, if left 
untreated, progresses rapidly to end stage renal failure. The clinical causes of Crgn can be 
classified into three groups according to the presence and distribution of immune deposits 
(Little and Pusey, 2005; Tarzi et al., 2011). The pauci-immune group is characterised by the 
presence of only a few or no immune deposits and are associated with the antineutrophil 
cytoplasm antibody (ANCA) associated vasculitides (AAV). This is the commonest cause of 
Crgn, linked with around 80% of cases and is characterised by the presence of ANCA to 
either proteinase 3 (PR3) or myeloperoxidase (MPO) in the serum of patients. ANCA 
vasculitis has an incidence of 20 cases per million individuals per year with a prevalence of 
200 cases per million individuals and occurs most commonly in the elderly (Harper and 
Savage, 2005; Pallan et al., 2009). It has a complex pathogenesis associated with 
environmental factors linked to infection and molecular mimicry and genetic factors that 
influence susceptibility. The development of ANCA itself and, within the immune system, T 
cell activation and regulation are central to disease development (Morgan et al., 2006; 
Tipping and Holdsworth, 2006; Tarzi et al., 2011). 
 
The second group is characterised by the linear deposition of immunoglobulin G (IgG) 
against the glomerular basement membrane (GBM), called anti-GBM disease, which 
accounts for 10-20% of cases of Crgn and 1-5% of cases of glomerulonephritis overall (Cui 
and Zhao, 2011; Tarzi et al., 2011). It is, therefore, a rare cause of Crgn with an incidence of 
between 0.5 and 2 cases per million per year (Cui and Zhao, 2011; Tarzi et al., 2011). 
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Classically it is referred to as Goodpasture disease when it occurs in combination with lung 
haemorrhage which is seen in 50-60% of cases and presents with severe acute renal failure. In 
contrast to AAV, its pathogenesis is better understood and is due to an autoimmune reaction 
against the noncollagen domain of the α3 chain of type IV collagen that is found in the lung 
and the GBM of the kidney (Cui and Zhao, 2011; Tarzi et al., 2011).  
 
The final group is more heterogeneous and is characterised by immune complex 
glomerulonephritis with granular immune deposits seen histologically (Tarzi et al., 2011). A 
number of different conditions belong to this group including, most prominently, renal 
involvement in systemic lupus erythematosus (SLE) along with membranoproliferative 
nephritis, IgA nephropathy and Henoch-Schonlein purpura, post infectious 
glomerulonephritis and cryoglobulinaemia (Tarzi et al., 2011).  Renal involvement in SLE is 
very common and up to 50% of patients can have clinically evident kidney disease at 
presentation (Bomback and Appel, 2010). Proliferative lupus nephritis defined as class III 
(focal) and class IV (diffuse) by the ISN/RPS classification (Weening et al., 2004) is the most 
severe end of the lupus nephritis spectrum and crescent formation is not infrequently seen. It 
is a very heterogeneous disease and has a marked ethnic bias as it is more common in patients 
of black or Asian origin than in white individuals (Tesar and Hruskova, 2011).  
 
Despite progress in the last 20 years in treating AAV, major deficiencies still exist in our 
ability to successfully treat let alone cure the disease. Historically, left untreated, AAV had 
mortality rates of the order of 80% at one year (Fauci and Wolff, 1973; Westman et al., 1998; 
Harper and Savage, 2005). The introduction of protocols based on high doses of 
immunosuppressive agents such as cyclophosphamide and prednisolone along with 
treatments like plasma exchange have brought remission rates in AAV up to as high as 90% 
(Hoffman et al., 1992; Westman et al., 1998; Jayne et al., 2003; Harper and Savage, 2005). 
Even through the treatment of vasculitis has improved, mortality remains substantial with 
five year mortality rates as high as 26% to 34% (Booth et al., 2003; Jayne et al., 2007). The 
treatments themselves are not without major side effects and in trials, severe life threatening 
adverse events such as leukopenia and infection occur in around half of patients (Jayne et al., 
2007). Of note, side effects linked to the actual treatment of the disease are one of the major 
causes of death in the first five years of the disease history (Harper and Savage, 2005). In 
addition, the high occurrence of relapse rates with studies reporting rates up to 40% presents 
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a continuing challenge for its management (Mukhtyar et al., 2007; Pallan et al., 2009). Whilst 
current treatment modalities do achieve remission, a relapse rate of 40% within 5 years is still 
unacceptably high and highlights the need to understand better the underlying pathogenesis 
and effector mechanisms within the immune system. Such efforts to understand the 
pathogenesis have enabled the rational use of newer therapies such as the anti-CD20 chimeric 
monoclonal antibody against B cells, rituximab (Pallan et al., 2009; Jones et al., 2010; 
Mansfield et al., 2011; Schonermarck and de Groot, 2011) which has quickly been accepted 
and recommended as an appropriate therapy for the disease (Guerry et al., 2011). A large 
array of compounds including those with general immunosuppressive effects as well as 
specific T and B cell and cytokine therapies along with small molecule inhibitors of 
downstream signalling pathways are now being considered as treatment options (Pallan et al., 
2009).  
  
Unlike ANCA associated vasculitis, anti-GBM antibodies have been conclusively shown to 
be pathogenic in adoptive transfer experiments where transfer of anti-GBM antibodies from 
patients induced immediate disease in recipient monkeys (Lerner et al., 1967) meaning that 
their removal using plasma exchange along with immunosuppression is a key part of 
treatment (Levy et al., 2001; Cui and Zhao, 2011). However, in some respects its treatment 
poses additional challenges as patients who present needing dialysis and have 100% 
involvement of glomeruli with crescents do not recover their independent renal function 
showing how limited current treatment paradigms are (Levy et al., 2001). As with ANCA-
vasculitis, the introduction of cytotoxic therapy and plasma exchange markedly improved 
clinical outcomes and the rates of persisting renal failure vary from between 15% to 60% of 
patients overall up to 95% in those who present with creatinine concentrations lower than 
500µmol/L (Levy et al., 2001; Cui and Zhao, 2011).  
 
Similar to the treatment of AAV, the introduction of cytotoxic agents along with steroids 
markedly improved the outcomes of patients with lupus nephritis though over 20 years of 
follow up, 25-30% of patients will still develop end state renal failure (Tesar and Hruskova, 
2011). The spectrum of disease is very heterogeneous amongst patients with proliferative 
nephritis and consequently remission rates identified in studies of modern treatment protocols 
do vary and can be as low as 50% and as high as 88% depending on treatment and the racial 
makeup of the studied population and critically the time taken to remission is often longer 
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than six months (Tesar and Hruskova, 2011). Alongside the current treatment protocols that 
involve cyclophosphamide and steroids, the use of rituximab is currently gaining favour 
(Appel and Appel, 2009; Appel et al., 2009; Radhakrishnan et al., 2009; Bomback and Appel, 
2010; Bosch, 2010; Tesar and Hruskova, 2011). 
 
Despite being quite different in their pathogenesis and clinical features, all three causes of 
Crgn share unresolved questions relating to the pathogenesis of Crgn and the effector 
mechanisms underlying its origin with major implications for its treatment. Despite many 
advances, relapse rates remain high demonstrating the need for further research into the 
pathogenic mechanisms particularly linked to macrophages that underlie the diseases in order 
for new treatment targets to be identified and therapeutics developed. It is perceived that one 
major limitation of current treatments is that macrophages are the one immune cell 
population that is not effectively and specifically targeted by current immunosuppression 
regimes (Han et al., 2011).  
 
1.2 The innate immune response 
The innate immune system is a universal and ancient host defence against infection (Kimbrell 
and Beutler, 2001; Janeway and Medzhitov, 2002).  It utilises genetically programmed 
receptors on its effector cells such as macrophages and neutrophils that are able to detect the 
fixed molecular patterns of invading microbes (Janeway and Medzhitov, 2002; Iwasaki and 
Medzhitov, 2010). Inflammation is characteristic of innate immune reactions and is triggered 
by macrophages and neutrophils through their innate immune receptors (Kimbrell and 
Beutler, 2001; Janeway and Medzhitov, 2002). Inflammation is highly complex and 
classically consists of swelling due to extravasation of fluid, the recruitment and activation of 
leukocytes as well as the destruction and remodelling of tissues. Cytokines produced by host 
cells, primarily tissue macrophages, act to organise the response (Kimbrell and Beutler, 
2001).  
 
The adaptive immune system is composed of T and B lymphocytes that express antigen 
receptors capable of recognising any pathogen that the host might encounter. These receptors 
are generated by each individual organism allowing for highly specific ‘adaptive’ responses 
to occur (Kimbrell and Beutler, 2001; Iwasaki and Medzhitov, 2010). The innate and 
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adaptive immune systems are not distinct but work together in inflammation. Innate immune 
cells once activated by a pathogen, attract naïve T cells to respond to the specific antigens of 
the pathogen triggering the adaptive immune response (Janeway and Medzhitov, 2002; 
Iwasaki and Medzhitov, 2010). 
 
Macrophages have been called the classical two-edged sword of the innate immune system 
(Nilsson et al., 2006). This refers to that fact that the main functions of macrophages are 
firstly as immune effector cells recognising and destroying microbes as part of the host 
defence, enabled by their expression of a range of pathogen-recognition receptors and their 
ability to respond to signals generated by antigen-specific immune cells. They also act as 
highly efficient phagocytes with roles in development, wound healing and homeostasis 
(Nilsson et al., 2006; Mosser and Edwards, 2008; Geissmann et al., 2010). However the other 
aspect of their function is that their destructive potential with the ability to secrete 
proinflammatory molecules, whilst strictly controlled under normal circumstances, when 
dysregulated is critical to the pathology of many acute and chronic inflammatory diseases in 
mammals (Nilsson et al., 2006).  Macrophages differentiate from circulating peripheral-blood 
mononuclear cells (PBMCs) or monocytes. Monocytes migrate into tissues both in normal 
steady state conditions and in response to inflammation enabling the differentiated 
macrophages that arise to contribute to the host defence along with tissue remodelling and 
repair (Gordon and Taylor, 2005; Mosser and Edwards, 2008). 
 
1.3 Macrophages as effector cells in renal disease 
Macrophages are important immune effector cells and are the predominant immune cell 
found within crescentic glomeruli playing pivotal roles in the inflammatory process and 
crescent formation including the production of cytokines and pro-inflammatory mediators 
and the activation and injury of intrinsic renal cells (Atkins et al., 1976; Hancock and Atkins, 
1984; Boyce et al., 1989; Cook et al., 1989; Ferrario and Rastaldi, 1999; Holdsworth, 2007). 
Biopsy studies have shown that macrophages are present in a wide variety of different types 
of glomerulonephritis (Ferrario et al., 1985) demonstrating that macrophages play an 
important role in inflammatory processes within the kidney and that they could be therapeutic 
targets in diseases other than Crgn.  
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1.3.1      Macrophages as effector cells in Crgn 
Macrophages are the predominant immune effector cell in Crgn. Early studies that cultured 
the glomeruli, obtained during renal biopsy, from patients with RPGN found that their 
glomeruli contained large numbers of macrophages which went against the belief at the time 
that crescents consisted mostly of proliferating epithelial cells (Atkins et al., 1976). These 
findings were confirmed in animal models of Crgn which went on to show that macrophages 
participate in the disease process by accumulating in damaged glomeruli and migrating into 
Bowman’s space where they contribute to crescent formation (Thomson et al., 1979). Studies 
of human biopsy sections confirmed that macrophages were the predominant cell type within 
cellular crescents in human RPGN and in contrast, that lymphocytes were not present 
(Hancock and Atkins, 1984). Indeed cells of the monocyte lineage were found to be the 
predominant immune cell type found in a wide variety of types of glomerulonephritis 
including ANCA associated vasculitis, lupus nephritis, essential cryoglobulinaemia, acute 
post infectious glomerulonephritis and IgA nephropathy. The numbers of monocyte lineage 
cells infiltrating the glomeruli also correlated with the degree of renal injury measured by 
proteinuria in the patients (Ferrario et al., 1985). 
 
Studies in animal models of Crgn, particularly in the rabbit, rat and mouse, have been able to 
conclusively demonstrate a role for macrophages in Crgn. Inhibition of macrophage 
infiltration with a sheep anti-macrophage serum in a rabbit model of Crgn was shown to 
prevent disease (Holdsworth et al., 1981) as did inhibition of monocyte chemoattractant 
protein one (MCP-1) in a rat model where a 38% reduction in macrophage number in the 
glomerulus led to a 45% reduction in proteinuria (Tang et al., 1996). Global depletion of 
macrophages using liposome-encapsulated dichloromethylene diphosphonate was performed 
in a WKY rat model of Crgn which decreased macrophage accumulation and damage in the 
glomerulus leading to reductions in crescent formation and proteinuria along with indirect 
effects on the recruitment of CD8
+
 T cells (Isome et al., 2004). A powerful approach used 
conditional ablation of inflammatory macrophages in a mouse Crgn model. A transgenic 
mouse was created in which the macrophages expressed the diphtheria toxin receptor. This 
allowed for diphtheria toxin to be used to selectively deplete macrophages in the model. The 
study found that macrophages were necessary for disease progression and macrophage 
depletion reduced the number of glomerular crescents and degree of proteinuria in the disease 
(Duffield et al., 2005).  
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Adoptive transfer experiments in a rat model of Crgn conclusively demonstrated that 
macrophages played an active part in causing renal injury rather than infiltrating as a 
response to tissue damage (Ikezumi et al., 2003). Rats were pre-treated with 
cyclophosphamide to remove any contribution to disease of endogenous immune cells and, 
similar to the intended aims of its use in humans, inhibited disease completely. Adoptive 
transfer using two independent macrophage populations resulted in macrophage mediated 
renal damage and this degree of renal injury correlated with numbers of macrophages 
transferred (Ikezumi et al., 2003). 
 
1.3.2      Macrophages as effector cells within the wider spectrum of renal disease 
The role of macrophages in renal disease is not confined to just severe glomerular 
inflammation. Understanding the mechanisms underlying macrophage behaviour in 
glomerular disease, therefore, has wider implications.  
 
In renal transplantation, macrophages can be identified within the transplanted kidneys and 
during rejection have been found to infiltrate all parts of the kidney including the glomeruli, 
interstitium and vessels acting both as effectors of tissue injury and as antigen presenting 
cells (Magil, 2009; Chadban et al., 2010). Macrophage infiltration of the graft is an 
independent predictor of poor outcomes highlighting the therapeutic potential for modulating 
macrophage infiltration and behaviour in this setting (Magil, 2009). Ischaemia-reperfusion 
injury is an unavoidable consequence of the transplantation process and macrophages play 
key roles in the early immune responses to the injury. (Chadban et al., 2010; Li and Okusa, 
2010). There is also evidence that in diabetic nephropathy, macrophages accumulate prior to 
a decline in renal function which suggests they could have a pathogenic role contributing to 
the development of renal injury and glomerulosclerosis (Tesch, 2010). Retrospective biopsy 
studies in human patients found that macrophages accumulated within glomeruli and the 
interstitium and the degree of the infiltration was correlated with the subsequent decline in 
renal function seen in patients (Nguyen et al., 2006). Animal models of diabetic nephropathy 
have shown that macrophages are the major immune cells that infiltrate the kidney in type 1 
and 2 diabetes contributing to the development of renal injury and sclerosis (Tesch, 2010).  
Renal fibrosis is the final common pathway of all renal diseases and macrophages are also 
36 
 
involved in the pathogenesis of renal fibrosis along with developmental roles in the kidney 
(Vernon et al., 2010; Williams et al., 2010). 
 
1.4 Macrophage activation and its implications for the pathogenesis of 
Crgn 
The behaviour of the macrophage within the glomerulus determines its ability to be an 
effector cell in disease. Activated macrophages within glomeruli play key roles in driving 
inflammation through their production of proinflammatory mediators and directly activating 
and injuring intrinsic renal cells (Holdsworth, 2007; Wang and Harris, 2011). However, 
macrophages within crescentic glomeruli can also display a heterogeneous range of 
functional capabilities not limited to these pro-inflammatory functions and include directing 
the resolution of acute inflammation and subsequent tissue repair in inflammatory renal 
injury. This highlights that modulation of macrophage behaviour in renal disease can have 
considerable therapeutic potential (Kluth et al., 2004; Holdsworth, 2007; Kluth, 2007). 
Understanding factors that drive macrophages to exhibit pro-inflammatory and anti-
inflammatory phenotypes is clearly beneficial in understanding the pathogenesis of Crgn.  
 
The attempt to understand how macrophages are activated and what it means for their 
function has been a longstanding area of inquiry and remains the subject of much discussion 
(North, 1978; Mosser, 2003; Mosser and Edwards, 2008; Rees, 2010). Early views still hold 
true in that the induction and functional expression of macrophage activation in vivo depends 
upon a complex set of events (North, 1978). North correctly predicted that the functional 
definitions of the activated macrophage would change because of the realization that large 
numbers of metabolic and functional changes can occur within macrophages (North, 1978). 
Such early writers were keen to keep the term ‘activated’ macrophage as a relatively vague 
one and defining what constitutes an activated macrophage continues to remain a challenge 
(North, 1978; Mosser and Edwards, 2008). Macrophages are the immune system’s primary 
sensors of danger and are able to sense multiple different signals that lead to their activation 
independently of adaptive immune responses (Mosser and Edwards, 2008). Macrophages are 
able to recognise a wide range of exogenous ligands through receptors such as the Toll-like 
receptors and intracellular pattern recognition receptors as well as endogenous host molecules 
resulting from cellular damage (Gordon, 2003).  
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Macrophages have traditionally been classified (Figure 1.1) as either M1/classically 
activated macrophages or M2/ alternatively activated macrophages (Gordon, 2003; Mosser 
and Edwards, 2008; Gordon and Martinez, 2010). The classification as classical or M1 
macrophages stems from the work of Mackness et al. where infections in mice with 
Mycobacterium bovis or Listeria monocytogenes enhanced the antibacterial behaviour of 
macrophages (Mackaness, 1964). The original characterisation of classically activated 
macrophages identified that interferon-gamma (IFN-γ) was a key priming stimulus along 
with cytokines such as tumour necrosis factor (TNF) and bacterial products such as 
lipopolysaccharide (LPS) (Mantovani et al., 2004; Mosser and Edwards, 2008; Rees, 2010). 
This M1 proinflammatory macrophage phenotype secretes high amounts of proinflammatory 
cytokines and mediators such as interleukin (IL)-1, IL-6 and IL-23 and reactive oxygen 
species (Mantovani et al., 2004; Mosser and Edwards, 2008). M1 macrophage activation also 
depends on the products of specially activated T helper (Th1) cells and natural killer cells 
such as interferon-gamma (IFN-γ) and cytokine networks involving IL-12 and IL-18 
(Gordon, 2003). Classically activated macrophages are central to the host defence but require 
tight regulation as the cytokines they produce can cause extensive tissue damage resulting in 
the links with autoimmune disease (Mosser and Edwards, 2008). 
 
Alternatively activated M2 macrophages are activated by cytokines linked with activated T 
helper cells (Th2) responses such as IL-4 and IL-13 as well as IL-10 and glucocorticoids and 
have been functionally linked to allergic and humoral responses to parasitic and extracellular 
pathogens (Gordon, 2003; Mantovani et al., 2004; Rees, 2010). The M2 classification has 
become a broad category that includes all types of macrophages that are not M1 (Mosser and 
Edwards, 2008). Such a restrictive classification has led to further sub-classification of the 
M1 and M2 groups according to the nature of their priming and activating signals (Mantovani 
et al., 2004; Rees, 2010). Another approach has been to move away from the fixed M1 and 
M2 terms altogether and to reclassify these two broad categories of macrophages into three 
groups (Figure 1.1); classically activated linked with host defence, wound healing and 
regulatory (Mosser and Edwards, 2008). 
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Figure 1.1 The Classification of macrophage activation 
Panel A displays a monochromatic depiction of classical macrophage nomenclature showing 
the linear scale of the two macrophage designations, M1 and M2. Panel B shows the three 
populations of macrophages arranged according to the three primary colours with red 
designating classically activated macrophages, yellow designating wound-healing 
macrophages and blue designating regulatory macrophages. Secondary colours, such as 
green, may represent tumour-associated macrophages, which have many characteristics of 
regulatory macrophages but also share some characteristics of wound-healing macrophages. 
 
This figure and adapted text was reproduced from the review article by David Mosser and Justin P 
Edwards, Exploring the full spectrum of macrophage activation in Nature Reviews Immunology, Vol. 
8, December 2008, pp. 958-969. 
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Key to this alternative classification proposed by Mosser and Edwards is that the different 
types of macrophage can share characteristics of the other, relaxing the definitions of what 
each state means for macrophage function (Mosser and Edwards, 2008). Wound healing 
macrophages develop in response to innate or adaptive signals such as IL-4 and IL-13. 
Macrophages exposed to these cytokines have a reduced ability to present antigen to T cells 
and produce less pro-inflammatory cytokine and reactive oxygen species (Edwards et al., 
2006; Mosser and Edwards, 2008). The regulatory macrophages predominantly suppress 
immune responses and are characterised by the  upregulation of IL-10 and  the 
downregulation of IL-12 (Mosser and Edwards, 2008). 
 
The classification proposed by Mantovani et al. took a more rigid approach and subclassified 
M1 macrophages as M1a if they were activated in the ‘classical’ manner by priming with 
IFN-γ and then exposure to a proinflammatory stimulus like LPS or M1b if only exposed to a 
proinflammatory stimulus. M2 macrophages were split into three subgroups namely M2a 
activated by IL-4 or IL-13, M2b which are primed with immune complexes and activated 
with LPS producing high levels of IL10 along with proinflammatory cytokines (Mosser, 
2003) and M2c which are activated by anti-inflammatory molecules such as IL10 and 
glucocorticoids (Mantovani et al., 2004; Rees, 2010). Figure 1.2 illustrates the main 
macrophage phenotypes described by Mantovani et al. 
 
Regardless of how macrophages are classified, it does seem clear that macrophages are not 
fixed to one phenotype or behavioural programme but can switch their behaviour over time. 
How they change and adapt to an inflammatory process will define the degree of tissue 
damage that their activation can cause. Understanding the effector role of macrophages in 
causing Crgn in animal models is one approach to furthering the understanding of 
macrophage behaviour in direct relation to a disease state, though trying to fit the 
macrophage behaviour within such models into a rigid classification may not be 
straightforward. One can view Crgn simplistically, in activation terms, where there is likely 
to be an initial M1-type related response of macrophages infiltrating the glomerulus which 
after the initial phase of inflammation and injury, is modulated and altered towards a more 
M2 phenotype both to limit damage and initiate reparative mechanisms.  
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Figure 1.2 Inducers and functional properties of different polarised 
macrophage populations 
Macrophages can polarize and acquire different functional properties in response to 
environment-derived signals. Macrophage exposure to IFN-γ and LPS drives M1 polarization 
with potentiated cytotoxic and anti-tumour properties. M2 macrophages exhibit 
immunoregulatory and pro-tumour activities. In particular, M2a (induced by exposure to IL-4 
and IL-13) and M2b (induced by combined exposure to immune complexes and TLR or IL-1 
receptor agonists) exert immunoregulatory functions and drive type II responses, whereas 
M2c macrophages (induced by IL-10) are more related to suppression of immune responses 
and tissue remodelling.  
 
Abbreviations: DTH, delayed-type hypersensitivity; IC, immune complexes; IFN-γ, interferon-
gamma; iNOS, inducible nitric oxide synthase; LPS, lipopolysaccharide; MR, mannose receptor; 
PTX3, the long pentraxin PTX3; RNI, reactive nitrogen intermediates; ROI, reactive oxygen 
intermediates; SLAM, signalling lymphocytic activation molecule; SRs, scavenger receptors; TLR, 
Toll-like receptor. 
 
This figure and adapted text was reproduced from the review article by Alberto Mantovani et al., The 
chemokine system in diverse forms of macrophage activation and polarization in Trends in 
Immunology, Vol. 25, Issue 12, December 2004, pp. 677-686 
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1.5 The NTN model of Crgn 
Study of Crgn in animal models has given unique insights into the pathogenesis of crescent 
formation and macrophage behaviour along with insights into genetic factors underlying 
disease susceptibility. The nephrotoxic nephritis (NTN) model of crescentic 
glomerulonephritis in rats is induced by the injection of a nephrotoxic antiserum (NTS) 
which is raised in rabbits against a preparation of rat glomerular basement membrane (GBM). 
The injection of NTS deposits rabbit antibody on the GBM and triggers an innate immune 
response against it leading to the development of Crgn (Kawasaki et al., 1992; Tam et al., 
1999). The NTN model has become a useful tool for studying the role of cell-mediated innate 
immunity, particularly of macrophages, in crescent formation as the speed of disease onset 
means an acquired immune response does not play an important role. In addition, the disease 
is highly similar to human crescentic glomerulonephritis featuring fibrinoid necrosis and 
macrophage infiltration of glomeruli which leads on to glomerular scarring (Cook et al., 
1999; Tam et al., 1999).  
 
In the original description of the model, Kawasaki et al. demonstrated that Wistar-Kyoto 
(WKY) rats were more susceptible to NTN than other strains such as Lewis (LEW), F344, 
Wistar and the spontaneously hypertensive rat (SHR), developing progressive proteinuria and 
proliferative necrotising Crgn at doses that were subnephritogenic in the other strains 
(Kawasaki et al., 1992). The other main advantage of the NTN model in the WKY rat was its 
high level of reproducibility allowing for the responses over time within the model to be 
carefully characterised by Tam et al. (Tam et al., 1999). Tam et al. found that by day four 
after NTS injection, albuminuria and microscopic haematuria were detectable in the urine of 
the rats and by six weeks the rats had developed renal failure. Macrophages were the major 
type of leukocyte found within the nephritic glomeruli, detectable as early as 2.5 hours 
following NTS injection, with infiltration peaking between days four and eight. 
Histologically, by day four, many glomeruli showed focal segmental necrosis with fibrin 
deposition in the glomerular tuft or Bowman’s space and by day eleven, 63% of glomeruli 
had cellular crescents present in them. By day eighteen the amount of scarring had increased 
in the crescents and by day twenty-nine, 64% of glomeruli showed fibrous crescents. By 44 
days there was severe scarring present with most glomeruli showing old crescents and 
mesangial sclerosis (Tam et al., 1999). The previous study by Kawasaki et al. had found that 
an uncharacterised CD8
+
 cell population, likely to be central to the pathogenesis of the 
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disease, infiltrated the glomeruli within four hours and peaked at day three (Kawasaki et al., 
1992). The study by Tam et al. was able to demonstrate that, alongside large numbers of 
macrophages characterised by ED1 positivity infiltrating the glomeruli, the majority of CD8
+
 
cells were made up of a subset of ED1+ monocytes/macrophages (Tam et al., 1999).  
 
An alternative model approach that had previously been used in the rat was to accelerate the 
development of inflammation using pre-immunisation against immunoglobulin from the 
species in which the NTS was raised but at best, this only resulted in 30% of glomeruli 
developing crescents at three weeks and relied on the individual animal’s immune response 
(Silva et al., 1984; Tam et al., 1999). Mouse models suffer from a similar lack of consistency 
with regard to disease response and the degree of disease that develops. The accelerated NTN 
model in mice uses pre-immunization with sheep immunoglobulin and, after five days, 
nephritis is induced with intravenous sheep anti-mouse glomerular basement membrane 
globulin. The result is rapid deposition of mouse immunoglobulin in the glomeruli with 
resulting glomerulonephritis (Tarzi et al., 2002). Such studies do show variability of disease 
and in some cases wild type mice develop crescents in between 31% and 56% of glomeruli 
(Tarzi et al., 2002; Tarzi et al., 2003; Chavele et al., 2010) whilst in other studies in the same 
model and wild type controls, the degree of damage caused can be significantly less though 
all animals studied do develop some degree of glomerular abnormality (Tarzi et al., 2004; 
Cook et al., 2011). This variability in the degree of damage seen is in sharp contrast to the 
highly reproducible and consistent nature of the  NTN model in WKY rats (Tam et al., 1999).  
 
There is also a rat model of anti-GBM disease in the WKY rat termed the experimental 
autoimmune glomerulonephritis (EAG) model which first used collagenase-solubilized rat 
GBM injection and subsequently the non-collagenous domain (NC1) of the alpha 3 chain of 
type IV collagen, alpha3(IV)NC1 to induce disease (Reynolds et al., 1998; Reynolds et al., 
2009). Animals developed antibody against the GBM 14 days after injection and developed 
albuminuria by day 14 which peaked at day 28. By week four, changes consistent with severe 
focal proliferative glomerulonephritis affected 90% of glomeruli and 25% had crescent 
formation or necrosis present (Reynolds et al., 1998). The pathogenesis of the disease in this 
model is however dependent on cell mediated mechanisms (Reynolds et al., 2000) 
particularly T cells and the length of time for disease development compared to the NTN 
model means its utility in studying macrophage function is much less. 
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1.6 Animal models of Crgn highlight the potential for the macrophage 
as a therapeutic target in renal inflammatory disease 
One of the major utilities of the NTN model and other Crgn models in the WKY rat has been 
to target effector molecules linked to macrophage function in order to gain understanding of 
disease pathogenesis and to test novel therapeutic approaches to Crgn. Molecules have been 
successfully tested that influence all levels of the immune response linked to the macrophage 
from effector cytokines such as TNF-α to signalling molecules and kinases such as spleen 
tyrosine kinase (Syk) and cytokines such as IL-4 that directly alter macrophage phenotypes 
(Cook et al., 1999; Khan et al., 2005; Smith et al., 2010). 
 
Pertinent to the discussion of macrophage phenotypes in section 1.4, one of the earliest 
studies in the WKY NTN model used IL-4 to ameliorate Crgn because it was hypothesised 
that cytokines that reduce macrophage activation would reduce glomerular damage in the 
acute phase of Crgn (Cook et al., 1999). IL-4 infusions prior to the induction of NTN 
abolished proteinuria and reduced the numbers of macrophages within the glomeruli. When 
IL-4 was given twice daily from day four to seven after induction of NTN, no reduction in 
macrophage number within the glomeruli was seen but there was still reductions in 
proteinuria and glomerular injury. The results suggested that, alongside reducing macrophage 
infiltration, IL-4 was able to change the characteristics of macrophages present in the 
glomeruli resulting in a less pro-inflammatory phenotype and a more M2-like phenotype 
(Cook et al., 1999). Similarly, the anti-inflammatory cytokine IL-11, at low doses, reduced 
glomerular injury in the NTN model without altering macrophage numbers whilst at high 
dose it reduced macrophage infiltration as well as reducing proteinuria and fibrinoid necrosis 
showing that reducing macrophage number as well as modulation of macrophage activation 
could ameliorate disease (Lai et al., 2001).  
 
Different strategies to alter global macrophage phenotype continue to be studied in rat Crgn 
models. Angiotensin II type 1 receptor blockade using the compound olmesartan is able to 
induce M2 macrophages in vivo and inhibit glomerular inflammation in WKY rats with Crgn 
(Aki et al., 2010). Low dose treatment had no effect on disease but at higher doses it reduced 
infiltration of ED1
+
 macrophages and CD8
+
 cells, decreased crescentic lesions and 
suppressed glomerular TNF-α and IFN-γ production. The high dose treatment also increased 
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the numbers of M2 macrophages and increased glomerular IL-4, IL-13, mannose receptor and 
IL-10 expression (Aki et al., 2010). Administration of the statin atorvastatin, which inhibits 
3-hydroxy-3 methylglutaryl CoA reductase and is a class of drugs primarily used to treat 
hypercholesterolemia was also used to treat disease and alter macrophage phenotype in a 
Crgn WKY rat model (Fujita et al., 2010). Statins are known to have anti-inflammatory and 
immunomodulatory functions and atorvastatin was used in this preventative treatment study 
design to reduce macrophage infiltration and crescent formation compared to controls. The 
protective effects were associated with a down regulation of M1 related cytokines such as 
TNF-α and IFN-γ and IL-12 whilst the statin also augmented alternatively activated 
macrophages and anti-inflammatory cytokines such as IL10 (Fujita et al., 2010).  
 
Mechanisms that control macrophage infiltration into the inflamed glomerulus have been 
explored and vascular cell adhesion molecule (VCAM-1) was found to be up-regulated 
within the glomeruli of rats with NTN but was not critical for macrophage migration whilst 
blockade of its related ligand, very late antigen four (VLA-4), did attenuate macrophage 
activation without reducing macrophage number or classical markers of M1 macrophage 
activation (Allen et al., 1999; Khan et al., 2003). More recently, blockade of c-fms, the 
macrophage specific receptor for macrophage colony stimulating factor (M-CSF) was 
undertaken in an anti-GBM model in WKY rats (Han et al., 2011). The study showed that 
inhibiting c-fms reversed glomerular macrophage infiltration from the blood and suppressed 
local macrophage proliferation in the kidney preventing the development of crescents 
however proteinuria did persist in the disease model. Of note, high dose treatment reduced 
the number of macrophages in the glomeruli with an M1-like phenotype and caused a relative 
increase in the expression of M2 markers suggesting that increasing alternative activation 
properties of the macrophages also contributed to the effect on disease (Han et al., 2011). 
 
Adoptive transfer experiments have shown that macrophages transferred by tail vein injection 
into a study animal which has been treated to eradicate any endogenous immune cells can 
cause disease in an NTN model (Ikezumi et al., 2003). Equally, transferring reprogrammed 
macrophages that have been switched to a more anti-inflammatory phenotype has been tested 
though not in the WKY related Crgn models (Ferenbach and Kluth, 2010). An NTN model in 
Sprague-Dawley rats was used to show how macrophages overexpressing IL-10 reduced the 
disease when given to rats six hours after NTN induction. This led to reduced numbers of 
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macrophages in glomeruli as did IL-4 expressing macrophages (Kluth et al., 2001; Wilson et 
al., 2002). Inhibiting NF-κB using a recombinant adenovirus expressing the inhibitor of 
protein κB in bone marrow derived macrophage (BMDMs) resulted in cells that produce less 
IL-12 and TNF-α when LPS stimulated and, in vivo, their transfer into diseased rats reduced 
disease and glomerular macrophage infiltration by host macrophages preventing their normal 
pro-inflammatory activation in the same Sprague-Dawley model (Wilson et al., 2005).  
 
Compounds that have been successfully used in other inflammatory diseases have led to their 
trials in the NTN model including blockade of TNF-α which had shown great success in the 
treatment of Crohn’s disease and rheumatoid arthritis (Khan et al., 2005). Anti-TNF-α 
therapy was effective in the early stages of the NTN model with a reduction seen in 
glomerular crescents and preserved renal function both when given at disease induction and, 
after four days, when macrophages peak in infiltration (Khan et al., 2005). However, in 
human randomised trials, when added to standard therapy, anti-TNF-α treatment did not 
improve response (The Wegener's Granulomatosis Etanercept Trial Research, 2005). This is 
likely to be a reflection of the more complex immune pathogenesis of ANCA vasculitis in 
humans compared to the innate immune responses driving the NTN model in WKY rats. 
 
Targeting of molecules within the signalling pathways of the macrophage response to 
stimulation has proven successful in Crgn models and aims largely to dampen the 
proinflammatory stereotypical M1 response of macrophages in the nephritic glomeruli. 
Activation of p38 mitogen-activated protein kinase (MAPK) plays an important role in 
cytokine production and its specific inhibition with a small molecule inhibitor in the NTN 
model markedly reduced renal injury as measured by proteinuria and reduced macrophage 
infiltration when given at the time of NTN induction or after disease was established 
(Sheryanna et al., 2007). Whilst not toxic to the rats in the NTN model, early first generation 
compounds blocking the kinase in humans were toxic to the liver though it is thought to still 
be an attractive drug target with early phase trials underway (Opar, 2010). Blockade of the c-
Jun amino terminal kinase (JNK), another proinflammatory signalling pathway activated in 
Crgn, also prevents crescent formation and treats established disease in a Crgn model in 
WKY rats (Ma et al., 2009). JNK blockade reduced the expression of a number of different 
proinflammatory mediators such as TNF-α and MMP-12 suggesting that one of the 
mechanisms of action of the JNK blockade was to inhibit the proinflammatory macrophage 
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response that was occurring (Ma et al., 2009). Inhibition of protein kinases has increasingly 
become a highly attractive therapeutic option. Imatinib is a selective tyrosine kinase inhibitor 
that blocks the activity of platelet derived growth factor receptors (PDGFR) and was 
successfully used in a Crgn model in WKY rats producing less proteinuria and crescentic 
glomeruli if given before or during disease. Glomerular macrophage infiltration was reduced 
by the treatment and the macrophages that did infiltrate the glomeruli expressed reduced 
levels of IL-1β and MCP-1 (Iyoda et al., 2009). Of note, the treatment also reduced renal 
cortical M-CSF receptor c-fms expression suggesting that it inhibits this signalling pathway 
which has also been shown to be an effective treatment in Crgn (Han et al., 2011). The orally 
delivered spleen tyrosine kinase (Syk) inhibitor R788 (fostamatinib disodium), which is a 
prodrug of a selective Syk inhibitor, was highly effective in reducing the severity of disease 
in the NTN model even when given after disease onset (Smith et al., 2010). Syk is essential 
for Fc gamma receptor mediated signalling and phagocytosis in macrophages (Crowley et al., 
1997; Kiefer et al., 1998) and has shown great promise in early phase trials in rheumatoid 
arthritis (Weinblatt et al., 2010). Fc gamma receptors are present on the cell surface of 
macrophages and recognise the fragment, crystallisable (Fc) region of IgG (Crowley et al., 
1997). 
 
Pharmacological studies in the WKY rat model of NTN have demonstrated the considerable 
utility of the model in investigating the pathogenesis of Crgn and have shown how multiple 
different parts of the immune response can be modified to treat disease and have given 
insights into the pathogenesis of the human disease. The overriding theme within these 
pharmacological studies is that successful treatment requires inhibition of the 
proinflammatory M1 type behaviour of macrophages and, if possible, promotion of reparative 
M2 or alternatively activated phenotypes. However such approaches are driven by the 
availability of inhibitory molecules or compounds used in other inflammatory diseases and, 
whilst certainly highly effective, such hypothesis driven candidate molecule approaches do 
not allow for more general investigations of the model to be made in order to understand 
what are the key effector molecules driving the macrophage effector response in Crgn.  
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1.7 The Genetic analysis of the NTN model 
One of the most striking features of the NTN model is that WKY rats are uniquely 
susceptible to NTN, developing progressive proteinuria and proliferative necrotising 
crescentic glomerulonephritis at doses of NTS that are sub-nephritogenic in the other rat 
strains such as Lewis, Wistar and Brown Norway (Kawasaki et al., 1992; Aitman et al., 
2006). The unique susceptibility demonstrated by the WKY rat compared to the Lewis rat, 
with which it shares the same MHC haplotype, along with the highly reproducible nature of 
the NTN model led to the study of its underlying genetic determinants (Aitman et al., 2006). 
 
The F1 cross performed between the WKY and Lewis rats had intermediate phenotypes for 
Crgn disease including crescent formation, proteinuria and macrophage infiltration whilst the 
F2 generation demonstrated phenotypes that spanned the whole range of the phenotypes 
observed in the WKY and Lewis parental strains (Aitman et al., 2006). Analysis in the F2 rats 
demonstrated that crescent formation was highly correlated with proteinuria and macrophage 
infiltration and all the phenotypes were highly heritable. The genome screen performed for 
NTN susceptibility loci in the F2 generation found two major quantitative trait loci (QTL) on 
chromosomes 13 and 16 which were designated as crescentic glomerulonephritis 1 (Crgn1) 
and 2 (Crgn2). Both loci were linked to crescent formation and proteinuria (with highly 
significant logarithm of odds (LOD) scores 7.4-9.1) and infiltration of macrophages was 
linked to Crgn1. A further 5 loci (Crgn3-7) were also identified with LOD scores > 3. 
Haplotype mapping was used to positionally clone Fcgr3 as the candidate gene for Crgn1. In 
the WKY rat, deletion of the rat-specific Fcgr3 paralogue, Fcgr3-related sequence (Fcgr3-rs) 
was identified as the molecular basis for the QTL whilst in humans, low copy number of 
FCGR3B, an orthologue of rat Fcgr3, was associated with glomerulonephritis (Aitman et al., 
2006).  
 
Whilst the NTN model is predominantly a macrophage dependent model it is important to 
recognise that intrinsic renal cells do still play a role in the pathogenesis of the disease (Smith 
et al., 2007). This was shown in bone marrow and kidney transplant experiments between the 
WKY and LEW rat strains. Bone marrow transplant experiments showed that the 
susceptibility of crescent formation was transferable to NTN resistant LEW rats by WKY 
bone marrow but this did not produce the full WKY disease phenotype. When WKY bone 
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marrow was transplanted to LEW, crescents formed in only 35% of glomeruli compared to 
89% in WKY rats (Smith et al., 2007). The role of the kidney itself in contributing to Crgn 
susceptibility was investigated. When kidneys were transplanted from WKY to LEW rats and 
vice versa, acute rejection occurred despite the shared MHC haplotype between the strains. F1 
rats derived from crossing WKY with LEW have an intermediate susceptibility phenotype to 
NTN and transplants from the parental strains into the F1 rat were successful with no 
rejection seen (Smith et al., 2007). In the analysis of these transplants, the severity of disease 
in the transplanted kidney was compared with the native kidney to mitigate the effects of the 
transplantation process. These results found that LEW kidneys did develop Crgn when 
transplanted into the F1 rats. However the severity relative to native kidneys was less than 
that of transplanted WKY kidneys indicating that the kidney itself contributed to 
susceptibility to Crgn (Smith et al., 2007). If susceptibility was mediated just by circulating 
cells, the degree of disease should have been the same whether a LEW or WKY kidney was 
transplanted into the F1 rats. The data therefore showed that whilst bone marrow derived cells 
do make the major contributions to disease; the susceptibility to Crgn is not solely dependent 
upon them. This has major implications for the on-going investigations in to the identity of 
genes underlying the other five Crgn QTLs. It is likely that as well as further macrophage 
linked susceptibility genes, genes affecting intrinsic glomerular cell phenotypes will be 
identified. 
 
1.7.1      Identification of JunD as a primary determinant of macrophage activation 
linked functionally to Crgn susceptibility 
Using congenic, linkage and microarray studies, the activator protein (AP)-1 transcription 
factor Jund was identified as a primary determinant of macrophage activation linked 
functionally to crescentic glomerulonephritis susceptibility encoded at Crgn2 (Behmoaras et 
al., 2008). Approaches that integrate genetic mapping, gene expression and computational 
analysis have been used to identify a number of genes underlying rat polygenic traits which 
have then been demonstrated in related traits in humans (Aitman et al., 1999; Hubner et al., 
2005; Aitman et al., 2008; Petretto et al., 2008; Pravenec et al., 2008). QTLs such as Crgn1-7 
are discrete chromosomal regions that control a quantitative trait such as crescent formation 
but can actually correspond to relatively large chromosomal segments containing hundreds of 
genes. Congenic strains are new inbred strains generated by backcrossing one strain onto 
another to produce a rat with a particular genomic region from one strain whilst the 
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remainder of its genome is from the other. They are used to confirm established QTLs, fine 
map candidate genes responsible for the phenotype controlled by the QTL and to characterize 
the biology of the QTL genes (Aitman et al., 2010). Figure 1.3 illustrates the breeding 
strategy for generating such a congenic strain. The congenic lines for Crgn2 were generated 
by backcrossing (WKYxLEW) F1 rats onto the recipient WKY or LEW parental strains for 
nine generations. During the process the region of interest remains in the heterozygous state 
and by brother-sister mating rats heterozygous for the chromosome 16 linkage region the 
congenic interval was fixed creating the congenic lines (Behmoaras et al., 2008).  
 
The use of congenic strains was a key step in identifying Jund as a primary determinant of 
macrophage activation and linking it functionally to crescentic glomerulonephritis 
susceptibility. Introgression of Crgn2 from the non-susceptible Lewis strain onto the WKY 
background, termed WKY.LCrgn2 allowed the effect of the introgressed Lewis region to be 
tested on the WKY genetic background. WKY.LCrgn2 rats had significant reductions in 
crescent formation, fibrin deposition and macrophage infiltration though no change in 
proteinuria was observed. Conversely the congenic strain where the WKY Crgn2 locus was 
introgressed onto the LEW background (LEW.WCrgn2) showed no difference compared to 
LEW in the formation of crescents or fibrin deposition but did demonstrate increases in 
macrophage infiltration and proteinuria (Behmoaras et al., 2008).  
 
The Crgn2 QTL had a major effect on disease but was found to correspond to a relatively 
large genetic interval of 22.6 centimorgans (cM). Multiple candidate nucleotide variants 
located within the interval could therefore underlie the phenotypic effects that had been 
observed. Behmoaras et al. therefore performed gene expression profiling using microarray 
analysis on normal glomeruli from WKY and LEW rats and on glomeruli following NTN 
induction to identify potential positional candidates for Crgn2. This demonstrated that there 
were three significantly upregulated transcripts and three significantly downregulated 
transcripts in non-nephritic glomeruli from WKY rats compared to LEW that were located 
within the Crgn interval. 
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Figure 1.3 Construction of a congenic strain from two inbred strains 
Breeding scheme for generating a congenic strain from 2 inbred strains, one of which is 
donor and the other recipient. Congenic strains are produced by repeatedly backcrossing to an 
inbred recipient strain with selection of a particular microsatellite marker locus M from the 
donor strain. The M1 allele is kept in the heterozygote state during breeding and the 
backcrosses are continued for ten generations to ensure that at least 99% of the background 
genome is from the recipient strain. Once this has been achieved, heterozygous males and 
females are intercrossed to generate the congenic line. Increasing shades of grey from light to 
dark represent increase in percentage genetic background of recipient that occurs with each 
backcross (BC). 
 
This figure and adapted text was reproduced from the review article by John P. Rapp, Genetic 
Analysis of Inherited Hypertension in the Rat in Physiological Reviews vol. 80, no. 1, January 2000, 
pp. 135-172.  
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Jund showed a highly significant 20.78-fold increase in expression in WKY glomeruli 
compared to LEW in normal glomeruli and 18.56-fold higher expression in WKY glomeruli 
after NTN-induction (Behmoaras et al., 2008). The overexpression of Jund in the WKY strain 
was confirmed by quantitative real time polymerase chain reaction (qRT-PCR) in glomeruli 
and in BMDMs. In addition, the segregation of Jund expression with the congenic interval 
was confirmed by qRT-PCR and the introgressed congenic interval was able to account 
totally for the differences in expression seen between WKY and LEW BMDMs. At the 
protein level, increased expression of JunD was observed in WKY glomeruli after induction 
of NTN (Behmoaras et al., 2008). 
 
No nucleotide variants were observed in the coding sequence of Jund between WKY and 
LEW BMDMs but sequence analysis of the proximal promoter identified a C/T 
polymorphism, 210 base pairs upstream of the transcriptional start site that was within two 
base pairs  of an octamer motif. The effect of the polymorphism on Jund promoter function 
was tested using a luciferase assay where the Jund promoter from LEW and WKY rats was 
cloned into an expression vector and assessed in COS7 cells. This showed that the WKY 
promoter sequence that contained the T allele had higher luciferase activity than the LEW 
promoter containing the C allele. As the C/T polymorphism had therefore been shown to be 
responsible, in part, for the increased expression of Jund in WKY rats, it was used to 
genotype the 177 F2 rats that were used in the original linkage analysis of NTN susceptibility 
in  the WKY and LEW strains (Aitman et al., 2006; Behmoaras et al., 2008). This was carried 
out using a PCR-based amplification refractory mutation system. The C/T polymorphism 
within the promoter of Jund was found to have complete linkage disequilibrium with the 
microsatellite marker D16Rat78 which mapped to the peak of linkage at Crgn2 and was 
associated significantly with glomerular crescents, proteinuria and macrophage infiltration. 
The linkage to glomerular macrophage infiltration was refined further by assessing the 
amount of macrophage infiltration that occurred after NTS injection in four closely related 
Kyoto-derived rat strains. The Ishibashi rat, ISR (IS/KYO) level of macrophage infiltration 
was similar to LEW rats whilst the WTC, the Kyoto substrain of Wistar Kyoto rats (WKYO) 
and Donryu (DON) rat strains had higher levels of infiltration. Using these strains, haplotype 
analysis on chromosome 16 identified that a 430 kilobase region segregated with macrophage 
infiltration across these strains and Jund was the only transcript from the microarray analysis 
present within this region. The other transcripts were mapped outside this interval. The data 
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therefore implicated Jund as the positional candidate for increased macrophage activation and 
cytokine production and glomerular macrophage infiltration encoded at the Crgn2 locus 
(Behmoaras et al., 2008). 
 
1.7.2      The pro inflammatory phenotype of WKY macrophages 
These studies of the genetic determinants underlying the unique NTN susceptibility of the 
WKY strain identified that one of the major reasons underlying the susceptibility was an 
enhanced pro-inflammatory activation state of WKY BMDMs. As the pervading view is that 
pro-inflammatory phenotypes of macrophages are central to the pathogenesis of Crgn, 
understanding the genetic mechanisms by which these are determined could be central to 
developing better treatments for the disease. The genetic and pharmacological studies in the 
WKY rat suggest that macrophages infiltrating the inflamed glomerulus have a more active 
M1 like behaviour. However it is equally possible that the persistence of this behaviour 
preventing a switch to a more M2 phenotype could be occurring in the model causing 
sustained glomerular damage.  
 
Mesangial cell damage and glomerular necrosis are key macrophage dependent features of 
NTN (Aitman et al., 2006). The enhanced ability of WKY macrophages to cause such renal 
injury was tested by an in vitro assay which measured the macrophage mediated killing of 
antibody coated mesangial cells. WKY BMDMs produced significantly high percentages of 
mesangial cell death than LEW demonstrating that they exhibit a stronger pro-inflammatory 
damaging phenotype (Aitman et al., 2006). Most laboratory rat strains including LEW were 
found to express two forms of Fcgr3 but WKY rats lack the inhibitory Fc receptor gene, 
Fcgr3-related sequence (Fcgr3-rs). This was found functionally to have an inhibitory role in 
Fc receptor function as COS7 cells that were transfected with both Fcgr3 and the inhibitory 
Fcgr3-rs demonstrated 70% inhibition of Fc mediated phagocytosis which partly explained 
the enhanced macrophage FC receptor mediated activity influenced by Crgn1 (Aitman et al., 
2006).  
 
The WKY macrophage phenotype was further assessed using the Fc oxyBURST assay which 
assesses immunoglobulin Fc receptor-mediated phagocytosis and its resulting oxidative burst 
and by investigating the ability of BMDMs to phagocytose antibody-opsonised beads 
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(Behmoaras et al., 2008). The Fc oxyBURST assay demonstrated a significant reduction in 
activation in WKY.LCrgn2 bone marrow derived macrophages (BMDMs) compared to 
WKY BMDMs at all timepoints and importantly the WKY.LCrgn2 behaved the same as 
LEW BMDMs. A similar result was found in the bead phagocytosis assay and there was also 
a significant reduction in inducible nitric oxide synthase 2 (Nos2) expression which is a 
marker of the classically activated M1 macrophage phenotype (Behmoaras et al., 2008). 
Together, this data suggested that a gene within the Crgn2 QTL played a major role in 
controlling macrophage activation in WKY BMDMs. Understanding the influence on the 
transcriptome of Crgn2 in both basal and LPS stimulated BMDMs between the WKY and 
WKY.LCrgn2 rat strains could therefore allow for the identification of candidate genes that 
could influence these key activation pathways and go some way to explaining the effects of 
the congenic interval in decreasing the severity of NTN disease. 
 
A role for JunD in macrophage activation was confirmed using siRNA knockdown of Jund 
mRNA. The Fc-oxyBURST assay was used to assess macrophage activation and showed a 
significant reduction in activation in BMDMs transfected with Jund siRNA compared to 
WKY BMDMs transfected with scrambled control siRNA. In addition Jund siRNA 
transfected BMDMs demonstrated reduced Nos2 expression following LPS stimulation 
(Behmoaras et al., 2008). The importance that this effect of altered Jund expression levels 
had on macrophage activation was shown by translational studies in human primary 
macrophages where siRNA knockdown of JUND significantly reduced the expression the 
important inflammatory cytokines IlL10, Il6 and TNF-α (Behmoaras et al., 2008). 
Differences in the macrophage transcriptomes have been confirmed by examining the profiles 
of bone marrow derived macrophages (BMDMs)  in the basal state and following 24 hours of 
lipopolysaccharide (LPS)  stimulation (Maratou et al., 2010). This found distinct differences 
in the transcriptome profiles of the two strains, identified some potential candidates for the 
five remaining un-investigated Crgn quantitative trait loci (QTLs) and defined groups of 
genes that could play a role in the differential regulation of macrophage activity (Maratou et 
al., 2010). 
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1.7.3      The interaction between Crgn1 and Crgn2 has an additive effect on NTN 
disease 
Further insights into genetic aspects of the NTN model in WKY rats were gained from the 
investigation of the phenotype of the double congenic strain where both Crgn1 and Crgn2 
from LEW were introgressed onto the WKY genetic background (WKY.LCrgn1,2) 
(Behmoaras et al., 2010). When NTN disease was induced, the Crgn2 single congenic had a 
reduction of 8% in glomerular crescents compared to WKY and the Crgn1 single congenic 
had a reduction of 18% in crescent number. The double congenic, WKY.LCrgn1,2 however, 
had a reduction of 34% showing that an additive effect was occurring when both loci were 
introgressed onto the WKY background (Behmoaras et al., 2010). Of note, this additive effect 
was not seen with either macrophage infiltration analysis or proteinuria. In addition, the 
glomerular expression of TNF-α and Nos2 in the double congenic were both significantly 
reduced compared to the WKY and the single congenic strains. Bone marrow transplant 
experiments confirmed that the effects of both Crgn1 and Crgn2 were on bone marrow 
derived and not intrinsic renal cells (Behmoaras et al., 2010). The additive effect seen when 
both Crgn1 and Crgn2 loci were combined suggests a major interaction between the strains 
and as a transcription factor, Jund could well be exerting effects in trans to alter effector 
genes within the Crgn1 locus that were important mediators of glomerular damage.  
 
Macrophage function was investigated using the Fc-oxyBURST assay. The effect of 
introgressing either Crgn1 or Crgn2, or both in the double congenic strain, resulted in the 
same degree of Fc receptor mediated activation as the LEW strain, which was significantly 
less than in WKY BMDMs (Behmoaras et al., 2010). The fact that either congenic interval 
influenced this pathway to such an extent that it behaved phenotypically as the LEW strain 
suggests that both intervals influence the functional pathway at critical points highlighting 
that multiple functional and therapeutic targets within such a pathway can exist. In addition, 
BMDMs from the congenic strains displayed the same reduction in TNF-α protein secretion 
compared to WKY strains though no additive effect was seen in the double congenic and the 
introgression of either or both intervals did not reduce the secretion to the level of LEW 
BMDMs demonstrating that other genetic factors still influenced this process. At the mRNA 
level, introgression of Crgn1 and/or Crgn2 from the Lewis into the WKY genetic background 
led to significant reduction in iNOS and IL-6 mRNA levels in BMDMs stimulated overnight 
with LPS (Behmoaras et al., 2010).  
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Whilst Crgn1 and Crgn2 have a major influence on macrophage activation in the WKY rat, 
they are not the sole genetic factors influencing this phenotype.  This was demonstrated by 
the fact that MMP-9 and MMP-12 expression was significantly increased in WKY BMDMs 
and WKY.LCrgn1,2 BMDMs compared to LEW. Of note, WKY.LCrgn1,2 BMDMs also 
demonstrated higher expression of both MMP-9 and MMP-12 demonstrating that the genetic 
context of the introgressed interval is also important because the interaction of Crgn1 and 
Crgn2 from the LEW on the WKY background did not produce the same expression as the 
WKY. 
 
1.8 AP -1 transcription factor and JunD  
AP-1 transcription factor (AP-1) is formed of homo or hetero-dimeric complexes of the Jun 
family of proteins (C-Jun, JunB, and JunD) along with proteins from the Fos (c-Fos, FosB, 
Fra and Fra-2) and activating transcription factor (ATF) families (ATF2, ATF3, B-ATF, 
JDP1, JDP2) (Zenz and Wagner, 2006). AP-1 dimers are thought to interact with two binding 
sites in the genome; the TPA response element (TRE) containing the motif 5’-TGAG/CTCA-
3’ (Angel et al., 1987; Lee et al., 1987) and, with lower affinity, to the cAMP responsive 
element (CRE) 5’-TGACGTCA-3’ (Nakabeppu et al., 1988; Rauscher et al., 1988). The 
ability of AP-1 to bind the motifs and trans activate genes is dependent upon its dimer 
composition, meaning that AP-1 has the potential for a wide range of functional effects on 
gene transcription depending on its exact dimer make up (Mechta-Grigoriou et al., 2001; 
Vogt, 2001; Hess et al., 2004). The effects of AP-1 on gene transcription also depend heavily 
upon on the tissue, cell and stimulation state studied (Kovary and Bravo, 1991; Shaulian and 
Karin, 2002; Hess et al., 2004).  AP-1 motifs are so widely found within the genome in 
promoters and enhancers of genes that it suggests that not all genes containing the motif 
would be regulated by AP-1. AP-1 has been found to interact with over 50 different proteins 
and these interactions, particularly with NFAT or proteins from the Ets and Smad families, is 
thought to alter the regulatory specificity of AP-1. This means that sequences that do not 
contain the classical form of the TRE or CRE motif can still be bound and regulated by AP-1 
(Chinenov and Kerppola, 2001; Shaulian, 2010). In terms of regulation, AP-1 protein levels 
and activity are largely regulated post-transcriptionally and are activated primarily by the 
MAPK cascades with the c-Jun amino-terminal kinase (JNK) playing a central part in this 
(Shaulian and Karin, 2002; Shaulian, 2010; Schonthaler et al., 2011). 
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AP-1 has been widely studied and linked with many cellular functions including 
proliferation, inflammation, differentiation, apoptosis, cellular migration and wound healing 
(Shaulian and Karin, 2001, 2002; Hess et al., 2004; Wagner and Eferl, 2005; Shaulian, 2010). 
Its activity is induced by multiple physiological stimuli including proinflammatory cytokines, 
chemokines, hormones and multiple environmental stressors (Brenner et al., 1989; Angel and 
Karin, 1991; Shaulian and Karin, 2001; Schonthaler et al., 2011). In the immune system, AP-
1 has been linked with roles in directly activating cytokine production, regulating naïve T-cell 
differentiation, controlling T cell cytokine responses and determining the activation status of 
macrophages (Brenner et al., 1989; Wagner and Eferl, 2005; Behmoaras et al., 2008; Zenz et 
al., 2008). In macrophages, stimulation with LPS through the TLR4 pathway triggers a 
signalling cascade that results in the early activation of AP-1 which in turn mediates the 
expression of multiple pro-inflammatory cytokine genes such as TNF-α and IL-6. This has 
led to hypotheses that AP-1 could play roles in the pathogenesis of inflammatory diseases and 
atherosclerosis (Newell et al., 1994; Hambleton et al., 1996; Tengku-Muhammad et al., 2000; 
Zenz et al., 2008). Nitric oxide production in macrophages, catalysed by inducible nitric 
oxide synthase (iNOS), is a major mechanism of macrophage cytotoxicity. Production of 
iNOS is regulated at the transcriptional level and mutation of AP-1 motifs in the murine and 
human iNOS gene promoters significantly reduce their function. (Marks-Konczalik et al., 
1998; Okada et al., 2003). AP-1 has also been linked with the pathogenesis of crescentic 
glomerulonephritis. AP-1 is activated in nephritic glomeruli of the WKY rat in the NTN 
model from day 1 after NTS injection and is proposed to have a regulatory role in the 
expression of pro-inflammatory factors in nephritic glomeruli (Sakurai et al., 1997; Sakurai 
and Sugita, 1998). AP-1 has been linked directly to inflammatory disease models. In human 
inflammatory disease, JunB is altered in psoriatic skin lesions and genetic mouse models 
have shown that deletion of JunB and C-Jun in animal models induces a psoriasis-like 
phenotype through alterations in cytokine expression control (Schonthaler et al., 2011).  
 
JunD was identified in the mouse 3T3 fibroblast cell line as the third member of the Jun gene 
family in 1989 (Hirai et al., 1989; Ryder et al., 1989). The relative amounts of Jun protein 
mRNAs were found to vary between different types of cells and tissues and Jund mRNA was 
found to be expressed constitutively at 5-10 fold higher levels than c-Jun mRNA raising the 
possibility of an involvement in the activation of immediate early genes (Ryder et al., 1989). 
This early response function is distinct to that of c-Jun and JunB which are classified as 
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immediate-early genes as their expression can be induced within minutes after exposing cells 
to either serum or different growth factors (de Groot et al., 1991). Unlike c-Jun and JunB 
which are essential for embryonic development, deletion of Jund is not fatal in utero though 
Jund
-/-
 knockout mice do demonstrate reduced postnatal growth, impaired spermatogenesis 
and hormone imbalances (Thepot et al., 2000). The constitutive expression of Jund is driven 
by an octamer-binding transcription factor-1 site in the promoter of the gene and the protein 
is not subject to ubiquitin-mediated degradation whilst its activity is regulated by a number of 
post transcriptional mechanisms including the MAPK cascades and the extracellular signal 
regulated kinase (ERK)-mitogen activated protein kinase pathway. (Hernandez et al., 2008). 
The Jun proteins are not functionally equivalent and whilst certainly redundancy is a feature 
of their function, demonstrated by the ability of JunD to substitute for C-Jun during fetal 
development, the proteins all have independent functional roles in the cell which can be 
antagonistic as demonstrated by the opposing functions of Jun and JunB in cell proliferation 
(Meixner et al., 2010). 
 
The ultimate function of JunD within the intricate regulatory networks of the cell may be to 
regulate the transcription of target genes that help the cell respond to environmental signals 
(Hernandez et al., 2008). JunD can both activate or repress the transcription of a diverse set 
of genes meaning that it has been associated with diverse cell type specific functions 
including roles in regulating cell proliferation and apoptosis and in protecting cells from 
responses to stress stimuli and oxidative stress, whilst in the immune system, JunD has 
previously been associated with the regulation of lymphocyte proliferation, differentiation 
and T helper cell cytokine expression along with macrophage activation (Weitzman et al., 
2000; Mechta-Grigoriou et al., 2001; Lamb et al., 2003; Gerald et al., 2004; Meixner et al., 
2004; Behmoaras et al., 2008; Cook et al., 2011). Whilst the exact functions of JunD certainly 
depends on the cell type studied, a general role for the factor in cell survival and protecting 
cells from senescence or apoptotic responses to stress stimuli has been proposed (Weitzman 
et al., 2000; Lamb et al., 2003; Hilfiker-Kleiner et al., 2005). JunD  has been linked with both 
positively and negatively regulating cell-cycle progression that depends on the cellular 
context studied but does not have as potent a pro-proliferative function as c-Jun does 
(Shaulian and Karin, 2002; Eferl and Wagner, 2003). JunD has been found to protect cells 
from oxidative stress and to reduce tumour angiogenesis by limiting the production of 
reactive oxygen species (ROS) but in human prostate cancer cells has also been linked to 
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mediating oxidative stress (Gerald et al., 2004; Mehraein-Ghomi et al., 2008). In the 
autoimmune disease systemic sclerosis, JunD is overexpressed and mediates the profibrotic 
effects of TGF-β in fibroblasts. Its deficiency reduces the activation of fibroblasts and 
prevents experimental fibrosis pointing to possible roles within the NTN model in modulating 
the fibrosis that occurs (Palumbo et al., 2011). 
 
1.9 LPS stimulation, TLR4 signalling and its implications for renal 
disease 
Macrophages possess a wide range of receptors on their surface to detect antigens from 
invading pathogens as well as the by-products and regulators of inflammation in the tissues. 
Pattern recognition receptors against microbial products can be located on the cell surface 
such as TLR4 or in the cytoplasm such as the NOD-like receptors (NLRs), RIG-like receptors 
(RLRs) and DNA sensors such as AIM2 (Plüddemann et al., 2011). As a  pattern  recognition  
receptor, TLR4 is able to detect both pathogen associated molecular patterns (PAMPs) and 
endogenous damage associated molecular patterns (DAMPs) which include degradation 
products of extracellular matrix, heat shock proteins, chromatin-DNA and ribonucleoprotein 
complexes as well as immune complex-containing self-antigens (Kawai and Akira, 2010; 
Rosin and Okusa, 2011). LPS derived from bacterial cell walls is commonly used as an 
agonist for TLR4 receptors, in vitro, initiating a now well characterised and robust innate 
immune response in the macrophage and these LPS activated signalling pathways intersect 
with many critical cellular pathways controlling proliferation, apoptosis, endocytosis and 
secretion (Nilsson et al., 2006). Whilst critical for an organism’s immune response to 
infection, an inappropriate TLR response can lead to acute and chronic inflammation and 
autoimmune disease (Kawai and Akira, 2010). There is also growing evidence that TLR4 
receptors play an important role in renal glomerular disease and autoimmunity (Brown et al., 
2007; Robson, 2009; Giorgini et al., 2010; Summers et al., 2010a; Summers et al., 2010b) 
along with a role for DAMPS in contributing to the pathogenesis of acute and chronic kidney 
disease (Rosin and Okusa, 2011). 
 
Investigating the response to LPS in macrophages has wide implications for macrophage 
biology as a way of gaining insights into the mechanisms that underlie the complex responses 
to infection and tissue injury that occur. It has been recognised for some time that the gene 
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changes that occur following LPS stimulation are rapid, occurring within minutes to a few 
hours, and affect the majority of genes in the cell. Only a minority of genes do not alter in 
their level of expression and many genes that are expressed at high levels initially are 
downregulated by LPS (Hume et al., 2002; Nau et al., 2002; Ravasi et al., 2007; Ramsey et 
al., 2008).  Three main families of proteins playing key roles in activating inflammatory gene 
expression are activated by LPS stimulation of TLR4 receptors. Along with the nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) family of proteins that are major 
drivers of the transcriptional activation of inflammatory genes and interferon regulator factor 
(IRF) proteins which drive type one interferon production and thereby the activation of 
interferon inducible genes, the MAP kinases are also activated including the extracellular 
signal-regulated kinases (ERKs), c-Jun N-terminal kinases (JNK) and p38 MAP kinases. The 
AP-1 family of transcription factors are the major mediators of the inflammatory effects of 
MAP kinases (Hu et al., 2007; Kawai and Akira, 2010, 2011). Some of the major key 
inducible genes have been categorised based on the kinetics of their response. Primary 
response genes (PRGs) are usually induced within one hour of stimulation whilst secondary 
response genes (SRGs) have a delayed response because of the requirement for new protein 
synthesis and chromatin remodelling at their promoters (Ramirez-Carrozzi et al., 2006; 
Hargreaves et al., 2009). 
 
The transcriptional controls that occur as part of the gene response to LPS stimulation in 
macrophages drive the inducible gene expression and regulate the overall response. The 
transcription factors involved can be divided into three categories based on function and how 
they are activated (Medzhitov and Horng, 2009). Constitutive factors form one class and are 
activated by signal-dependent post-translational modifications and includes proteins which 
are known to play important roles in inflammation including NF-κB factors, IRFs and cAMP-
responsive-element-binding protein 1 (CREB1) all of which function to induce the primary 
response genes. The second group are induced during the initial phases of the gene 
expression response to LPS and regulate later waves of gene expression over a number of 
hours. Examples include the inducible repressor activating transcription factor (ATF)3 and 
the activator CCAAT/enhancer-binding protein-δ (C/EBPδ) (Gilchrist et al., 2006; Litvak et 
al., 2009). The final class are lineage specific and their expression is induced during 
macrophage differentiation and include PU.1 (Spl1), C/EBPδ, runt-related transcription factor 
1 (RUNX1) and IRF8. They function to turn on constitutively expressed genes as well as 
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remodelling chromatin at inducible genes and silencing genes specific for other cell types. 
One view is that in mature macrophages they mediate cell specific responses to inflammation 
by maintaining a permissive chromatin state on macrophage specific genes (Medzhitov and 
Horng, 2009). 
 
The drive to understand the transcriptional regulation of the immune response and in 
particular the response to LPS has been most successful when performed using integrative 
approaches combining microarray analyses, quantitative polymerase chain reaction (qPCR) 
analyses of gene expression and promoter analyses with chromatin immunoprecipitation 
(ChIP) approaches (Nilsson et al., 2006). Such approaches have identified ATF3 as a major 
regulator of macrophage LPS stimulation alongside nuclear factor, erythroid derived 2, like 2  
(NRF-2) and v-ets erythroblastosis virus E26 oncogene homolog 2 (avian) (ETS-2) (Nilsson 
et al., 2006). In a systems biology approach that was applied to a timecourse of LPS response 
in mouse macrophages, a prominent group of genes, regulated by ATF3, were identified 
which acted as part of a transcriptional complex with NF-κB family factors. ATF3 inhibited 
Il-6 and Il-12b transcription by altering chromatin structure and restricting access to 
activating transcription factors and, because it was induced by LPS, was identified as a key 
regulatory of TLR-stimulated inflammatory responses as one component of a negative 
feedback loop in the macrophages (Gilchrist et al., 2006). Harnessing the power of high 
throughput sequencing technology to investigate transcription factor binding patterns and 
functions in ChIP-Seq has given insights into the transcriptional control of the LPS response 
in macrophages. ChIP-Seq studies have shown how cell lineage determining factors such as 
p300 and PU.1 define the overall context of the LPS response in macrophages by  organising 
the transcriptional regulatory system at enhancer regions within the genome (Ghisletti et al., 
2010; Heinz et al., 2010; Natoli et al., 2011). ChIP-Seq studies have identified important 
major regulatory factors in the LPS response such as B-cell lymphoma 6 protein (Bcl-6)  
(Barish et al., 2010) as well as factors with more subtle modulatory effects such as the JmjC 
family histone demethylase, Jmjd3 (De Santa et al., 2009). 
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1.10 Genome technologies as tools for investigating gene function in the 
Crgn model 
The laboratory rat has been used for over 150 years to investigate the basis of human 
physiology and disease and the genomic and gene targeting resources available in the rat in 
combination with human genetic studies are continuing to provide the basis for identifying 
disease genes and understanding disease pathophysiology (Jacob, 1999; Aitman et al., 2008; 
Jacob et al., 2010; Aitman et al., 2011). New genome technologies and resources have 
consistently been applied to aid the identification of genes and pathways underlying disease 
phenotypes (Aitman et al., 2008). Such resources include the rat genome sequence published 
in 2004 (Gibbs et al., 2004) and the application of gene expression technologies such as 
microarrays to identify expression QTLs (eQTLs) and quantitative trait transcript (QTT) 
analyses (Petretto et al., 2006; Monti et al., 2008; Petretto et al., 2008). More recently 
advances in high throughput sequencing technology have allowed the sequencing of multiple 
genomes from rat disease models (Atanur et al., 2010) whilst advances in modern systems 
genetics approaches to identify an IRF7-driven inflammatory network which was regulated 
by a trans-acting locus in macrophages in the rats, that was also shown to play a role in the 
pathogenesis of type 1 diabetes in humans (Heinig et al., 2010). In addition the advance in 
technology that has enabled the use of zinc finger nucleases to create knockout rats (Geurts et 
al., 2009; Moreno et al., 2011) along with the ability to establish and culture embryonic and 
pluripotent stem cells has increased the opportunities for using the rat as an important 
research model (Jacob et al., 2010). 
 
1.10.1      High throughput sequencing technology 
The advent of high throughput sequencing technologies has revolutionised the way genomic 
experiments can be analysed, primarily because genome wide analyses can be performed 
with the vast volumes of data generated by each instrument run. (Bentley et al., 2008; Mardis, 
2008; Metzker, 2010). The ability to sequence the whole genome has enabled large scale 
comparative and evolutionary studies to be performed including sequencing laboratory rat 
strains such as the spontaneously hypertensive rat genome (Atanur et al., 2010), genomes 
from 17 inbred strains of laboratory mice (Keane et al., 2011), the domestic cow Bos Taurus 
(Zimin et al., 2009) and the giant panda genome (Li et al., 2010) to large scale human 
projects such as the 1000 Genomes Project which aims to discover and genotype all forms of 
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human DNA polymorphisms in multiple human populations using high throughput 
sequencing technologies (The 1000 Genomes Project Consortium, 2010). The technology has 
changed the way rare and common human disorders can be investigated enabling whole 
exome sequencing to be used for the identification of causal variants in Mendelian disease as 
well as enabling the entire sequence of cancer genomes, as in chronic lymphocytic leukaemia 
to be analysed, identifying key mutations that lead to its development (Ng et al., 2009; Ng et 
al., 2010a; Ng et al., 2010b; Puente et al., 2011). The technologies are also being widely 
applied and changing the fields of epigenetics to allow for the analysis of whole genome 
binding profiles of transcription factors and histones to global methylation patterns and the 
analysis of whole transcriptomes with the advances seen in RNA sequencing (Park, 2009; 
Laird, 2010; Ozsolak and Milos, 2011). 
 
1.10.1.1 Chromatin immunoprecipitation (ChIP) coupled with high throughput 
sequencing technology (ChIP-Seq) 
Analysis of the DNA libraries generated by chromatin immunoprecipitation experiments 
(ChIP) using high throughput sequencing (ChIP-Seq) was one of the first applications to 
harness this advance in technology (Barski et al., 2007; Johnson et al., 2007; Robertson et al., 
2007). ChIP is a technique to enrich for the parts of the genome where a protein of interest 
has bound using formaldehyde to cross-link it to the chromatin followed by 
immunoprecipitation with specific antibodies of interest (Solomon et al., 1988). As detailed 
in Figure 1.4, the initial process within ChIP is to fix the transcription factor of interest onto 
the chromatin with formaldehyde. After cell lysis the isolated chromatin is sheared into 
fragments of between 200 and 700 base pairs in size. Incubation with an antibody specific to 
the protein of interest is then carried out, usually overnight, along with a negative IgG control 
antibody that does not bind any specific proteins. The antibody DNA fragments are purified 
from the samples using protein G coated magnetic beads. The samples undergo reverse cross 
linking to remove any bound protein to the DNA along with a further control of ‘input’ 
chromatin which is chromatin not subjected to any immunoprecipitation. After clean up 
processing the enriched DNA can be used in a number of applications including PCR and 
qPCR, hybridisation on to a microarray that contains probes for known promoters or 
enhancers in ChIP-Chip (Blat and Kleckner, 1999; Ren et al., 2000) and preparation for 
whole genome sequencing in ChIP-Seq to capture the genome wide binding profile for the 
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transcription factor. ChIP-Seq has higher resolution, fewer artifacts, greater coverage and a 
larger dynamic range than analysis with microarrays (Park, 2009).  
 
1.10.2      Transcriptome analysis using microarrays and RNA-Seq 
Gene expression profiling is a powerful tool for investigating the changes in expression of 
large numbers of genes in a single experiment compared to candidate gene approaches. Such 
an approach is clearly useful when examining the influence of a QTL such as Crgn2 in 
congenic rat strains as a candidate gene approach is inherently biased to the limited set of 
genes investigated and would be unlikely to identify the full scope of effect of the genomic 
regions. The major method for gene expression profiling that has been used over the past 
decade has been array based where spots of oligonucleotide probes are placed on a slide to 
which cDNA is hybridised and its quantity determined to detected the relative abundance of 
mRNA in the cells. Microarrays are a hybridization-based technology that rely on the binding 
of oligonucleotides together using Watson-Crick base pairing and are limited in the fact that 
only known transcripts and genes are placed on the array and have a limited dynamic range of 
detection. Full eukaryote genome arrays were used first in 1997 by Lashkari et al  (Lashkari 
et al., 1997). Affymetrix arrays use a photolithographic process to spot tens of thousands of 
oligonucleotide probes, 25 base pairs in length, onto an array to allow a quantitative 
assessment of RNA abundance to be made (Pease et al., 1994; Lockhart et al., 1996). More 
recently, high throughput sequencing technology has altered the ability to investigate the 
transcriptome, by the use of massively parallel cDNA sequencing or RNA-Seq (Ozsolak and 
Milos, 2011). This technology is extending the ability to map transcriptional start sites and 
splice sites, perform stand-specific measurements, detect gene fusion events and characterise 
small noncoding RNAs (Ozsolak and Milos, 2011). As with any emerging technology there 
are limitations that arise from the need to amplify and manipulate the RNA to enable the 
sequencing and this is a particular issue for short-lived transcripts. This means that whilst the 
technology is effective for qualitative applications, quantitative analysis still requires further 
advances (Ozsolak and Milos, 2011). 
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Figure 1.4 Chromatin immunoprecipitation  
Flow chart and diagram describing the main steps contained within the chromatin 
immunoprecipitation workflow. This figure was adapted from Farnham PJ, Insights from 
genomic profiling of transcription factors, Nature Review Genetics 2009 (Farnham, 2009) 
and Mardis ER, ChIP-seq: welcome to the new frontier, Nature Methods, 2007 (Mardis, 
2007) 
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1.10.3      RNA interference as a tool in genomic research 
RNA interference (RNAi) describes the process where double stranded RNA (dsRNA), 
homologous to a target, activates an enzymatic mechanism leading to specific silencing of a 
target mRNA (Fire et al., 1998). The process has transformed the understanding of 
mechanisms that underlie gene regulation in cells and has made RNAi an essential tool in 
biological research for manipulating gene expression (Hull and Aitman, 2012). The 
mechanism of RNAi consists of two major steps; first the dsRNA is processed by the Dicer 
enzyme into a 22 nucleotide long siRNA. This guide siRNA is incorporated into a nuclease 
complex, the RNA-induced silencing complex (RISC) which targets single-stranded mRNAs 
for degradation that are homologous to the guide siRNA. Whilst the original research used 
pure double stranded RNA to achieve RNAi, further advances soon led to its application as a 
research tool. RNAi was achieved using synthetic siRNAs uncoupling the process from any 
dsRNA-processing step and showed that siRNA (Elbashir et al., 2001b) and its application to 
mammalian cells using 21-nucleotide siRNAs was the other major advance that opened the 
way for siRNA as a tool for the specific regulation of gene expression in functional genomics 
(Caplen et al., 2001; Elbashir et al., 2001a). Genome wide screens using RNAi have become 
increasingly employed as effective tools for genome-scale and high throughput analysis of 
gene function giving important insights into biological function identifying novel oncogenes 
and potential targets for the development of therapeutic treatments (Echeverri and Perrimon, 
2006; Mohr et al., 2010).  
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1.11 Aims of the PhD project 
The results presented in this thesis aim to investigate the mechanisms underlying the 
regulation of macrophage activation and glomerular inflammation by JunD in both the NTN-
susceptible WKY rat strain and in human patients with Crgn. The results of investigations in 
the disease model describe a number of genomics based approaches including microarray 
analyses of macrophage transcriptomes and ChIP-Seq to investigate the genome wide pattern 
of JunD binding. In addition, the thesis contains the results of histological techniques that 
were used to investigate JunD and AP-1 transcription factor expression in the kidney in both 
the rat disease model and in human tissue as well as a candidate gene association study of the 
JUND locus in patients with Crgn that investigated the association of genetic polymorphisms 
with disease susceptibility. 
 
The main objectives of the project were: 
  
1. To increase understanding of the role of JunD, as part of AP-1 transcription factor, in 
the pathogenesis of renal disease focusing on increasing our understanding of the 
mechanisms underlying JunD-mediated activation of macrophages. 
 
2. To identify the key genes and pathways underlying JunD-mediated activation of 
macrophages by utilising state-of-the-art genomic technologies including the 
combined use of high throughput sequencing with genome-wide expression analysis. 
 
3. To identify whether genetic variation at the JUND and other AP-1 member loci in 
patients with renal disease is linked with susceptibility to glomerular disease 
 
Chapter 3 and Chapter 4 describe the investigations carried out on the transcriptome of 
BMDMs from the parental WKY and LEW strains and the WKY.LCrgn2 congenic strain. A 
major dataset was generated from the microarray analysis of cDNA obtained during an LPS 
stimulation timecourse performed in BMDMs that were cultured simultaneously from four 
individual biological replicates for each of the WKY, LEW and WKY.LCrgn2 strains. This 
large scale experiment allowed for a number of aspects of the LPS response in NTN model 
related BMDMs to be investigated. The results of the analysis of the transcriptome 
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differences between BMDMs from the NTN-susceptible WKY strain compared to the NTN-
resistant LEW strain in the dataset are detailed in Chapter 3. This chapter discusses the 
implications that differences in gene expression found between the parental rat strains have 
for macrophage behaviour in the NTN model and for the identification of candidate genes 
underlying the Crgn3-7 QTLs. Chapter 4 leads directly on from the investigations between 
WKY and LEW BMDMs and describes the more focused analysis into the effect of the 
Crgn2 locus on the WKY transcriptome giving inferences to the function of the different 
expression levels of JunD in macrophage activation and the NTN model. Results are 
presented of the differences found in gene expression between WKY and WKY.LCrgn2 
BMDMs following LPS stimulation and the effector molecules and pathways that Jund could 
influence in the macrophage LPS response and in the NTN model. In addition, the chapter 
contains the results from microarray analysis of siRNA knockdown of Jund in basal and LPS 
stimulated BMDMs detailing therefore the direct effects that acute alterations in Jund 
expression have on the macrophage transcriptome. 
 
Chapter 5 details the investigation into the genome wide binding pattern of JunD performed 
using ChIP-Seq. ChIP-Seq for JunD was performed on the JunD enriched chromatin obtained 
from basal and LPS stimulated BMDMs of the WKY and WKY.LCrgn2 strains. This chapter 
presents data detailing the pattern of JunD binding in WKY macrophages and the effect that a 
genetically mediated reduction in expression has on this profile in WKY.LCrgn2 BMDMs 
and gives mechanistic insights into how the altered levels of JunD expression can result in the 
gene expression differences detailed in Chapters 3 and 4. The experimental plan is 
summarised in Figure 1.5. 
 
Chapter 6 details the translational work performed in this PhD project. Histological 
investigations were performed in kidney sections from the rat NTN model and human 
patients with severe inflammatory glomerulonephritis to investigate the role of JunD and AP-
1 transcription factor in disease. In addition the chapter details the results of a tagging SNP 
study performed in human patients with Crgn to investigate whether genetic variation at the 
JUND locus is associated with susceptibility to developing Crgn. 
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Chapter 7 consists of the final general discussion chapter for the thesis. It brings together the 
major themes of the work and summarises the important findings from all the data chapters as 
well as the recommendations for future work related to the project. 
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Figure 1.5 Summary of experimental workflow 
The top panel illustrates the LPS timecourse, the timepoints used and the samples used for 
each of the gene expression analysis, ChIP-Seq and siRNA knockdown experiments. The 
lower flow chart illustrates the main analysis methods and aims used for the identification of 
the genes and pathways underlying the JunD-mediated activation of macrophages.  
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Chapter 2. Materials and Methods 
2.1 Stock Solutions 
 
5% pepsin A  (433U/Mg; Sigma) diluted at 0.5g per 100ml in 1M HCL 
EDTA 0.2 M ethylenediaminotetraacetic acid (Sigma-Aldrich), pH 
8.0 
Levamisole 12.04mg dissolved in 10ml dH2O to give 5mmol/L 
Lysis buffer 25ml 0.1M EDTA (Sigma-Aldrich), 50ml 1M tris 
aminomethane hydrochloride (Sigma-Aldrich), 10ml 10% 
SDS, 20 5M NaCl in 395ml distilled water  
 
ChIP-Seq loading buffer  
 
50mM Tris pH 8.0, 40mM EDTA, 40% (w/v) sucrose)   
NBT/BCIP Detection solution for alkaline phosphatase. Nitroblue 
tetrazolium chloride and 5-bromo-4-chloro-3-indolyl 
phosphate (NBT/BCIP); 1 tablet in 10 ml RNase free water 
 
Orange G 2.5g of Ficoll 400, 0.25g Orange G made up to 10ml in H2O 
Poly dI-dC For stock solution: dissolve powder in 1428μl of dH2O, 0.5 
micrograms per ml of buffer SWH buffer1 used. 
SWH buffer 1 10mM HEPES (Sigma-Aldrich), 40mM NaCl (Sigma-
Aldrich), 10mM MgCL2 (Sigma-Aldrich), 1mM 
Dithiothreitol (DTT, Sigma-Aldrich), 1mM EDTA (Sigma-
Aldrich) and 0.25% BSA, pH7.4 
 
SWH buffer 2 10mM HEPES (Sigma-Aldrich), 40mM NaCl (Sigma-
Aldrich), 1mM DTT (Sigma-Aldrich), 10mM EDTA (Sigma-
Aldrich) and 0.25% BSA, pH 7.4 
 
SWH washing buffer 0.03% Tween20, 0.1M Maleic acid (Sigma-Aldrich), 0.15M 
NaCl, pH 7.5 
SWH blocking 0.01% 20x standard saline citrate (SSC),solution  10% 
sodium dodecyl sulphate (SDS) solution 
SWH buffer 3  0.1M Tris-HCL (Sigma-Aldrich), 0.1M NaCl (Sigma-
Aldrich) and 50mM MgCl2, pH 9.5 
 
TE buffer  10mM Tris and 1mM EDTA, pH8.0 
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2.2 Origin of rats used in experimental procedures and generation of 
congenic lines 
2.2.1      Rats 
Wistar-Kyoto (WKY/NCrl, designated as WKY) and Lewis (LEW/Crl, designated as LEW) 
rats were purchased from Charles River (UK). All procedures were performed in accordance 
with the United Kingdom Animals (Scientific Procedures) Act. 
 
2.2.2      Generation of congenic rat lines 
Congenic lines to investigate the effect of the QTL on chromosome 16 are a genomic 
resource generated as previously described (Behmoaras et al., 2008). Single congenic strains 
were generated by introgressing the QTL from chromosome 16 (Crgn2) from a Lewis donor 
onto a WKY recipient genome and vice versa. To achieve this, a backcross of (WKY_LEW) 
F1 rats to WKY and Lewis parental strains was carried out for nine generations. Rats 
heterozygous for the chromosome 16 linkage region were brother-sister mated to fix the 
congenic interval and obtain the congenic lines. The resulting strains were designated 
WKY.LCrgn2 for strains with a WKY background. 
 
2.3 Source of human DNA and biopsy material for investigation 
2.3.1      DNA for human sequencing and genotyping experiments 
DNA from French patients with confirmed diagnosis of vasculitis and Anti-neutrophil 
cytoplasmic antibody (ANCA) positivity and controls were provided by Dr Luis Teixeira, 
Cochin Hospital, Paris, France. 
 
DNA from UK patients with vasculitis from the MRC/Kidney Research UK 
Glomerulonephritis DNA Bank (MRCGN) cohort, which consists of patients aged 18 to70 
years with histological evidence of necrotising glomerulonephritis with crescent formation 
and the presence of ANCA in the circulation, were provided in a collaboration with Professor 
Timothy Vyse, Immunogenetics, Department of Medical and Molecular Genetics, King’s 
College, London. The control samples used were from the Panel 1 of UK Blood Services 
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collection of common controls, obtained under an MTA from the University of Cambridge by 
Professor Tim Aitman. 
 
2.3.2      Histological material for human biopsy project 
Ethical approval for the human biopsy project was obtained from the St Mary’s Hospital 
Research Ethics Committee (Reference number: 09/H0712/15) by Dr Richard Hull and 
Professor T Cook. Patient samples were identified from the existing collection of diagnostic 
samples held by Professor T Cook of the Department of Pathology at Hammersmith Hospital. 
 
2.4 Rat bone marrow-derived macrophage (BMDM) extraction and 
culture 
2.4.1      Extraction and differentiation of BMDMs 
BMDMs were prepared from the femurs of parental and congenic strains using previously 
described methods (Behmoaras et al., 2008) with some key modifications. For all 
applications, ‘full culture’ medium was used to differentiate bone marrow stem cells into 
BMDMs and consisted of DMEM and 2mM L-glutamine (Gibco, Invitrogen Ltd, Paisley, 
UK) and 25mM Hepes buffer (Sigma-Aldrich, Gillingham, UK), 25% L929 conditioned 
media, 25% decomplemented foetal bovine serum (F-539, M.B. Meldrum, Bourne End, UK), 
penicillin (100U/ml, Invitrogen) and streptomycin (100μg/ml, Invitrogen).  
 
Femurs were isolated from adult male rats aged 8-10 weeks of age. The femurs were stripped 
of all muscle tissue and washed twice in 100% ethanol. The ends of the femurs were cut off 
with bone scissors and 10ml of cold Hanks buffer flushed through each end of the femur into 
a 50ml falcon tube using a 20 gauge needle to extract the bone marrow. The samples were 
centrifuged at 4
0
C for 5 minutes at 1500 rpm and the supernatant discarded. The resulting cell 
pellets were resuspended in 10ml Hanks and the 50ml tubes incubated for 15 minutes in a 5% 
CO2 incubator to allow for the lysis of the red cells to occur. The cells were centrifuged at 
4
0
C for 5 minutes at 1500 rpm and the supernatant discarded prior to resuspension of the cell 
pellet in 1ml of full culture media. The cells were dispensed equally (250μl of resuspension) 
amongst 4 large (15cm) petri dishes (Sterilin, Newport, UK) prefilled with 30ml of full 
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culture media for chromatin immunoprecipitation (ChIP) and siRNA knockdown experiments 
and 50μl of cell resuspension in 6cm petri dishes (Nunc, Roskilde, Denmark) filled with 5ml 
full culture media for gene expression experiments. BMDMs were cultured for 4 days in a 
5% CO2 incubator at 37
0
C. The resulting cells were characterised as macrophages by ED-1 
(CD68) immunohistochemistry as per 2.16.1 (Figure 2.1). 
 
2.4.2      Stimulation of macrophages with lipopolysaccharide (LPS) 
On day 5 of BMDM culture, petri dishes were washed with cold Hanks solution and culture 
medium changed to fresh full culture medium supplemented with 100ng/ml LPS 
(lipopolysaccharides from Salmonella typhosa purified by gel-filtration chromatography, 
Sigma-Aldrich) for chromatin immunoprecipitation and gene expression studies. BMDMs 
were incubated for the desired time and then processed accordingly for the appropriate 
experiment. 
 
2.4.3      RNA isolation from BMDMs 
RNA was isolated from cultured BMDMs using TRIzol reagent (Invitrogen). To each 6cm 
petri or well of a 6 well culture plate, 1ml TRIzol reagent was added and TRIzol-lysed cell 
solution stored at -80
o
C prior to RNA extraction (see 2.6.1) 
 
2.4.4      siRNA knockdown of BMDMs 
2.4.4.1 siRNA details and preparation 
siRNA knockdown was carried out as previously described. (Behmoaras et al., 2008). The 
siRNA used was siGENOME SMARTpool, rat JUND (24518) M-092127-00-0010, 10nmol 
(Dharmacon, Lafayette, CO, USA) (Table 2.1) and the scrambled control siRNA was 
siGENOME Non-targeting siRNA Pool #1 D-001206-13-20, 20nmol (Dharmacon, Lafayette, 
CO, USA). siRNA was resuspended as per manufacturer’s instructions by adding RNase-free 
water to achieve a working concentration of 20nmol and then incubated at room temperature 
on an orbital mixer for 30 minutes. Aliquots were made to ensure minimisation of freeze 
thaw events on the siRNA. 
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Figure 2.1  Characterisation of bone marrow derived macrophage 
(BMDM) cultures 
Positive staining for ED-1/CD68 (a 100kDa transmembrane glycoprotein member of the 
lysosomal/endosomal-associated membrane glycoprotein (LAMP) family highly expressed 
by macrophages) in representative BMDM cultures from WKY (A), LEW (B) and 
WKY.LCrgn2 (C). Negative staining is demonstrated for the presence of T cells using both 
the marker OX-8/CD8alpha for all three strains; WKY (D), LEW (E) and WKY.LCrgn2 (F) 
and THY-1/CD90 for all strains WKY (G), LEW (H) and WKY.LCrgn2 (I). Negative 
antibody controls are demonstrated for each strain (J, K, L). 
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Table 2.1 Jund siRNA sequence of the four individual siRNAs that comprise 
siGENOME SMARTpool M-092127-00-0010 (Dharmacon). 
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2.4.4.2 BMDM preparation 
BMDMs were extracted and differentiated, as described in 2.4.1, in full culture medium for 4 
days. On day 4 the BMDMs were harvested and replated in 6 well culture plates (Nunc). 
Briefly, the 15cm petri dish was washed with 10ml cold Hank’s balanced salt solution 
(HBSS, Gibco, Invitrogen Ltd, Paisley, UK) then 12ml of non-enzymatic cell dissociation 
solution (Sigma-Aldrich) was added and the petri dish placed in the incubator for 30 minutes. 
The dish was removed and 5ml of full culture media added to the petri dish to stop the action 
of the dissociation solution and the plate was washed to dislodge the cells. The resulting cell 
suspension was transferred to a 50ml falcon tube and kept on ice until all cells were 
recovered from the remaining petri dishes. The cells were centrifuged at 1500rpm for 5 
minutes at 4
o
C. The supernatant was discarded and the cells resuspended in 1ml of complete 
media. 2ml of pre warmed full culture media was added into each well of the 6 well culture 
plates (Nunc). The cell concentration was counted using a haemocytometer and 1 million 
cells dispensed into each well. The plate was rocked gently back and forth to ensure even cell 
distribution.  
 
2.4.4.3 siRNA transfection protocol 
Transfections with siRNA were carried out as previously described (Behmoaras et al., 2008) 
and commenced on day 6 of culture. To prepare the transfection mixture, 2.64 ml Optimem 
(Invitrogen) was incubated with 60μl Dharmafect 1 (Dharmacon) for 5 minutes at room 
temperature. At the same time 240μl of Optimem was incubated with 60μl siRNA (20μM) for 
5 minutes at room temperature. The two preparations were then mixed and incubated at room 
temperature for 20 minutes with frequent mixing by tube inversion to allow the integration of 
siRNA particles into the liposomal particles contained within Dharmafect transfection 
reagent. Meanwhile the media in the 6 well culture plates was removed, the cells washed with 
DMEM and then 1.5ml DMEM only with no supplementation was added to each well as the 
presence of serum containing medium inhibits adequate transfection with siRNA (J. 
Behmoaras, Centre for Complement and Inflammation Research, Imperial College, personal 
communication). Five hundred microlitres of the transfection mixture was added to each well 
and mixed resulting in a final siRNA concentration of 100nM. The cells were incubated for 
48 hours in a 5% CO2 incubator at 37
o
C. On day 8 the cells were stimulated with LPS or kept 
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in the basal state and the supernatants collected and stored at -80
o
C and the cells 
homogenised using 1ml TRIzol reagent for future RNA extraction (see 2.4.1). 
 
2.4.5      BMDM fixation and harvest for chromatin immunoprecipitation (ChIP) 
BMDMs were stimulated with 100ng/ml LPS for two hours or kept in the basal state then 
proteins were cross-linked to DNA by fixation for 10 minutes using 0.54ml 37% 
formaldehyde (Sigma-Aldrich) in 20ml DMEM (Gibco). The fixation solution was removed 
and the fixed cells washed by adding 10ml ice-cold 1x phosphate-buffered saline (PBS, MRC 
Clinical Sciences Centre (MRC CSC) media kitchen) to each plate. The plates were rocked 
for 5 seconds and the PBS removed. The fixation reaction was topped by adding 10ml 
glycine stop-fix solution (1ml 10x glycine buffer (Active Motif) diluted with 9ml 1x PBS and 
incubating the cells at room temperature for 5 minutes. The cells were washed again in PBS 
as above. The cells were scraped from the plate using a rubber policeman in 10ml of cell 
scraping solution (10ml 1x PBS supplemented with 50μl at 100mM of the serine protease 
inhibitor phenylmethylsulfonyl fluoride (PMSF, Active Motif). The cells were transferred to 
a 50ml conical tube kept on ice and the cells pelleted by centrifugation for 10 minutes at 2500 
rpm at 4
o
C. The supernatant was discarded and 1μl 100mM PMSF and 1μl protease inhibitor 
cocktail (PIC, Active Motif) added to the cell pellet which was frozen at -80
o
C. 
 
2.5 DNA extraction and purification 
2.5.1      DNA extraction from rat tail biopsy 
DNA was extracted from rat tail biopsies for genotyping of the congenic rat strains. 
Proteinase K was diluted to a concentration of 0.1mg/ml by dissolving 50µl proteinase K in 
10ml lysis buffer. 0.75ml of this solution was added to each tail biopsy in a 1.5ml 
microcentrifuge tube and was incubated in a shaking water bath overnight at 55
0
C. Samples 
were removed and vortexed then centrifuged at 10,000rpm for 10 minutes. The supernatant 
from each sample was added to 750µl isopropanol in a clean microcentrifuge tube. The tube 
was inverted several times until DNA strands appeared. The DNA was removed with an 
inoculating loop and placed in 500µl TE buffer in a fresh microcentrifuge tube and left to 
resuspend overnight on a tube rotator. DNA was quantified using the NanoDrop prior to use 
(see  2.7.1). 
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2.5.2      Purification of amplified DNA products using G50 spin columns 
PCR products from human DNA samples were purified using G50 spin columns (RBC 
Bioscience, Rome, Italy) as per manufacturer’s instructions. The resin in the columns was 
resuspended in the column by vortexing. The cap was loosened ¼ turn and the column placed 
in a collection tube. Columns were centrifuged for 1 minute at 3000 rpm and the cap then 
removed. The column was transferred to a clean collection tube. The sample was applied to 
the centre of the resin bed without disturbing the resin and the column spun for 2 minutes at 
3000 rpm. The purified sample was quantified using NanoDrop™ spectrophotometer 
(Thermo Scientific, Wilmington, DE, USA) (see 2.7.1) prior to Sanger sequencing of the 
sample (see 2.13.1). 
 
2.5.3      Purification of DNA products using QIAquick spin columns 
QIAquick PCR purification kits (Qiagen, Crawley, West Sussex, UK) and MinElute PCR 
purification kits (Qiagen, Crawley, West Sussex, UK) were used to purify single or double 
stranded DNA fragments from PCR and other enzymatic reactions as per manufacturer’s 
instructions with some modifications. The key difference between the two purification 
methods is the volume that the desired product was eluted in. For the MinElute protocol this 
was 15μl and for the QIAquick kit this was 50μl of elution buffer (EB), Qiagen). The 
protocol followed was otherwise the same. 
 
Prior to commencing the protocols, 100% ethanol was added to buffer PE (Qiagen). Five 
volumes of buffer PB were added to each volume of the DNA product (e.g. 1000μl added to 
200μl of DNA product) and mixed by pipetting. The sample was applied to the column and 
centrifuged for 1 minute at 17,900xg (13,000 rpm). The flow-through was reapplied to the 
column which was centrifuged for a further 1 minute at 17,900xg (13,000 rpm). The flow-
through was discarded and 750μl of buffer PE applied and the column centrifuged for 1 min 
at 17,900xg (13,000 rpm). The flow-through was discarded and the column replaced in the 
collection tube and spun ‘dry’ for a further 1 minute at maximum speed. The column was 
then transferred to a clean 1.5ml TubeOne microcentrifuge tube (Starlab, Milton Keynes, 
UK). To elute DNA, the required volume of buffer EB heated to 55
o
C was added to the 
column which was left to stand for 2 minutes prior to centrifugation at 17,900xg (13,000 
rpm) for 1 minute. 
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2.5.4      Purification of amplified DNA products using QIAquick vacuum plates 
PCR products amplified in 96 well plates were purified using QIAquick vacuum plates 
(Qiagen, Crawley, West Sussex, UK) and a vacuum manifold as per manufacturer’s 
instructions. The PCR products were added to the purification plate wells and the vacuum 
machine turned on to a pressure of 600kPa for 10 minutes. After 10 minutes, the machine was 
switched off and the pressure in the system allowed to fall to atmospheric pressure. Fifty 
microliters of RNase free water was added to each well and the vacuum applied at the same 
pressure for 10 minutes. The base of the plate was dried then 30µl RNase free water was 
applied to each well and the plate covered with an adhesive PCR lid. The plate was then 
shaken on a vortex with a polystyrene plate holder for 5 minutes. The resulting purified 
product was removed from the plate and placed in a clean storage plate prior to quantification 
using a NanoDrop™ spectrophotometer (see 2.7.1) and preparation for Sanger sequencing 
(see 2.13.1). 
 
2.5.5      Purification of DNA products from agarose gels 
QIAquick gel extraction kits (Qiagen) were used to extract and purify DNA from agarose 
gels in Tris-acetate-EDTA (TAE) buffer. Prior to commencing this protocol, 100% ethanol 
was added to buffer PE as per bottle instructions. The excised gel slice containing the DNA 
fragments to be purified was weighed in a colourless tube. As 2% agarose gels were used for 
ChIP-Seq applications (see 2.10.4), 6 volumes of buffer QG (Qiagen) were added to one 
volume of gel (where 100mg gel approximates to 100μl volume). The sample was incubated 
at room temperature until the gel slice was completely dissolved aided by occasional mixing 
by vortexing as opposed to using the protocol temperature of 50
o
C in order to minimise any 
dissociation of double-stranded DNA fragments and biases that may arise from re-annealing 
of GC rich fragments. After the gel slice had dissolved, 1 gel volume of isopropanol was 
added to increase the yield of DNA fragments <500bp. To bind DNA, the sample was applied 
to the QIAquick column and centrifuged at 17,900xg (13,000 rpm) for 1 minute. The flow-
through was reapplied to the QIAquick column and centrifuged again at 17,900xg (13,000 
rpm) for 1 minute. The flow-through was discarded and 0.5ml of buffer QG applied to the 
column which was centrifuged at 17,900xg (13,000 rpm) for 1 minute to remove all traces of 
agarose. The column was washed by adding 750μl of buffer PE (Qiagen) and centrifuging the 
column at 17,900xg (13,000 rpm) for 1 minute. The flow-through was discarded and the 
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column replaced in the collection tube and spun ‘dry’ for a further 1 minute at 17,900xg. The 
column was then transferred to a clean 1.5ml microcentrifuge tube. To elute DNA (13,000 
rpm), the required volume of buffer EB (Qiagen) heated to 55
o
C was added to the column 
which was left to stand for 2 minutes prior to centrifugation at 17,900xg (13,000 rpm) for 1 
minute. 
 
2.6 RNA preparation and purification 
2.6.1      RNA extraction by the TRIzol method 
Total RNA was extracted from BMDMs using TRIzol. Phase separation of the sample was 
performed by adding 0.2ml of chloroform (Sigma-Aldrich) per sample. The microcentrifuge 
tube was shaken manually by inverting for 15 seconds and incubated at room temperature for 
3 minutes. The samples were centrifuged at 14,000rpm for 15 minutes at 4
o
C. This separated 
the mixture into a lower red phenol-chloroform phase, an interphase containing DNA and 
protein and an upper colourless aqueous phase containing RNA. The expected volume of this 
was 50% of the volume of TRIzol used (400-500μl). RNA was precipitated by carefully 
transferring only the aqueous phase to a fresh microcentrifuge tube and adding 0.5ml of 
isopropyl alcohol (Sigma-Aldrich). After mixing, the samples were incubated overnight at      
-20
o
C then centrifuged at 14000 rpm for 10 minutes at 4
o
C which resulted in the formation of 
an RNA pellet at the bottom of the tube. The supernatant was discarded and the pellet washed 
with 1ml 75% ethanol (Sigma-Aldrich). Following manual mixing of the sample, it was 
centrifuged at 14,000 rpm for 5 minutes at 4
o
C. The supernatant was removed and the RNA-
pellet air dried for 20 min. The pellet was resuspended in 40μl of RNase-free water (Sigma-
Aldrich) and either stored at -80
o
C following incubation at 65°C for 10 minutes and 
quantification on the NanoDrop™ spectrophotometer (see 2.7.1) or taken through further 
clean-up for microarray, cDNA synthesis and q-RT PCR applications.  
 
2.6.2      RNA sample clean-up with genomic DNA removal columns 
RNA sample clean-up was performed using RNeasy Plus columns (Qiagen). Prior to starting, 
the RLT PLUS buffer (Qiagen) was prepared by adding 10μl beta-mercaptoethanol (β-ME) 
(Sigma-Aldrich) per 1ml Buffer RLT Plus needed and 100% ethanol was added to the RPE 
buffer (Qiagen) as per manufacturer’s instructions. 
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The RNA sample volume was adjusted to 100µl with RNase-free H2O. 350µl of prepared 
RLT PLUS buffer was added to the RNA and mixed by pipetting. The solution was 
transferred to a genomic DNA removal column and spun at 10,000g for 1 minute. Two 
hundred and fifty microliters of 100% ethanol (Sigma-Aldrich) was added to the flow-
through and mixed by pipetting and then transferred to an RNeasy mini spin column with 
collection tube and centrifuged at 10,000g for 30 seconds. The flow-through was transferred 
back into the spin column and centrifuged again at 10,000g for 30 seconds. The flow through 
was then discarded, the collection tube replaced and 700µl RW1 buffer (Qiagen) added to the 
sample and the column was centrifuged at 10,000g for 30 seconds. The flow-through was 
discarded and the collection tube replaced. 500µl RPE buffer was added to the sample and 
the column centrifuged at 10,000g for 30 seconds. The flow-through was discarded and a 
further 500µl RPE buffer added to the column which was then centrifuged for 2 minutes at 
10,000g. The flow-through was again discarded and the collection tube replaced before the 
sample was centrifuged ‘dry’ at full speed for 1 minute. At this point the spin column was 
transferred to a fresh 1.5ml microcentrifuge tube. 30µl of RNase-free H2O was added 
carefully to the spin column membrane and the samples heated at 55
o
C for 2 minutes. The 
spin column was then centrifuged at 10,000g for 1 minute. The RNA concentration in the 
sample was then quantified using a NanoDrop™ spectrophotometer (see 2.7.1). 
 
2.7 Quantification and quality assessments of DNA and RNA 
2.7.1      NanoDrop™ spectrophotometer 
For routine measurement of nucleic acid concentrations, the Thermo Scientific NanoDrop™ 
ND-1000 spectrophotometer (Thermo-Scientific, Wilmington, DE USA) was used as per 
manufacturer’s instructions. After initialisation and before any measurements were made, a 
blanking cycle was performed using the appropriate solvent in which the nucleic acid sample 
was dissolved (e.g. RNase free dH2O or Qiagen buffer EB). 1.5μl of DNA or RNA was 
loaded onto the sample pedestal and the concentration (in ng/µl) obtained as well as the 
260:280 absorption ratio. For DNA a 260:280 ratio of ~1.8 indicated sufficiently purified 
DNA and for RNA, a 260:280 ratio of ~2.0 indicated sufficiently purified RNA. 
82 
 
2.7.2      Quant-iT™ assay using Qubit™ fluorometer 
The Quant-iT
 
assay was used to assess the concentration of double stranded DNA (dsDNA) 
for high throughput sequencing applications. Compared to the NanoDrop, the Quant-iT assay 
uses a dye based method that only binds to dsDNA to allow more accurate measurement of 
nucleic acid concentration. Due to the nature of the ChIP protocol, the Quant-iT was used to 
better assess sample and library concentration due to the possible presence of residual protein 
from the ChIP protocol.  
 
The assay was used according to manufacturer’s instructions. The Quant-iT working solution 
was made by diluting the Quant-iT
 
reagent 1:200 in Quant-iT
™ buffer. 200μl of this working 
solution was needed for each sample and standard. Standards were used for each 
measurement session. The standard assays were made by adding 190μl of working solution to 
10μl of the kit Standard (1 and 2). Samples to be assessed were made by adding 199μl of 
working solution to 1μl of sample for a total volume of 200μl. The volume of sample could 
be varied and increased if at low concentration maintaining the total volume of 200μl. Only 
specific thin-wall, clear 0.5ml Qubit assay tubes (Invitrogen) were used. Following sample 
preparation, the tubes were vortexed for 3 seconds and incubated at room temperature for 2 
minutes. The tubes were read in the Qubit fluorometer and the concentration of sample 
obtained. 
 
2.7.3      Assessment of chromatin library for ChIP-Seq library preparation 
DNA was assessed for fragment size at the end of the sample preparation for ChIP-Seq using 
the High Sensitivity DNA assay and LabChip
™ 
(Santa Clara, CA, USA). Prior to starting the 
protocol, the High Sensitivity reagents were left to equilibrate at room temperature for 30 
minutes and the electrodes washed according to the MRC CSC Genomics Laboratory 
instructions. The Gel-dye mix was prepared by vortexing the blue-capped High Sensitivity 
DNA dye concentrate for 10 seconds and adding 15μl of it to the High Sensitivity DNA gel 
matrix vial. The tube was vortexed for 10 seconds then the gel-dye mix was transferred to the 
top receptacle of a spin filter and centrifuged for 10 minutes at 2240g. The filter was 
discarded and 40μl aliquots of gel-dye mix made. The Chip Priming station was set with the 
base plate at position C and the syringe clip at its lowest point. 9μl of the gel dye mixed was 
pipetted into a marked well. After ensuring the syringe plunger was at 1ml the Chip Priming 
83 
 
Station was closed and the plunger pushed down so that it was held by the syringe clip for 1 
minute. Following its release, 9μl of gel-dye mix was pipetted into the other three marked 
wells and then 5μl of HS DNA marker was then pipetted into the ladder well and each of the 
11 sample wells. 1μl of ladder was placed into the ladder marked well and 1μl of sample 
pipetted into its assigned well. If fewer than 11 samples were run then 1μl of additional 
marker was added into the empty wells. The chip was placed in the adapter of a vortex mixer 
and shaken for 1 minute exactly at a previously determined ‘set’ point. The chip was inserted 
into the Bioanalyzer and the ‘High Sensitivity DNA’ program was run. 
 
2.7.4      Assessment of RNA quality and purity for microarray 
RNA was assessed for quality and genomic DNA contamination prior to its preparation for 
analysis on microarrays using the Agilent Bioanalyzer and RNA 6000 LabChip
™
 according 
to manufacturer’s instructions with some modifications made by the MRC CSC Genomics 
Laboratory. Prior to starting the protocol, the RNA Nano reagents were allowed to equilibrate 
to room temperature for 30 minutes. The Agilent Bioanalyzer electrodes were 
decontaminated according to the MRC CSC Genomics Laboratory instructions. Gel matrix 
mix was made by pipetting 550μl of RNA gel matrix into top of spin filter provided. It was 
centrifuged at 1500g for 10 minutes and 65μl aliquots made and stored at 4oC. A gel-dye mix 
was also prepared by vortexing the RNA dye concentrate for 10 seconds. 1μl of RNA dye 
concentrate was added to the 65μl aliquot of filtered gel. Following thorough vortexing, the 
tube was centrifuged for 10 minutes at room temperature at 13000g. RNA was used at a 
concentration between 25-500ng/µl. The samples were denatured along with a 1.2μl aliquot 
of RNA 6000 ladder by incubating them at 70
o
C for 2 minutes and then kept on ice. The Chip 
priming station was set at base place position C with the syringe clip at the topmost position. 
9μl of the gel-dye mix was pipetted into the bottom of the well-marked with a G on a dark 
background. The chip was placed in the priming station and the syringe pushed down from 
1ml until it was held by the syringe clip for 30 seconds. Following its release the plunger 
moved back to the 1ml position. 9μl of the gel-dye mix was then pipetted into the 2 
remaining wells marked G. 5μl of the RNA 6000 Nano marker was pipetted into the 13 
remaining empty wells including the ladder marked well. 1μl of the denatured RNA 6000 
ladder was pipetted into the ladder marked well. 1μl of each sample was then pipetted into its 
assigned well. When less than 12 samples were run, an extra 1μl of the RNA 6000 Nano 
marker was used instead. The chip was placed in the adapter of a vortex mixer and shaken for 
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1 minute exactly at a previously determined ‘set’ point. The ChIP was then placed into the 
Bioanalyzer and the Eukaryote Total RNA Nano Series II programme run. Figure 2.2 
demonstrates typical outputs from the quality control of microarray samples. 
 
2.8 Microarray sample preparation 
Two different whole transcript labelling assays were used in this project, 2.8.1 and 2.8.4 
reflecting the development and improvements that commonly occur with genome 
technologies. The basic principles of both kits are identical, differing only in the enzymes and 
primers used. The work flow schematic for the protocols is detailed in Figure 2.3. The 
preliminary microarray work investigating an early LPS timepoint used the whole transcript 
labelling assay from Affymetrix, the GeneChip WT cDNA Synthesis and Amplification Kit 
(Affymetrix, High Wycombe, UK) which was carried out as per the protocol instructions 
from Affymetrix with some modifications made by the MRC CSC Genomics Laboratory. 
This kit was phased out during the timecourse of the project and replaced with the Ambion 
WT Expression Kit (Ambion, Austin, Tx, USA). This newer Ambion product uses the same 
basic chemistry as the Affymetrix WT Expression protocol but there were significant 
improvements in both the sample processing workflow and, critically, the technology 
improvements in primer design and enzyme quality led to a better signal to noise ratio 
(Figure 2.4) allowing for better identification of differentially expressed genes (Ambion WT 
Expression Kit Product Bulletin ABI, 2011). Whilst the mean background was relatively 
similar in each case, the positive matched probe signal was significantly higher with the 
newer methodology. The signal histogram profile also demonstrates this finding showing the 
frequency of signals across the spectrum of expression values resulting in more transcripts 
passing our threshold for expression (Figure 2.5). This substantial signal to noise 
improvement was substantial allowing for the detection of differentially expressed genes 
between WKY and WKY.LCrgn2 BMDMs (see Chapter 4) and enhanced the analysis of the 
WKY and LEW BMDMs transcriptomes (see Chapter 3). 
 
The Ambion labelling process was carried out as per manufacturer’s instructions and as the 
first primary user with the MRC CSC Genomics Laboratory; I optimised and modified the 
protocol which was subsequently adopted by the centre. 100ng of quality assessed RNA was 
used per sample for the initial run with the Affymetrix GeneChip WT cDNA synthesis and  
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Figure 2.2 Agilent Bioanalyzer traces for 3 quality control (QC) stages of 
microarray sample preparation 
RNA prior to processing was first assessed for quality on the Agilent Bioanalyser (A). The 
18S and 28S peaks are visible with no DNA contamination and most small RNAs have been 
removed. A RIN score is automatically generated and serves as an objective measure of RNA 
quality (RIN= 8.70 in this example). Prior to fragmentation, the cDNA size range was 
assessed on the Bioanalyser (B) and compared to the post fragmentation trace (C) to ensure 
adequate fragmentation has occurred. The sample used, replicate one WKY basal BMDMs, is 
representative of the results obtained for all samples. 
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amplification Kit and for the first run using the Ambion WT Expression kit to analyse the 
timecourse experiment between WKY, WKY.LCrgn2 and LEW BMDMs. Following further 
protocol optimisation and work with Ambion technical support the input RNA amount was 
increased to 150ng for the siRNA microarray experiment. The microarrays used were 
GeneChip Rat Gene 1.0 ST Arrays. 
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Figure 2.3 Affymetrix WT expression protocol for microarray sample 
preparation 
This protocol details the individual steps followed to convert, amplify and label RNA in 
preparation for hybridization to rat Gene 1.0 ST arrays 
 
This figure was adapted from the Affymetrix GeneChip Whole Transcript (WT) Sense Target 
Labelling Assay Manual. 
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Figure 2.4 Mean perfect matched probe and background intensity 
comparison 
Mean matched probe and background intensity values from Affymetrix WT Sense Target 
Labeling Assay (A) and Ambion WT Expression kit (B) demonstrating the improved signal: 
noise ratio obtained with the Ambion kit. Background signal levels indicated by the blue line 
(bgnd_mean) are lower with the Affymetrix kit ranging from 163 to 246 compared to the 
Ambion kit which ranges from 305 to 440. The perfect matched probe mean level 
(pm_mean), indicated by the red line, is higher with a maximum mean intensity of 339 from 
the Affymetrix kit compared to a minimum of 710 and a maximum of 1114 with the Ambion 
kit. 
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Figure 2.5 Signal intensity plots comparing Affymetrix and Ambion labelling 
kits 
Signal intensity plots demonstrating the pattern of expression values obtained using 
Affymetrix WT Sense Target Labelling assay (A) and Ambion WT Expression Kit (B). The 
dotted line indicates the expression threshold cut off used in microarray analysis. 
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2.8.1      GeneChip WT cDNA synthesis and Amplification kit protocol 
All master mixes were prepared for at least 10 reactions to prevent pipetting small volumes 
and errors. Values given in the method below are 1x amounts. 100ng of quality assessed 
RNA was used per sample for the initial run with the Affymetrix GeneChip WT cDNA 
synthesis and Amplification Kit. 
 
2.8.1.1 First cycle: first strand cDNA synthesis 
Poly A controls provided by the Microarray centre were diluted by adding 2μl of the Poly A 
controls in 18μl of RNase free H2O (Affymetrix). A T7-(N)6 primer/Poly A master mix was 
prepared in 0.2ml RNase free tube by adding 0.2μl T7-(N)6 primer (2.5μg/µl), 0.1μl diluted 
Poly A Controls and 1.7μl RNase free H2O to give a volume of 2μl for a 1x mixture. For each 
reaction, 2μl of primer/Poly A mix was added to 100ng of Total RNA (maximum volume 
3μl) in a 0.2ml RNase free tube. The samples were mixed by vortexing and spun briefly as 
necessary. The reaction tubes were placed in a thermocycler and run with the following 
programme (with heated lid): 70°C for 5 minutes, 4°C for 2 minutes and held at 4°C. The 
samples were spun briefly and placed on ice. A second master mix was then prepared 
consisting of 2.0μl 5X First Strand Buffer,1.0μl (0.1M) DTT, 0.5μl (10mM) dNTP Mix, 0.5μl 
RNase Inhibitor and 1.0μl Superscript II for a total volume of 5μl for a 1x mixture. 5μl of the 
master mix was added to each of the reaction tubes which were mixed by pipetting and spin 
briefly. The tubes were placed in a thermocycler and run with the following programme (with 
heated lid): 25°C for 10 minutes, 42°C for 1 hour, 70°C for 10 minutes, 4°C for 2 minutes. 
The tubes were spun briefly and placed on ice and the first cycle: second strand cDNA 
synthesis step proceeded to immediately. 
 
2.8.1.2 First cycle: second strand cDNA synthesis 
A fresh dilution of 17.5mM MgCl2 was made each time. 2μl (1M) MgCl2 was diluted with 
112μl RNase free dH2O. The second strand cDNA synthesis master mix was prepared using 
4.8μl RNase free dH2O, 4.0μl diluted MgCl2 (17.5mM), 0.4μl dNTP mix (10mM), 0.6μl 
DNA polymerase I and 0.2μl RNase H for a total volume of 10.0μl for a 1x mixture. 10μl of 
this master mix was added to each reaction tube and after mixing and brief centrifugation 
they were incubated at 16
o
C in a thermocycler with the following programme: 16
o
C for 2 
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hours without the heated lid option then at 75°C in a thermocycler for 10 minutes with the 
heated lid option then 4°C for 2 minutes. The tubes were spun briefly and placed on ice then 
the cRNA synthesis step immediately commenced. 
 
2.8.1.3 cRNA synthesis 
In this step the samples were processed at room temperature to prevent precipitation of DNA. 
The 10xIVT buffer, IVT NTP mix and IVT enzyme mix (Affymetrix) were thawed at room 
temperature. Any precipitates in the IVT buffer were dissolved by heating the buffer at 37
o
C.  
A master mix was prepared using 5.0μl 10x IVT buffer, 20.0μl IVT NTP mix and 5.0μl IVT 
enzyme mix for a total volume of 20μl for a 1x mix. 30μl of this master mix was added to 
each sample and after mixing; the samples were incubated in thermocycler at 37
o
C for 16 
hours with the heated lid option then held at 4
o
C. The samples were spun briefly and spun on 
ice and clean-up of the cRNA immediately commenced. 
 
2.8.1.4 cRNA clean-up 
Prior to commencing the protocol, 20ml of 100% ethanol was added to the cRNA Wash 
Buffer (Affymetrix). All centrifugations were performed at maximum centrifuge speed 
(≥8000g and ≤25,000g) and the protocol was carried out at room temperature. 
 
Each sample (~50μl) was transferred to a 1.5ml RNase free tube and 50μl RNase free dH2O 
added. Then 350μl cRNA Binding Buffer was added to each sample which were mixed 
thoroughly by vortexing for 3 seconds. 250μl 100% ethanol was then added to each sample 
and mixed by pipetting. Each sample was applied to an IVT cRNA clean-up spin column 
(Affymetrix) and spun at maximum speed for 30 seconds. The spin columns were transferred 
to a fresh 2ml collection tube and 500μl of cRNA Wash Buffer was added then the columns 
spun at maximum speed for 30 seconds. The collection tubes were emptied and 500μl 80% 
ethanol added onto the spin columns. The columns were spun at maximum speed for 15 
seconds and emptied. The caps of the spin columns were cut off at this point and the columns 
then centrifuged at maximum speed for 5 minutes to completely dry the membrane. The spin 
columns were then transferred into a new 1.5ml tube and elution performed by placing 15μl 
of RNase-free H2O (Affymetrix) directly onto the middle of the spin column membrane. The 
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columns were incubated at room temperature for 5 minutes and spun at maximum speed for 1 
minute. Elution was performed again by pipetting the flow-through (~13.5μl) back onto the 
spin column, further incubating it for 5 minutes at room temperature and spinning it at 
maximum speed for 1 minute. The expected volume of eluate should have been ~13.5μl. The 
sample quality and yield was assessed using the NanoDrop. The acceptable 260:280 ratio was 
1.9-2.1 and the first cycle cRNA yield (concentration x eluate volume) had to be > 16μg. A 
lower yield indicated there may be a problem with the reaction. 10μg cRNA at a minimum 
concentration of 1.54μg/µl was needed for second cycle cDNA synthesis.  
 
2.8.1.5 Second cycle cDNA synthesis 
In a 0.2ml reaction tube, 1.5μl of random primers (3μg/µl) were added to the 10μg single 
stranded cRNA from 2.7.1.4 made up to 8.0μl total volume with RNase free dH2O. After 
mixing, the samples were incubated in thermocycler with the following programme using a 
heated lid: 70°C for 5 minutes, 25°C for 5 minutes, 4°C for 2 minutes, and held at 4°C. The 
tubes were spun briefly and placed on ice. The following master mix was then prepared on 
ice using 4.0μl 5x first strand buffer, 2.0μl DTT (0.1M), 1.25μl dNTP + dUTP and 4.75μl 
Superscript II for a total volume of 12μl for a 1x master mix. 12μl of the master mix was 
added to each of the reaction tubes and after mixing, the samples were incubated in 
thermocycler with the following programme using a heated lid: 25°C for 10 minutes, 42°C 
for 90 minutes, 70°C for 10 minutes, 4°C for 2 minutes and held at 4°C. The tubes were 
briefly spun and the hydrolysis of cRNA commenced immediately. 
 
2.8.1.6 Hydrolysis of cRNA 
For the cRNA hydrolysis step, 1μl of RNase H (Affymetrix) was added to each single 
stranded cDNA sample. After mixing, the samples were incubated in thermocycler with the 
following programme using a heated lid: 37°C for 45 minutes, 95°C for 5 minutes, 4°C for 2 
minutes and held at 4°C. The tubes were briefly spun and the clean-up of single stranded 
cDNA commenced. 
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2.8.1.7 Clean-up of single stranded cDNA 
Prior to commencement of this step, 24ml ethanol was added to the cDNA wash buffer 
(Affymetrix). Centrifugations were carried out at maximum speed (≥8000g and ≤25,000g) 
and the protocol performed at room temperature. Each sample was transferred to a new 1.5ml 
RNase free tube then 80μl RNase free dH2O (Affymetrix) and 370μl cDNA Binding Buffer 
(Affymetrix) were both added. The tubes were mixed thoroughly by vortexing for 3 seconds 
and the samples applied to a cDNA Spin Column (Affymetrix) which was then spun at 
maximum speed for 1 minute. The spin columns were next transferred to a fresh 2ml 
collection tube and 750μl of cDNA Wash Buffer added onto the spin columns which were 
then spun at maximum speed for 1 minute. The collection tubes were emptied and the cap of 
the spin columns opened. The columns were then centrifuged at maximum speed for 5 
minutes to completely dry the membrane. The spin columns were transferred to a new 1.5ml 
tube and elution carried out by placing 15μl of cDNA Elution Buffer (Affymetrix) directly 
onto the middle of the spin column membrane. The samples were incubated at room 
temperature for 3 minutes and spun at maximum speed for 1 minute. A further 15μl of cDNA 
Elution Buffer was then added directly onto the middle of the spin column membrane and 
incubated at room temperature for 3 minutes before the column was spun at maximum speed 
for 1 minute. The expected eluate volume after this was ~28μl. The yield and quality of 
product was assessed using the NanoDrop™. The single stranded cDNA yield was expected 
to be >5.5μg. A 1.5μl aliquot of each sample was prepared for size analysis using the Agilent 
2100 Bioanalyser and the fragmentation of single stranded cDNA commenced (Figure 2.3). 
 
2.8.2      GeneChip WT Terminal Labelling Kit 
Following the production of single stranded cDNA, both the Affymetrix and Ambion 
protocols used the GeneChip WT Terminal Labelling Kit (Affymetrix) and this was followed 
as per manufacturer’s instructions with minor modifications from the MRC CSC Genomics 
Laboratory. 
 
2.8.2.1 Fragmentation of single stranded cDNA 
Following the clean-up of single stranded cDNA, 5.5μg of single stranded cDNA was 
transferred to a fresh 0.2ml tube and RNase free dH2O added to make the total volume up to 
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31.2μl. A master mix was prepared using 10.0μl RNase free H2O, 4.8μl 10x cDNA 
fragmentation buffers, 1.0μl UDG (Uracil-DNA-Glycosylase, 10u/µl) and 1.0μl APE 
(Apurinic/apyrimidinic (AP) endonuclease,1000u/µl) to give a total volume of 16.8μl for a 1x 
master mix. 16.8μl of the master mix was added to each of the reaction tubes and after 
mixing, the samples were incubated in thermocycler with the following programme using a 
heated lid: 37°C for 60 minutes, 93°C for 2 minutes, 4°C for 2 minutes and held at 4°C. The 
tubes were spun briefly and a 1.5μl aliquot of each fragmented cDNA sample prepared for 
size analysis using the Agilent 2100 Bioanalyzer. The ideal fragment size achieved should be 
~40-70bp. 1μl of the unfragmented samples (prepared previously) was run along-side the 
fragmented samples for comparison (Figure 2.3). 
 
2.8.2.2 Labelling of fragmented single-stranded DNA 
45μl of the fragmented cDNA was transferred to a new 0.2ml RNase free tube and a master 
mix prepared using 12.0μl 5x TdT buffer, 2.0μl TdT and 1.0μl DNA labelling reagent to give 
a total volume of 15.0μl for a 1x master mix. 15.0μl of the master mix was added to each of 
the reaction tubes and after mixing, the samples were incubated in thermocycler with the 
following programme using a heated lid: 37°C for 60 minutes, 70°C for 10 minutes, 4°C for 2 
minutes then held at 4°C. Using a pipette, the volume of the labelled extract was measured. 
For each sample, sufficient RNase free water was added so that the final volume of the 
labelled extract was 60μl. The tubes were frozen by being placed on dry ice and stored at       
-80
o
C. 
 
2.8.3      Hybridisation and washing 
Hybridisation to the arrays and washing of the samples was carried out by the MRC CSC 
Genomics Laboratory according to Affymetrix protocols using a single batch of buffers for 
all arrays and samples. Each experiment used the same batch of GeneChip Rat Gene 1.0 ST 
arrays. 
 
2.8.4      Ambion WT Expression kit protocol 
Master mixes were prepared for each step of the procedure to save time, improve 
reproducibility and minimise pipetting error. Before preparing the master mixes, the buffer 
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mixes were inspected for precipitates and, if necessary, the buffer mixes were warmed at 
<55
o
C for 1 to 2 min, or until the precipitate was fully dissolved. Each buffer mix was 
thoroughly vortexed prior to use and enzymes were mixed by gently flicking the tubes. 
Buffer mixes were kept at room temperature until needed to prevent re-precipitation whilst 
enzyme mixes were kept on ice at all times. The thermocycler used was programmed in 
advance with the requisite heated lid option set. All reagents used in this protocol were 
provided by Ambion. 
2.8.4.1 Preparation of Poly-A RNA controls 
Premixed controls from the Affymetrix GeneChip Poly-A RNA Control Kit were added to 
the total RNA samples. The controls were designed to provide exogenous positive controls to 
monitor the entire target labelling process and are added prior to the First Strand Synthesis 
step (Table 2.2). Each Rat GeneChip 1.0 ST array contains probes for several B. subtilis 
genes that are absent in eukaryotic samples and these polyadenylated transcripts for the B. 
subtilis genes are premixed at staggered concentrations and then in vitro synthesised as part 
of the protocol. The concentrated Poly-A control stock was diluted with Poly-A control 
dilution buffer prior to spiking directly into the RNA samples to obtain the final 
concentrations as detailed in Table 2.3.The serial dilution performed depended on whether 
100 or 150ng RNA was used. To prepare the Poly-A RNA dilutions, 2 µl of the Poly-A 
Control Stock was added to 38 µl of Poly-A Control Dilution Buffer for the first dilution 
(1:20). This was mixed thoroughly and the microcentrifuge tube spun down to collect the 
liquid at the bottom of the tube. To prepare the second dilution (1:50), 2µl of the first dilution 
was added to 98 µl of Poly-A Control Dilution Buffer. This was again mixed thoroughly and 
briefly spun down to collect liquid. To prepare the third dilution (1:50), 2µl of the second 
dilution was added to 98 µl of Poly-A Control Dilution Buffer. To prepare the fourth dilution, 
2µl of the third dilution was added to 18µl of Poly-A Control Dilution Buffer to prepare the 
fourth dilution (1:10) if 100ng input RNA was used and 3µl of the third dilution added to 
16.7µl of Poly-A Control Dilution Buffer to prepare the fourth dilution (1:6.67) if 150ng 
input RNA was used. As the first dilution of the Poly-A RNA controls could be stored up to 6 
weeks in a non-frost-free freezer at − 20 ºC and frozen/thawed up to eight times this allowed 
for a single aliquot to be used for all batches.  
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Table 2.2 Final concentrations of Poly-A RNA controls following their addition to 
total RNA samples 
 
 
 
 
Table 2.3 Serial dilution scheme for Poly-A RNA control depending on total RNA 
input amount 
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2.8.4.2 First strand cDNA synthesis 
Prior to commencing this step, 2μl of the fourth Poly A dilution was added to the Total RNA 
volume ensuring the Total RNA volume did not exceed 3μl and RNase free water was added 
to a total volume of 5μl. The first strand master mix was prepared at room temperature and 
the 1x mix consisted of 4μl first strand buffer mix and 1μl of first strand enzyme mix. This 
was thoroughly mixed and briefly centrifuged prior to the addition of 5μl of the First-Strand 
Master Mix to each sample. The final mixture was mixed thoroughly by gentle flicking then 
centrifuged and was incubated with a heated lid fixed at 50
o
C for 60 minutes at 25°C, 60 
minutes at 42°C then at 4°C for at least 2 minutes in thermal cycler. The samples were spun 
briefly and placed on ice for 2 minutes to cool the plastic because transferring second strand 
master mix to hot plastics can significantly reduce cRNA yields as could holding the first 
strand cDNA synthesis reaction at 4°C for longer than 10 minutes. 
 
2.8.4.3 Second strand cDNA synthesis 
The second strand master mix was prepared on ice by mixing 32.5μl nuclease-free water with 
12.5μl second strand buffer mix and 5μl second strand enzyme mix (1x volume). This was 
thoroughly mixed and briefly centrifuged prior to the addition of 50μl of the master mix to 
each sample. The final mixture was mixed thoroughly by gentle flicking then centrifuged and 
was incubated with the heated disabled for 60 minutes at 16°C then 10 minutes at 65°C and at 
4°C for at least 2 minutes in the thermal cycler. The sample was briefly centrifuged and 
placed on ice. 
 
2.8.4.4 cRNA synthesis by In Vitro transcription (IVT) 
The IVT master mix was prepared at room temperature by mixing 24μl of IVT buffer mix 
with 6μl of IVT enzyme mix (1x volume). After thorough mixing, 30μl of IVT master mix 
was added to each sample and was thoroughly mixed again. The samples were incubated with 
the heated lid at 50
o
C for 16 hours at 40°C and then held at 4°C. 
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2.8.4.5 cRNA purification 
Prior to commencing this stage, the bottle of elution solution was preheated to 50 to 58
o
C for 
at least 10 minutes and 100% ethanol was added to the bottle of Nucleic acid wash solution 
concentrate before use. The nucleic acid binding beads were vortexed vigorously before use 
to ensure they are fully dispersed. Isopropanol was used in this step as opposed to ethanol in 
the later purification step. 
 
A cRNA binding mix was prepared by adding 10μl nucleic acid binding beads to 50μl of 
nucleic acid binding buffer concentrate. Samples were transferred to a well of a U-bottom 
plate and then 60µl of cRNA binding mix was added to each sample and pipetted up and 
down three times to mix followed by 60µl of 100% isopropanol which was also pipetted up 
and down three times to mix. The plate was sealed with PCR film and incubated for 5 
minutes without shaking. The plate was then gently shaken for 2 minutes to thoroughly mix 
(setting 0 on Vortex genie 2 with plate adapter) to allow cRNA to bind to the beads. The plate 
was briefly centrifuged (<5 seconds) to remove liquid from the film prior to its removal. The 
nucleic acid binding beads were captured by placing the plate on a magnetic stand for 5 
minutes. The capture was complete when the mixture was transparent with the beads pelleted 
on the side of the wells. The supernatant was carefully aspirated and discarded without 
disturbing the beads and the plate removed from the stand. The beads were washed twice 
with 100µl of nucleic acid wash solution by shaking the plate sealed with PCR film at a 
moderate speed for 1 minute (setting 1 on Vortex genie 2 with plate adapter). After each was 
the plate was moved to a magnetic stand and the beads captured for 5 minutes with aspiration 
of the supernatant each time. After the second wash, the plate was moved to the shaker and 
vigorously shaken for 1 minute (setting 1 on Vortex genie 2 with plate adapter). The beads 
were dried until no liquid was visible but the pellet still appeared shiny. The cRNA was 
eluted with 40µl of preheated elution solution by incubating without shaking for 5 minutes 
then vigorously shaking the plate for 3 minutes (setting 2 on Vortex genie 2 with plate 
adapter). The beads were captured again using the magnetic stand and the supernatant, which 
contains the eluted cRNA, was transferred to a nuclease free PCR tube. 
 
99 
 
2.8.4.6 Assess cRNA yield and size distribution 
The cRNA yield was assessed using the NanoDrop. An acceptable ratio of the absorbance at 
260 and 280nm was around 2.0, with an acceptable range being 1.9 to 2.1. The first cycle 
cRNA yield (concentration x eluate volume) should be > 20μg (Ambion quoted range 15 to 
50μg depending upon tissue type). A minimum of 455ng/µl was needed for the next step, 
equal to 10μg in a volume of 22μl. 
 
2.8.4.7 2nd-cycle cDNA synthesis 
The 10µg cRNA was prepared on ice using nuclease free water to bring the total sample 
volume to 22µl. For the siRNA experiment, on the advice of Ambion and following protocol 
optimisation, 12µg cRNA was prepared. The cRNA was combined with random primers by 
adding 2µl of random primers to the sample and then incubating in a thermocycler with a 
heated lid set at 75
o
C for 5 minutes at 70°C then for 5 minutes at 25
o
C then 2 minutes at 4
o
C. 
The 2
nd
 cycle cDNA mix was then prepared at room temperature by mixing 8µl of 2
nd
-cycle 
buffer mix with 8µl of 2
nd
-cycle enzyme mix for a 1x volume. 16μl of the 2nd-cycle master 
mix was added to each (24μl) cRNA/random primer sample before incubating with a heated 
lid at 75
o
C for 10 minutes at 25°C then 90 minutes at 42°C, 10 minutes at 70°C then 4°C  for 
at least 2 minutes. 
 
2.8.4.8 RNA hydrolysis using RNase H 
Residual RNA was hydrolysed using RNase H, 2µl of RNase H  which was added to the 2
nd
-
cycle cDNA on ice and was mixed by pipetting up and down 3 times to ensure all of the 
enzyme was dispensed from the pipette tip. The sample was then incubated with a heated lid 
at 75
o
C for 45 minutes at 37°C then 5 minutes at 95°C then for 2 minutes at 4°C. The sample 
was spun briefly and placed on ice.  
 
2.8.4.9 2nd-cycle cDNA purification 
The 2
nd
 cycle cDNA purification was performed in a similar manner to the cRNA purification 
with some key differences. 100% ethanol was used in this step not isopropanol as in 2.8.4.4. 
The cDNA binding mix was prepared by adding 10 µl of nucleic acid binding beads to 50µl 
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of nucleic acid binding buffer concentrate. At the stage of sample addition to the U-bottom 
plate, 18µl of nuclease free water along with 60µl of cDNA binding mix was added to each 
sample and mixed by pipetting up and down 3 times to mix followed by the addition of 120µl 
of ethanol to each sample. cDNA binding and washes with nucleic acid wash solution were 
carried out as per 2.8.4.5. cDNA was eluted using 30µl of preheated elution solution. 
 
2.8.4.10 Assessment of cDNA yield and size distribution 
The concentration of cDNA solution was determined by using 1.5µl of cDNA sample on the 
NanoDrop. In theory, using 10µg of input cRNA should yield 6 to 9µg of cDNA though in 
practice this was usually closer to 6µg than the higher concentrations. The single stranded 
cDNA samples were then fragmented and labelled as detailed in 2.8.2. A 1.5μl aliquot was 
taken for each sample for size analysis using the Agilent 2100 Bioanalyser.  
 
2.9 Chromatin immunoprecipitation 
2.9.1      Chromatin shearing 
BMDMs used for ChIP were fixed in formaldehyde and prepared as per 2.4.3. The cell pellet 
was thawed, resuspended in 1ml ice-cold lysis buffer (Active Motif Europe, Rixensart, 
Belgium) supplemented with 5µl PIC (protease inhibitor cocktail) and 5µl PMSF and 
incubated on ice for 30 minutes. The lysed cells were transferred to a 1.5ml microcentrifuge 
tube and centrifuged at 5000rpm for 10 minutes at 4
o
C to pellet the nuclei. 
 
2.9.1.1 Enzymatic shearing of chromatin 
Enzymatic shearing was carried out as per manufacturer’s instructions. The nuclei pellet 
prepared in 2.9.1 was resuspended in 350µl digestion buffer supplemented with 1.75µl PIC 
and 1.75µl PMSF and incubated at 37
o
C for 5 minutes. A working stock solution of 
Enzymatic Shearing Cocktail (200U/ml, Active Motif) was prepared by diluting the supplied 
Enzymatic Shearing Cocktail (2x10
4
U/ml) 1:100 with 50% glycerol in dH2O and 17µl of this 
working stock was added to the pre-warmed nuclei and incubated for 10 minutes. The 
reaction was stopped by adding 7µl of ice-cold 0.5M ethylenediaminotetraacetic acid 
(EDTA) to each tube and incubating for 10 minutes on ice. The sheared chromatin was 
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centrifuged at 14000rpm at 4
o
C for 10 minutes and the supernatant collected. An aliquot was 
removed at this point to assess shearing efficiency by purifying a 30μl aliquot of the 
chromatin solution and visualising it on a 2% TAE agarose gel stained with ethidium bromide 
run at 100V for 50 minutes, as per 2.9.1.1, and the remainder was frozen at -80
o
C. 
 
2.9.1.2 Shearing by sonication using Covaris S2 
The cell pellet was thawed and the cells lysed as above (2.9.1). The pellet was resuspended in 
300µl shearing buffer supplemented with 1.75µl PIC. The resuspended cross linked 
chromatin was sheared using the Covaris S2 (Covaris Inc.) in 300μl shearing tubes (Covaris 
Inc.) with the following settings that were optimised for the cell type and number: 20% Duty 
cycle, Intensity 8 and 200 cycles/burst for 23 to 30 thirty second cycles according to 
macrophage number in the sample. Sheared chromatin was recovered with centrifugation at 
15,000 rpm in a 4
0
C microcentrifuge for 10 minutes and the resulting supernatant contaiing 
the chromatin was stored at -80
0C. DNA shearing efficiency was assessed by purifying a 30μl 
aliquot of the chromatin solution and visualising it on a 2% TAE agarose gel stained with 
ethidium bromide run at 100V for 50 minutes as per 2.9.1.1. 
 
2.9.1.1 Assessment of shearing efficiency 
Shearing efficiency was assessed on a 2% agarose gel (Figure 2.6). The chromatin was first 
cleaned up by adding 10µl 5M NaCl (Active Motif) to the reserved chromatin aliquot and the 
volume was made up to 210µl with dH2O. The aliquot was heated at 95
o
C for 15 minutes to 
reverse crosslinks between protein and chromatin formed by the formaldehyde incubation of  
BMDMs as detailed in 2.4.3 and then incubated with 1µl RNase A (Active Motif) at 37
o
C for 
15 minutes to remove unwanted RNA products and then with 1µl proteinase K (Active 
Motif) at 67
o
C for 15 minutes to remove residual protein contaminants. The sample was 
purified in a QIAquick MinElute column (Qiagen) as per 2.5.3 and eluted in 10µl RNase free 
water. Orange G loading buffer was added to the sample which was run on a 2% agarose 
(Invitrogen) gel in TAE (CSC media kitchen) for 50 minutes. Optimal shearing was defined 
as a smear ranging from 200-1000 base pairs identified with the use of a 2-Log ladder 
(Quick-Load 2-Log DNA ladder (0.1-10kb), New England Biolabs, Hitchin, Hertfordshire, 
UK). 
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Figure 2.6 Examples of chromatin shearing quality check agarose gels 
2% TAE agarose gels showing size range of sheared chromatin. Each lane represents a 
different preparation of chromatin subjected to identical shearing conditions. Enzymatic 
digestion was used (A) resulting in well sheared chromatin but with banding occurring every 
150 base pairs. Sonication using the Covaris S2 was performed (B) resulting in sheared 
chromatin in the desired size range without evidence of bias or banding. 
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2.9.2      Immunoprecipitation 
Chromatin immunoprecipitation was performed using Active Motif ChIP-IT Express 
according to manufacturer’s protocols with some modifications. Immunoprecipitation 
reactions were set up in a total volume of 100μl using 25μl of sheared chromatin in each 
reaction along with 25µl protein G-coated magnetic beads (Active Motif), 10µl ChIP Buffer 
1 (Active Motif), 1µl PIC and 2µg of antibody (JunD (sc-74X) and IgG (sc-2026) antibodies 
obtained from Santa Cruz Biotechnology (Santa Cruz, California, USA) and incubated on an 
end-to-end rotator overnight at 4
0
C. Protein G is an immunoglobulin-binding protein 
expressed in group C and G Streptococcal bacteria which exhibits high affinity for subclasses 
of IgG (Sjöbring et al., 1991). When the recombinant form, which does not bind albumin, is 
used attached to a magnetic particle it allows for the removal of antibody bound chromatin 
fragments.  
 
10µl of chromatin was reserved as the ‘input’ control for later processing at this point. After 
overnight incubation, the beads were washed three times with ChIP Buffer 1 (Active Motif) 
and two times with ChIP Buffer 2 (Active Motif) to minimise background by using a 
magnetic stand to pellet beads to the side of the microcentrifuge tube allowing any 
supernatant to be removed. 
 
2.9.3      Recovery of immunoprecipitated DNA 
Chromatin was eluted from the protein G-coated magnetic beads by first incubating the beads 
for 15 minutes in 50μl elution buffer AM2 (Active Motif) at room temperature on an end-to-
end rotator and then adding 50μl reverse crosslinks buffer (Active Motif). After pelleting the 
magnetic beads the resulting supernatant containing eluted chromatin was transferred to a 
fresh microcentrifuge tube. Cross links between DNA and bound proteins were reversed by 
heating the samples at 65
oC for 5 hours. Incubation of the samples with 1μl proteinase K at 
37
o
C was performed to remove any remaining protein. The reaction was stopped by the 
addition of 1μl proteinase K stop buffer (Active Motif). The resulting enriched DNA was 
stored at -20
0
C prior to processing for downstream applications 
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2.10 Amplification of genomic DNA 
2.10.1      Polymerase chain reaction (PCR) using KOD Hot Start DNA polymerase 
KOD Hot Start DNA polymerase (Merck, Nottingham) was used for the amplification of 
DNA (prior to Sanger sequencing). KOD Hot Start DNA polymerase is a premixed complex 
of KOD DNA polymerase and two monoclonal antibodies that inhibit DNA polymerase and 
3’→5’ exonulcease activities at ambient temperatures. The enzyme has high fidelity which is 
the accuracy with which DNA is replicated and as a hot start preparation it benefits from the 
high specificity of such a preparation which reduces nonspecific amplification and 
mispriming events during reaction setup. Betaine was used in the reactions involved in the 
sequencing of the JUND locus to improve DNA amplification in GC rich regions such as the 
JUND locus by reducing secondary structure formation. 
 
100ng of genomic DNA was amplified in 1x buffer for KOD Hot Start DNA Polymerase 
with 1.5mM MgSO4, 0.2 mM dNTP, 1.6mM Betaine (Sigma-Aldrich) and 0.3μM of each 
primer with 0.02U/µl KOD Hot Start polymerase in a total volume of 20μl. Samples were 
incubated in a thermocycler with the following program: 94
o
C for 2 min then 40 cycles of 
94
o
C for 20 seconds, 60
o
C for 10 seconds and 68
o
C for 10 seconds then held at 10
o
C forever. 
 
2.10.2      Microsatellite genotyping 
Microsatellite genotyping was used to confirm the status of the WKY.LCrgn2 congenic 
strain. This was performed by Ms Zelpha D’Souza, PGM Group. DNA samples were 
extracted as per 2.5.1 and diluted to 25ng/µl concentration. BIOTAQ polymerase (Bioline, 
London, UK) was used for the amplification reaction. 50ng of DNA was amplified in 1x 
BioTaq buffer (Bioline) with1.5mM MgSO4, 0.2mM dNTP, and 0.4μM of each primer with 
0.75units of BIOTAQ polymerase in a total volume of 10µl. Samples were incubated in a 
thermocycler with the following program: 95C for 2 minute then 40 cycles of 95
o
C for 45 
seconds, 57
o
C for 45 seconds and 72
o
C for 1 minute then held at 10
o
C forever. Following the 
PCR, the samples were diluted in 30µl of dH2O. A mastermix of 15µl ROX dye in 1ml 
formamide was made. 8µl of this mix was added to 2µl of the diluted PCR sample in a 
GeneScan plate (Life Technologies, Warrington, UK) and submitted for analysis by the CSC 
Genomics Laboratory using the 3730xl DNA analyser (Life Technologies, Warrington, UK). 
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2.11 Agarose gel electrophoresis 
2.11.1      Analysis of PCR samples 
Agarose gel electrophoresis of PCR amplified DNA samples was performed in 
electrophoresis tanks with 1xTAE buffer used as the gel and running buffer. Gels were 
prepared by heating 100ml of 1xTAE buffer with 1.5-2% agarose added until the agarose was 
dissolved. Following cooling in running water, 1μl of ethidium bromide was added to the 
agarose-1xTAE buffer mix and the mixture poured into a gel mould. DNA samples were 
mixed using 2μl Orange G per 10μl PCR product and loaded into the agarose gel. A 2-log 
ladder (New England Biolabs) was used as a DNA size standard. The samples were 
electrophoresed at 120V for 1 hour and the gels visualised on an ultra-violet transilluminator 
(BioRad, Hemel Hempstead, Hertfordshire, UK) and photographed using the gel doc system 
(BioRad). 
 
2.12 Preparation of DNA for Sanger sequencing 
PCR products were prepared for sequencing on the 3730xl DNA analyser (Applied 
Biosystems) according to CSC/IC Genomics Core specifications. PCR product yield was 
assessed using the NanoDrop as per 2.7.1. In a 0.2ml PCR tube, the appropriate volume of 
PCR template for10ng per 100bp of expected PCR product was added to 3.2pmole of primer 
made up to a total volume of 10μl with dH2O and submitted to the MRC CSC Genomics 
Core laboratory. 
 
2.13 cDNA preparation 
cDNA was used in qRT-PCR analysis to assess gene expression. RNA prepared as detailed in 
2.6.1 from rat BMDMs was used for these experiments. cDNA was made with the iScript 
Select cDNA synthesis kit (Bio-Rad, Hemel Hempstead, Hertfordshire, UK) according to 
manufacturer’s instructions. The kit components were thawed prior to use, mixed thoroughly 
and briefly centrifuged to collect the contents at the bottom of the tube. A 1μg sample of 
RNA was converted in each reaction in a 0.2ml PCR tube with 4μl 5x iScript  select reaction 
mix, 2μl Oligo(dT)20 primer and 1μl iScript reverse transcriptase in a total volume of 20μl. 
Each reaction was gently mixed and incubated for 90 min at 42
o
C then at 85
o
C for 5 min to 
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heat inactivate the reverse transcriptase. The resulting cDNA yield was assumed to be 1μg 
and the cDNA was diluted 10 fold to 5ng/µl concentration by adding 180μl dH2O to the 20μl 
reaction mix for analysis in qRT-PCR. Standard curve samples were diluted 1:2 to 25ng/µl by 
adding 25μl dH2O. 
 
2.14 Quantitative real time PCR (qRT-PCR) 
A number of different methods of qRT-PCR were used as detailed below depending on the 
desired application. TaqMan genotyping assays were used for human genotyping 
experiments. SYBR green based methods were used for quantitative assessment of cDNA for 
gene expression experiments and for the assessment of ChIP samples. 
 
2.14.1      qRT-PCR with TaqMan probes for human genotyping 
Genotyping of tagging SNP was performed with TaqMan pre-designed SNP genotyping 
assays and TaqMan genotyping mix (Applied Biosystems, Life Technologies Group, 
Warrington, UK) as per manufacturer’s instructions. The assay mix contains the genotyping 
master mix along with forward and reverse primers, the two TaqMan minor groove binding 
(MGB) probes and the genomic DNA. Each TaqMan MGB probe specifically anneals to the 
complementary sequence if present between the forward and reverse primer sites. If the probe 
does not bind to any complementary sequence then the proximity of the quencher dye to the 
reporter dye is enough to suppress the reporter’s fluorescence. If the probe is able to bind to 
the DNA sequence, the 5’-3’ exonulcease activity of the AmpliTaq Gold DNA polymerase in 
the reaction cleaves the probes that are hybridized to the target during the extension phase of 
the PCR reaction separating the reporter dye from the quencher dye which increases 
fluorescence by the reporter. This signal indicates which alleles are within the sample. 
(Figure 2.7) 
 
10ng DNA per sample was amplified in 1xABI genotyping master mix and 20xSNP mix in a 
total volume of 5μl in 384 well plates (Applied Biosystems) on an ABI 7900HT Fast real 
time machine for 10 min at 95
0
C then 40 cycles of 15 seconds at 95
0
C, 1 minute at 60
0
C. 
Plate reading for genotypes was performed before and after the amplification program and 
analysed in SDS v2.3 (Applied Biosystems). 
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2.14.2      Two step qPCR with SYBR green 
qRT-PCR was performed on an ABI 7900HT Sequence Detection System (Applied 
Biosystems, Warrington, UK) using SYBR
®
 Green JumpStart
™
 Taq ReadyMix
™
 (Sigma-
Aldrich). A total of 10ng of cDNA (2μl of 5ng/µl concentration cDNA stock) was amplified 
per sample in 1X SYBR Green ready mix (12.5μl), 0.25μl ROX standard and 0.5μl of 10μM 
forward and reverse primer and 9.25μl dH2O for a total volume of 25μl for reactions carried 
out in 96 well plates. In 384 well plates, a total of 10ng cDNA was again used in 1x SYBR 
Green ready mix (5μl), 0.1μl ROX standard and 0.2μl of 10μM forward and reverse primers 
with 2.5μl dH2O for a total volume of 10μl. cDNA samples were amplified in triplicate. Five 
point standard curve consisting of 50ng, 10ng, 2ng. 0.4ng and 0.08ng of cDNA were made by 
serially diluting the 25ng/µl standard curve samples five times to assess reaction efficiency 
and primer specificity and were amplified in duplicate. qRT-PCR was performed on an ABI 
7900HT using the following program: 94
o
C for 2 minutes then 40 cycles of 94°C for 15 
seconds, 60°C for one minute and 72°C for one minute. 
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Figure 2.7 Principle of TaqMan genotyping assays 
This diagram details the principles behind TaqMan genotyping assays. The assay consists of 
forward and reverse primers specific to the region and complementary probes for the two 
alleles in question. Each probe consists of the fluorophore (VIC or FAM) and the minor 
groove binder quencher.  After the probe has bound to its complementary sequence, the 
fluorophore is cleaved by the 5’-3’ exonulcease activity of the AmpliTaq Gold DNA 
polymerase and this fluorescence can then be measured and the balance between the two dyes 
allows the genotype to be called.  
 
From: TaqMan® Genotyping Master Mix Protocol by Applied Biosystems 
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Data collection of fluorescence was performed during the 72
o
C for one minute incubation. 
Analysis of the data was carried out using SDS software v2.3 as detailed below. For standard 
curve runs, to confirm that only a single product was produced from a set of primers, a 
dissociation curve analysis using a temperature ramp was performed on default settings: 
following a dissociation step of 94
o
C for 15 seconds, the temperature was ramped from 60
o
C 
to 94
O
C with fluorescence readings taken for 15 seconds at each degree. The results of the 
dissociation curve analysis were analysed within the dissociation curve tab of the SDS 
software v2.3 plate document as detailed in. 
 
2.14.3      qPCR with SYBR green of ChIP enriched DNA 
Immunoprecipitated DNA fragments were analysed by real-time PCR on an ABI 7900 
Sequence Detection System (Applied Biosystems, Warrington, UK). JunD-enriched 
chromatin post-processing along with IgG control-enriched chromatin and input chromatin 
was diluted 1:2 with RNase free water and was amplified as per 2.14.1. Primers used are 
listed in Supplementary table E. All samples were amplified using a set of 3 biological 
replicates with three technical replicates used per sample. After an initial denaturation step of 
94
0
C for 2mins, the samples were cycled 40 times at 94
0
C for 15seconds, 60
0
C for 1 minute 
and 72
0
C for 1 minute with data collection performed during the 72
0
C elongation step. 
Sequence detection software (SDS) version 2.3 (Applied Biosystems) was used to obtain the 
Ct values and each sample was analysed with reference to Ct values for matched control 
‘Input’ non-immunoprecipitated chromatin. A standard curve of 1:5 dilutions of Input DNA 
was used to assess the accuracy of the Input DNA dilutions.  
 
2.15 Library preparation of immunoprecipitated DNA for high-
throughput sequencing applications 
Library preparation for Illumina Genome Analyzer IIx HT sequencing was performed as per 
manufacturer’s instructions with some key modifications. The protocol entails end repair of 
DNA fragments, addition of ‘A’ bases to their 3’ end, ligation of adaptors, size selection of 
fragments and a limited PCR amplification (Figure 2.8). Each immunoprecipitated sample 
for library preparation was the product of five separate technical replicates of 
immunoprecipitation pooled together and purified using Qiagen MinElute columns as 
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detailed in 2.5.3 and quantified using the hsDNA Qubit assay (Invitrogen, Life Technologies, 
California, USA) as per 2.7.2. Input samples were also purified using Qiagen MinElute 
columns as detailed in 2.5.3 and were also quantified using Qubit dsDNA kits as per 2.7.2. 
Each sample consisted of 10ng of DNA made up to a total volume of 30μl dH2O. Initial 
ChIP-Seq library preparations were performed using the ChIP-Seq Sample Prep Kit by 
Illumina (Illumina Inc. United Kingdom, Little Chesterford, Essex, UK). Library preparations 
for the data presented within this thesis used the New England Biolabs (NEB) ChIP-Seq 
Sample Prep Master Mix Set 1 (E6240S, New England Biolabs, Hitchin, Herts, UK) for all 
the enzymatic reactions. The adaptor oligo mix (part # 100521) and PCR primer 1.1 (part # 
1000537) and PCR primer 2.1 (part # 1000538) used in conjunction with the NEB kit were 
manufactured by Illumina. 
 
2.15.1      End repair of DNA fragments 
Prior to commencing the protocol, the Klenow DNA polymerase (NEB) was diluted 1:5 with 
water for a final Klenow concentration of 1U/µl. A master mix was prepared consisting of 
10μl dH2O, 5μl T4 DNA ligase buffer (NEB) with 10mM ATP (NEB), 2μl dNTP mix (NEB), 
1μl T4 DNA polymerase (NEB), 1μl Klenow DNA polymerase (NEB) and 1μl T4 PNK 
(NEB) for a total volume of 20μl for a 1x master mix. 20μl of the master mix was added to 
the 30μl of ChIP enriched DNA and the samples incubated in the thermocycler for 30 
minutes at 20
o
C. Following the incubation the samples were purified using a QIAquick PCR 
purification kit as detailed in 2.5.3 and were eluted in 34μl of buffer EB. 
 
2.15.2      Addition of adenosine bases to 3’ ends 
In this stage, an adenosine ‘A’ base is added to the 3' end of the now blunt phosphorylated 
DNA fragments, using the polymerase activity of Klenow fragment (3' to 5' exo minus) in 
readiness for the ligation of the sequencing adapters, which have a single ‘T’ base overhang 
at their 3' end. A master mix consisting of 5μl Klenow buffer (NEB), 10μl dATP (NEB) and 
1μl Klenow exo (3’ to 5’ exo minus) (NEB) to give a total volume of 16μl for a 1x volume of 
master mix was prepared and added to the DNA sample (34μl).  The sample was incubated in 
a thermocycler for 30 minutes at 37
o
C and purified using a MinElute PCR purification kit as 
detailed in 2.5.3 eluting in 10μl of EB buffer. 
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Figure 2.8 Schematic of the library preparation workflow for ChIP-Seq on 
the Illumina Genome Analyzer IIx 
This figure was adapted from the Preparing Samples for ChIP Sequencing of DNA manual 
published by Illumina, 2007. 
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2.15.3      Adaptor ligation 
Adaptor ligation allows for the eventual hybridisation of the DNA fragments to the 
sequencing flow cell. A modified dilution of adaptor oligo mix (Illumina, part # 1000521) at 
1:20 with RNase free water compared to the manufacturer’s protocol of 1:10 was used to 
prevent formation of excessive adaptor dimers. A master mix consisting of 15μl DNA ligase 
buffer (NEB), 1μl diluted adapter oligo mix, 3μl dH2O and 1μl DNA ligase (NEB) to give a 
total volume of 20μl for a 1x volume of master mix was prepared and added to the DNA 
sample (10μl). The sample was incubated for 15 minutes at room temperature and then 
purified with a MinElute PCR purification kit as detailed in 2.5.3 eluting in 10μl of buffer 
EB. 
 
2.15.4      Size selection of fragments 
This stage removed excess adaptors and selected a size range of templates to go on the 
sequencing flow cell. At this gel extraction stage, a gel piece containing fragments ranging 
from 150-300bp was cut out to maximize library yield. 
 
A 100 ml 2% agarose gel with TAE buffer and added ethidium bromide was prepared as per 
2.12.1. All gel apparatus was thoroughly cleaned prior to commencement and fresh stocks of 
TAE buffer were made each time. DNA samples from the purified ligation reaction were 
loaded onto each gel by adding 3μl of loading buffer to 10μl of the DNA. The entire sample 
was loaded onto the gel and DNA ladder was loaded leaving 2 empty lanes between it and the 
DNA sample. A maximum of 2 DNA samples were loaded per gel. 
 
The gel was run at 120 V for 60 minutes. The gel was viewed on a UV transilluminator for 
the minimum time possible in order to reduce the effect of UV light damage to the samples. 
Each sample was cut out using a fresh scalpel blade and care taken to avoid any cross 
contamination of samples and size contamination with larger sized fragments. The gel slice 
was cut to give fragments ranging from 150 to 300 bp. A slice of the same size was cut from 
an empty control well on the same gel and taken through gel purification and the PCR stage 
in 2.10.5 as a negative control. The DNA was purified from the agarose slices using the 
Qiagen Gel Extraction Kit as detailed in 2.5.4 and the DNA was eluted in 36µl of buffer EB 
(Qiagen). 
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2.15.5      PCR amplification of adapter modified size selected DNA fragments 
A limited PCR amplification of the DNA fragments allows sufficient library to be produced 
for cluster generation and sequencing. The PCR primers supplied by Illumina (PCR primer 
1.1 and 2.1) were diluted 1:2 at this stage with water to prevent the formation of primer 
dimers as evidenced in trial experiments. A PCR master mix consisting of 10μl 5x Phusion 
buffer (NEB), 1.5μl dNTP mix (NEB), 1μl diluted PCR primer 1.1 (part # 1000537), 1μl 
diluted PCR primer 2.1 (part # 1000538)  and 0.5μl Phusion polymerase (NEB) to give a total 
volume of 14μl for a 1x volume master mix was prepared and added to the DNA sample 
(36μl). The reaction was amplified on a thermocycler with the following Illumina supplied 
thermo cycler protocol: 30 seconds at 98°C then 18 cycles of: 10 seconds at 98°C, 30 seconds 
at 65°C, 30 seconds at 72°C then 5 minutes at 72°C before holding at 4°C . The samples were 
purified using a MinElute PCR purification kit as per 2.5.3 eluting in 15μl of buffer EB 
(Qiagen). 
 
The samples were quantified using the hsDNA Qubit assay (Invitrogen) and the size range 
analysed using a HS DNA chip on a 2100 Bioanalyser (Agilent Technologies) prior to 
submission for qPCR analysis and cluster generation and sequencing by the CSC Genomics 
Laboratory (Figure 2.9).  
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Figure 2.9 Agilent Bioanalyzer traces demonstrating successful ChIP-Seq 
library preparations 
The completed ChIP-Seq libraries were run on an Agilent Bioanalyser high sensitivity DNA 
chip at a 1:10 and 1:20 dilution demonstrating the desired size selection of adaptor ligated 
DNA fragments produced by the protocol. The heights of peaks reflect the differences in 
dilution used and concentration of the finished library. The FW16 samples shown are a single 
WKY.LCrgn2 replicate in the basal state (‘con’), stimulated state (‘stim’) with the relevant 
input libraries (‘StimInp’ and ‘ConInp’) as well as negative controls from the gel selection 
stage demonstrating no contamination of the libraries from this stage and the Bioanalyser 
ladder trace.  
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2.16 Histological techniques 
2.16.1      ED-1 staining of rat BMDMs 
Immunohistochemical staining of macrophages was performed using the Dako Envision Kit 
(DakoUK Ltd, Ely, Cambridgeshire, Uk). Antibodies used were ED-1 (MCA341R, AbD 
Serotec) as a macrophage marker and OX-8/CD8alpha (MCA48R, AbD Serotec) and THY-
1/CD90 (MCA47R AbD Serotec) as T cell markers (Figure 2.1). BMDMs were dissociated 
from 15cm petri dishes as per 2.4.2.2 and 1x10
5
 cells per well were incubated overnight in 
tissue culture chamber slides (Thermo Scientific Nunc) in 400µl full culture medium. The 
medium was removed and the slides allowed to air dry before fixation with methanol/acetone 
(50:50) for 2 minutes in a glass chamber. The slides were then hydrated in PBS for 3 minutes 
and a wax pen used to draw round each cell spot. Peroxidase block using peroxidase-blocking 
reagent (phosphate buffer containing hydrogen peroxide, 15mmol/L NaN3 and detergent) 
was performed using one drop per cell spot for 10 minutes. The slides were washed in PBS 
and blocked with 50µl Marvel milk per cell section for 10 minutes prior to incubation with 
antibody for 1 hour. ED-1 antibody was used at 1:500 diluted with 5% goat serum 
(20%normal goat serum X0907 Dako) in PBS, OX-8 1:100 with 5% goat serum in PBS and 
THY-1 at 1:100 with 5% goat serum in PBS. Negative controls for each antibody were 
performed using 5% goat serum in PBS. Following antibody incubation, slides were washed 
in a glass chamber containing PBS for 2 separate 3 minute washes with stirring. One drop of 
anti-mouse horseradish peroxidase (HRP) polymer was then added to each cell spot (dextran 
coupled with peroxidase molecules and goat secondary antibody molecules against rabbit and 
mouse immunoglobulins in a buffered solution containing stabilizing protein and 
preservative). DAB (diaminobenzidine) was diluted 1:50 with chromagen and 50µl was 
added to each cell spot. Colour was allowed to develop then the slides were washed in PBS. 
Counterstaining was performed by filtering haematoxylin into the glass chamber and 
immersing the slides for 30 seconds. The slides were then placed into water until the sections 
turned blue and then dehydrated in 3 chambers of 100% ethanol then xylene for 3 minutes 
each. Slides were mounted and viewed.  
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2.16.2      Immunohistochemical staining for JUND and CD68 on human renal 
biopsies 
The Immunohistochemical staining for JUND and CD68 in human renal biopsies was 
performed by Ms Sarah Horton, Senior Biomedical Scientist in the Department of Histology, 
Hammersmith Hospital. The methodology allows for the detection of specific antigens in 
tissues based on antigen-antibody interactions and the site of the antibody binding can be 
identified by using secondary labelling methods. To do this, secondary antibodies against the 
rabbit primary antibodies used was conjugated to a poly-HRP reagent to allow visualisation 
as it produces an insoluble brown precipitate when incubated with the chromogen 
diaminobenzidine (DAB). Antigen retrieval was performed using a heat method where 
samples were heated using a microwave in 0.01M citrate buffer for 20 minutes. 
 
2.16.3      Southwestern histochemistry 
2.16.3.1 Sample preparation and probe incubation 
Kidney sections had been previously fixed in 4% formaldehyde in phosphate-buffered saline 
(PBS) and dehydrated prior to embedding in paraffin wax. Sections were cut 4μm thick, 
dewaxed in xylene and rehydrated. The sections were first incubated with 5mmol/L 
levamisole (Sigma-Aldrich) to quench endogenous alkaline phosphatase for 30 minutes at 
room temperature. The samples were washed with PBS then fixed with 0.2% 
paraformaldehyde for 30 minutes at 28
0
C. Preparations were digested with 0.5% pepsin A 
(433 U/mg; Sigma) in 1 N HCL for 35 minutes at 37
0
C. They were washed twice with buffer 
1(HEPES-bovine serum albumin (BSA) buffer (10mmol/L HEPES, 40mmol/L NaCl, 10mM 
MgCl2, 1mmol/L dithiothreitol (DTT), 1mmol/L EDTA, and 0.25% BSA, pH 7.4) and 
incubated with 0.1mg/ml DNase I in buffer 1 for 30 minutes at 30
0
C and washed once with 
buffer 2 (buffer 1 with 10mM EDTA instead of 10mM MgCl2) to end the reaction. The 
sections were exposed over three minutes to decreasing alcohol gradients (70%, 90%, and 
100%). The labelled probes were diluted in buffer 1 containing 0.5μg/ml poly (dI-dC) 
(Pharmacia LKB, Piscataway, NJ, USA) at a range of concentrations from 100pM to 
20000pM concentration. 100μl of this solution was applied to each slide and they were 
incubated overnight at 37
0
C in a humidified box. 
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2.16.3.2 Preparation of probes 
Double stranded oligonucleotide probes used were as used in publications of the technique 
(Hernandez-Presa et al., 1999; Mezzano et al., 2001; Zheng, 2006). The sense AP-1 probe 
used was 5’-CGCTTGATGAGTCAGCCGGAA-3’ and the mutant AP-1 probe used was 5’ 
CGCTTGATAAATCAGCCGGAA-3’ as per Hernandez-Presa (Hernandez-Presa et al., 
1999). The probes were resuspended using TE buffer (Sigma-Aldrich) and were annealed 
with their complementary DNA using a thermocycler and heating them to 95
o
C for 2 minutes 
then ramping cooling to 25
o
C over a period of 4
o
C. They were subsequently aliquoted and 
stored at -20
o
C. 
 
Digoxigenin labelling of the oligonucleotides was carried out using the DIG oligonucleotide 
3’-end labelling kit as per manufacturer’s instructions. 1μl of 100μM primer was diluted in 
9μl RNase free water then 4μl of 5x reaction buffer, 4μl of CoCl2, 1μl of  DIG-dUTP and 1μl 
(400 units) terminal transferase were added on ice. The sample was mixed and centrifuged 
then incubated at 37
0
C for 15 minutes and placed on ice. The reaction was stopped by adding 
2μl 0.2M EDTA (pH 8.0). 
 
2.16.3.3 Detection of labelled probes 
On day 2, the sections were washed twice with buffer 1 and washing buffer (0.03% Tween 20 
in buffer 1, consisting of 0.1mol/L maleic acid, 0.15mol/L NaCl, pH 7.5) then incubated for 1 
hour in blocking solution (0.1 x SSC, 0.1% SDS diluted 1:10 in washing buffer). The 
preparations were washed once more in washing buffer then incubated with anti-digoxigenin 
antibody conjugated with alkaline phosphatase (1:250 in blocking solution; Boehringer 
Mannheim) overnight at 4
0
C. 
 
On day 3 the sections were washed with washing buffer and buffer 3 (Tris-HCL 0.1M, 0.1M 
NaCl, 50mM MgCl2, pH9.5). The alkaline phosphatase was visualised using detection 
solution (45μl NBT (nitroblue tetrazolium chloride) solution and 35μl 5-bromo-4-chloro-3-
indolyl-phosphate (NBT/BCIP)) in 10ml of RNase free water and the colour developed in the 
dark at 37
0
C for one hour or until a visible precipitate developed. The reaction was stopped 
by incubation in TE buffer (10mM Tris and 1mM EDTA pH 8.0) and the samples mounted in 
glycerol. 
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2.17 In silico analysis techniques 
2.17.1      Primer design 
The design of primers used for the PCR and sequencing of human DNA (2.11.1, 2.13.1) was 
carried out using Primer3plus (http://www.bioinformatics.nl/cgi-
bin/primer3plus/primer3plus.cgi) (Rozen and Skaletsky, 2000; Untergasser et al., 2007). 
Primers for this application were designed with an optimum primer size of 20 (range 18-27) 
and an optimal primer melting temperature (Tm) of 60
o
C (range 57.0-63.0
0
C) for amplicons 
in the size range of 500-750bp.  Primers for use in qRT-PCR experiments for gene expression 
(2.15.2) and qPCR of ChIP enriched DNA (2.15.3) were designed in Primer-BLAST 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) which uses Primer3 as above to design the 
primers but then automatically analyses them using a BLAST search to avoid nonspecific 
primer pairs (Altschul et al., 1990).  Primers were designed to have a product size in the 
range of 100-140bp for cDNA use with an optimal Tm of 60.0
o
C (range 57.0-63.0
o
C). Where 
possible, primers used for qRT-PCR for gene expression were designed to span exon-exon 
junctions. 
 
2.17.2      Analysis of Sanger sequencing results using Sequencher 
DNA sequences generated by Sanger Sequencing as per  2.12 were analysed using 
Sequencher v4.8 (Gene Codes Corporation, Ann Arbor, Michigan, USA). Both forward and 
reverse sequencing reads were analysed to ensure accurate call of any polymorphisms seen. 
 
2.17.3      Analysis of genotyping experiments 
Amplified samples were analysed using the allelic discrimination programme within SDS 
v2.3 (Applied Biosystems). Statistical analyses were performed using analysis tools included 
in Haploview v4.2 (Barrett et al., 2005). The methodology and statistical analyses were 
performed with advice from Dr Deborah Cunningham-Graham, Immunogenetics, Department 
of Medical and Molecular Genetics, King’s College, London. 
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2.17.4      Analysis of qRT-PCR experiments 
qRT-PCR reactions as detailed in 2.15.2 were analysed in SDS v2.3 in order to extract Ct values 
and assess reaction efficiency and primer specificity. The linear scale amplification plot was 
inspected and the baseline set so that the amplification curve growth begins at a cycle number 
greater than the stop baseline cycle. The default setting in the SDS software system uses a range 
of cycles 3-15 and this was kept at default unless the individual reaction required alteration. The 
threshold Ct was set in the exponential phase of the PCR reaction. The standard curve reactions 
for a primer were analysed to generate the R2 value to evaluate the performance of the reaction. 
The R2 is the coefficient of correlation obtained for the standard curve and the reaction was 
deemed acceptable if the R2 was >0.99. The ideal efficiency of a PCR reaction should be 100% 
meaning that for each cycle the amount of product doubles. The efficiency of the reaction was 
calculated by the SDS v2.3 software and is derived from the slope of the standard curve. An 
efficiency of 100% equates to a reaction slope of -3.32. A reaction was acceptable if it had an 
efficiency of between 90% and 110% which corresponds to a slope range between -3.58 and         
-3.10.  
 
Ct values for the gene of interest and the housekeeping gene were exported to SDS software 
v2.3. Technical duplicate or triplicate Ct values were averaged to obtain one value per 
biological replicate or standard curve sample and a maximum standard deviation of 0.2 was 
used as the threshold for excluding one of the technical replicate samples from the averaging 
and downstream analysis. The housekeeping gene used was hypoxanthine guanine 
phosphoribosyl transferase (HPRT) as previously published (Maratou et al., 2010). The 2
-ΔΔCt
 
method was used to calculate the relative expression levels of transcript in the samples where: 
 
ΔCt= ΔCtsample – ΔCtreference 
 
As the 2
-ΔΔCt
 method was used to calculate the relative expression levels, the amplification 
efficiencies of the target and endogenous housekeeping reference had to be similar. The 
relative expression levels were calculated using Excel and the results then visualized in 
GraphPad Prism v5.02 (GraphPad Software, Inc. La Jolla, CA, USA) and analysed using one-
way and two-way analyses of variance (ANOVA), depending on whether static timepoints or 
a timecourse were assessed, followed by Bonferonni’s multiple comparison posttest to 
compare different rat strains and time points. A Bonferroni-corrected P-value <0.05 was 
considered statistically significant. 
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2.17.5      Analysis of qPCR from ChIP enriched DNA 
For the analysis of ChIP enriched DNA qPCR, the standard curve method was used to 
calculate the % Input level of the transcription factor binding at the investigated locus. The 
standard curve was constructed from the Input DNA sample for the appropriate strain and 
condition and analysed within the SDS software v2.3. For each test gene the % Input levels 
were then determined using %total = 2
ΔCt x (% of input sample used) where Δ = Ct (Input) - 
Ct (sample). Fold change over IgG was expressed using 2
-ΔCt
 where ΔCt= ΔCtJund – ΔCtIgG. 
 
2.17.6      Microarray analysis 
2.17.6.1 Quality control overall of microarray samples 
Following sample hybridisation and scanning of the individual arrays, Affymetrix Expression 
Console v1.1.2 was used to assess the overall quality control of each batch within the array 
experiment and overall using Robust multichip average (RMA) normalisation (Bolstad et al., 
2003; Irizarry et al., 2003) and Affymetrix default chip annotations. The main quality control 
indices examined were the bacterial spike in controls for the hybridisation stage (2.8.3) and 
the Poly-A controls used in both the Affymetrix WT cDNA synthesis and Amplification kit 
(2.8.1) and the Ambion WT Expression Kit (2.8.4) to assess for uniformity of these controls 
as well as the overall mean probe signal and background signal as well as the overall signal 
histogram. Figure 2.10 illustrates example plots from one batch of a microarray experiment 
typical for the hybridisation and poly-A labelling controls using the Ambion ET expression 
kit.  
 
2.17.6.2 RMA normalisation and filtering of probes containing single nucleotide 
polymorphisms 
Probes defined on the Rat Gene 1.0 ST chip were filtered for the presence of the 2,520,602 
single-nucleotide polymorphisms and 689,940 insertions and deletions present between the 
WKY and LEW genomes derived from whole genome sequencing of the strains on the 
Illumina HiSeq platform  (Mr Santosh Atanur, Physiological Genomics and Medicine Group, 
MRC Clinical Sciences Centre, Imperial College, personal communication and unpublished 
data) through the creation of a custom chip definition file (CDF) which also reflected the up 
to date information from current genome and transcriptome databases to give greater  
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Figure 2.10 Quality controls for Affymetrix Rat Gene 1.0 ST arrays 
This data demonstrates example plots for a single batch generated by Affymetrix Expression 
Console v1.1 for the main quality control measures including Poly-A controls used in the 
amplification and labelling process (A), bacterial spike in hybridisation controls (B) and 
mean positive match probes and background signals (C). Each line in (A) represents the 
results of one of the Poly-A spikes for each sample. Each line in (B) represents the eight 
different bacterial spike in hybridisation controls. The red line in (C) represents the mean 
positive matched probes detected and the blue line the mean background probe result. 
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accuracy of the probe set definitions than the standard Affymetrix CDF files (Dai et al., 
2005). The SNP filtering reduced the number of probes from 8,460,613 to 8,250,260, a 
reduction of 2.5% in total.  RMA normalisation was performed on the sample set and probe 
sets were removed that showed that a transcript was not expressed in the cell using a signal 
threshold of 100 (log2 value = 6.64). Probe sets were removed if this threshold was not 
passed in at least one sample from the whole series of strains and time points for that probe 
set.  
 
This analysis was performed by Dr Prashant Srivastava, Physiological Genomics and 
Medicine Group, MRC Clinical Sciences Centre, Imperial College. 
 
2.17.6.3 Detection of differentially expressed genes 
Detection of differentially expressed genes was carried out in two main ways. These analyses 
were performed by Dr Prashant Srivastava, Physiological Genomics and Medicine Group, 
MRC Clinical Sciences Centre, Imperial College. 
 
Significance analysis of microarrays (SAM) v3.0 (Tusher et al., 2001) was used to detect 
differentially expressed genes at static time points and for area under the curve timecourse 
analyses. The moderated T test within SAM was implemented using a q-value (FDR) 
threshold of 0.05 (5%) for significant differential expression. The area under the time curve 
analysis used by SAM was also used. Whilst SAM is implemented as an Excel plug-in 
allowing analyses to be performed, it only allows for a limited number of permutation 
corrections to be performed. Therefore the version implemented in R was used on a node 
cluster to perform 40,000 permutations to increase the robustness of the analysis. 
 
Timecourse analysis was performed using EDGE v1.1 (Storey et al., 2005; Leek et al., 2006; 
Storey et al., 2007). An R based GUI (graphical user interface) allowed for initial 
explorations of the algorithm and data to be made by Dr Richard Hull. The R implementation 
was used on a node cluster again to perform 40,000 permutations to increase the robustness 
of the analysis.  
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2.17.6.4 Hierarchical clustering 
Hierarchical clustering analysis was performed by Dr Prashant Srivastava, PGM Group, 
using hclust implemented in R 2.13.2. Complete clustering was performed with the Euclidean 
distance measure. The heatmap was created using heatmap.2, also implemented in R 2.13.2. 
 
2.17.6.5 Gene ontology and pathway analysis 
Gene ontology analysis was carried out using the functional annotation tools within DAVID, 
the Database for Annotation, Visualisation and Integrated Discovery v6.7 (Huang et al., 
2009a, b) to look for enriched functional terms specifically biological processes as well as 
enrichment for Kyoto Encyclopaedia of Genes and Genomes pathways (KEGG, 
http://www.genome.jp/kegg/pathway.html). Additional pathway analysis was performed 
using Gene Set Enrichment Analysis (GSEA) (Subramanian et al., 2005; Subramanian et al., 
2007). This is a computational method that determines whether an a priori set of genes shows 
statistically significant differences between two groups of samples. The gene sets used were 
the curated gene sets from the Molecular Signatures Database v 3.0 which sources gene sets 
from the BioCarta pathway database (http://www.biocarta.com/genes/index.asp)., the KEGG 
pathway data base (http://www.genome.jp/kegg/pathway.html) and REACTOME pathway 
database (http://www.reactome.org/). 
 
2.17.6.6 Motif enrichment analysis 
Two tools were used to perform motif enrichment analysis that aimed to predict the set of cis-
binding elements involved in the LPS gene response. MotifModeler (Liu et al., 2006) was run 
on default settings using the server based implementation of the algorithm 
(http://watson.compbio.iupui.edu/cgi-bin/webmotif/TFBSandmicroRNA.cgi) and the 
Transfac vertebrate motifs (version 2009 consisting of 673 matrices) was used. Motifs were 
identified as significantly enriched when ranked greater than two standard deviations above 
the mean value for all the identified motifs. TransFind was also used to predict the set of cis-
binding elements (Kiełbasa et al., 2010).  The server based implementation was used 
(http://transfind.sys-bio.net/) on default settings using their promoter definition as a region 
800 base pairs upstream and 200 base pairs downstream of the transcriptional start site and 
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the Transfac vertebrate motifs (version 2009, 673 matrices) was used as the motif data set. A 
transcription factor matrix was defined as significant if the FDR was <0.05.  
  
2.17.7      ChIP-Seq data analysis 
2.17.7.1 Sequencing and Alignment of sequencing reads to rat genome 
Sequencing of the ChIP-Seq libraries was carried out on the high throughput Illumina 
Genome Analyzer II. Initial data processing was performed using Illumina Real Time 
Analysis (RTA) v1.6.32 software (equivalent to Illumina Consensus Assessment of Sequence 
and Variation, CASAVA 1.6) with default filter and quality settings. Reads were initially 
aligned using the ELAND extended algorithm (part of the Illumina Suite pipeline version 1.6) 
against the rat reference genome, RGSC3.4 (Gibbs et al., 2004) as part of the Illumina 
pipeline implemented by the CSC genomics laboratory bioinformatics support. However, 
reads that are mapped before quality filtering meaning low quality reads can be aligned to the 
reference which can in turn produce large numbers of false positive peaks. Therefore the data 
was first filtered for quality and these quality filtered reads were then realigned to the 
reference rat genome (RGSC3.4) using the Burrows Wheeler Alignment tool v0.5.9 (BWA) 
which uses an algorithm based on the Burrow-Wheeler Transform (Li and Durbin, 2009). 
Default parameters were used except for the parameters used to trim the reads based on Phred 
scaled base quality scores. Read ends were trimmed if Phred-scaled base quality scores 
dropped below 20. Phred quality scores were originally developed by the Phred base calling 
programme used in the Human Genome Project and characterise the quality of the DNA 
sequence and are linked to the base calling error probability. For example a Phred quality 
score of 10 is linked to 90% base call accuracy, 20 to 99%, 30 to 99.9%, 40 to 99.99% and 50 
to 99.999% accuracies. 
 
This analysis was performed by Mr Santosh Atanur, Physiological Genomics and Medicine 
Group, MRC Clinical Sciences Centre, Imperial College. 
 
2.17.7.2 Identification of JUND binding peaks using BayesPeak 
Reads that uniquely mapped to the reference genome were used to detect areas of enrichment 
with BayesPeak v1.1.3 (Spyrou et al., 2009; Cairns et al., 2011) using a posterior probability 
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threshold of 0.9. BayesPeak uses a hidden Markov model to the aligned reads by dividing the 
genome into ‘jobs’ which are short regions on which the algorithm runs independently. These 
regions are split into smaller bins and the model applied and the process repeated on the 
whole job region offsetting all the bins by half their width. Each job gives a posterior 
probability of each of the sites being enriched and the data is then summarised to form the 
final set of peaks. Instead of the default setting of 0.5, a more stringent threshold of 0.9 was 
used to filter all the bins passing the threshold to form the final contiguous peak regions as 
this produced a more accurate reflection of true peak calls. As part of the quality control, an 
over fitting diagnostic was performed using λ1 < 0.7 and score < -2.25 which aim to filter out 
those regions which show no enrichment but had a high enough background for the algorithm 
to try and call peaks in. 
 
This analysis was performed by Dr Prashant Srivastava, Physiological Genomics and 
Medicine Group, MRC Clinical Sciences Centre, Imperial College. in consultation with Dr 
Christiana Spyrou, Integrative Genomics and Medicine Group, MRC Clinical Sciences 
Centre, Imperial College. 
 
2.17.7.3 Annotation of peaks 
The interval files for areas of binding enrichment or peaks generated by the calling 
algorithms were annotated using CARPET (Cesaroni et al., 2008). The gene intervals notator 
(GIN) implemented in CARPET was used to assign the peak regions to known Ensembl 
transcripts using a gene priority approach to give the associated transcript I.D., the associated 
gene feature and the distance of the peak to the nearest transcriptional start site. 
 
2.17.7.4 Motif analysis 
HOMER was used to predict motif occurrence within peaks (Barish et al., 2010; Heinz et al., 
2010) with default settings for a maximum motif length of 12 base pairs. This analysis was 
Dr Prashant Srivastava, PGM group. 
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2.17.7.5 Peak visualisation 
The outputs of the peak calling algorithms were visualised in the IGV genome browser (Kent 
et al., 2002) using custom WIG files generated from the output data generated by BayesPeak.  
These files were created by Dr Prashant Srivastava, PGM Group. 
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Chapter 3. The WKY and LEW macrophage transcriptomes 
– insights into macrophage function in the NTN 
model 
3.1 Introduction 
The aim of the work presented in this chapter was to investigate how the transcriptomes of 
bone marrow-derived macrophages (BMDMs) derived from the NTN-susceptible WKY 
strain and the NTN-resistant LEW strain differed over a timecourse of lipopolysaccharide 
(LPS) stimulation. Understanding the nature of these transcriptomic differences and the 
response to LPS could give insights into why BMDMs from the two strains differ in their 
phenotypes and how this relates to their different susceptibility to NTN. 
 
3.1.1      Transcriptome analysis previously identified differences between the WKY 
and LEW transcriptomes 
Differences in the macrophage transcriptomes were originally identified by examining the 
profiles of bone marrow derived macrophages (BMDMs)  in the basal state and following 24 
hours of lipopolysaccharide (LPS) stimulation (Maratou et al., 2010). This study found 
distinct differences in the transcriptome profiles of the two strains, identified potential new 
candidates for the Crgn3-7 quantitative trait loci (QTL) and defined groups of genes that 
could play a role in the differential regulation of macrophage activity. As discussed below, 
major transcriptome changes occur in macrophages in the early time period following LPS 
stimulation. Importantly the previous work was not designed to capture this early response of 
macrophages to stimulation.  The work in this chapter therefore aims to understand better 
these early changes in response that may define macrophage behaviour and give more 
insights into the macrophage role in the NTN model.  
 
3.1.2      Toll like receptors and the response to lipopolysaccharide (LPS) in 
macrophages 
Macrophages possess a wide range of receptors on their surface to detect antigens from 
invading pathogens as well as by-products of inflammation. These include phagocytic 
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receptors such as non-opsonic receptors for example C-type lectins and opsonic receptors for 
example the Fc receptors. Pattern recognition receptors including the toll-like receptor four 
(TLR4) against microbial products are located on the cell surface whilst others, including the 
NOD-like receptors, RIG-like receptors and the DNA sensor AIM2, are located in the 
cytoplasm of the cell (Plüddemann et al., 2011). 
 
As a pattern recognition receptor, TLR is able to detect both pathogen-associated molecular 
patterns (PAMPs) and endogenous damage associated molecular patterns (DAMPs) which 
include degradation products of extracellular matrix, heat shock proteins, chromatin-DNA 
and ribonucleoprotein complexes and immune complex-containing self-antigens (Kawai and 
Akira, 2010; Rosin and Okusa, 2011). Their activation initiates a well characterised and 
robust innate immune response in the macrophage turning on transcriptional programmes that 
allow the macrophage to respond to the stimulus. LPS derived from bacterial cell walls is 
used as an agonist for TLR4 receptors in in vitro experiments and it activates two major 
signalling pathways; the Myd88-dependent pathway leading to induction of nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) and mitogen-activated protein 
(MAP) kinases, and the TRIF-dependent pathways leading to the activation of interferon 
regulatory factors (IRFs) and NF-κB. The result of the activations is the production of 
inflammatory cytokines, type 1 interferon and chemokines (Kawai and Akira, 2010, 2011).  
 
The investigation of the response to LPS in macrophages has wide implications for 
macrophage biology as a way of gaining insights into the mechanisms that underlie the 
complex responses to infection and tissue injury that occur. It has been recognised for some 
time that the changes in mRNA expression that occur following LPS stimulation are rapid, 
occurring within minutes to a few hours, and are also widespread, with only a minority of 
genes not altering in their level of expression. Many genes that are expressed at high levels 
prior to stimulation are repressed by LPS (Hume et al., 2002; Nau et al., 2002; Ravasi et al., 
2007; Ramsey et al., 2008). Whilst critical for an organism’s immune response to infection, 
an inappropriate TLR response can lead to acute and chronic inflammation and autoimmune 
disease (Kawai and Akira, 2010). There is also growing evidence that TLR4 receptors play an 
important role in renal glomerular disease and autoimmunity (Brown et al., 2007; Robson, 
2009; Giorgini et al., 2010; Summers et al., 2010a; Summers et al., 2010b) along with a role 
for DAMPS in contributing to the pathogenesis of acute and chronic kidney disease (Rosin 
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and Okusa, 2011). In the rat NTN model, initial activation of the macrophages is most likely 
due to recognition of glomerular bound immunoglobulin G (IgG) by Fc-receptors, which may 
account for the important impact and effects of both the Crgn1 and Crgn2 loci on disease 
susceptibility. DAMPs created in this hyper-acute response particularly in WKY BMDMs 
could also lead to heightened responses in these cells accounting for some of the phenotypic 
differences that have been seen in disease outcome. LPS was chosen as the stimulus therefore 
for its ability to initiate robust transcriptional responses in BMDMs giving insights into the 
genetic mechanisms underlying the different responses to stimulation in the strains.  
 
3.2 Results 
3.2.1      Dynamic transcriptome changes occur in response to LPS stimulation in 
both WKY and LEW BMDMs 
The analyses of the microarray dataset detailed in this chapter aimed to gain understanding of 
how BMDMs from the NTN-susceptible WKY strain and the NTN-resistant LEW strain 
responded to LPS stimulation at the transcriptional level and to see whether any fundamental 
differences in this response could be seen between the strains. The analysis of the microarray 
dataset detailed in Chapter 4 details the comparisons between WKY and WKY.LCrgn2 
BMDMs to investigate the effect of the introgression of the Crgn2 locus from the LEW strain 
on macrophage gene expression in WKY BMDMs. 
 
Significance analysis of microarrays (SAM) v3.0 (Tusher et al., 2001) using 40,000 
permutations with a FDR threshold of 5% as per Methods 2.17.6 was used to analyse the 
normalised and filtered expression values derived from the microarrays. This analysis was 
carried out by Dr Prashant Srivastava, Physiological Genomics and Medicine Group, MRC 
Clinical Sciences Centre. The microarray experiment data is presented to the Minimum 
Information About a Microarray Experiment standards (MIAME 2.0) as an appendix on the 
DVD enclosed with this thesis (Brazma et al., 2001). This data presentation includes the raw 
data files produced by the microarray image analysis software, the processed data for the set 
of hybridisations in the experiment and the essential sample annotation for the hybridisations. 
The experimental data processing protocols are detailed in Chapter 2, sections 2.4, 2.8 and 
2.17.6. The full dataset of all genes showing significant differential expression at a <5% FDR 
threshold are listed in a supplementary appendix on the enclosed DVD. 
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LPS stimulation induced a strong transcriptional response in both WKY and LEW BMDMs 
with large numbers of genes increasing their expression upon stimulation but, of note, the 
majority of genes were downregulated (Table 3.1). The four hours of LPS stimulation 
timepoint showed the greatest number of differentially expressed genes during the timecourse 
compared to the basal state. Figure 3.1 demonstrates that the majority of genes that are 
differentially expressed following LPS stimulation are common to both strains. Across all the 
time point comparisons it was notable that LEW BMDMs showed a greater number of 
significantly differentially expressed genes than the WKY BMDMs and proportionally fewer 
were down regulated. However, the number of differentially expressed genes exhibiting fold 
differences greater than threefold was comparable in each strain at each time point (Table 
3.2) and the majority were common between the strains (Figure 3.2) suggesting that the 
strongest responses to LPS in each strain were highly similar.  
 
3.2.1.1 Functional consequence analysis of differentially expressed gene sets 
At the earliest timepoint of two hours LPS stimulation, 7,509 genes in WKY and 10,234 
genes in LEW BMDMs were differentially expressed demonstrating how early and 
widespread the response to LPS is and highlighting that these early responses to the stimulus 
could be critical in defining the overall response of the BMDMs. Functional consequence 
analysis was performed to understand better the sets of genes making up this response using 
the Database for Annotation, Visualization and Integrated Discovery (DAVID) (Huang et al., 
2009a, b). DAVID was used both to investigate enriched biological process functional terms 
using the BP_FAT subset which filters the broadest GO terms so that they do not overshadow 
the more specific terms and enrichment for KEGG (Kyoto Encyclopedia of Genes and 
Genomes) canonical pathways (Kanehisa and Goto, 2000; Kanehisa et al., 2006; Kanehisa et 
al., 2010). The cut-off for enrichment of both biological process terms and KEGG pathway 
terms was set at <5% FDR and fold enrichment >1.5. 
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Table 3.1 Microarray results detailing the numbers of differentially expressed genes  
following LPS stimulation in WKY and LEW BMDMs  
 
Results detailing differentially expressed transcripts in the WKY and LEW strains (four 
biological replicates per strain) at each timepoint compared to the basal state using SAM v3.0 
(Tusher et al., 2001) with 40,000 permutations and a <5%FDR threshold. Numbers within 
brackets detail percentage of the total number of differentially expressed genes at that 
timepoint comparison.  
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Figure 3.1 Venn diagram of differentially expressed genes following LPS 
stimulation between WKY and LEW BMDMs 
The Venn diagrams displayed show the unique and common differentially expressed genes 
between WKY and LEW BMDMS following LPS stimulation between the basal state and 
two hours (A), four hours (B) and eight hours (C) of LPS stimulation. Statistical methods for 
detecting differential gene expression between baseline and each timepoint are detailed in 
Table 3.1. 
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Table 3.2 Numbers of differentially expressed genes demonstrating fold changes 
greater than three-fold following LPS stimulation in WKY and LEW BMDMs 
 
Statistical methods for detecting differential gene expression between baseline and each 
timepoint are detailed in Table 3.1. 
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Figure 3.2 Venn diagram of differentially expressed genes following LPS 
stimulation demonstrating fold changes greater than three-fold between WKY 
and LEW BMDMs 
The Venn diagrams displayed show the unique and common differentially expressed genes 
with a greater than threefold change in expression between WKY and LEW BMDMS 
following LPS stimulation between the basal state and two hours (A), four hours (B) and 
eight hours (C) of LPS stimulation. Statistical methods for detecting differential gene 
expression between baseline and each timepoint are detailed in Table 3.1. 
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This analysis demonstrated that the main LPS response between WKY and LEW BMDMs is 
common between the strains. Multiple terms were significantly enriched for genes with 
increased expression in WKY BMDMs following two hours LPS stimulation (Table 3.3) 
including immune responses, regulation of cell death and apoptosis, cytokine production and 
the responses to molecules of bacterial origin and lipopolysaccharide. Enriched pathways 
included the NOD like receptor signalling pathway, toll-like receptor signalling pathway and 
the mitogen-activated protein kinase (MAPK) signalling pathway. Genes downregulated after 
two hours of LPS stimulation in the WKY (Table 3.4) were enriched for DNA metabolic and 
repair processes as well as RNA processing and transcription and pathways such as ubiquitin 
mediated proteolysis and cell cycle indicating the downregulation of more homeostatic 
cellular functions was occurring in response to LPS stimulation. A highly similar pattern of 
enrichment was observed in both the sets of genes with increased expression in LEW 
BMDMs (Table 3.5) and with decreased expression (Table 3.6). 
 
3.2.1.2 Motif enrichment analysis 
Motif enrichment analysis was performed on the sets of differentially expressed genes to 
understand the major transcription factor groups that might be driving gene expression 
changes by detecting enrichment for known transcription factor binding motifs in the genes’ 
regulatory regions. The groups of transcription factors that commonly regulate the LPS 
response are well recognised and in particular the NF-κB family and the IRF family have key 
roles to play in driving the inducible expression of genes. The motif enrichment analysis in 
the promoter of genes was performed by combining the results of two separate tools.  
 
MotifModeler was used to predict the set of cis-binding elements involved in the gene 
response (Liu et al., 2006).  It is based upon the premise that gene expression is controlled by 
the combined actions of transcription factors present at different expression levels and by the 
numbers of their binding motifs within the regulatory region of the gene (Liu et al., 2006).  
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Table 3.3 Gene ontology analysis using DAVID for genes demonstrating increased 
expression in WKY BMDMs following 2 hours of LPS stimulation compared to basal 
state 
 
Enrichment for biological process functional annotation terms and KEGG canonical 
pathways used a threshold of <5% FDR and fold enrichment >1.5. Top ten terms in each 
category are listed. 
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Table 3.4 Gene ontology analysis using DAVID for genes demonstrating decreased 
expression in WKY BMDMs following 2 hours of LPS stimulation compared to basal 
state 
 
Enrichment for biological process functional annotation terms and KEGG canonical 
pathways used a threshold of <5% FDR and fold enrichment >1.5. Top ten terms in each 
category are listed. 
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Table 3.5 Gene ontology analysis using DAVID for genes demonstrating increased 
expression in LEW BMDMs following 2 hours of LPS stimulation compared to basal 
state 
 
Enrichment for biological process functional annotation terms and KEGG canonical 
pathways used a threshold of <5% FDR and fold enrichment >1.5. Top ten terms in each 
category are listed. 
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Table 3.6 Gene ontology analysis using DAVID for genes demonstrating decreased 
expression in LEW BMDMs following 2 hours of LPS stimulation compared to basal 
state 
 
Enrichment for biological process functional annotation terms and KEGG canonical 
pathways used a threshold of <5% FDR and fold enrichment >1.5. Top ten terms in each 
category are listed. 
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This algorithm used the Transfac vertebrate motifs data set (version 2009.4, 673 matrices) 
and gene expression data in a linear modelling approach to identify the set of motifs that best 
explain the gene expression data pattern. It allows for the contribution of each motif to the 
transcriptional process (transcriptional contribution score, TCS) to be derived which is the 
measure used to select the set of motifs that best fit the data and the estimated functional level 
of the transcription factor to also be calculated (Xm score).  
 
The second tool used was TransFind (Kiełbasa et al., 2010) which uses an approach that 
predicts a binding affinity of a transcription factor overall to a promoter region not just the 
individual bindings sites within them (Roider et al., 2007). TransFind also uses the 
TRANSFAC vertebrate matrices data set (version 2009.4, 673 matrices) as the reference set. 
The algorithm uses a Fisher’s exact test to quantify enrichment of the putative high affinity 
targets of a transcription factor in the data set and correction for multiple testing is then 
performed. A transcription factor matrix is deemed as significant if the FDR is <0.05. An 
overlap between the significantly enriched transcription factor binding sites was then used to 
define the list of enriched factors. 
 
The motif enrichment analysis demonstrated that the main transcription factors driving the 
LPS response were common to each strain. The motif enrichment analysis in genes 
demonstrating increased expression in WKY BMDMs following two hours LPS stimulation 
(Table 3.7) identified that NF-κB and IRF motifs along with a signal transducer and activator 
of transcription (STAT) protein binding motif made up the majority of the enriched motifs. 
The picture in LEW BMDMs was similar (Table 3.7) with similar enrichment for NF-κB and 
IRF demonstrated. Genes downregulated after LPS stimulation demonstrated enrichment for 
CREB and E2F transcription factors in both WKY and LEW BMDMs (Table 3.8)  
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Table 3.7 Motif enrichment analysis of genes demonstrating increased expression in 
WKY or LEW BMDMs following 2 hours of LPS stimulation compared to basal state 
 
Enriched TRANSFAC vertebrate transcription factor binding sites (TFBS) in common 
between MotifModeler and TransFind. The transcription factor binding site ID given is the 
enriched TRANSFAC vertebrate motif identified. Enriched TFBS from MotifModeler 
selected on basis of a transcriptional contribution (TCS) score two standard deviations above 
the mean value for all the TFBS identified. A higher TCS score indicates a stronger 
contribution. MotifModeler Xm score is the estimated functional level of the transcription 
factor. Factors identified by TransFind selected on basis of enriched TFBS with an FDR<5%.  
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Table 3.8 Motif enrichment analysis of genes demonstrating decreased expression 
in WKY or LEW BMDMs compared to basal state following 2 hours of LPS stimulation 
 
Enriched TRANSFAC vertebrate transcription factor binding sites (TFBS) in common 
between MotifModeler and TransFind. The transcription factor binding site ID given is the 
enriched TRANSFAC vertebrate motif identified. Enriched TFBS from MotifModeler 
selected on basis of a transcriptional contribution (TCS) score two standard deviations above 
the mean value for all the TFBS identified. A higher TCS score indicates a stronger 
contribution. MotifModeler Xm score is the estimated functional level of the transcription 
factor. Factors identified by TransFind selected on basis of enriched TFBS with an FDR<5%.  
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3.2.2      Differential gene expression analysis between WKY and LEW BMDMs 
The analysis of the LPS response in WKY and LEW BMDMs identified a clear pattern of 
common gene responses to LPS driven by a similar set of transcription factors but there were 
differences in the response as demonstrated by the numbers of genes that altered during the 
LPS response (Figures 3.2 and 3.3). This was confirmed by the analysis of differentially 
expressed genes at each the individual timepoints during the LPS response (Table 3.9). SAM 
v3.0 with a FDR threshold of 5% following 40,000 permutations as per Methods 2.17.6 
(Tusher et al., 2001) was used to analyse the normalised and filtered expression values 
derived from the microarrays. This analysis was carried out by Dr Prashant Srivastava, 
Physiological Genomics and Medicine Group, MRC Clinical Sciences Centre. The 
microarray experiment data is presented as an appendix on the DVD enclosed with this thesis 
along with the full lists of the differentially expressed genes from the comparison of the 
WKY and LEW BMDMs for each timepoint. 
 
3.2.2.1 Differential gene expression in basal BMDMs 
As shown in Table 3.9, 1,926 genes were differentially expressed between the WKY and 
LEW strains in the basal condition, of which 1,022 (53%) showed higher expression in WKY 
BMDMs and 904 (47%) had higher expression in LEW BMDMs. At this timepoint, 16 genes 
demonstrated very strong differential gene expression of greater than 5-fold (Table 3.10). 
The genomic location of the genes with reference to the Crgn3-7 QTL regions using the 
limits to the QTL regions, as previously published (Aitman et al., 2006; Maratou et al., 2010), 
was also investigated. Of the nine genes with higher expression in WKY BMDMs, only one 
gene, Cyp2j4, cytochrome P450, family 2, subfamily j, polypeptide 4, was located in a Crgn 
QTL locus, Crgn5. In the LEW BMDMs, three genes out of seven demonstrating greater than 
5-fold expression difference were located in Crgn1 namely SH2 domain containing 1B 
(Sh2d1b), transforming growth factor, beta 2 (Tgfb2) and Fcgr3, Fc fragment of IgG, low 
affinity IIa, receptor (CD32). Fcgr3 was previously positionally cloned as the candidate gene 
for Crgn1 (Aitman et al., 2006). It is worth noting that the positional candidate for Crgn2, 
Jund was differentially expressed between WKY and LEW BMDMs at the <5% FDR 
threshold but, similar to previous findings, the fold difference between the strains was more 
modest at 1.27-fold higher in WKY BMDMs (Maratou et al., 2010). 
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Table 3.9 Microarray results detailing the numbers of differentially expressed genes 
between WKY and LEW BMDMs at each timepoint 
 
Results detailing differentially expressed transcripts between WKY and LEW BMDMs at 
each timepoint (four biological replicates per strain) at each time point using SAM v3.0 
(Tusher et al., 2001) with 40,000 permutations and a <5%FDR threshold. 
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Table 3.10 Microarray results of transcripts demonstrating greater than five- fold 
difference in expression between WKY and LEW BMDMs in the basal condition 
 
Microarray results detailing differentially expressed transcripts with a fold change greater 
than 5-fold between WKY and LEW BMDMs (four biological replicates per strain) analysed 
using Significance analysis of microarrays (SAM) v3.0 (Tusher et al., 2001) with 40,000 
permutations and a <5% FDR threshold. Transcripts listed are sorted according to fold 
change. The presence of a transcript within a QTL for Crgn is listed. Transcripts encoding for 
pseudogenes were excluded from this table. The full dataset of genes demonstrating 
differential expression at <5%FDR are listed in a supplementary table in the appendix on the 
DVD enclosed with the thesis. A positive fold change indicates higher expression in WKY 
BMDMs. 
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Functional annotation analysis of the differentially expressed genes identified enrichment for 
multiple immune processes and regulation of programmed cell death and apoptosis in the 
overall gene set (Table 3.11 and Appendix A, Table A.1). KEGG pathway analysis (Table 
3.11) similarly showed a number of different immune processes in particular cell adhesion 
molecules, antigen processing and presentation and endocytosis fitting in with core functions 
of a macrophage as well as a number of immune disease pathogenesis pathways. However, 
analysing the whole gene set only gave a limited understanding of the contribution of 
overexpressed genes in each strain to their presumed phenotype. Analysing genes with higher 
expression in WKY basal BMDMs compared to LEW BMDMs (Table 3.12) found 
enrichment for immune response genes, antigen processing and presentation as well as other 
cellular functions such as lipid localization and transport and cofactor and coenzyme 
metabolic processes. In LEW basal BMDMs there was enrichment for lymphocyte mediated 
immunity, adaptive immune response and, unlike WKY BMDMS, for the regulation of 
programmed cell death (Table 3.13) suggesting different macrophage linked processes were 
enriched in the different strains. Pathway analysis only identified significant enrichment in 
WKY BMDMs, giving a similar picture to the whole gene set analysis in Table 3.11, 
suggesting genes differentially expressed with higher expression in WKY BMDMs played 
key roles in these basic macrophage functions.  
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Table 3.11 Gene ontology analysis using DAVID for genes demonstrating differential 
expression between WKY and LEW basal BMDMs 
 
Enrichment for biological process functional annotation terms and KEGG canonical 
pathways used a threshold of <5% FDR and fold enrichment >1.5. The top 20 biological 
process functional annotation terms are listed in this table. The full list of enriched terms is 
detailed in Appendix A, Table A.1. 
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Table 3.12 Gene ontology analysis using DAVID for genes demonstrating increased 
expression in WKY basal BMDMs compared to LEW basal BMDMs 
 
Enrichment for biological process functional annotation terms and KEGG canonical 
pathways used a threshold of <5% FDR and fold enrichment >1.5.  
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Table 3.13 Gene ontology analysis using DAVID for genes demonstrating increased 
expression in LEW basal BMDMs compared to WKY basal BMDMs 
 
Enrichment for biological process functional annotation terms and KEGG canonical 
pathways used a threshold of <5% FDR and fold enrichment >1.5.  
 
 
  
150 
 
3.2.2.2 Differential gene expression in two hour LPS stimulated BMDMs  
After two hours of LPS stimulation, 2,236 genes were differentially expressed between WKY 
and LEW BMDMs with 1,351 (60%) genes showing higher expression in WKY BMDMs and 
885 (40%) genes showing higher expression in LEW BMDMS (Table 3.9). There were 
fourteen genes differentially expressed with a strong fold difference greater than five (Table 
3.14). Five genes had higher expression in LEW BMDMs and were also found in the basal 
state comparison; transient receptor potential cation channel, subfamily C, member 6 (Trpc6), 
matrix metallopeptidase 7 (Mmp7), nephroblastoma overexpressed gene (Nov), Fcgr3a and 
Tgfb2. Of the nine genes with higher expression in WKY BMDMs, only four genes (Cyp2j4, 
fatty acid desaturase 2 (Fads2), zinc finger protein 334 (Zfp344) and pleckstrin homology 
domain containing, family H member 2 (Plekhh2)) were differentially expressed at this fold 
change in the basal state (Table 3.10). Five new genes now showed this robust level of 
differential expression and Cd244, Cd244 molecule natural killer cell receptor 2B4, was 
located in Crgn1.  
 
Functional annotation analysis was performed for individual sets of genes showing higher 
enrichment in each strain. With no fold change cut-off, enrichment was seen in WKY 
BMDMs for immune processes including responses to endogenous stimulus, molecule of 
bacterial origin, hormone stimulus and lipopolysaccharide but also for other cellular 
processes including cofactor and coenzyme metabolic processes, nitrogen compound 
biosynthetic process and  fatty acid metabolic process (Table 3.15). In contrast, there was 
widespread strong enrichment for multiple immune processes in LEW BMDMs including the  
response to wounding and inflammatory response as well as the regulation of cell death and 
apoptosis (Table 3.16 and Appendix A, Table A.2). KEGG pathway analysis found 
enrichment for non-immune cellular processes such as biosynthesis of unsaturated fatty acids, 
cell adhesion molecules, oxidative phosphorylation and nicotinate and nicotinamide 
metabolism in WKY BMDMs (Table 3.15). In LEW BMDMs there was enrichment for 
pathways in cancer and sphinoglipid metabolism (Table 3.16).  
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Table 3.14 Microarray results of transcripts demonstrating greater than five- fold 
difference in expression between WKY and LEW BMDMs following 2 hours of LPS 
stimulation  
 
Microarray results detailing differentially expressed transcripts with a fold change greater 
than 5-fold between WKY and LEW BMDMs (four biological replicates per strain) analysed 
using Significance analysis of microarrays (SAM) v3.0 (Tusher et al., 2001) with 40,000 
permutations and a <5% FDR threshold. Transcripts listed are sorted according to fold 
change. The presence of a transcript within a QTL for Crgn is listed. Transcripts encoding for 
pseudogenes were excluded from this table. The full dataset of genes demonstrating 
differential expression at <5%FDR are listed in a supplementary table in the appendix on the 
DVD enclosed with the thesis. A positive fold change indicates higher expression in WKY 
BMDMs. 
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Table 3.15 Gene ontology analysis using DAVID for genes demonstrating increased 
expression in WKY BMDMs compared to LEW BMDMs following two hours of LPS 
stimulation  
 
 Enrichment for biological process functional annotation terms and KEGG canonical 
pathways used a threshold of <5% FDR and fold enrichment >1.5.  
  
153 
 
Table 3.16  Gene ontology analysis using DAVID for genes demonstrating increased 
expression in LEW BMDMs compared to WKY BMDMs following two hours of LPS 
stimulation 
 
Enrichment for biological process functional annotation terms and KEGG canonical 
pathways used a threshold of <5% FDR and fold enrichment >1.5. The top 20 biological 
process functional annotation terms are listed in this table. The full list of enriched terms is 
detailed in Appendix A, Table A.2. 
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3.2.2.3 Differential gene expression in four hour LPS stimulated BMDMs  
There were 3,114 differentially expressed genes identified after four hours of LPS stimulation 
and again more genes had higher expression in the WKY strain, 1918 genes (62%), compared 
with the 885 genes (38%) in the LEW strain (Table 3.9). Eighteen genes demonstrated very 
strong differential gene expression of greater than fivefold difference and again WKY 
BMDMs had a greater proportion of this type of gene with 12 genes identified (Table 3.17). 
Additional genes had now demonstrated this strong fold change including epidermal growth 
factor receptor pathway substrate 15 (Eps15) lying in Crgn5 along with carbonic anhydrase 
5b (Car5b), mediator complex subunit 22 (Medd22) and arginase, liver (Arg1). Six genes 
were identified with greater than fivefold difference in the LEW BMDMs with only one 
additional gene identified, matrix metallopeptidase 8 (Mmp8).  
 
Functional enrichment analysis for all genes showing significantly higher expression in WKY 
BMDMs (Table 3.18 and Appendix A, Table A.3) was similar to the two hour LPS 
stimulation analysis with multiple cellular processes enriched along with immune response 
linked processes involving cell activation and responses to stimuli. In LEW BMDMs there 
was enrichment for multiple immune pathways again including positive regulation of 
MAPKKK cascade and protein kinase cascades (Table 3.19 and Appendix A, Table A.4). 
Enrichment for the regulation of programmed cell death and apoptosis was still present. 
KEGG pathway analysis enriched for the Toll-like receptor signalling pathway, pathways in 
cancer and cytokine-cytokine receptor interaction in both WKY and LEW BMDMs (Table 
3.18, 3.19).  
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Table 3.17 Microarray results of transcripts demonstrating greater than five- fold 
difference in expression between WKY and LEW BMDMs following four hours of LPS 
stimulation  
Microarray results detailing differentially expressed transcripts with a fold change greater 
than 5-fold between WKY and LEW BMDMs (four biological replicates per strain) analysed 
using Significance analysis of microarrays (SAM) v3.0 (Tusher et al., 2001) with 40,000 
permutations and a <5% FDR threshold. Transcripts listed are sorted according to fold 
change. The presence of a transcript within a QTL for Crgn is listed. Transcripts encoding for 
pseudogenes were excluded from this table. The full dataset of genes demonstrating 
differential expression at <5%FDR are listed in a supplementary table in the appendix on the 
DVD enclosed with the thesis. A positive fold change indicates higher expression in WKY 
BMDMs. 
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Table 3.18 Gene ontology analysis using DAVID for genes demonstrating increased 
expression in WKY BMDMs compared to LEW BMDMs following four hours of LPS 
stimulation 
 
Enrichment for biological process functional annotation terms and KEGG canonical 
pathways both used a threshold of <1% FDR and fold enrichment >1.5. The top 20 biological 
process functional annotation terms are listed in this table. The full list of enriched terms is 
detailed in Appendix A, Table A.3. 
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Table 3.19 Enrichment of biological process functional annotation terms and KEGG 
pathways from DAVID for genes demonstrating increased expression in LEW BMDMs 
compared to WKY BMDMS following four hours of LPS stimulation  
 
Enrichment for biological process functional annotation terms and KEGG canonical 
pathways used a threshold of <5% FDR and fold enrichment >1.5. The top 20 biological 
process functional annotation terms are listed in this table. The full list of enriched terms is 
detailed in Appendix A, Table A.4. 
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3.2.2.4 Differential gene expression in eight hour LPS stimulated BMDMs  
By eight hours of LPS stimulation, 2,090 genes were differentially expressed between WKY 
and LEW BMDMs. Of these genes, 1,282 (61%) had higher expression in WKY BMDMs 
and 808 (39%) had higher expression in LEW BMDMs (Table 3.10). At this timepoint, 
fourteen genes had a fold change greater than five (Table 3.20). Six of these genes were 
overexpressed in WKY BMDMs whilst eight were overexpressed in LEW BMDMs including 
a number of genes not previously demonstrating such a fold change including protein kinase 
A  (PRKA) anchor protein 5 (Akap5), mast cell antigen 32 (Mca32), ephrin B2 (Efnb2) and 
rat guanine nucleotide exchange factor (GEF) 5 (Rapgef5).  
 
Functional annotation analysis identified a predominance of immune related processes in 
genes at this time point with higher expression in WKY BMDMs including response to 
wounding, positive regulation of signal transduction and cell activation (Table 3.21). As 
previously there was also enrichment seen for similar immune processes in LEW BMDMs 
though notably no enrichment was seen for cell proliferation or regulation of cell death or 
apoptosis (Table 3.22 and Appendix A, Table A.5).  
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Table 3.20 Microarray results of transcripts demonstrating greater than five- fold 
difference in expression between WKY and LEW BMDMs following eight hours of LPS 
stimulation at <5% FDR 
 
Microarray results detailing differentially expressed transcripts with a fold change greater 
than 5-fold between WKY and LEW BMDMs (four biological replicates per strain) analysed 
using Significance analysis of microarrays (SAM) v3.0 (Tusher et al., 2001) with 40,000 
permutations and a <5% FDR threshold. Transcripts listed are sorted according to fold 
change. The presence of a transcript within a QTL for Crgn is listed. Transcripts encoding for 
pseudogenes were excluded from this table. The full dataset of genes demonstrating 
differential expression at <5%FDR are listed in a supplementary table in the appendix on the 
DVD enclosed with the thesis. A positive fold change indicates higher expression in WKY 
BMDMs. 
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Table 3.21 Gene ontology analysis using DAVID for genes demonstrating increased 
expression in WKY BMDMs compared to LEW BMDMs following eight hours of LPS 
stimulation  
 
Enrichment for biological process functional annotation terms and KEGG canonical 
pathways used a threshold of <5% FDR and fold enrichment >1.5.  
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Table 3.22 Gene ontology analysis using DAVID for genes demonstrating increased 
expression in LEW BMDMs compared to WKY BMDMs following eight hours of LPS 
stimulation  
 
Enrichment for biological process functional annotation terms and KEGG canonical 
pathways used a threshold of <5% FDR and fold enrichment >1.5. The top 20 biological 
process functional annotation terms are listed in this table. The full list of enriched terms is 
detailed in Appendix A, Table A.5). 
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3.2.2.5 Analysis of the overall LPS response in WKY and LEW BMDMs 
SAM v 3.0 (Tusher et al., 2001) was used to analyse the overall timecourse to identify genes 
that were consistently different between the strains through its implementation of a signed 
area algorithm. This calculates the area under the curve to detect differences in gene 
expression. Such an approach was important for this data set as it includes genes that can rise 
and fall during the timecourse of LPS stimulation. Application of this approach to the overall 
timecourse identified that 1259 genes were differentially expressed at <5% FDR with 792 
genes (63%) showing higher expression in WKJY BMDMs and 466 (37%) showing higher 
expression in LEW BMDMs (Figure 3.10). Genes showing significant fold enrichment over 
threefold higher in WKY BMDMs are listed in Table 3.23. No new genes lying in QTL 
regions with large fold differences were identified and many of the genes had been observed 
in the static timepoint analyses. Similarly, in LEW BMDMs, similar genes as had been 
identified in the static time point analyses were found (Table 3.24). 
 
Functional annotation analysis again revealed enrichment for cellular processes in WKY 
macrophages including oxidation reduction and fatty acid metabolic processes as had been 
seen before whilst in Lew BMDMs there was enrichment for the response to wounding and 
acute inflammatory response (Table 3.25).  
 
3.2.2.6 Motif enrichment analysis in differentially expressed gene sets 
The motif enrichment analysis of the LPS response in WKY and LEW BMDMs, as detailed 
in 3.2.2.2, identified the main transcription factors contributing to the LPS response after two 
hours of LPS stimulation. The contributions of the different factors to the response, as 
demonstrated by the different MotifModeler TCS and Xm scores (Table 3.7), suggested that 
the same transcription factors could be having different levels of functional effect in each 
strain. MotifModeler directly utilises the fold changes derived from differential gene 
expression data in its analysis. It was therefore used in isolation to gain an overall insight into 
the enriched transcription factor binding sites in the entirety of the differentially expressed 
gene sets between WKY and LEW BMDMs to understand the directionality of the 
contribution of different transcription factors to the differentially expression of genes.  
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Table 3.23 Microarray results of transcripts demonstrating greater than threefold 
difference in expression over the eight hour timecourse of LPS stimulation in WKY 
BMDMs over LEW BMDMs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Microarray results detailing differentially expressed transcripts with a fold change greater than 5-
fold between WKY and LEW BMDMs (four biological replicates per strain) analysed using 
Significance analysis of microarrays (SAM) v3.0 (Tusher et al., 2001) with 40,000 permutations 
and a <5% FDR threshold. Transcripts listed are sorted according to fold change. The presence of 
a transcript within a QTL for Crgn is listed. Transcripts encoding for pseudogenes were excluded 
from this table. The full dataset of genes demonstrating differential expression at <5%FDR are 
listed in a supplementary table in the appendix on the DVD enclosed with the thesis. A positive 
fold change indicates higher expression in WKY BMDMs  
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Table 3.24 Microarray results of transcripts demonstrating greater than threefold 
difference in expression over the eight hour timecourse of LPS stimulation in LEW 
BMDMs over WKY BMDMs 
 
Microarray results detailing differentially expressed transcripts with a fold change greater 
than 5-fold between WKY and LEW BMDMs (four biological replicates per strain) analysed 
using Significance analysis of microarrays (SAM) v3.0 (Tusher et al., 2001) with 40,000 
permutations and a <5% FDR threshold. Transcripts listed are sorted according to fold 
change. The presence of a transcript within a QTL for Crgn is listed. Transcripts encoding for 
pseudogenes were excluded from this table. The full dataset of genes demonstrating 
differential expression at <5%FDR are listed in a supplementary table in the appendix on the 
DVD enclosed with the thesis. 
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Table 3.25 Gene ontology analysis using DAVID for genes demonstrating increased 
expression in WKY or LEW BMDMs over the LPS stimulation timecourse   
 
 
Enrichment for biological process functional annotation terms and KEGG canonical 
pathways used a threshold of <5% FDR and fold enrichment >1.5.  
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Fitting in with the pattern of more genes showing higher expression in WKY BMDMs, the 
majority of enriched transcription factor binding motifs were linked with a positive 
MotifModeler Xm score fitting with a positive effect on transcription in favour of WKY 
BMDMs (Table 3.26). The motifs with the highest TCS and Xm score were in favour of 
WKY BMDMs and included three IRF binding motifs. There was enrichment for E4F1 and 
c-Myc in favour of LEW BMDMs. AP-1 transcription factor also showed enrichment in the 
basal state in favour of WKY BMDMs with a TCS score of 4.01E-03 and Xm score of 
8.89E+05. 
 
At two hours of LPS stimulation, 18 enriched transcription factor binding sites were 
identified all with Xm scores in favour of WKY gene expression (Appendix A, Table A.6). 
The overall range of TCS scores were lower than in the basal state suggesting a less strong 
drive on transcription. Again a predominance of IRF factors was seen along with other 
factors such as Oct-1, RORalpha2, YY1 and AP-1. By four hours of LPS stimulation, fewer 
factors were enriched in favour of WKY BMDMs (Appendix A, Table A.7). The landscape 
had also altered with loss of enrichment for IRF transcription factors and enrichment albeit 
with lower TCS scores for AhR and Sp-1 along with En-1, c-Ets2, Lef1, Stat and YY1 
showing that a new phase of the LPS response had been entered with different transcriptional 
regulators. However by eight hours of LPS stimulation the number of enriched binding sites 
had increased with strong TCS scores than previously (Appendix A, Table A.8). Enrichment 
was highest again in favour of WKY BMDMs and Stat4 was the most highly enriched whilst 
the HP1 site factor with a TCS score of 5.02E-03 was in favour of transcription in LEW 
BMDMs with an Xm score of -1.05E+06.  
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Table 3.26 Motif enrichment analysis of genes demonstrating differential expression 
between WKY and LEW basal BMDMs 
 
Enriched TRANSFAC vertebrate transcription factor binding sites (TFBS) in genes 
differentially expressed between WKY and LEW BMDMs. Genes with higher expression in 
WKY BMDMs were given a positive fold change whilst genes with LEW BMDMs were 
given a negative fold change. MotifModeler Xm score is the estimated functional level of the 
transcription factor. A positive Xm score indicates increased expression in favour of WKY 
BMDMs. Enriched TFBS from MotifModeler selected on basis of a transcriptional 
contribution (TCS) score two standard deviations above the mean value for all the TFBS 
identified. A higher TCS score indicates a stronger contribution. The transcription factor 
binding site ID given is the enriched TRANSFAC vertebrate motif identified. 
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3.2.3      Validation of microarray data 
Extensive experiments were carried out to validate the microarray-based gene expression data 
by quantitative PCR (qRT-PCR) as per Methods 2.15.2 which were analysed as per Methods 
2.17.2. Four biological replicates were analysed, each amplified in triplicate to ensure 
accuracy and reproducibility of the results. qRT-PCR results were normalised to the 
housekeeping gene hypoxanthine phosphoribosyl transferase (Hprt) as used in previous 
analyses (Maratou et al., 2010) and because its expression did not vary between the strains  
and timepoints (data not shown). Candidate genes were selected to include a set of genes 
encompassing a range of fold differences between the WKY and LEW strains. In addition, 
candidate genes underlying a Crgn QTL and candidate effector genes for macrophage 
function were selected. Sixteen candidate genes for validation were analysed using a two-way 
ANOVA to capture the extent of the LPS response over the timecourse and Bonferroni’s post 
tests were performed to identify at which time points there was a significant difference 
between the two strains in the context of the overall timecourse. Figures 3.3 and 3.4 are 
examples of the validation analysis used and the remaining results graphs are detailed in 
Appendix A, Figures A.1 to A.14. A plot of the normalised and SNP filtered expression 
values (log2 transformed) for the relevant gene is shown with each set of validations. Table 
3.27 summarises the timecourse data analysis validation with respect to the dataset detailed in 
3.2.2.3.  
 
In addition, the results of a separate data analysis of individual timepoint are detailed in 
Table 3.28 alongside the fold changes between WKY and LEW BMDMs from the relevant 
microarray analysis. Overall, the validation of the individual timepoints (Table 3.28) 
confirmed the microarray changes and directionality of fold changes seen between the WKY 
and LEW strains. Only the -1.34-fold difference identified by the microarray analysis for 
Ccr2 at two hours of LPS stimulation was not validated by qRT-PCR. There were six 
instances where the microarray data did not show a significant difference between the strains 
(marked ‘ns’ in the text) but a significant difference was detected on qRT-PCR analysis. A 
number of genes did show a marked difference in the fold changes identified, particularly for 
Arg1 where extensive fold differences in the qRT-PCR validation were found in comparison 
to the microarray data.  
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Figure 3.3 Validation of the microarray data for Cyp2j4, cytochrome P450, 
family 2, subfamily j, polypeptide 4, by qRT-PCR 
Validation of microarray data by qRT-PCR. (A) Microarray expression values (log2 
transformed). (B) Samples were amplified using a set of four biological replicates with three 
technical replicates per sample. Relative gene expression was measured by qRT-PCR and 
normalised with Hprt for WKY and LEW BMDMs. *P<0.05; **P<0.01;***P<0.001 
statistically significantly different to WKY using a two way ANOVA to compare the overall 
timecourse with Bonferonni’s post-tests to compare individual time points. (C) Two way 
ANOVA results of the overall timecourse indicating contribution of different factors to the 
variation seen in graph B. Error bars represent standard error of the mean 
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Figure 3.4 Validation of the microarray data for Mmp8, matrix 
metallopeptidase 8, by qRT-PCR 
Validation of microarray data by qRT-PCR. (A) Microarray expression values (log2 
transformed). (B) Samples were amplified using a set of four biological replicates with three 
technical replicates per sample. Relative gene expression was measured by qRT-PCR and 
normalised with Hprt for WKY and LEW BMDMs. *P<0.05; **P<0.01;***P<0.001 
statistically significantly different to WKY using a two way ANOVA to compare the overall 
timecourse with Bonferonni’s post-tests to compare individual time points. (C) Two way 
ANOVA results of the overall timecourse indicating contribution of different factors to the 
variation seen in graph B. Error bars represent standard error of the mean. 
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Table 3.27 Summary table of the analysis of the microarray validation over the 
overall LPS stimulation timecourse 
 
 
 
Microarray data for 16 genes over the eight hour LPS stimulation timecourse was validated 
by qRT-PCR. Microarray fold changes identified at <5% FDR for each timecourse 
comparison between WKY and LEW BMDMs using the signed area algorithm implemented 
in SAM v3.0 (Tusher et al., 2001) are listed, ns; non-significant at this threshold. Positive 
fold changes indicate upregulated expression in WKY BMDMs over the whole timecourse. 
qRT-PCR validation was carried using a set of four biological replicates with three technical 
replicates per strain. A two way ANOVA was used to compare the timecourse of gene 
expression changes between the two strains and the results above detail the significance of 
the contribution of strain, time and their interaction to the overall variation seen between the 
strains. The full data for the microarray and gene expression timecourse for these 16 genes 
are shown in Figures 3.3, 3.4 and Appendix A. Figures A.1 to A.14. 
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Table 3.28 Validation of microarray data for individual timepoints by quantitative 
PCR 
 
 
Microarray data for 16 genes was validated by qRT-PCR. Microarray fold changes at <5% 
FDR for each timepoint comparison between WKY and LEW BMDMs are listed, ns; non-
significant. Positive fold changes indicate upregulated expression in WKY BMDMs. qRT-
PCR validation was carried using a set of four biological replicates with three technical 
replicates per strain. Relative gene expression was normalised to Hprt and used to generate 
fold change values. Positive fold changes indicate upregulated expression in WKY BMDMs. 
A two-tailed unpaired t-test was used to detect statistically significant differences between the 
WKY and LEW replicates. The full data for the microarray and gene expression timecourse 
for these 16 genes are shown in Figures 3.3, 3.4 and Appendix A. Figures A.1 to A.14. 
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The examination of the overall timecourse gave useful insights into the overall LPS response 
between the strains. Cyp2j4 (Figure 3.3) is a candidate gene for the Crgn5 QTL and 
demonstrated significantly higher expression for the whole timecourse (P-value <0.0001 in 
the two-way ANOVA analysis) and at each timepoint in the WKY similar in the 
Bonferonni’s post-test analysis.  Interleukin 1 receptor antagonist (Il1rn) (Appendix A, 
Figure A.1) validation was successful as detailed in Table 3.27 and 3.28 demonstrating that 
a narrowing in the fold change difference in the differential gene expression between the  
strains was occurring. The overall LPS response analysis demonstrates the marked increase in 
expression at the four hour and eight hour timepoint that was occurring in response to LPS 
and these timepoints were identified as being significant between the strains. The validations 
for Arg1 (Appendix A, Figure A.2), Serpinb2 (Appendix A, Figure A.3) and Tnfrsf14 
(Appendix A, Figure A.4) demonstrated that the major responses and differences following 
LPS stimulation were occurring at the four hour and eight hour timepoint. Whilst the 
individual static timepoint analyses did demonstrate significant differences between the 
strains at the basal (0 hours) and two hour timepoints (Table 3.28), in the context of the 
whole response using Bonferroni’s post-test comparisons, they were not significant.  
 
The qRT-PCR analysis of Gzmb (Appendix A, Figure A.6) found significantly increased 
gene expression in WKY BMDMs at all four of the individual time points in contrast to the 
microarray data analysis which only identified significant differences at four and eight hours 
of LPS stimulation. Of note, in the context of the overall LPS response only the four and 
eight hour timepoints demonstrated significant differences between the strains in the qRT-
PCR analysis. The validation of Ccr2 in the overall timecourse analysis confirmed the 
differential gene expression at four and eight hours LPS stimulation and the lack of difference 
in the basal state but was unable to confirm the more subtle fold difference seen at two hours 
of LPS stimulation (Appendix A, Figure A.7). The microarray analysis of Mafb identified 
that there was only a significant difference at the <5% FDR threshold at the basal and eight 
hour timepoint whilst the individual qRT-PCR analysis identified significant differences at all 
timepoints. In the overall timecourse analysis (Appendix A, Figure A.10), significant 
differences were seen at the basal, four and eight hour timepoints with the pattern of 
expression matching that of the microarray data. Genes demonstrating higher expression in 
LEW BMDMs were also successfully validated. The robust differences seen in the 
microarray dataset for Mmp8 (Figure 3.4), Mmp7 (Appendix A, Figure A.11) and Tgfb2 
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(Appendix A, Figure A.12) were confirmed by the timecourse analysis and the data analysis 
results are summarised in Table 3.27.  
 
3.3 Discussion 
3.3.1      Macrophages and the response to LPS 
TLRs, acting as pattern recognition receptors play critical roles in the inflammatory response 
particularly in activating a tightly controlled response to infection and as such are some of the 
best characterised inducers of acute inflammation (Gilchrist et al., 2006; Foster et al., 2007; 
Medzhitov and Horng, 2009). Bacterial LPS is a component of bacterial cell walls and binds 
to and signals through TLR4 receptors. It has been recognised for some time that the gene 
changes that occur following LPS stimulation are widespread with only a minority of genes 
not altering in their level of expression with many genes repressed by LPS (Hume et al., 
2002; Nau et al., 2002; Ravasi et al., 2007; Ramsey et al., 2008). Such work, in addition, has 
been able to define the range of genes that are induced in response to LPS. These include 
cytokines and chemokines such as TNF-α, Il1-α and β, IL6, IL10 and IL18 as well as 
receptors and antagonists such as the TLR receptors, and the IL-1 receptor family, regulatory 
enzymes and proteins such as iκB kinase, PI-3-kinase and protein kinase C isoforms, 
apoptosis regulators, non-cytokine secretory products such as substance P, inducible 
metabolic pathways including nitric oxide related pathways, cytochrome P450 enzymes and 
arachidonate metabolism and as many as 100 transcription factors ranging from interferon 
response factors such as IRF-1, IRF-2 to the NF-κB family of proteins as well as AP-1 
transcription factors including the Jun family proteins (Hume et al., 2002; Ramsey et al., 
2008).  Some of the major key inducible genes have been categorised based on the kinetics of 
their response which is underpinned by their requirement for new protein synthesis. Primary 
response genes (PRGs) are usually induced within one hour of stimulation whilst secondary 
response genes (SRGs) have a delayed response because of the requirement for new protein 
synthesis and chromatin remodelling at their promoters (Ramirez-Carrozzi et al., 2006; 
Hargreaves et al., 2009). Transcription of inducible genes is triggered by the signal-
dependent activation of inducible DNA binding transcription factors which account for the 
specific patterns of gene expression that occur in response to TLR stimulation. The 
transcription factors recruit a variety of proteins to the promoter of the gene that initiate gene 
expression including RNA polymerase II and chromatin modifiers (Kadonaga, 2004). 
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3.3.2      The need to understand better the WKY and LEW transcriptomes and their 
response to LPS 
Multiple microarray-based studies of macrophages have been performed to investigate the 
LPS response but are notable for the lack of investigations in rat strains (Ravasi et al., 2007). 
In addition, these microarray based studies on the LPS response do not consider the 
possibility that genetically determined differences in individual responses may be important 
in shaping the LPS response. Within such a context, one can see also the importance of a 
macrophage-dependent disease model where the macrophages of the NTN-susceptible WKY 
and NTN-resistant LEW strains exhibit strikingly different phenotypes which are under 
genetic control. These include the increased killing of antibody-coated mesangial cells, Fc 
receptor mediated phagocytosis and oxidization (Fc-OxyBURST assay) and phagocytosis of 
antibody-opsonised beads in WKY BMDMs compared to LEW BMDMs (Aitman et al., 
2006; Behmoaras et al., 2008; Behmoaras et al., 2010). Studying the transcriptomes of WKY 
and LEW BMDMs following LPS stimulation allows for genetically determined differences 
in the response to be investigated and linked to the phenotypic differences observed between 
the strains.   
 
With such strikingly different behaviour patterns it is likely therefore that significant 
differences in the transcriptomes of each strain would be occurring that might underlie these 
phenotypes and potentially the susceptibility of the WKY strain or the resistance of the LEW 
strain to NTN. Indeed the basal transcriptomes in each strain have been investigated along 
with the transcriptome following 24 hours of LPS stimulation in WKY and LEW BMDMs 
finding that in both basal and LPS stimulated macrophages there was enrichment for  immune 
processes as well as identifying a number of potential susceptibility genes that had not been 
linked previously with a function in macrophages (Maratou et al., 2010). However, as the 
discussion above in 3.1.1 indicates, the critical early phase of this response was not surveyed 
in this study and differentially expressed regulatory factors, effector genes and genes that 
may impact on NTN susceptibility could have been missed. It is important to acknowledge 
that this study only investigates the transcriptome of the WKY and LEW BMDMs and whilst 
mRNA expression levels are usually correlated with mature protein, this might not always be 
the case and such relationships might not always be linear. It will, however, provide 
candidate genes that can form the basis of further investigations within the WKY and LEW 
BMDMs and NTN model. 
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3.3.3      The LPS response in WKY and LEW BMDMs 
In both WKY and LEW BMDMs, LPS stimulation induced massive changes in the BMDM 
transcriptomes at every time point assessed. The largest number of differentially expressed 
genes compared to baseline occurred at the four hour timepoint (Table 3.1) Whilst the 
numbers of genes changing at each timepoint did differ between the strains, the most robust 
changes were very consistent (Table 3.2) with similar numbers of genes at each time 
exhibiting fold changes greater than threefold. Stimulation by LPS rapidly altered the BMDM 
transcriptome and this was evident at two hours where the inducible gene sets were 
functionally linked to immune response pathways and regulation of cell death pathways in 
both strains (Tables 3.3, 3.5) along with predominant enrichment for genes involved in the 
response to LPS. The downregulation of genes forms a major part of the LPS response and 
this was clearly seen by two hours of LPS stimulation both in the large numbers of 
downregulated genes (Table 3.1) and also in the functional analysis of the pathways where 
non-essential homeostatic processes were downregulated (Tables 3.4, 3.6).  
 
It was also important when initially examining the data set to be certain that by selecting this 
range of time points that the major gene expression changes and characteristics could be 
captured in an experiment which was limited to four time points. A set of prominent early 
response genes have been characterised and used in a number of major publications 
(Ramirez-Carrozzi et al., 2006; Hargreaves et al., 2009; Ramirez-Carrozzi et al., 2009). 
Whilst these data were gathered in mouse macrophages, the rat BMDMs should still exhibit 
similar profiles and patterns. The genes were classified as primary and secondary response 
with PRGs usually induced within one hour of stimulation whilst SRGs had a delayed 
response because of the requirement for new protein synthesis and chromatin remodelling at 
their promoters (Ramirez-Carrozzi et al., 2006; Hargreaves et al., 2009). PRGs could also be 
subclassified broadly into a group where a degree of nucleosome remodelling was needed or 
not. Table 3.29 lists the set of PRGs that require no chromatin remodelling along with the 
fold changes at each time point in WKY and LEW BMDMs. It is clear that the majority of 
genes by two hours of LPS stimulation show a significant fold change from baseline. Whilst  
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Table 3.29 Primary response gene expression changes following LPS stimulation in 
WKY and LEW BMDMs 
Table of primary response genes that require no chromatin remodelling for their induction as 
classified by Ramirez-Carrozzi et al. (Ramirez-Carrozzi et al., 2009). All fold changes given 
are relative to the basal state BMDM for that strain. Grey highlights indicate genes that show 
minimal or no fold change compared to baseline. 
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some maintain or increase their expression over a number of time points (e.g. Irf1, Sod2, 
Il1a), many others have declining expression profiles suggesting that the peak of expression 
was at two hours or even earlier (e.g. Cd83, Ccrn4l, Nfkbiz). The highlighted genes showed 
no fold change different from baseline in the case of Tnfsf9 and Fosb, only a limited 
expression change in WKY BMDMs, for example Tnfaip3, or downregulation in the case of 
Egr2. The primary response genes requiring chromatin remodelling (Table 3.30), apart from 
the highlighted genes which were not differentially expressed, had initial expression 
differences at two hours which for the majority were then increased or maintained at four 
hours of LPS stimulation, a different pattern to the other primary response group. At least 
three of the genes did decline over the timecourse with a peak at two hours (Ccl2, Ifnb1, 
Ccl12). The small secondary response gene group tended to have the biggest fold changes 
around four hours of LPS stimulation or a continually increasing change from baseline.  
 
This data suggests both that similar patterns in primary and secondary response genes are 
occurring in the rat BMDMs as to that published previously. It validates the type of response 
chosen and the ability to identity these changes in this experimental model that used four 
biological replicates for each strain and that the time points that were chosen produced a 
robust and highly significant data set able to capture the majority of changes in gene 
expression.  
 
The transcription factors driving the inducible gene responses and the repression of genes 
were investigated using a motif enrichment analysis approach. MotifModeler gave two scores 
in the results output which describe the contribution and functional level of the transcription 
factor to the gene response (Liu et al., 2006). The second tool, TransFind, gave a more 
traditional P-value and FDR to describe whether significant enrichment for that transcription 
factor binding site was present in the promoters of the differentially expressed genes 
(Kiełbasa et al., 2010). Both tools were used to survey proximal promoter regions defined by 
MotifModeler, as 1,000 base pairs upstream of the transcriptional start site (TSS) and by 
TransFind, as 800 base pairs upstream and 200 base pairs downstream of the TSS. Their clear 
limitation assumes that only this region would show activity in driving transcription and does 
not take into account the presence or effect of enhancer regions. 
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Table 3.30 Primary and secondary response gene expression changes following LPS 
stimulation in WKY and LEW BMDMs 
Table of primary response genes that require chromatin remodelling for their induction and 
secondary response genes as classified by Ramirez-Carrozzi et al. (Ramirez-Carrozzi et al., 
2009). All fold changes given are relative to the basal state BMDM for that strain. Grey 
highlights indicate genes that show minimal or no fold change compared to baseline. 
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Nevertheless, the data do give important insights into transcriptional drivers of the LPS 
response. By two hours in WKY BMDMs there was enrichment in the induced gene set for 
NF-κB and IRF transcription factors fitting in with their known contributions to inducible 
gene expression (Table 3.7). A similar pattern was seen in LEW BMDMs with the major 
contributors again being NF-κB and IRF transcription factors though the overall TCS score 
that they produced was slightly lower than in WKY BMDMs. In genes with downregulated 
expression after two hours of LPS stimulation, there was prominent enrichment in both 
strains for the transcription factor CREB which plays a major role in immune responses 
including inhibiting NF-κB activation and inducing macrophage survival (Wen et al., 2010). 
Alongside this in both strains was prominent enrichment for the E2F family which is linked 
with multiple biological processes including DNA replication and repair along with apoptosis 
(Polager and Ginsberg, 2009). 
 
3.3.4      Differential gene expression in WKY and LEW BMDMs 
The similarities in the LPS response between WKY and LEW BMDMs explain some of the 
shared behaviour of the BMDMs from each strain but not the differences in phenotype and, in 
view of the fact that sequencing of the WKY and LEW genomes has identified 2,520,602 
SNPs and 689,940 insertion and deletion polymorphisms between the strains (S Atanur, PGM 
Group, MRC CSC, personal communication), it is not surprising that there would be major 
transcriptome differences between the strains despite the common LPS response pattern. This 
was confirmed in the analysis of differential gene expression at the static time points and for 
the overall timecourse (Table 3.9). Within this set of genes, therefore, there could be new 
candidate genes influencing the susceptibility of the WKY to NTN and key effector genes 
that determine the differences seen in macrophage activation and important phenotypic 
pathways such as Fc-OxyBURST and bead phagocytosis. At every timepoint analysed, a 
large number of genes were found to be differentially expressed with the WKY BMDM gene 
set having a greater number of genes with higher expression. This suggested that a difference 
in the transcriptome of WKY BMDMs was driving inducible gene transcription. This was 
evident even in the basal state showing that genetic factors were a major part of this effect. In 
keeping with this, Fcgr3 which was linked to macrophage activation and glomerulonephritis 
susceptibility at Crgn1 was significantly differentially expressed in the basal state and at all 
the time points (Aitman et al., 2006). This had also been demonstrated in a previous 
microarray study (Maratou et al., 2010). Jund which was functionally linked to macrophage 
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over activation and associated with glomerulonephritis susceptibility was also differentially 
expressed in the dataset though at a lower fold change of 1.27 in favour of WKY BMDMs at 
<5% FDR (Behmoaras et al., 2008). The previous investigation into the WKY and LEW 
transcriptomes only identified 800 transcripts in total that were differentially expressed in the 
basal state (Maratou et al., 2010). The study by Maratou et al. used Rat Exon 1.0 ST arrays 
which is a different microarray platform from the Rat Gene 1.0 ST array used in this study. 
However, it is important to note that the probes used in the Rat Gene 1.0ST array are a subset 
of those used on the Rat Exon 1.0ST array. There were also a number of other key 
differences between the studies that could account for the differences in results. Firstly the 
current study was performed using the updated Ambion WT Expression Kit which, as 
demonstrated in Figure 2.4 and Figure 2.5, gave much superior signal: noise ratios and this 
alone could account for a large proportion of the differences between the experiments. The 
culture methods also differed between the two experiments as the current L929 conditioned 
medium is able to differentiate bone marrow stem cells into BMDMs by five days of culture 
as opposed to the six days used by Maratou et al. Critically, the stimulation response in the 
Maratou et al. study was not focused purely on LPS responses as, alongside the 24 hour LPS 
stimulation, the BMDMs underwent 16 hours of serum starvation which is an additional 
stimulus in its own right that can cause time-dependent and cell type dependent effects 
(Pirkmajer and Chibalin, 2011). Serum starvation was not used in the BMDM preparation 
used for the experiments detailed in this thesis. 
 
The current experiment also benefits from the sequencing of the genomes of both the WKY 
and LEW strains allowing probes that contain SNPs to be removed improving the accuracy of 
the dataset. The data analysis was also different both in that this current experiment used a 
custom definition file to reflect up to date genome information as per Dai et al. (Dai et al., 
2005) and the moderated t-test implemented in SAM v4.0 was used to analyse the dataset as 
opposed to the ANOVA model employed by the Partek Genomics Suite 6.4.  
 
3.3.4.1 Candidate genes for Crgn QTLs 
At each timepoint there were a number of genes demonstrating robust fold differences greater 
than fivefold between WKY and LEW BMDMs. However only a minority were located 
within a Crgn QTL suggesting that the majority of the genes were effector proteins 
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differentially expressed due to different transcriptional processes within the two strains and 
not primary drivers of Crgn susceptibility. Of note, cytochrome P450, family 2, subfamily j, 
polypeptide 4 (Cyp2j4) was differentially expressed with a greater than fivefold difference at 
every static timepoint analysis and in the overall timecourse analysis, and was validated by 
qRT-PCR (Figure 3.4). Cyp2j4 is located on chromosome 5 and lies in the Crgn5 QTL 
which showed significant linkage with crescent formation (Aitman et al., 2006). It was 
differentially expressed in the Maratou et al dataset but at a low fold difference of 2.2-fold in 
basal BMDMs and 4.2-fold in 24 hour LPS stimulated BMDMs. It is therefore a plausible 
candidate gene for Crgn5 especially as the differential expression of the gene is only seen in 
BMDMs and is not differentially expressed in mesangial cells (J Behmoaras, Centre for 
Complement and Inflammation Research (CCIR), Imperial College, personal 
communication). 
 
Cyp2j4 was first cloned and characterised in 1997 in rat small intestinal epithelial cells and 
the protein was noted to be very similar to human CYP2J2 (Zhang et al., 1997). The activity 
of the enzyme was functionally investigated in a reconstituted system with NADPH-P450 and 
dilauroylphospatidylcholine and the enzyme was found to have activity against arachidonic 
acid (AA) producing eicosanoid products (Zhang et al., 1997). Further work found linked 
CYP2J4 and its metabolites 20-hydroxyeicosatetraenoic acid (20-HETE) and 
epoxyeicosatrienoic acids (EETs) to the modulation of pulmonary vascular tone in rats with 
pneumonia with a reduction in the protein found in pneumonia (Yaghi et al., 2003). Inhbition 
of inducible nitric oxide synthase (iNOS) increased the activity and amount of CYP2J4 in the 
infected lung linking the normal action of nitric oxide (NO) via this metabolic pathway as a 
modulator of contractility in the arteries in the pulmonary circulation (Yaghi et al., 2003).  
 
The human literature has focused on the role of all cytochrome P450 (CYP) enzymes 
including CYP2J2 on cardiovascular disease because EETs are highly expressed in 
endothelial cells and cardiac myocytes and they have vasodilatory, anti-inflammatory, anti-
apoptotic, anti-thrombotic and cardioprotective effects. Genetic polymorphisms in the genes 
linked to the  risk of cardiovascular disease have also been identified, although there is 
conflicting evidence as to the extent of their role in disease susceptibility (Wu et al., 1996; 
Node et al., 1999; Zordoky and El-Kadi, 2010; Xu et al., 2011). CYP2J2 is also expressed in 
human monocytic leukocytes and is induced by stimulation with phorbol 12-myristate 13-
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acetate (PMA) with a potential key role in regulating atherogenesis mooted to explain its 
function (Nakayama et al., 2008).  
 
Understanding a potential role in WKY BMDMs and crescentic glomerulonephritis is more 
challenging especially with the anti-inflammatory links of EETs  including  inhibition of NF-
κB and VCAM-1 expression (Node et al., 1999) and the attenuation of disease in a mouse 
diabetic nephropathy model though its action was in endothelial cells not macrophages (Chen 
et al., 2011b). The haematological cancer literature does point to some potential roles relevant 
to disease where overexpression was found to promote proliferation and inhibit apoptosis in 
in vitro studies of leukaemia cells and mechanistically the EGFR, PI-3-kinase/Akt, AMPK 
and JNK pathways were activated (Chen et al., 2011a). The other main metabolite 20-HETE 
may have similar functions and, whilst there is little literature on its function in macrophages, 
it has been shown to activate the Raf/MEK/ERK pathway in renal epithelial cells along with 
the Alt/PI-3-kinase pathway and its inhibition protects the kidney from  
ischaemia/reperfusion injury (Akbulut et al., 2009)  
 
Whilst the gene expression data and literature points to a possible functional role for Cyp2j4 
as a plausible candidate for Crgn5, there were other genes identified at the locus that could 
also play a role (Table 3.31). Heat shock protein family B (small), member 11 (Hspb11) 
referred to also as C1orf41 or Hsp16.2 in the human literature is 3-fold overexpressed in 
LEW BMDMs and is thought to prevent apoptotic cell death through a number of 
mechanisms including stabilization of the mitochondrial membrane system, activation of the 
heat shock protein Hsp90 and the activation of the cytoprotective PI-3-kinase/Akt pathway 
(Bellyei et al., 2007a; Bellyei et al., 2007b). Phosphatidic acid phosphatase type 2B (Ppap2b) 
was overexpressed in WKY BMDMs and may have a significant function in Th2-deviated 
states in monocyte-derived type 2 of dendritic cells (Hata et al., 2009) whilst spermatogenesis 
associated 6 (Spata6) was previously identified and validated by Maratou et al. though its 
link to NTN pathogenesis is somewhat harder to rationalise (Maratou et al., 2010).  
 
The other QTLs also contain potential candidate genes for Crgn susceptibility. Genes 
differentially expressed in the basal state are plausible candidates especially as their 
genetically controlled expression difference could lead to a major phenotype change. 
However, genes that are expressed after stimulation and remain differentially expressed could  
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Table 3.31 Candidate genes for Crgn QTLs three to seven 
 
Candidate genes were identified using the QTL positions determined in Maratou et al. 
(Maratou et al., 2010) and were selected on the basis of a minimum 1.5-fold change between 
WKY and LEW BMDMs. Genes in the bold highlighted row are differentially expressed in 
more than one timepoint analysis. 
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also be genetically controlled due to polymorphisms in their promoter regions affecting 
transcription factor binding sites and these differences could still lead to NTN susceptibility. 
Crgn4 located on chromosome two is linked with crescent formation and proteinuria and a 
large number of genes were differentially expressed between the strains of which mucolipin 3 
(Mcoln3) was previously validated (Maratou et al., 2010) and mucolipin 2 (Mcoln2) was 
validated in this dataset (Appendix A, Figure A.5). Breast cancer anti-estrogen resistance 3 
(Bcar3) was overexpressed in WKY BMDMs (2.5-fold in basal BMDMs and 2.4-fold in 2 
hour LPS stimulated) and has been found to regulate non-receptor protein-tyrosine kinase c-
Src in breast cancer cells with links to cell proliferation, survival, adhesion signalling and 
migration (Schuh et al., 2010). Crystillin zeta (Cryz), an NADPH-dependent quinone 
reductase causes higher stability and overexpression of the anti-apoptotic gene Bcl-2 in T cell 
acute lymphocytic leukaemia (Lapucci et al., 2010) and is 1.9-fold overexpressed in basal 
WKY BMDMs and 1.95-fold after two hours LPS stimulation.  
 
Crgn6 linked to proteinuria on chromosome ten contains a number of candidate genes though 
the higher expression of the haemoglobin alpha 2 chain (Hba2) is difficult to link to NTN 
whilst nucleophosmin (nucleolar phosphoprotein B23, numatrin, Npm1) is overexpressed in 
LEW BMDMs only in the basal state and after two hours of LPS stimulation. Along with an 
involvement in the maintenance of cell survival in homeostasis, it has been shown to be 
released from activated macrophages acting to release cytokines and activate cells. However 
linking this in with the disease process in the LEW strain is also difficult (Nawa et al., 2009). 
Mediterranean fever (Mefv) demonstrated differential expression only later in the timecourse 
at two and eight hours of LPS stimulation. Mefv is also known as pyrin and mutations in this 
gene are associated with the hereditary periodic fever syndrome, Familial Mediterranean 
Fever (The International FMF Consortium,  1997; Bosch and Pomares, 1998). It is also 
associated with inflammasomes which are key regulators of the innate immune response 
linked to multiple autoinflammatory disorders (Lamkanfi, 2011). Inflammasome complexes 
assemble around members of the NOD-like receptor family, a prominent pathway in the LPS 
response enriched in WKY and LEW BMDMs (Table 3.3, 3.5) and function to detect 
PAMPS and DAMPS within the cell. Assembly of the inflammasome results in the activation 
of caspase 1 which is a cysteine proteinase that matures the proinflammatory forms of 
interleukin-1β (Il-1β) and IL-18 (Lamkanfi, 2011). In this context, pyrin has been linked with 
anti-inflammatory roles as it was shown to inhibit Il1-β by regulating caspase-1 (Chae et al., 
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2003; Chae et al., 2006; Papin et al., 2007) though there is some conflict with other evidence 
suggesting it can have a proinflammatory role activating caspase-1 (Yu et al., 2005; Seshadri 
et al., 2007). One view is that the regulation of IL1-β processing is not its main function 
(Seshadri et al., 2007). In keeping with this, mice with mutated forms of the protein also 
show heightened sensitivity to endotoxin and a defect in macrophage apoptosis through an Il-
1-independent pathway (Chae et al., 2003).  
 
Crgn7 on chromosome 15 again has a number of potential candidate genes. Early growth 
response three (Egr3) is moderately overexpressed in WKY BMDMs and has an essential 
downstream role in VEGF-mediated endothelial functions (Liu et al., 2007). VEGF-mediated 
stimulation of Egr-3 results in the inducible binding of NFATc, serum response factor, and 
CREB to the upstream promoter region of Egr3 leading to its upregulation. Interestingly in 
accelerated NTN in the mouse, loss of Jund in podocytes caused increased oxidative stress in 
podocytes which led to increased VEGFA expression and subsequent glomerular injury 
(Cook et al., 2011). Fermitin family homolog 2 (Drosophila) (Fermt2) also known as 
Kindlin-2 shows moderate overexpression in WKY BMDMs and is part of a class of focal 
adhesion proteins implicated in integrin activation (Lai-Cheong et al., 2010) whilst lysyl 
oxidase-like 2 (Loxl2) is an amine oxidase for formation of lysine-derived cross-links found 
in collagen and elastin (Kim et al., 2011c) and as such inhbitiors might have therapeutic 
potential in treating fibrosis inflammation and cancer (Rodriguez et al., 2010).  In addition 
solute carrier family 22, member 17 (Slc22a17) overexpressed in WKY BMDMs is a cell 
surface receptor for lipocalin 24p3 which has been found to be part of a biological pathway 
that regulates apoptosis through intracellular iron concentration (Devireddy et al., 2005). 
 
3.3.4.2 Candidate key effector genes in Crgn 
Whilst other differentially expressed genes may not be linked to susceptibility QTL, their 
relevance for disease pathogenesis could still be very significant and as such could act as 
therapeutic targets for the disease model. In basal BMDMs, differential gene expression of 
matrix metallopeptidase (Mmp7) was validated in this dataset (Table 3.27, 3.28 and 
Appendix A, Figure A.11) and was also previously identified by Maratou et al. though its 
role as an effector protein with its overexpression in LEW BMDMs is uncertain (Maratou et 
al., 2010). Functional uncertainty is a common feature of many of the differentially expressed 
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transcripts highlighting the potential for novel biological insights that this experimental 
approach has produced. The transient receptor potential cation channel, subfamily C, Member 
6 (Trpc6) is highly overexpressed in LEW BMDMs in basal BMDMs (23.54-fold) and up to 
four hours of LPS stimulation. It is highly relevant to renal disease where mutations within 
are linked to proteinuric renal disease particularly focal segmental glomerulosclerosis (Winn 
et al., 2005) and it may have roles in VEGF-mediated angiogenesis (Fearnhead et al., 2005) 
and platelet activation (Dionisio et al., 2011) though again it is harder to link it with a process 
in the NTN model.   
 
After LPS stimulation, a number of effector candidates became highly differentially 
expressed. Serpin peptidase inhibitor, clade B (ovalbumin), member 2 (Serpinb2) is 
overexpressed in WKY BMDMs (Table 3.14) is induced in inflammation and though its 
exact functions remain uncertain it may have regulatory roles in immune responses (Schroder 
et al., 2010; Lee et al., 2011) whilst purinergic receptor P2X, ligand-gated ion channel, 7 
(P2RX7) has a well-recognised proinflammatory role in immune-mediated renal injury 
(Turner et al., 2007; Taylor et al., 2009). By four hours of LPS stimulation major differences 
in a number of additional effector genes were seen (Table 3.17) including the upregulation in 
WKY BMDMs of macrophage activation 2 like (Mpa2l) also known as guanylate binding 
protein 6 (Gbp6) linked with a role in interferon-gamma mediated killing of intracellular 
pathogens through the harnessing of phagocyte oxidase, antimicrobial peptides, and 
autophagy effectors. Whilst other family members have been linked directly to superoxide 
production, the functions of Gbp6 are still not fully clear (Kim et al., 2011a; Leavy, 2011). In 
addition the tumour necrosis factor (ligand) superfamily, member 10 (Tnfsf10) also known as 
TRAIL shows significantly higher expression in WKY BMDMs particularly at this time 
point. TRAIL is able to trigger the extrinsic pathway of apoptosis induction with important 
immunoregulatory, immunosuppressive and immune effector functions (Falschlehner et al., 
2009) and has been shown to be upregulated in human lupus nephritis where it was thought to 
have an effect enhancing the proliferation of proximal tubular epithelial cells as well as 
exerting proinflammatory activities (Nguyen et al., 2009).  
 
The extensive validation of the microarray data set using qRT-PCR highlighted a number of 
additional candidate effector genes. In WKY BMDMs, there was consistently higher 
expression of tumour necrosis factor receptor superfamily, member 14 (Tnfrsf14) compared 
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to LEW BMDMs (Appendix A, Figure A.4). Tnfrsf14 is a membrane bound receptor, known 
to activate the NF-κB pathway leading to the induction of proinflammatory and cell survival-
promoting genes. It binds the TNF family molecule LIGHT (TNFSF14) as well as two 
members of the immunoglobulin superfamily and acts as an important immune regulatory in 
autoimmunity and infection (del Rio et al., 2010; Shui et al., 2011). In human genome wide 
association studies and meta-analyses, it has been linked with susceptibility to ulcerative 
colitis and rheumatoid arthritis (Raychaudhuri et al., 2008; Stahl et al., 2010; Anderson et al., 
2011). It has also been linked with macrophage function in atherogenesis where activation of 
a human monocyte cell line with anti-TNFRSF14 antibody triggered the production of TNF-α 
and IL-8 along with the induction MMP1, MMP9 and MMP13 expression (Lee et al., 2001) 
suggesting that it could have important effector functions in WKY BMDMs.  
 
Granzyme B (Gzmb) showed marked overexpression in WKY BMDMs (Appendix A, 
Figure A.6) and is a potential effector molecule for causing cellular injury though it has 
classically linked with the cytotoxic activities of lymphocytes rather than macrophages 
(Kurschus and Jenne, 2010). It is a granule stored serine protease and is translocated into the 
cytoplasm of target cells by the perforin protein where it is then able to activate intrinsic 
apoptosis pathways (Kurschus and Jenne, 2010). Its expression and function in macrophage 
activation is not well defined especially as the pathway has been thought to be unique to 
cytotoxic lymphocytes and natural killer cells. It has, however, been shown to be highly 
expressed, along with perforin and Fas ligand, in a subpopulation of cytotoxic macrophages 
that co-express CD4 and CD8 in Wistar rats which have antitumor cytotoxicity in vitro (Baba 
et al., 2006; Baba et al., 2008). Such findings do suggest that Gzmb could have the potential 
of a tissue damaging role in the NTN model highlighting a need for further study of its role in 
the model.  
 
The mesangial cells from the glomeruli of WKY rats along with BMDMs have previously 
been shown to produce significantly higher levels of monocyte chemoattractant protein 1 
(MCP-1) than the LEW strain (Smith et al., 2007). MCP-1 has chemotactic activity for 
monocytes and administration of anti-MCP-1 antibodies has been shown to reduce crescent 
formation in WKY NTN disease by reducing the numbers of macrophages within the 
glomerulus (Wada et al., 1996).  It is notable therefore that the receptor for MCP-1, 
chemokine (C-C motif) receptor 2 (Ccr2) is also overexpressed in WKY BMDMs after four 
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hours of LPS stimulation (Table 3.28 and Appendix A, Figure A.7). This suggests that its 
upregulation could contribute to the increased infiltration of macrophages to the glomerulus 
seen in WKY NTN.  
 
Not all genes upregulated in WKY BMDMs have pro-inflammatory roles. The interleukin-1 
receptor antagonist (Il1rn) (Appendix A, Figure A.1) is one such example and inhibits the 
activities of Il-1α and Il-1β. Administration of IL-1rn in a Sprague-Dawley anti-glomerular 
basement membrane disease model was able to suppress the development of disease and 
demonstrated a pathogenic role for IL-1 in Crgn (Lan et al., 1993). As a gene linked with 
anti-inflammatory functions, a role for its overexpression in WKY BMDMs is less certain but 
could be a reflection of negative feedback mechanisms controlling inflammation within the 
setting of a heightened immune response in WKY BMDMs, possibly as a response to the 
higher expression of mature IL-1β levels in WKY BMDMs compared to LEW BMDMs (J 
Behmoaras, CCIR, personal communication).  
 
The early response genes that are differentially expressed between WKY and LEW BMDMs 
could play a key role in shaping the response of the macrophage to LPS and the gene groups 
defined by Ramirez-Carrozzi et al. and detailed in Tables 3.29 & 3.30 (Ramirez-Carrozzi et 
al., 2006; Ramirez-Carrozzi et al., 2009), encompass a range of types including transcription 
factors, cytokines, signalling molecules and receptors. The genes in this list were therefore 
examined to see whether any showed significant differential expression and could function as 
key effector proteins in the BMDMs (Table 3.32). Twenty-three of the genes had fold change 
differences greater than 1.5 fold. Amongst the primary response genes, immunresponsive 
gene 1 (Irg1) had prominent differential expression and is known to be induced by LPS and 
TNF stimulation but still has an uncertain function in immune responses (Degrandi et al., 
2009). C-type lectin domain family 4, member E (Clec4e) showed higher expression from the 
basal state in LEW BMDMs. It has been shown to be an activating receptor coupled with 
immunoreceptor tyrosine-based activation motifs (ITAM) and was found to be able to detect  
non-homeostatic cell death and produce inflammatory cytokines and chemokines to assist in 
the response to tissue damage and the clearance of dead cells (Yamasaki et al., 2008). Such a 
process could be protective in the LEW strain against inflammatory damage. 
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Table 3.32 Differentially expressed primary and secondary response genes between 
WKY and LEW BMDMs 
 
The list of primary and secondary response genes were as defined by Ramirez-Carrozzi et al. 
(Ramirez-Carrozzi et al., 2009). From this list, genes that were also differentially expressed 
in the analysis between WKY and LEW BMDMs using SAM v3.0 (Tusher et al., 2001) with 
40,000 permutations and a <5% FDR threshold were identified. Fold changes are expressed 
such that positive values indicate genes with higher expression in WKY BMDMs. 
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A number of transcription factors demonstrated different expression patterns in WKY 
BMDMs compared to LEW BMDMs from this primary and secondary response gene list. 
Interferon regulatory factor 7 (IRF7) plays a major role in regulating the expression of 
interferon inducible genes along with early growth response 1 (Egr1) and 2 (Egr2) which are  
important regulators of the immune response were differentially expressed (Table 3.32). 
EGR1 is a positive regulatory factor whilst EGR2 is a negative regulator linked to apoptosis 
(Gómez-Martín et al., 2010). Differences in transcription factor expression and ultimately 
function could have a major impact on cell phenotype as has been evidenced by the effect of 
overexpression of Jund on macrophage activation and Crgn susceptibility (Behmoaras et al., 
2008). It was notable, therefore, that AP-1 binding sites within the genes showing higher 
expression in WKY BMDMs were enriched, fitting in with the findings above (Table 3.26 
and Appendix A, Table A.6).  
 
In addition, the motif enrichment analysis of the differentially expressed gene sets found a 
positive enrichment of IRF binding sites with a higher contribution to the increased 
expression of genes in basal WKY BMDMs compared to LEW BMDMs (Table 3.26) which 
persisted during the initial phase of LPS stimulation (Appendix A, Table A.7). IRF binding 
sites along with NF-κB binding sites were highly enriched in the genes with significant 
differential expression after two hours of LPS stimulation in both WKY and LEW BMDMs 
(Table3.7). However, IRF binding sites, not NF-κB, were identified as enriched in a 
comparison between the strains. This suggests that genetic factors could be altering the IRF 
driven transcriptional response after LPS stimulation in WKY BMDMs compared to LEW 
BMDMs but not the overall NF-κB response. IRFs are activated by the TLR signalling 
pathways and promote the transcription of type 1 interferon and proinflammatory cytokine 
genes such as Il-6 and are key elements in regulating immune responses (Santana-de Anda et 
al., 2011). IRF-7 functions as the master regulator for IFN-α and along with IRF-5 are key 
elements for the regulation of proinflammatory cytokines (Tamura et al., 2008; Santana-de 
Anda et al., 2011). IRF-7 demonstrates higher expression in WKY BMDMs compared to 
LEW BMDMs. IRF5 has direct links to renal disease. IRF5 polymorphisms have been 
associated with susceptibility to systemic lupus erythematosus (SLE) in humans (Hom et al., 
2008; Han et al., 2009; Chung et al., 2011) and for other autoimmune inflammatory 
conditions such as rheumatoid arthritis (Stahl et al., 2010). In a murine model of SLE, Irf5 
was found to be a driver of lupus development and Irf-5 deficient mice had reduced antibody 
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production and mild glomerulonephritis compared to non-deficient mice (Tada et al., 2011). 
Irf1 induces the expression of interferon inducible genes such as inducible nitric oxide 
synthase (iNOS) and Caspase-1 (Tamura et al., 2008) and  has a role in mediating renal 
disease, also in a murine SLE model where it reduced production of, the key 
pathophysiological mediator, nitric oxide production (Reilly et al., 2006). 
 
Such findings suggest that different transcriptional drivers exist within the different strains, 
leading onto the major differences seen in enrichment for transcription factor binding sites 
associated with differentially expressed genes at later timepoints (Appendix A, Table A.7, 
A.8) and  accounting potentially for some of the major phenotypic differences seen between 
the WKY and LEW strains.  
 
3.3.4.3 Functional analysis revealed effector processes and pathways in WKY 
and LEW BMDMs 
The functional enrichment analysis performed using DAVID gave insights into the processes 
and pathways unique to each strain and, in the basal state, the overall gene set of enriched 
genes revealed enrichment for multiple immune related functions and, of note, the regulation 
of cell death and apoptosis. Similar enriched terms had been seen between the two strains in 
the previous array analysis of Maratou et al., as had the enrichment for pathways such as 
endocytosis though not for cell adhesion molecules and antigen processing and presentation 
(Table 3.11). Unlike Maratou et al. the individual sets of genes demonstrating higher 
expression in each group were examined.  
 
In both strains there was enrichment for immune response processes in the basal condition 
and these findings persisted at the other time points though many of the genes involved 
seemed to have only moderate fold changes less than 1.5-fold in LEW BMDMs and the 
persistence of gene sets for enriched immune processes was stronger in WKY BMDMs. Most 
striking was the enrichment for processes involving the regulation of various immune 
responses terms in LEW BMDMs at the early timepoints. In addition there was also 
enrichment in LEW BMDMs in the basal state (Table 3.13) and after LPS stimulation (Table 
3.16) for processes linked to apoptosis and programmed cell death. WKY BMDMs did show 
enrichment for responses to stimuli in particular LPS in the early phase of the LPS response 
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(Table 3.12, 3.15) and this might mean that the higher inducible gene responses seen and the 
heightened overall activation of the BMDMs are due to amplified responses in signalling 
pathways to stimulation which leads on to increased effector gene transcription, whilst in 
LEW BMDMs a tighter control on the response served to enrich for regulatory genes causing 
earlier termination of the LPS response (Table 3.16).  
 
3.3.4.4 Transcriptomic differences between WKY and LEW BMDMs point to the 
basis of differences in functional phenotypes. 
Increased macrophage activation in WKY BMDMs is key to the increased susceptibility of 
the strain to NTN. This has been previously assayed using the Fc-OxyBURST assay and bead 
phagocytosis (Behmoaras et al., 2008). WKY BMDMs demonstrate increased Fc receptor 
mediated phagocytosis and oxidization (Fc-OxyBURST assay) and phagocytosis of antibody-
opsonised beads and cytokine secretion (Behmoaras et al., 2008; Behmoaras et al., 2010). 
The key differentially expressed genes in the pathway causing this difference are still not 
known and importantly congenic rats where the QTLs for Crgn1 and Crgn2 from the LEW 
rat strain were introgressed onto a WKY background either alone (WKY.LCrgn1, 
WKY.LCrgn2) or in combination (WKY.LCrgn1,2) behave exactly like the LEW strain in 
the FC-OxyBURST assay. In the bead phagocytosis assay, WKY.LCrgn2 BMDMs behaved 
similarly to LEW BMDMs (Behmoaras et al., 2008). 
 
Both assays take advantage of the ability of the FcγR receptor to recognise IgG, whether in 
the form of immune complexes in the Fc-oxyBURST reaction or beads opsonized with IgG. 
Such engagement leads to diverse cellular responses including phagocytosis, cytokine 
production, degranulation, gene regulation, apoptosis and reactive oxygen species (ROS) 
generation (Ravetch and Bolland, 2001). In the NTN model, a similar process of FcγR 
receptor activation is likely to occur. The other key features of the assay are the rapid speed at 
which the activation and measured responses occur. BMDMs stimulated with Fc oxyBURST 
reagent are assessed over a two minute period after stimulation whilst in the macrophage 
bead phagocytosis assay, the BMDMs are exposed to the beads for ten minutes suggesting 
that the basal phenotype of the macrophage is critical in determining the response 
(Behmoaras et al., 2008). Therefore to gain an idea of possible effector genes, the 
differentially expressed genes in the basal state and at two hours following LPS stimulation  
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were interrogated using the Fc-gamma-mediated phagocytosis pathway curated by KEGG 
pathways to identify key parts of the pathway (Kanehisa and Goto, 2000; Kanehisa et al., 
2006; Kanehisa et al., 2010).  Genes found to be differentially expressed and part of the 
pathway were highlighted in bold (Figure 3.5 & 3.6) and colour coded according to the 
strength of the fold difference where a positive value indicated higher expression in WKY 
BMDMs. It is striking that in WKY BMDMs, a number of key genes have increased mRNA 
expression in both the basal condition which remains after two hours LPS stimulation which 
could play key roles in the pathway. These include phospholipase D1 (Pld1) which is 1.7-fold 
higher in WKY BMDMs, and protein kinase C, alpha (Prkca) which is 1.6-fold higher. After 
two hours LPS stimulation, Pld1 remained higher at 1.3-fold, Ppap2b at 1.6-fold and Prkca at 
1.6-fold as well. Prkca is a key part of the process as alongside the fact that its activation 
regulates NADPH oxidase and superoxide production driving the respiratory burst, it is has 
also been linked with multiple biological processes including cell proliferation, 
differentiation, migration and adhesion as well as apoptosis (Li et al., 1999; Nakashima, 
2002; Konopatskaya and Poole, 2010). Pld1 is an ubiquitous enzyme that hydrolyses 
phosphatidylcholine to phosphatidic acid (PA) and regulates FcγR-mediated phagocytosis 
(Iyer et al., 2004; Corrotte et al., 2006; Corrotte et al., 2010) along with additional roles in 
cell adhesion and TNF-alpha signalling (Iyer et al., 2006; Sethu et al., 2008). A number of the 
other genes highlighted including Dynamin 3 (Dnm3) which is known to play important roles 
in phagocytosis (Di et al., 2003). 
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Figure 3.5 Fc gamma R-mediated phagocytosis pathway highlighted with 
differential expressed genes between basal WKY and LEW BMDMs 
This annotated Fc gamma R-mediated phagocytosis pathway is adapted from the KEGG 
pathways database. Highlighted and coloured genes indicate differentially expressed genes 
between WKY and LEW BMDMs. Positive fold changes are associated with higher 
expression in WKY BMDMs.  
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Figure 3.6 Fc gamma R-mediated phagocytosis pathway highlighted with 
differential expressed genes in two hour LPS stimulated WKY and LEW 
BMDMs 
This annotated Fc gamma R-mediated phagocytosis pathway is adapted from the KEGG 
pathways database. Highlighted and coloured genes indicate differentially expressed genes 
between WKY and LEW BMDMs. Positive fold changes are associated with higher 
expression in WKY BMDMs.  
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3.3.5      The regulation of cell death and apoptosis as a key factor determining the 
different susceptibilities of the WKY and LEW BMDMs to NTN 
The regulation of cell death and apoptosis is a recurring theme within the functional analysis 
of the LPS response in the WKY and LEW strains and in the candidate genes and effector 
genes highlighted in this chapter. Such terms were prominent in the genes induced by the 
LPS response in both strains (Tables 3.3, 3.5) and prominent in the functional enrichment 
analyses of genes with higher differential expression in LEW BMDMs (see for example 
Tables 3.13, 3.16). A number of candidate QTL genes such as Cyp2j4 and effector genes 
such as tnfrsf14 in WKY BMDMs were linked with a possible function in increasing cell 
survival and reducing apoptosis suggesting an important feature of the cells could be 
prolonged survival in the nephritic glomeruli in otherwise lethal conditions compared to 
LEW BMDMs which, along with their heightened activation, could lead to increased 
inflammatory damage and the strain susceptibility to NTN disease. Differences in apoptosis 
have been shown to account for differences in NTN as seen in the role for a pattern 
recognition receptor, the mannose receptor (MR), in the development of Crgn in mice 
(Chavele et al., 2010). Mice that were mannose receptor deficient (MR
-/-
) were protected 
from disease and alongside reduced macrophage activation and mesangial cell Fc receptor-
mediated functions such as the Fc oxyBURST, the mesangial cells from the MR
-/-
 mice 
demonstrated increased apoptosis compared to wild type which could exert 
immunosuppressive effects on infiltrating macrophages and, indeed, can induce an anti-
inflammatory phenotype (Lucas et al., 2003; Lucas et al., 2006; Chavele et al., 2010).  
 
3.4 Conclusions 
The work presented in this chapter aimed to identify the genes and pathways underlying the 
phenotypic differences between WKY and LEW BMDMs seen in functional assays, in how 
the cells respond to stimulation as well as suggesting new candidates for the Crgn QTLs. 
Macrophages are the major effector cell in the NTN model and understanding the 
transcriptome differences between BMDMs from the WKY and LEW strains could give 
valuable insights into the disease process. BMDMs from the WKY and LEW strains share 
many responses to LPS stimulation in common and demonstrate a shared transcriptional 
response, but in the basal state and during a timecourse of LPS stimulation major 
transcriptome differences were evident. A number of candidates lying in QTL regions were 
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identified as were potential key effector genes underlying the BMDM phenotype. In addition, 
candidates were identified that could explain the differences seen in the phenotypic assays 
used to differentiate the strains. The regulation of cell death and apoptosis was a recurring 
theme in genes and pathways that were different between the strains and further work would 
be invaluable in assessing the extent to which such differences were occurring in the NTN 
model and in the behaviour of BMDMs from the two strains. 
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Chapter 4. The effect of Crgn2 and siRNA knockdown of 
Jund on the WKY macrophage transcriptome 
4.1 Introduction 
The aim of the work presented in this chapter was to investigate, through the study of the 
congenic strain WKY.LCrgn2, the influence that the Crgn2 QTL, linked with crescentic 
glomerulonephritis (Crgn) susceptibility and macrophage activation, has on the transcriptome 
of WKY bone marrow-derived macrophages (BMDMs) during the response to LPS 
stimulation; and how altering Jund expression directly using small interfering RNA (siRNA) 
also alters the WKY transcriptome in basal and LPS stimulated BMDMs. These approaches 
aimed to provide insights into the genes and pathways influencing macrophage activation in 
WKY BMDMs by Crgn2 and Jund that could additionally also play a role in the 
pathogenesis of crescentic glomerulonephritis. 
 
4.1.1      The Crgn2 quantitative trait locus and its control of macrophage activation 
and association with NTN susceptibility. 
The Crgn2 QTL is located on chromosome 16 and was shown by linkage analysis to be 
causally associated with glomerular crescent formation and proteinuria (Aitman et al., 2006). 
The ability to investigate the effect of Crgn2 on Crgn was made possible in the nephrotoxic 
nephritis (NTN) disease model in WKY rats by the generation of reciprocal congenic rat lines 
in which the LEW Crgn2 locus was introgressed onto the WKY genetic background, termed 
WKY.LCrgn2, and the WKY Crgn2 locus was introgressed onto the LEW genetic 
background (LEW.WCrgn2). Induction of NTN in the congenic strains demonstrated that 
WKY.LCrgn2 rats had a significant reduction in the formation of crescents, fibrin deposition, 
macrophage infiltration compared to WKY rats though no difference in the amount of 
proteinuria was observed (Behmoaras et al., 2008). LEW.WCrgn2 rats in comparison showed 
no difference compared to LEW rats in the formation of crescents or fibrin deposition but did 
show a significant increase in macrophage infiltration and proteinuria.  
 
As macrophages are critical for the pathophysiology of Crgn in the NTN model, macrophage 
phenotypes were also investigated in the parental and the WKY.LCrgn2 congenic rat strains 
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(Behmoaras et al., 2008). In this study, macrophage activation was investigated by using the 
Fc oxyBURST assay, which assesses Fc receptor mediated phagocytosis and the resulting 
oxidative burst, and by investigating the ability of BMDMs to phagocytose antibody-
opsonised beads. The Fc oxyBURST assay demonstrated a significant reduction in activation 
in WKY.LCrgn2 bone marrow derived macrophages (BMDMs) compared to WKY BMDMs 
at all timepoints and, importantly, the WKY.LCrgn2 behaved the same as LEW BMDMs. A 
similar result was found in the bead phagocytosis assay and there was also a significant 
reduction in the classically activated macrophage marker inducible nitric oxide synthase 2 
(Nos2) expression which together suggested that a gene within the Crgn2 QTL played a 
major role in controlling macrophage activation in WKY BMDMs (Behmoaras et al., 2008). 
Understanding the influence on the transcriptome of Crgn2 in both basal and LPS stimulated 
BMDMs between the WKY and WKY.LCrgn2 rat strains could allow for the identification 
of candidate genes that influence these activation pathways and explain the effects of the 
congenic interval in decreasing the severity of NTN disease. 
 
4.1.2      JunD as a determinant of macrophage activation 
The positional candidate gene for the Crgn2 QTL was identified using a combination of gene 
expression profiling and linkage analysis which has become a widely used approach in 
identifying candidate genes that underlie the phenotypes linked to QTLs (Aitman et al., 1999; 
Hubner et al., 2005; Swanberg et al., 2005; Petretto et al., 2008; Pravenec et al., 2008). The 
activator protein-1 (AP-1) transcription factor Jund was highly overexpressed in both the 
normal and nephritic glomeruli of WKY rats compared to LEW rats in microarray analysis of 
glomerular RNA and there was also increased protein expression in WKY glomeruli 
compared to those from the LEW strain (Behmoaras et al., 2008). The expression of Jund 
segregated with the Crgn2 congenic interval in the congenic strains and a promoter 
polymorphism in the proximal promoter of the gene was found to explain, in part, the 
difference seen in expression. A TransAm assay, which is a DNA binding ELISA that 
quantifies the amount of transcription factor binding to a consensus sequence, confirmed that 
specific JunD binding to AP-1 consensus sequence nucleotides (5’-TGAGTCA-3’) was 
significantly higher in nuclear extracts from WKY BMDMs compared to both LEW and 
WKY.LCrgn2 extracts (Behmoaras et al., 2008).  
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The role of JunD in macrophage activation was confirmed using siRNA knockdown of Jund 
mRNA. The Fc-oxyBURST assay was used to assess macrophage activation and showed a 
significant reduction in activation in BMDMs transfected with Jund siRNA compared to 
WKY BMDMs transfected with scrambled control siRNA. In addition the Jund siRNA 
transfected BMDMs demonstrated reduced Nos2 expression following LPS stimulation. The 
importance that this effect of altered Jund expression levels had on macrophage activation 
was shown by translational studies in human primary macrophages, where siRNA 
knockdown of JUND significantly reduced the expression of the inflammatory cytokines 
interleukin-10 (IL10), tissue necrosis factor alpha (TNFα) and IL-6. Therefore, similar to the 
value that investigating the effect of the Crgn2 interval on macrophage gene expression in the 
congenic and parental strains would have in informing about macrophage activation and 
effector genes for NTN susceptibility, the effect of an acute reduction in Jund expression 
level by siRNA knockdown could also highlight the genes and pathways that could directly 
alter macrophage activation and potentially influence the Crgn disease course. Such 
information is essential if inhibition of Jund is, in the future, to be considered as a therapeutic 
option. 
 
4.2 Results 
4.2.1      The LPS response in WKY.LCrgn2 BMDMs 
A comparison between the responses of WKY and LEW BMDMs to LPS is detailed in 
Chapter 3 and found that though the overall responses were similar in both strains, there 
were significant differential gene expression differences found at all the time points between 
the strains. In the LPS timecourse experiment the BMDMs from four biological replicates per 
strain from WKY and LEW were cultured and stimulated with LPS over the eight hour 
timecourse in a single experiment. BMDMs were also cultured and stimulated with LPS at 
the same timepoints alongside WKY and LEW and these data are presented in this chapter. 
RNA isolations, purifications and subsequent preparations of fragmented and labelled cDNA 
for microarray hybridisation were carried out in four separate batches containing the 12 
samples from the three strains for each of the four time points.  
 
This experimental design therefore allowed for a number of different aspects of the LPS 
response to be investigated and the data presented in this chapter aims to gain further 
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understanding of how much the Crgn2 congenic interval derived from the LEW strain 
influences and impacts upon the LPS response in WKY BMDMs. The overall LPS response 
in WKY.LCrgn2 BMDMs was analysed along with the analysis of differential gene 
expression at each of the static timepoints between WKY and WKY.LCrgn2 using 
significance analysis of microarrays v3.0 (SAM) with a FDR threshold of 5% following 
40,000 permutations as per Methods 2.17.6 (Tusher et al., 2001). This analysis was carried 
out by Dr Prashant Srivastava, Physiological Genomics and Medicine Group, MRC Clinical 
Sciences Centre. The microarray experiment data is as an appendix on the DVD enclosed 
with this thesis as detailed in 3.2.2. 
 
Stimulation of WKY.LCrgn2 BMDMs with LPS induced a robust transcriptional response 
(Table 4.1) with thousands of genes altering their expression at each of the timepoints 
compared to baseline. The largest number of genes changing compared to baseline occurred 
at the four hour timepoint and the majority of genes were downregulated following LPS 
stimulation. In terms of total gene numbers, this response was more similar to the WKY 
strain than the LEW strain but crucially at each time point there were fewer genes than the 
WKY strain that were differentially expressed (Table 4.1). The effect of the Crgn2 locus 
when introgressed onto the WKY background was not to increase the number of genes that 
were differentially expressed after LPS, as seen in the LEW strain, but to reduce the overall 
response suggesting that Crgn2 was dampening the response. The proportion of genes that 
showed increased expression or decreased expression at each time point were very similar to 
the proportions seen for WKY BMDMs. A common response was evident between all three 
strains at all timepoints (Figure 4.1), with the majority of differentially expressed genes at 
each time point common between the strains. 
 
The overall numbers of differentially expressed genes demonstrating fold changes greater 
than threefold following LPS stimulation were also decreased in WKY.LCrgn2 BMDMs 
compared to the WKY and LEW strains (Table 4.2). The majority of these significantly 
differentially expressed genes with fold changes greater than threefold were shared in 
common with either WKY or LEW or both strains (Figure 4.2).  
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Table 4.1 Differentially expressed genes following LPS stimulation in WKY, 
WKY.LCrgn2 and LEW BMDMs 
 
Microarray results detailing differentially expressed transcripts in each of the WKY, LEW 
and WKY.LCrgn2 strains (four biological replicates per strain) at each time point compared 
to the basal state using SAM v3.0 (Tusher et al., 2001) with 40,000 permutations and a 
<5%FDR threshold. The results for WKY.LCrgn2 are highlighted in bold. Numbers within 
brackets detail percentage of the total number of differentially expressed genes at that time 
point comparison. 
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Figure 4.1 Venn diagram showing overlap of differentially expressed genes in 
WKY, LEW and WKY.LCrgn2 BMDMs 
The Venn diagrams displayed showing the unique and common differentially expressed 
genes between the WKY, LEW and WKY.LCrgn2 BMDMs between the basal state and two 
hours (A), four hours (B) and eight hours (C) of LPS stimulation. Statistical methods for 
detecting differential gene expression between baseline and each timepoint are detailed in 
Table 4.1. 
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Table 4.2 Numbers of differentially expressed genes demonstrating fold changes 
greater than threefold following LPS stimulation in WKY, WKY.LCrgn2 and LEW 
BMDMs 
 
 
 
 
 
 
 
 
 
 
Statistical methods for detecting differential gene expression between baseline and each 
timepoint are detailed in Table 4.1. 
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Figure 4.2 Venn diagram showing overlap of differentially expressed genes 
with greater than threefold change in expression in WKY, LEW and 
WKY.LCrgn2 BMDMs 
The Venn diagrams displayed showing the unique and common differentially expressed 
genes with a greater than threefold change in expression between the WKY, LEW and 
WKY.LCrgn2 BMDMs between the basal state and two hours (A), four hours (B) and eight 
hours (C) of LPS stimulation. Statistical methods for detecting differential gene expression 
between baseline and each timepoint are detailed in Table 4.1. 
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4.2.1.1 Functional and motif enrichment analysis of the LPS response 
The data suggested that the LPS response in WKY.LCrgn2 was most similar to the WKY 
strain, as would be expected from the highly similar genetic background, but also that an 
attenuated LPS response was occurring compared to the other strains. Gene ontology analysis 
of the differentially expressed genes did confirm that a highly similar response was occurring. 
As seen in the analysis of both the WKY and LEW strains (Table 3.3-3.6), the genes with 
higher expression after two hours LPS stimulation were associated functionally with the 
immune response and the regulation of cell death, programmed cell death, apoptosis and 
cytokine production (Table 4.3). KEGG pathway analysis similarly linked the genes with the 
NOD-like receptor signalling pathway, cytokine-cytokine receptor interactions and the Toll-
like receptor signalling pathway (Table 4.3). Genes downregulated after LPS stimulation 
showed enrichment for functional processes such as DNA metabolic processes, regulation of 
transcription and chromosome organisation and pathways such as ubiquitin mediated 
proteolysis and cell cycle (Table 4.4) as seen in the WKY and LEW analyses. 
 
Motif enrichment analysis was performed on the sets of genes with increased expression and 
decreased expression following two hours of LPS stimulation using MotifModeler (Liu et al., 
2006) in combination with TransFind (Kiełbasa et al., 2010) as per Methods 2.17.6.5 and 
Chapter 3.2.2. Genes with increased expression showed enrichment for nuclear factor kappa-
light-chain enhancer of activated B cells (NF-κB) and interferon regulatory factor (IRF) 
families (Table 4.5). These findings were similar to the results of the equivalent analysis in 
the WKY and LEW strains (Table 3.7). Examination of the genes with decreased expression 
after two hours LPS stimulation compared to the basal state did not identify any enriched 
factors residing above the significance threshold applied. This is in contrast to the WKY and 
LEW strains where enrichment for the CREB and E2F factors was demonstrated (Table 3.8). 
In WKY.LCrgn2 BMDMs, enrichment for CREB was only seen with a TCS score of 6.31E-
03 but the TransFind FDR was not significant at an FDR of 0.28 whilst enrichment for E2F 
was seen at a TCS score of 6.08E-03 and a TransFind FDR of 0.029. 
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Table 4.3 Gene ontology analysis of genes demonstrating increased expression in 
WKY.LCrgn2 BMDMs following 2 hours of LPS stimulation compared to basal state 
 
The top terms in each category are listed. Enrichment for biological process functional 
annotation terms and KEGG canonical pathways used a threshold of <5% FDR and fold 
enrichment >1.5.  
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Table 4.4 Gene ontology analysis of genes demonstrating decreased expression in 
WKY.LCrgn2 BMDMs following 2 hours of LPS stimulation compared to basal state 
 
 
The top ten terms in each category are listed. Enrichment for biological process functional 
annotation terms (BP_FAT) and KEGG canonical pathways used a threshold of <5% FDR 
and fold enrichment >1.5.  
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Table 4.5 Motif enrichment analysis of genes demonstrating increased expression in 
WKY.LCrgn2 BMDMs following 2 hours of LPS stimulation 
 
Enriched TRANSFAC vertebrate transcription factor binding sites (TFBS) in common 
between MotifModeler and TransFind. The transcription factor binding site ID given is the 
enriched TRANSFAC vertebrate motif identified. Enriched TFBS from MotifModeler 
selected on basis of a transcriptional contribution (TCS) score two standard deviations above 
the mean value for all the TFBS identified. A higher TCS score indicates a stronger 
contribution. MotifModeler Xm score is the estimated functional level of the transcription 
factor. Factors identified by TransFind selected on basis of enriched TFBS with an FDR<5%.  
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4.2.2      Differential gene expression analysis between WKY and WKY.LCrgn2 
BMDMs 
The analysis of the response to LPS in WKY.LCrgn2 BMDMs highlighted the similarity in 
the response in this congenic strain with the WKY and LEW strains though differences in the 
overall numbers of genes differentially expressed during the LPS response were different. 
The analysis of the differential gene expression between the WKY and LEW strains using 
SAM v3.0 (Tusher et al., 2001) with 40,000 permutations and a <5%FDR threshold  
identified large numbers of differentially expressed genes at each timepoint and across the 
overall timecourse (Table 3.9). The same approach was therefore applied to the analysis 
between the WKY and WKY.LCrgn2 strains to see whether the effect of the Crgn2 locus 
would be to have significant effects on gene expression in the basal state and at the LPS 
stimulation timepoints, or whether the effect would only be seen in the overall response to 
stimulation (Table 4.6). As a constitutive transcription factor with major phenotypic 
consequences of its deletion evident in a knockout mouse (Thepot et al., 2000) and its 
potential to act as an early response gene, it was expected that key genes might be 
differentially expressed basally and sets of genes would differ following stimulation. 
 
As detailed in Table 4.6, analysis of differentially expressed genes between WKY and 
WKY.LCrgn2 BMDMs in the basal state identified only fourteen genes that were 
differentially expressed and all the genes showed higher expression in WKY.LCrgn2 
BMDMs. Unexpectedly differential expression of Jund was not identified at this 5%FDR 
threshold though it was found to be differentially expressed 1.36-fold higher in WKY 
BMDMs at an FDR of 7.72%. Two genes on chromosome 16 that were differentially 
expressed were identified in the analysis, CCR4-NOT transcription complex, subunit 7 
(Cnot7) at 1.46-fold higher in WKY.LCrgn2 BMDMs and sorting nexin 25 (Snx25) at 1.38-
fold higher in WKY.LCrgn2 BMDMs. Both were located just beyond the congenic interval 
in the recombination zone on chromosome 16. The majority of transcripts at this timepoint 
were located in chromosome six and are only partially annotated (Table 4.7). 
 
The analysis of the timepoints following LPS stimulation also found only a small number of 
genes to be differentially expressed (Table 4.6). At two hours of LPS stimulation, 25 genes 
were differentially expressed and again the majority showed higher expression in 
WKY.LCrgn2BMDMs (Table 4.8). Microfibrillar-associated protein 3-like (Mfap3l) was  
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Table 4.6 Microarray results detailing the numbers of differentially expressed genes 
between WKY and WKY.LCrgn2 BMDMs 
 
Results detailing differentially expressed transcripts between WKY and WKY.LCrgn2 
BMDMs (four biological replicates per strain) at each timepoint using SAM v3.0 (Tusher et 
al., 2001) with 40,000 permutations and a <5%FDR threshold.  
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Table 4.7 Differentially expressed genes identified between basal WKY and 
WKY.LCrgn2 BMDMs 
 
Results detailing differentially expressed transcripts between WKY and WKY.LCrgn2 basal 
BMDMs (four biological replicates per strain) using SAM v3.0 (Tusher et al., 2001) with 
40,000 permutations and a <5%FDR threshold.  
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Table 4.8 Differentially expressed genes identified between WKY and 
WKY.LCrgn2 BMDMs following two hours LPS stimulation 
 
Results detailing differentially expressed transcripts between WKY and WKY.LCrgn2 
BMDMs (four biological replicates per strain) following two hours LPS stimulation using 
SAM v3.0 (Tusher et al., 2001) with 40,000 permutations and a <5%FDR threshold.  
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found to show higher expression in WKY BMDMs at 1.59-fold and was located in the 
congenic interval. Two other genes demonstrating higher expression in WKY.LCrgn2 
BMDMs were located in the congenic interval namely pleckstrin and Sec7 domain containing 
3 (Psd3) and dCMP deaminase (Dctd) whilst toll-like receptor three (Tlr3) was located just 
beyond the bounds of the Crgn2 congenic interval. Along with the genes previously 
identified on chromosome six in the basal state, other genes were found including caveolin 1 
(Cav1) on chromosome 4,  ubiquitin specific peptidase 48 (Usp48) and carbonic anhydrase 6  
(Car6) on chromosome five and phosphoribosyl pyrophosphate synthetase-associated protein 
2 (Prpsap2) on chromosome ten.  
 
Sixteen genes were identified as being differentially expressed following four hours of LPS 
stimulation (Table 4.9). Along with previously identified transcripts such as Mfap3l and 
Car6, additional genes were identified including POU class homeobox2 (Pou2f2) on 
chromosome one and transforming growth factor, beta 2 (Tgfb2) on chromosome 14 which is 
also differentially expressed between the WKY and LEW strains. In contrast to the other 
timepoints, by eight hours there were 31 differentially expressed genes identified of which 13 
demonstrated higher expression in WKY BMDMs (Table 4.10). Additional transcripts were 
identified that were not found to be differentially expressed at other timepoints such as 
protein phosphate 1 regulator (inhibitor) subunit 3B (Ppp1r3b) and CREB regulated 
transcription coactivator 1 (Crtc1) on chromosome 16 with higher expression seen in WKY 
BMDMs. A number of genes showed higher expression in WKY.LCrgn2 BMDMs including 
Fc fragment of IgG, receptor transporter, alpha (Fcgrt) on chromosome one, tumour necrosis 
factor (ligand) superfamily, member 18 (Tnfsf18) on chromosome 13, slit homolog 2 (Slit2) 
on chromosome 14 and matrix metallopeptidase 8 (Mmp8) on chromosome eight. Mmp8 is 
also significantly differentially expressed between WKY and LEW BMDMs in a static 
timepoint analysis of four hours LPS stimulation (Table 3.20). 
 
This relatively small number of differentially expressed genes meant that functional analysis 
of the differentially expressed gene sets using DAVID did not identify any enriched 
biological process functional annotation terms or KEGG pathway terms at 1.5-fold 
enrichment and <5% FDR. 
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Table 4.9 Differentially expressed genes identified between WKY and 
WKY.LCrgn2 BMDMs following four hours LPS stimulation 
 
Results detailing differentially expressed transcripts between WKY and WKY.LCrgn2 
BMDMs (four biological replicates per strain) following four hours LPS stimulation using 
SAM v3.0 (Tusher et al., 2001) with 40,000 permutations and a <5%FDR threshold.  
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Table 4.10 Differentially expressed genes between WKY and WKY.LCrgn2 BMDMs 
following eight hours LPS stimulation 
 
 
Results detailing differentially expressed transcripts between WKY and WKY.LCrgn2 
BMDMs (four biological replicates per strain) following two hours LPS stimulation using 
SAM v3.0 (Tusher et al., 2001) with 40,000 permutations and a <5%FDR threshold. 
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4.2.2.1 Confirmation of Crgn2 congenic interval and differential Jund expression 
The finding of a number of strongly differentially expressed transcripts between WKY and 
WKY.LCrgn2 BMDMs within a 4.85 megabase region towards the end of chromosome 6 
(Chr6: 138,287,132 -143,134,139) raised the possibility that residual donor LEW genome 
was present in this region during the generation of the congenic line that could account for 
this difference. Of note, whilst these transcripts have been identified by the Ensembl database 
as potential transcripts, none are confirmed genes in the NCBI reference sequence database 
lie within this region. In addition, no major large scale deletions are present between the 
WKY and LEW genomes in this region (S. Atanur, Physiological Genomics and Medicine 
(PGM) Group, MRC Clinical Sciences Centre, personal communication). There was 
variability between timepoints of the number of Ensembl transcripts within this region that 
were differentially expressed between WKY and WKY.LCrgn2 BMDMs and the degree and 
direction of fold changes in the comparisons also differed (Table 4.11).  
 
To confirm whether there was a segment of donor LEW genome at this locus, genotyping 
using polymorphic microsatellite markers was performed by Ms Zelpha D’Souza, PGM 
group, MRC CSC. A range of informative markers located within the 4.5 Mb segment under 
query and at end side of the region were consistent with the parental genotype in all the 
strains examined (Figure 4.3). This confirmed that there was not a segment of donor LEW 
genome at this locus and that an additional congenic region was influencing the gene 
expression data results. 
 
An additional, unexpected, finding was that the differential expression of Jund was not 
identified at the 5%FDR threshold between WKY and WKY.LCrgn2 BMDMs though it was 
found to be differentially expressed 1.36-fold higher in WKY BMDMs at an FDR of 7.72% 
in the basal state. The integrity of the congenic strain had been assessed and confirmed as 
part of the experimental methodology in the microarray LPS timecourse experiment (Figure 
4.4). Of note, the LEW marker at D16Rat85 is a small donor segment from a Harlan LEW 
strain used in initial crosses prior to the use of LEW from Charles River for the subsequent 
crosses. Jund was linked to the D16Rat78 marker previously by ARMS assay and is also 
located close to this marker in the genome (Behmoaras et al., 2008). 
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Table 4.11 Differentially expressed transcripts between WKY strain and the LEW 
and WKY.LCrgn2 strains in chromosome 6: 138,287,132-143,134,139 
 
Differentially expressed transcripts detected in comparisons between WKY and LEW 
BMDMs and WKY and WKY.LCrgn2 BMDMs at <5% FDR threshold using SAM v3.0 
(Tusher et al., 2001). A positive fold change indicates higher expression in WKY BMDMs in 
each comparison. Blank cells indicate no significant difference was observed between the 
strains at <5% FDR. 
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Figure 4.3 Genotyping and sequencing at a Chromosome 6 locus possibly 
containing a donor segment from LEW genome 
Genotyping of microsatellites and sequencing of polymorphisms at a locus on chromosome 6 
that contains a potential donor segment of LEW genome on WKY background. Genotyping 
results indicated by letter A (LEW) and letter B (WKY). This confirms that the 
WKY.LCrgn2 strain does not contain any donor segments of LEW genome at this locus. 
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Figure 4.4 Genotyping to confirm introgression of Crgn2 congenic interval 
Genotyping of microsatellite markers was performed by Ms Zelpha D’Souza of the PGM 
group, MRC CSC. This confirmed that the LEW Crgn2 QTL had been introgressed onto the 
WKY background successfully. In the results table, ‘A’ signifies a LEW genotype and ‘B’ a 
WKY genotype. 
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Different primer strategies had been reported to alter the ability to detect the difference in 
Jund expression between the strains (J Behmoaras, CCIR, Imperial College, personal 
communication). The differential expression of Jund between the WKY and LEW strains was 
identified originally using the Affymetrix Rat Genome U34 Set which used an oligo (dT) 
primer based strategy to reverse transcribe mRNA prior to amplification, fragmentation and 
biotinylation of cRNA and its microarray hybridisation (Behmoaras et al., 2008).  This found 
that the difference in expression was 20.75-fold higher in WKY control glomeruli versus 
LEW and 18.56-fold higher in WKY nephritic glomeruli (Behmoaras et al., 2008). A more 
recent microarray analysis between the WKY and LEW strains identified that the gene had a 
modest (1.42-fold) difference between the strains which was highly significant (P=3.5E04, 
<5%FDR) (Maratou et al., 2010). The differences in gene expression were detected more 
easily using qRT-PCR where over fourfold relative differences were seen between the strains 
suggesting, as is recognised, that microarrays can show a compression of measured fold 
changes (Behmoaras et al., 2008; Maratou et al., 2010). In this experiment Jund was found to 
be differentially expressed between WKY and LEW at an FDR of 1.68% and a modest fold 
change of 1.27 (see supplementary appendices enclosed on DVD). The sample preparation 
protocols used by Maratou et al and in this work (Methods 2.8) use an initial oligo(dT) 
priming step in the synthesis of the first strand of cDNA but random primers were used to 
convert antisense RNA (cRNA) into cDNA (Figure 2.3).  
 
This suggested that a difference between the primers used could potentially affect the degree 
of amplification of the mRNA in its conversion to cDNA altering the level of fold change 
seen. Notably the GC content of the Jund locus is relatively high at 63.2%. cDNA synthesis 
was compared using a one-step reaction kit using gene specific primers, a random primer 
method and two different cDNA synthesis kits that use an oligo (dT) based primer method. 
The oligo (dT) primer strategy allowed for better resolution of differences in Jund expression 
between the WKY and LEW BMDMs (Figure 4.5). The differential expression of Jund 
between WKY BMDMs compared to both LEW and WKY.LCrgn2 BMDMs was confirmed 
using qRT-PCR (Figure 4.6). 
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Figure 4.5 Comparison of different primer strategies for use in cDNA 
synthesis 
cDNA synthesis was performed as per manufacturer’s instructions and a qRT-PCR 
performed using primers specific for Jund in WKY and LEW BMDMs using gene-specific 
primers in a one-step reaction (A), random primers (B) and oligo-dT primers with the 
Ambion Cells to cDNA kit (C) and iScript select cDNA synthesis kit (D) in two-step 
reactions. Gene specific primers (A) produced a non-significant mean Ct difference of 0.62Ct 
units and random primers produced a non-significant mean Ct difference of 1.30 Ct units 
whilst oligo-dT primers produced a significant mean Ct difference of 5.20 Ct units (C) and 
3.63 Ct units (B). Four biological replicates amplified in triplicate (A,B,C) and three 
biological replicates amplified in triplicate (D) were analysed by qRT-PCR and an unpaired t-
test used to compare Ct values between strains for each primer. 
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Figure 4.6 Differential expression of Jund between WKY, LEW and 
WKY.LCrgn2 BMDMs  
The differential expression of Jund between WKY and both LEW and WKY.LCrgn2 
BMDMs was assessed by qRT-PCR using the same cDNA synthesis kit as used in Figure 
4.5D. (A) Microarray expression values (log2 transformed). (B) Samples were amplified 
using a set of four biological replicates with three technical replicates per sample. Relative 
gene expression was measured by qRT-PCR and normalised with Hprt for WKY and LEW 
BMDMs. *P<0.05; **P<0.01;***P<0.001 statistically significantly different to WKY using a 
two way ANOVA to compare the overall timecourse with Bonferonni’s post-tests to compare 
individual time points versus WKY. Stars at top relate to the WKY versus WKY.LCrgn2 
comparison, the bottom the WKY versus LEW comparison. (C) Two way ANOVA results of 
the overall timecourse indicating contribution of different factors to the variation seen in 
graph B. Error bars represent standard error of the mean.   
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4.2.2.2 Gene set enrichment analysis 
The analysis of the overall LPS response in WKY.LCrgn2 BMDMs indicated that the LPS 
response was different between the WKY and WKY.LCrgn2 strains but this difference could 
be subtle in the overall context of the robust response to LPS. Gene set enrichment analysis 
(GSEA) was used to analyse the static timepoints as the approach evaluates microarray data 
at the level of gene sets (Subramanian et al., 2005; Subramanian et al., 2007). The effect of 
Crgn2 on the macrophage transcriptome could lie in changing the coordinated response to 
LPS rather than changing the expression of only a smaller number of effector genes. GSEA 
was performed using the Java based software implementation (GSEA-P 2.0) with default 
settings. The default Signal2Noise metric was used for ranking genes and 1000 permutations 
were performed using the gene set permutation type not phenotype as the latter is only 
suitable for large sample sizes. The canonical pathways gene set from the Molecular 
Signatures Database (MSigDB) was used for the analysis (Subramanian et al., 2005; 
Subramanian et al., 2007). 
 
In the basal state, no genes sets were enriched in WKY BMDMs at <5% FDR whilst three 
were identified in WKY.LCrgn2 BMDMs (Table 4.12). The gene sets were all part of the 
Reactome database linked with cell cycle and replication processes. A graphical display of 
the results illustrates the typical output from GSEA used to define the gene sets (Figure 4.7). 
After two hours of LPS stimulation, four pathways in WKY BMDMs were significantly 
enriched associated with peptide ligand binding receptors, a subset of the Class A/1 
(Rhodopsin-like) family which bind peptide ligands including chemokines along with the 
enrichment of the KEGG cytokine-cytokine receptor interaction as well as G-protein coupled 
receptors (Table 4.13). Thirty-five gene sets were enriched in WKY.LCrgn2BMDMs and the 
majority of gene sets were linked with cell cycle and DNA replication functions and DNA 
repair (Table 4.13). The analysis of the four hour timepoint identified five enriched gene sets 
in WKY BMDMs again linked with chemokine and peptide ligand binding receptors and 
KEGG complement and coagulation cascades (Table 4.14) whilst the ten enriched gene sets 
in WKY.LCrgn2 BMDMs were linked to the cell cycle and DNA replication. After eight 
hours of LPS stimulation only three genes sets were differentially enriched. Two sets were 
enriched in the WKY BMDMs (Table 4.15).  
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Table 4.12 Gene set enrichment analysis (GSEA) results between basal WKY and 
WKY.LCrgn2 BMDMs 
 
 
GSEA result from the analysis between WKY and WKY.LCrgn2BMDMs. Significantly 
enriched gene sets were identified with <5% FDR threshold. Enrichment score (ES) is the 
degree to which a gene set is overrepresented at the top or bottom of the list. Normalised 
enrichment score (NES) is a normalised ES score that allows comparison of results across 
gene sets. P-value estimates the statistical significance of the enrichment score for a single 
gene set and the false discovery rate (FDR) q-value is the P-value corrected for multiple 
testing. 
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Figure 4.7 Enrichment plot for GSEA analysis of basal BMDMs 
Enrichment plot displaying graphically the results of the enriched pathways in 
WKY.LCrgn2BMDMs namely Reactome cell cycle mitotic (A), Reactome mitotic 
prometaphase (B) and Reactome mitotic M_M_G1 phases (C). The plot displays the running 
enrichment score (ES) for the gene set as the analysis processes the gene set. The leading 
edge subset of the gene set is the set of genes contributing most to the ES score and in his 
case are the genes that appear after the peak ES score is reached. The lower part of the plot 
shows the value of the ranking metric through the list of ranked genes which gives a measure 
of a gene’s correlation with a phenotype in this case the strain. 
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Table 4.13 Gene set enrichment analysis (GSEA) results in two hour LPS stimulated 
WKY and WKY.LCrgn2 BMDMs 
 
GSEA result from the analysis between WKY and WKY.LCrgn2BMDMs. Significantly 
enriched gene sets were identified with <5% FDR threshold. Enrichment score (ES) is the 
degree to which a gene set is overrepresented at the top or bottom of the list. Normalised 
enrichment score (NES) is a normalised ES score that allows comparison of results across 
gene sets. P-value estimates the statistical significance of the enrichment score for a single 
gene set and the false discovery rate (FDR) q-value is the P-value corrected for multiple 
testing. 
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Table 4.14 Gene set enrichment analysis (GSEA) results in four hour LPS stimulated 
WKY and WKY.LCrgn2 BMDMs 
 
GSEA result from the analysis between WKY and WKY.LCrgn2BMDMs. Significantly 
enriched gene sets were identified with <5% FDR threshold. Enrichment score (ES) is the 
degree to which a gene set is overrepresented at the top or bottom of the list. Normalised 
enrichment score (NES) is a normalised ES score that allows comparison of results across 
gene sets. P-value estimates the statistical significance of the enrichment score for a single 
gene set and the false discovery rate (FDR) q-value is the P-value corrected for multiple 
testing. 
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Table 4.15 Gene set enrichment analysis (GSEA) results in eight hour LPS 
stimulated WKY and WKY.LCrgn2 BMDMs 
 
 
 
GSEA result from the analysis between WKY and WKY.LCrgn2BMDMs. Significantly 
enriched gene sets were identified with <5% FDR threshold. Enrichment score (ES) is the 
degree to which a gene set is overrepresented at the top or bottom of the list. Normalised 
enrichment score (NES) is a normalised ES score that allows comparison of results across 
gene sets. P-value estimates the statistical significance of the enrichment score for a single 
gene set and the false discovery rate (FDR) q-value is the P-value corrected for multiple 
testing. 
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As previously, the complement and coagulation cascades were enriched but, alongside this, 
was enrichment for the JAK-STAT signalling pathway whilst in WKY.LCrgn2 BMDMs 
there was only one gene set enriched linked again with the cell cycle. 
 
The GSEA approach identified multiple pathways at each timepoint that were enriched in 
each strain suggesting subtle gene effects were contributing to the phenotypic differences 
therein. The gene sets linked with WKY BMDMs were associated with receptor interactions 
and as a consequence, the potential responses and induction of inflammation as well 
complement and coagulation pathways and the JAK-STAT pathway. In contrast 
WKY.LCrgn2 BMDMs associated only with basic cellular functions including the cell cycle 
and DNA replication suggesting that there was a failure to downregulate these core 
homeostatic pathways in response to LPS compared to WKY BMDMs and that the 
transcriptional drivers in the cell had been altered by the presence of LEW Crgn2 on the 
WKY background. 
 
4.2.2.3 Timecourse analysis between LPS stimulated WKY and WKY.LCrgn2 
BMDMs 
The evidence thus far suggested that subtle differences in the response to LPS were present 
between the two strains. However, the static timepoint analysis using SAM v3.0 (Tusher et 
al., 2001) did not capture the dynamic behaviour of the LPS response between BMDMs from 
the WKY and WKY.LCrgn2 strains. The analysis performed using GSEA suggested it was 
likely that small changes within sets of genes were the result of the introgression of the LEW 
Crgn2 QTL onto the WKY genome rather than larger scale changes in differential 
expression. An overall assessment of the whole LPS timecourse was performed using two 
different approaches. 
 
An area under the curve based analysis as implemented in SAM v3.0 (Tusher et al., 2001) 
was used to examine the overall timecourse. This approach identified 44 differentially 
expressed transcripts, all of which demonstrated higher expression in WKY.LCrgn2 BMDMs 
(Table 4.16). This approach did identify a number of genes that were not in the static 
timecourse analyses including myosin 1D (Myo1d) on chromosome ten, dedicator of cyto-
kinesis 3 (Dock3) on chromosome eight, lymphatic vessel endothelial hyaluronan receptor 1 
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Table 4.16 Differentially expressed genes between WKY and WKY.LCrgn2 BMDMs 
over the whole LPS stimulation timecourse using SAM v3.0 
Results detailing differentially expressed transcripts between WKY and WKY.LCrgn2 
BMDMs (four biological replicates per strain) over the LPS stimulation timecourse using 
SAM v3.0 (Tusher et al., 2001) with 40,000 permutations and a <5%FDR threshold.  
233 
 
(Lyve1) on chromosome 1 and cadherin 5 (Cdh5) on chromosome 19. No enriched functional 
terms or KEGG pathways were identified by DAVID analysis in this gene set. 
 
The overall LPS response over the entire timecourse was thus examined with an approach 
that identifies genes that show temporal differential expression as implemented in EDGE 
v1.1.291 (Storey et al., 2005; Leek et al., 2006). This algorithm uses a spline based method to 
model the gene expression differences over time with a significance measure assigned to each 
gene (Storey and Tibshirani, 2003; Leek et al., 2006).  
 
This identified that 161 genes at an FDR of 1% and 830 genes at an FDR of 5% had a 
significantly different timecourse between WKY and WKY.LCrgn2 BMDMs (Figure 4.8). 
In comparison, 5,068 genes at a 1% FDR and 8,510 genes at 5% FDR were identified as 
having a different timecourse between WKY and LEW BMDMs (data detailed in 
supplementary appendix on enclosed DVD). This demonstrated that the difference in 
response caused by the Crgn2 interval was subtle and modulated the LPS response rather 
than causing major transcriptome differences. 573 genes out of the 830 genes in the WKY 
versus WKY.LCrgn2 comparison at 5% FDR were also present in the WKY versus LEW 
comparison, indicating that the effect of Crgn2, for a substantial proportion of genes, was 
having a similar effect in both the congenic and the LEW strain compared to WKY genes. 
 
Functional analysis was performed of the 830 genes identified as having different time course 
profiles at 5% FDR between the WKY versus WKY.LCrgn2 BMDMs. This analysis 
identified significant enrichment for a large number of biological processes including 
responses to organic substance, hormone stimulus, wounding and endogenous stimulus and 
the response to molecules of bacterial origin and LPS. Processes linked with cell activation, 
regulation of anti-apoptosis, programmed cell death and cell death were also enriched (Table 
4.17 and Appendix B, Table B.1). KEGG pathway analysis also identified four significantly 
enriched pathways including the Jak-STAT signalling pathway which had also been 
identified by GSEA analysis of the eight hour static timepoint (Table 4.17). 
 
Functional analysis of the 573 genes overlapping with the timecourse analysis performed 
between WKY and LEW BMDMs also identified significant enrichment for a large number 
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Figure 4.8 Heat map demonstrating results of hierarchical clustering of 830 
genes differentially expressed between WKY and WKY.LCrgn2 BMDMs over 
the LPS timecourse. 
The 830 differentially expressed genes between WKY and WKY.LCrgn2 BMDMs over the 
LPS stimulation timecourse using EDGE 1.1.291 (Leek et al., 2006) were hierarchically 
clustered. Eight separate main clusters were identified of which, five clusters demonstrated 
functional enrichment for biological processes using DAVID at a threshold of <5% FDR and 
fold enrichment >1.5. 
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Table 4.17 Gene ontology analysis for genes demonstrating differential expression 
over the LPS timecourse between WKY and WKY.LCrgn2 BMDMs  
 
Genes demonstrating differential expression over time identified using EDGE 1.1.291 (Leek 
et al., 2006). Enrichment for biological process functional annotation terms used a threshold 
of <5% FDR and fold enrichment >1.5. The top 20 biological process functional annotation 
terms are listed in this table. The full list of enriched terms is detailed in Appendix B, Table 
B.1. 
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of biological process terms including a number of different stimulus responses, cell activation 
and cell death and apoptosis along with enrichment for the Jak-STAT cascade (Table 4.18  
and Appendix B, Table B.2). KEGG pathways were also enriched including the 
neurotrophin signalling pathway containing genes that link with the differentiation and 
survival of neural cells as well as cell adhesion molecules, leukocytes transendothelial 
migration and Fc gamma R-mediated phagocytosis (Table 4.18). 
 
Hierarchical clustering was used to display the 830 genes differentially expressed over the 
timecourse of LPS stimulation between WKY and WKY.LCrgn2BMDMs (Figure 4.8) and 
this analysis demonstrates the subtle differences that occur between the strains. Eight major 
gene clusters were identified and five of these sets of genes demonstrated functional 
enrichment for biological process terms (Figure 4.8). Cluster 1 was associated with responses 
to stimulation along with programmed cell death and apoptosis. The genes functionally 
linked with these processes are listed in Table 4.19 and include multiple members of the 
JAK-STAT pathway and a number of genes located within Crgn1 such as Fcgr3a and Atf3 
suggesting important related interactions of the two major susceptibility loci for Crgn in the 
WKY rat. Cluster 2 associated with aging, oxidation reduction and the response to wounding 
and the genes are listed in Table 4.20. Both clusters contained genes with high levels of 
expression over the LPS timecourse. Clusters 3, 4, and 5 were associated with lower 
expression levels but still enriched for immune function terms (Figure 4.8, Table 4.21). The 
clusters that were not functionally associated with any biological process terms still 
encompassed a large set of genes demonstrating that genes with known immune functions 
and unknown functions could both play important roles in mediating the effects of Crgn2 on 
the BMDM activation phenotype. 
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Table 4.18 Gene ontology analysis for genes demonstrating differential expression 
over the LPS timecourse between WKY and WKY.LCrgn2 BMDMs and between WKY 
and LEW BMDMs  
 
Genes demonstrating differential expression over time identified using EDGE 1.1.291 (Leek 
et al., 2006). Enrichment for biological process functional annotation terms used a threshold 
of <5% FDR and fold enrichment >1.5. The top 20 biological process functional annotation 
terms are listed in this table. The full list of enriched terms is detailed in Appendix B, Table 
B.2. 
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Table 4.19 Genes associated with biological process terms from the gene ontology 
analysis of cluster 1 
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Table 4.19 continued 
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Table 4.20  Genes associated with biological process terms from the gene ontology 
analysis of cluster 2  
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Table 4.20 continued 
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Table 4.21 Genes associated with biological process terms from the gene 
ontology analysis of clusters 3, 4 and 5   
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4.2.2.4 Validation of microarray data by qRT-PCR 
The microarray dataset of the LPS response in BMDMs consists of expression values for 
WKY, LEW and WKY.LCrgn2 BMDMs in the basal state and at two, four and eight hours of 
LPS stimulation. qRT-PCR validation was used to successfully validate 16 genes identified 
by static timepoint analyses of the microarray data between WKY and LEW BMDMs at each 
of the timepoints (Table 3.28) as well as genes identified by timecourse analyses between the 
two strains (Table 3.27  and Figures 3.3 and 3.4  and Appendix A, Figures A.1-A.14). This 
analysis gave confidence in the overall integrity of the microarray dataset and the biological 
conclusions that could be drawn from the analysis.  
 
In comparison to the analysis of static timepoints between the WKY and LEW BMDMs, very 
few genes showed such robust fold changes in the comparison between WKY and 
WKY.LCrgn2 BMDMs (Table 4.7-4.10). GSEA analysis demonstrated that subtle 
differences were occurring between these parental and congenic strains. Overall timecourse 
analysis using EDGE 1.1.291 (Leek et al., 2006) between WKY and WKY.LCrgn2 BMDMs 
was therefore used to identify these more subtle differences between the strains as the static 
timepoint analysis had failed to identify robust fold changes at the static timepoints in more 
than a handful of genes. This analysis identified 830 genes that had different profiles over the 
eight hour LPS stimulation at a 5% FDR threshold. These effects were subtle and of a fine 
tuning or modulatory nature. This timecourse dataset was validated using qRT-PCR of four 
biological replicates, each amplified in triplicate to examine the overall timecourse response. 
A two-way ANOVA statistical analysis was used to identify whether the difference in strain 
had a significant effect on any variation between the strains as well as whether it interacted 
over the timecourse to cause a difference between the strains. Genes were selected from the 
set of 830 genes identified in the timecourse analysis between WKY and WKY.LCrgn2 
BMDMs that had also been shown to be differentially expressed between the WKY and 
WKY.LCrgn2 BMDMs in static timecourse analyses or were differentially expressed 
between the WKY and LEW BMDMs previously.  
 
Thirteen genes were analysed as part of the timecourse validation between WKY and 
WKY.LCrgn2 BMDMs and the results of the validations are summarised in Table 4.22. 
Exemplars of the validation results are shown in Figures 4.9 and 4.10 and the full set of 
validated genes are  
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Table 4.22 Summary of the validation of microarray data using qRT-PCR 
 
Microarray data for 13 genes over the eight hour LPS stimulation timecourse were validated 
by qRT-PCR. Microarray P-values and FDR results for each timecourse comparison between 
WKY and WKY.LCrgn2 BMDMs using EDGE 1.1.291 (Leek et al., 2006) are listed. qRT-
PCR validation was carried using a set of four biological replicates with three technical 
replicates per strain. A two way ANOVA was used to compare the timecourse of gene 
expression changes between the two strains and the results above detail the significance of 
the contribution of strain, time and their interaction to the overall variation seen between the 
strains. The full data for the microarray and gene expression timecourse for these 16 genes 
are shown in Figures 4.9 and 4.10 and Appendix B. Figures B.1 to B.11. 
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Figure 4.9 Validation of microarray data for Cdo1, cysteine dioxygenase type 
1, by qRT-PCR 
Validation of microarray data by qRT-PCR. (A) Microarray expression values (log2 
transformed). (B) Samples were amplified using a set of four biological replicates with three 
technical replicates per sample. Relative gene expression was measured by qRT-PCR and 
normalised with Hprt for WKY and WKY.LCrgn2 BMDMs. *P<0.05; 
**P<0.01;***P<0.001 statistically significantly different to WKY using a two way ANOVA 
to compare the overall timecourse with Bonferonni’s post-tests to compare individual time 
points. (C) Two way ANOVA results of the overall timecourse indicating contribution of 
different factors to the variation seen in graph B. Error bars represent standard error of the 
mean 
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Figure 4.10 Validation of microarray data for Mmp8, matrix metallopeptidase 
8, by qRT-PCR 
Validation of microarray data by qRT-PCR. (A) Microarray expression values (log2 
transformed). (B) Samples were amplified using a set of four biological replicates with three 
technical replicates per sample. Relative gene expression was measured by qRT-PCR and 
normalised with Hprt for WKY and WKY.LCrgn2 BMDMs. *P<0.05; 
**P<0.01;***P<0.001 statistically significantly different to WKY using a two way ANOVA 
to compare the overall timecourse with Bonferonni’s post-tests to compare individual time 
points. (C) Two way ANOVA results of the overall timecourse indicating contribution of 
different factors to the variation seen in graph B. Error bars represent standard error of the 
mean 
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detailed in Appendix B, Figures B.1– B11. The left hand panel of each figure details the 
microarray data and the right hand panel the results of the qRT-PCR validation. The results of 
the two-way ANOVA analysis are given below the graphs. The qRT-PCR validation of Cdo1 
(Figure 4.9), Serpinb2 (Appendix B, Figure B.1), Arg1 (Appendix B, Figure B.2), Vcam1 
(Appendix B, Figure B.3) and Vegfa (Appendix B, Figure B.4) demonstrated that over the 
initial part of the timecourse the WKY and WKY.LCrgn2 BMDMs were largely similar in 
their initial LPS response with a difference in response occurring after eight hours of LPS 
stimulation, matching the profile observed in the microarray data set. In all five validations, 
the major contribution to variance was the LPS response over time compared to the smaller 
contribution of the strain effect, though in all three the interaction between the two factors 
was highly significant. The qRT-PCR validation of the Il-10 microarray data demonstrated a 
large contribution to the variation from the effect of strain (Appendix B, Figure B.5) with a 
larger effect seen after four hours and eight hours than seen with the microarray expression 
values (Appendix B, Figure B.5C). Mfap3l (Appendix B, Figure B.6) and Crtc1 
(Appendix B, Figure B.7) are located on chromosome 16 within the Crgn2 congenic 
interval. The validation of Mfap3l demonstrated a difference between the WKY and 
WKY.LCrgn2 strains at all four timepoints (Appendix B, Figure B.6) such that the 
contribution of strain to the variation was 79.21% in the two-way ANOVA analysis. Of note, 
whilst this could suggest that genetic factors acting in cis were altering its expression, the 
gene is actually under the direct influence of Jund as demonstrated by its differential 
expression following siRNA knockdown of Jund. The microarray data results for Crtc1 
suggested a fixed difference between the WKY and WKY.LCrgn2 strains (Appendix B, 
Figure B.7C)  but the qRT-PCR validation found that differences between the strains only 
occurred in the basal state and after eight hours of stimulation suggesting a more complex 
mode of transcriptional control could be occurring (Appendix B, Figure B.7C).  
 
Mmp8 (Figure 4.10), Crim1 (Appendix B, Figure B.8) and Slit2 (Appendix B, Figure B.9) 
demonstrated higher expression in the microarray dataset in WKY.LCrgn2 BMDMs 
compared to WKY BMDMs and these differences were confirmed by qRT-PCR validation. 
The qRT-PCR method did however fail to validate two genes identified as having different 
timecourse profiles. Both Cables2 (Appendix B, Figure B.10) and Tlr5 (Appendix B, 
Figure B.11) demonstrated subtle differences in profile between WKY and WKY.LCrgn2 
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BMDMs which were beyond the resolution of qRT-PCR over the timecourse to allow the 
differences to be confirmed. 
 
4.2.3      Identification of differentially expressed effector genes for the LPS response 
between WKY and WKY.LCrgn2 BMDMs  
The qRT-PCR validation of the microarray analysis for the LPS timecourse comparing WKY 
and WKY.LCrgn2 BMDMs identified a number of genes that could act as effector genes in 
the NTN model. To test this further, analysis of the qRT-PCR data of the timecourse between 
WKY, LEW and WKY.LCrgn2 BMDMs was carried out from the results of qRT-PCR of 
four biological replicates per strain, each amplified in triplicate. A two-way ANOVA 
statistical analysis was used to identify whether a significant difference was present between 
the strains over the timecourse (Table 4.23) and a Bonferonni’s post-test analysis was used to 
assess whether a significant difference was present in LEW or WKY.LCrgn2 BMDMs 
compared to WKY BMDMs. The differences between WKY and WKY.LCrgn2 BMDMs for 
these genes were similar in direction to that as the difference between WKY and LEW 
BMDMs (Figure 4.11-4.13). For some genes such as Serpinb2 (Figure 4.11A) and Arg1 
(Figure 4.11B) the effect of introgression of Crgn2 on the WKY background was to partly 
correct the difference between the WKY and LEW strains, showing that Crgn2 modulated 
gene expression but that other genetic factors were involved in the LPS response in those 
genes. For others, Crgn2 accounted fully for the difference between the WKY and LEW 
strains, for example Cdo1 (Figure 4.11C), Crtc1 (Figure 4.11D) and Mfap3l  (Figure 4.12A) 
or had an enhanced effect on the WKY background for example Vcam1 (Figure 4.12B) and  
Il-10 (Figure 4.12C) and Slit 2 (Figure 4.12D). For other genes such as Vegfa (Figure 
4.13A) the effect of Crgn2 was the opposite when in a WKY genomic context or in the 
parental LEW strain. The context of the difference between WKY and WKY.LCrgn2 
BMDMs over the LPS timecourse was highlighted by the analysis of Mmp8 (Figure 4.13B). 
Whilst in a comparison between WKY and WKY.LCrgn2 BMDMs alone (Figure 4.10), 
there was a significant difference between the strains, when put in context with the LEW 
BMDM timecourse, this difference was not significant (Figure 4.13). 
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Table 4.23 Two-way ANOVA analysis of qRT-PCR timecourse analysis of the LPS 
response in WKY, Lew and WKY.LCrgn2 BMDMs 
 
 
 
Samples were amplified using a set of four biological replicates with three technical 
replicates per sample. Relative gene expression was measured by qRT-PCR and normalised 
with Hprt. Two-way ANOVA was used to compare the overall timecourse results as 
displayed in Figure 4.10-4.12. The contribution and related P-value of the effect of strain, 
time and their interaction on the differences observed in the timecourse are displayed. 
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Figure 4.11 Identification of the effector genes differentially expressed in the 
LPS response between WKY and Lew BMDMs influenced by Crgn2 
qRT-PCR was used to investigate the effect of Crgn2 on the LPS response in WKY, LEW 
and WKY.LCrgn2 BMDMs for Serpinb2 (A), Arg1 (B), Cdo1 (C) and Crtc1  (D). Samples 
were amplified using a set of four biological replicates with three technical replicates per 
sample. Relative gene expression was measured by qRT-PCR and normalised with Hprt. 
*P<0.05; **P<0.01;***P<0.001 statistically significantly different to WKY using a two way 
ANOVA to compare the overall timecourse with Bonferonni’s post-tests to compare 
individual time points. 
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Figure 4.12 Identification of the effector genes differentially expressed in the 
LPS response between WKY and Lew BMDMs influenced by Crgn2 
qRT-PCR was used to investigate the effect of Crgn2 on the LPS response in WKY, LEW 
and WKY.LCrgn2 BMDMs for Mfap3l (A), Vcam1 (B), Il-10 (C) and Slit2 (D). Samples 
were amplified using a set of four biological replicates with three technical replicates per 
sample. Relative gene expression was measured by qRT-PCR and normalised with Hprt. 
*P<0.05; **P<0.01;***P<0.001 statistically significantly different to WKY using a two way 
ANOVA to compare the overall timecourse with Bonferonni’s post-tests to compare 
individual time points. 
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Figure 4.13 Identification of the effector genes differentially expressed in the 
LPS response between WKY and Lew BMDMs influenced by Crgn2 
qRT-PCR was used to investigate the effect of Crgn2 on the LPS response in WKY, LEW 
and WKY.LCrgn2 BMDMs for Mmp8 (A) and Vegfa (B). Samples were amplified using a 
set of four biological replicates with three technical replicates per sample. Relative gene 
expression was measured by qRT-PCR and normalised with Hprt. *P<0.05; 
**P<0.01;***P<0.001 statistically significantly different to WKY using a two way ANOVA 
to compare the overall timecourse with Bonferonni’s post-tests to compare individual time 
points. 
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4.2.4      Microarray analysis examining the effect of siRNA mediated knockdown of 
Jund on the WKY BMDM transcriptome 
The comparison of the transcriptomes of WKY and WKY.LCrgn2 BMDMs defined the 
transcriptional changes mediated by the Crgn2 congenic interval in which Jund, the gene 
shown in previous work to underlie altered macrophage function resides (Behmoaras et al., 
2008).  Jund is markedly over expressed in WKY BMDMs compared to WKY.LCrgn2 
BMDMs (Figure 4.6) and the analysis of the effect of introgressing the Crgn2 QTL onto the 
WKY background demonstrates the effect of a chronic physiological difference in the 
expression of the transcription factor. The relatively small number of differentially expressed 
genes could be the result of adaptation and redundancy with other members of the AP-1 
transcription factor family filling the role of Jund in the congenic strain. It had been 
previously shown that siRNA knockdown of Jund had a major phenotypic effect on 
macrophage activation in WKY BMDMs (Behmoaras et al., 2008). In order to investigate the 
direct and acute effects of altering Jund expression on the BMDM transcriptome, siRNA 
knockdown of Jund was performed using the same methodology as published previously 
(Behmoaras et al., 2008). A microarray analysis was performed between WKY BMDMs 
transfected with scrambled control siRNA or Jund siRNA in both unstimulated BMDMS and 
following eight hours of LPS stimulation.   
 
Successful knockdown of Jund was achieved in both unstimulated and eight hour LPS 
stimulated BMDMs following 48 hours of transfection with siRNA (Figure 4.13). This was 
assessed prior to hybridisation of the labelled and fragmented cDNA onto Rat Gene 1.0 ST 
arrays.  A mean knockdown of 70.5% for Jund was achieved in unstimulated BMDMs and 
73.8% in eight hour LPS stimulated BMDMs transfected for 48 hours with the Jund 
compared to the scrambled control siRNA. Differentially expressed genes between  
scrambled control and Jund siRNA transfected BMDMs were identified using significance 
analysis of microarrays v3.0 (SAM) with a FDR threshold of 5% following 40,000 
permutations as per Methods 2.17.6 (Tusher et al., 2001) and as used in the comparisons of 
the WKY and LEW parental strains (Chapter 3) and WKY and WKY.LCrgn2 strains (4.2.1 
and 4.2.2) . This analysis was carried out by Dr Prashant Srivastava, Physiological Genomics 
and Medicine Group, MRC Clinical Sciences Centre. The raw microarray data is presented as 
an appendix on the DVD enclosed with this thesis as detailed in 3.2.2. 
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Figure 4.14 siRNA mediated knockdown of Jund in WKY BMDMs 
Assessment of the efficiency of siRNA knockdown of Jund in the unstimulated state (A) and 
following eight hours LPS stimulation (B) using qRT-PCR. Four samples per condition and 
siRNA type were amplified in triplicate. ***P<0.001 using two tailed unpaired t-test to 
compare BMDMs transfected for 48 hours with either scrambled control siRNA or Jund 
siRNA. Error bars represent standard error of the mean.  
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Jund siRNA mediated knockdown in WKY BMDMs was found to significantly alter gene 
expression (Table 4.24) compared to BMDMs transfected with scrambled control siRNA in 
both the unstimulated state and eight hour LPS stimulated state. This analysis identified that 
JunD could act as an activator or repressor of gene expression. In the unstimulated state, 
1,672 genes were differentially expressed between BMDMs transfected with scrambled 
control siRNA and Jund siRNA. Transfection with Jund siRNA, thereby lowering Jund 
expression, resulted in the reduced expression of 868 genes demonstrating that Jund had an 
activatory role in gene transcription. Alongside this, Jund knockdown also increased the 
expression of 804 genes demonstrating that Jund could also have a repressive effect on 
transcription. After eight hours of LPS stimulation, 1,476 genes were differentially expressed 
between the two siRNA groups. Similarly, 638 genes had reduced expression in the Jund 
siRNA knockdown group compared to controls and 838 genes demonstrated higher 
expression following Jund knockdown.  
 
The perturbation of Jund level by siRNA caused marked changes in a number of genes with 
11 genes showing greater than three-fold differences in the unstimulated state and two genes 
following LPS stimulation (Table 4.25). Eight of the genes in the unstimulated state were 
more highly expressed in the control siRNA group i.e. the higher Jund expression level was 
having a significant and positive activatory effect on transcription. However, the presence of 
strongly differentially expressed genes linked with the decreased level of Jund, following its 
siRNA knockdown, again confirmed its ability to exert both inducible and repressive effects 
on gene expression. It is, however, important to note that in both the unstimulated and 
stimulated states, the majority of differentially expressed genes had fold changes less than 
1.5-fold showing that the main effect of Jund on gene expression was to fine tune rather than 
cause major fold changes in gene expression. 
 
Functional enrichment analysis of the differentially expressed genes for biological process 
and KEGG pathway terms using DAVID identified distinct functional groups of genes linked 
with alterations in Jund expression. In unstimulated BMDMs (Table 4.26), genes with 
decreased expression following siRNA knockdown of Jund were associated with responses to 
LPS, molecules of bacterial origin and the response to wounding as well as the regulation of 
cell activation. Genes with increased expression following Jund siRNA transfection 
demonstrated enrichment for processes linked with basic cellular  
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Table 4.24 Microarray results detailing the numbers of differentially expressed genes 
between WKY BMDMS transfected with control and Jund siRNA 
 
 
Results detailing differentially expressed transcripts between WKY BMDMs transfected with 
either scrambled control or Jund siRNA for 48 hours in the unstimulated condition and 
following eight hours of LPS stimulation (four technical replicates per strain) using SAM 
v3.0 (Tusher et al., 2001) with 40,000 permutations and a <5%FDR threshold.  
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Table 4.25 Microarray results of transcripts demonstrating greater than three-fold 
difference in expression between Jund siRNA and scrambled control siRNA transfected 
WKY BMDMs  
 
Results detailing differentially expressed transcripts with greater than three-fold difference in 
expression (four technical replicates per strain) using SAM v3.0 (Tusher et al., 2001) with 
40,000 permutations and a <5% FDR threshold between BMDMs transfected with scrambled 
control and Jund siRNA transfected for 48 hours in the unstimulated state and following eight 
hours LPS stimulation. A positive fold change indicates higher expression in BMDMs 
transfected with scrambled control siRNA i.e. with a higher level of Jund expression 
compared to Jund siRNA. 
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Table 4.26 Gene ontology analysis of genes demonstrating differential expression 
following Jund siRNA knockdown in basal WKY BMDMs 
Enrichment for biological process functional annotation terms used a threshold of <5% FDR  
and fold enrichment >1.5 
  
259 
 
functions such as protein amino acid phosphorylation regulation of transcription, mRNA 
processing and phosphate metabolic processes though there was also lower level enrichment 
present for protein kinase cascades and intracellular signalling cascades (Table 4.26). 
Enrichment for KEGG pathways identified pathways such as NOD-like receptor signalling 
pathway, cytokine-cytokine receptor interaction and apoptosis for the set of genes with 
decreased expression after Jund knockdown but of note, in genes with higher expression 
following Jund knockdown, there was enrichment for the Fc gamma R-mediated 
phagocytosis pathway and the MAPK signalling pathway (Table 4.27). The analysis of 
differentially expressed genes at the eight hour LPS stimulation timepoint found enrichment 
in the genes with decreased expression following Jund knockdown for the response to abiotic 
stimulus and the regulation of programmed cell death, cell death and apoptosis along with the 
cellular response to stress whilst genes with higher expression following Jund knockdown 
enriched for response to oestradiol stimulus, Golgi vesicle transport as well as positive 
regulation of immune system process (Table 4.28). 
 
Gene set enrichment analysis was performed on each of the gene sets for the different siRNA 
in the unstimulated and LPS stimulated state (Table 4.29). For the set genes with decreased 
expression following Jund siRNA knockdown, significant enrichment was seen for multiple 
processes linked with chemokine and cytokine receptor interactions and peptide ligand 
binding receptors along with Toll like receptor signalling pathways. This strong enrichment 
for signalling pathways was in stark comparison to the enrichment for only a telomerase 
pathway in genes with increased expression after Jund knockdown. After LPS stimulation 
there was only enrichment for a single term, in genes with increased expression after Jund 
knockdown, for Prion diseases (Table 4.29).  
 
Motif enrichment analysis using MotifModeler was performed on the basal and LPS 
stimulated gene sets. In the basal state there was enrichment with a positive effect in favour 
of the set of genes with decreased expression following Jund knockdown for PEA3, OCT-1, 
E2F-1, TTF1 ARP-1 and c-Myc factor binding sites whilst there was enrichment for KROX 
and Pax-1 in genes with increased expression after Jund knockdown (Table 4.30). After LPS 
stimulation there was notable increased enrichment with a positive effect in genes with 
decreased expression after Jund knockdown for YY1, ICSBP (interferon consensus binding 
protein or interferon regulatory factor (IRF)-8) along with IRF7 and three AP-1 binding  
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Table 4.27 Enrichment of KEGG pathways annotation terms from DAVID for genes 
demonstrating differential expression following Jund siRNA knockdown in basal WKY 
BMDMs  
 
Enrichment for KEGG canonical pathway analysis used a threshold of <5% FDR  and fold 
enrichment >1.5. 
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Table 4.28 Enrichment of biological process functional annotation terms and KEGG 
pathways from DAVID for genes demonstrating differential expression following Jund 
siRNA knockdown in eight hour LPS stimulated WKY BMDMs  
 
Enrichment for biological process functional annotation terms and KEGG canonical pathway 
analysis used a threshold of <5% FDR  and fold enrichment >1.5. 
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Table 4.29 Gene set enrichment analysis (GSEA) results in siRNA transfected 
BMDMs 
GSEA results from the comparison of control and Jund siRNA transfected basal BMDMs. 
Significantly enriched gene sets were identified with <5% FDR threshold. Enrichment score 
(ES) is the degree to which a gene set is overrepresented at the top or bottom of the list. 
Normalised enrichment score (NES) is a normalised ES score that allows comparison of 
results across gene sets. P-value estimates the statistical significance of the enrichment score 
for a single gene set and the false discovery rate (FDR) q-value is the P-value corrected for 
multiple testing. 
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factor motifs reflecting that the difference seen in Jund level was having an outcome on the 
transcriptional drivers in the LPS response (Table 4.30). 
 
4.2.4.1 Validation of differentially expressed genes following siRNA knockdown 
of Jund 
Validation of differentially expressed genes identified by the microarray data analysis was 
performed using qRT-PCR. Genes were selected that were differentially expressed between  
scrambled control siRNA transfected and Jund siRNA transfected BMDMs in the 
unstimulated condition or following eight hours of LPS stimulation. The genes selected 
encompassed a range of fold change differences between the two siRNA types and included 
genes that were also differentially expressed in an LPS timecourse between WKY and 
WKY.LCrgn2 BMDMs. Table 4.31 details the results of the validation experiment alongside 
the relevant microarray results for each gene tested whilst Figures 4.15 and 4.16 display the 
qRT-PCR findings in graphical form.  
 
As detailed in Table 4.31, the microarray data set for the unstimulated and eight hour LPS 
stimulated comparison between scrambled control and Jund siRNA transfected BMDMs was 
successful. However, two genes identified by microarray could not be validated. Dot1l had a 
fold change of -1.53 at 4.9% FDR in the microarray dataset of unstimulated BMDMs but 
whilst the fold change identified by qRT-PCR was similar, the variation between replicates 
resulted in a non-significant P-value result of 0.36. The validation of Mgat4a in the 
unstimulated state also showed the same degree of fold difference but replicate variability 
resulted in a P-value of 0.10.  
  
264 
 
Table 4.30 Motif enrichment analysis of genes demonstrating differential expression 
in siRNA transfected BMDMs  
Enriched TFBS from MotifModeler selected on basis of a transcriptional contribution  (TCS) 
score two standard deviations above the mean value for all the TFBS identified. A higher 
TCS score indicating a stronger contribution. The MotifModeler Xm score is the estimated 
functional level of the transcription factor.  
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Table 4.31 Validation of differentially expressed genes identified by siRNA 
microarray data analysis with quantitative PCR 
 
Microarray data for the comparisons between scrambled control and Jund siRNA transfected 
unstimulated (A) and eight hour LPS stimulated (B) BMDMs was validated by qRT-PCR. 
Microarray FDR % and fold changes are listed for each gene. A positive fold change 
indicates higher expression in scrambled control siRNA transfected BMDMs i.e. those 
BMDMs with higher levels of Jund expression. qRT-PCR validation was carried out using a 
set of four biological replicates with three technical amplification replicates per siRNA type. 
Relative gene expression was normalised to Hprt and used to generate fold change values. 
Positive fold changes indicate upregulated expression in scrambled control transfected 
BMDMs. A two-tailed unpaired t-test was used to detect statistically significant differences 
between the WKY and LEW replicates. 
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Figure 4.15 Validation of differentially expressed genes identified by siRNA 
microarray data analysis by qRT-PCR for unstimulated siRNA transfected 
BMDMs  
qRT-PCR validation of genes with decreased expression (A) or increased expression (B) following 
siRNA knockdown of Jund was carried out using a set of four biological replicates with three 
technical amplification replicates per siRNA type. Relative gene expression was normalised to Hprt 
and used to generate fold change values. A two-tailed unpaired t-test was used to detect statistically 
significant differences between the WKY and LEW replicates. Microarray data for this set of 
validated genes is listed in Table 4.31. 
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Figure 4.16 Validation of differentially expressed genes identified by siRNA 
microarray data analysis by qRT-PCR for eight hour LPS stimulation siRNA 
transfected BMDMs  
qRT-PCR validation of genes with decreased expression (A) or increased expression (B) following 
siRNA knockdown of Jund was carried out using a set of four biological replicates with three 
technical amplification replicates per siRNA type. Relative gene expression was normalised to 
Hprt and used to generate fold change values. A two-tailed unpaired t-test was used to detect 
statistically significant differences between the WKY and LEW replicates. Microarray data 
for this set of validated genes is listed in Table 4.31. 
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4.2.4.2 The LPS response in siRNA transfected BMDMs 
The response to eight hours of LPS stimulation compared to the unstimulated baseline was 
examined in BMDMs transfected for 48 hours with scrambled control siRNA or Jund siRNA. 
This gave the opportunity to investigate how a change in Jund level affected the overall LPS 
response and to draw inferences on the effect of Jund in the Crgn2 congenic interval. The 
analysis of the LPS response in WKY BMDMs identified that after eight hours of LPS 
stimulation, 3,717 genes were differentially expressed in scrambled control siRNA 
transfected BMDMs compared to their baseline and 2,709 genes were differentially expressed 
in Jund  siRNA transfected BMDMs compared to their baseline at a 5% FDR threshold using 
SAM v3.0 with 40,000 permutations (Tusher et al., 2001) (Table 4.32). In the scrambled 
control siRNA transfected BMDMs gene set, 1,782 (47.9%) genes were upregulated and 
1,935 (52.1%) genes were downregulated after eight hours LPS stimulation compared to their 
unstimulated state whilst in Jund siRNA transfected BMDMs, 1367 (50.5%) genes were 
upregulated and 1,342 (49.5%) were downregulated in comparison to their unstimulated state. 
The possible attenuation of the LPS response in Jund siRNA transfected BMDMs compared 
to scrambled control siRNA transfected BMDMs was also apparent from these analyses. 
 
The overall numbers of genes responding to LPS in either the control siRNA transfected or 
Jund siRNA transfected BMDMs was less than that seen for WKY BMDMs. In the analysis 
of the LPS response in WKY BMDMs at eight hours of LPS stimulation compared to the 
basal state, 9,807 genes were differentially expressed at a 5% FDR threshold using SAM v3.0 
with 40,000 permutations (Tusher et al., 2001). Of these genes, 3,658 (37.3%) were 
upregulated and 6,149 (62.9%) were downregulated after LPS stimulation. One reason for 
these differences could be the different culture conditions that the BMDMs undergoing 
transfection have been exposed to. The RNA from BMDMs following siRNA transfection is 
harvested at day eight following extraction from rat femurs compared to day five for the 
WKY BMDMs and in addition the siRNA transfection involves a 48 hour period of serum 
starvation. 
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Table 4.32 Microarray results detailing the numbers of differentially expressed genes 
between basal and 8 hour LPS stimulated WKY BMDMS transfected with either 
control or Jund siRNA 
 
 
Results detailing differentially expressed transcripts between the basal state and after 8 hours 
of LPS stimulation in WKY BMDMs transfected with either scrambled control or Jund 
siRNA with a threshold of FDR<5% 
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Functional enrichment analysis demonstrated that the basic response to LPS was broadly 
similar in both control siRNA transfected and Jund siRNA transfected BMDMs. Genes with 
higher expression following LPS stimulation were associated with responses to LPS and 
regulation of protein kinase cascades (Appendix B, Table B.3, B.4). The enriched KEGG 
pathways included the NOD-like receptor signalling pathway, apoptosis, MAPK signalling 
and the Toll-like receptor pathway (Appendix B, Table B.3, B.4). The group of genes with 
decreased expression after LPS in the scrambled control siRNA transfected group associated 
with some basic cellular functions such as phospholipid metabolism vacuole organisation and 
lysosome organization along with the response to abiotic stimulus, insulin stimulus and the 
intracellular signalling cascade. Enriched pathways included lysosome and 
phosphatidylinositol signalling system (Appendix B, Table B.5). In the Jund siRNA group, 
there was enrichment for cellular processes such as response to DNA damage stimulus and 
phosphate metabolic processes along with the cellular response to stress and the intracellular 
signalling cascade (Appendix B, Table B.6). 
 
4.3 Discussion 
The aim of the work presented in this chapter was to investigate how the Crgn2 locus and the 
AP-1 transcription factor Jund, the positional candidate for NTN susceptibility at that locus, 
exert their effects on the NTN phenotype and macrophage activation at the gene expression 
level. As discussed in 4.1, the congenic rat strain where the Crgn2 locus from the NTN-
resistant LEW strain was introgressed onto the NTN-susceptible WKY genetic background 
was found to show a significant reduction on the formation of crescents, fibrin deposition and 
macrophage infiltration (Behmoaras et al., 2008). This was thought to be largely due to an 
alteration in macrophage behaviour and WKY.LCrgn2 BMDMs demonstrated reduced 
macrophage activation assessed by Fc-oxyBURST assay and antibody-opsonised bead 
phagocytosis. The positional candidate gene for the Crgn2 QTL was identified as the AP-1 
transcription factor Jund and it was also found to have a major effect on macrophage 
activation by assessing the effect of siRNA knockdown of Jund on the macrophage 
phenotype. The Fc-oxyBURST assay showed a significant reduction in activation in BMDMs 
transfected with Jund siRNA (Behmoaras et al., 2008). 
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The evidence suggested therefore that both the Crgn2 locus and a key gene within it, Jund, 
had the potential to dramatically alter macrophage activation. Therefore, understanding the 
transcriptomic changes that were present between the WKY and WKY.LCrgn2 strain 
BMDMs and the direct effects of altering Jund expression level in the BMDMs could reveal 
the key effector genes and pathways that mediate these phenotypic differences in macrophage 
activation and also form part of effector pathways in the NTN model. Such an approach also 
allowed for a comparison to be made of the chronic and more physiological effects of a 
genetically determined alteration in transcription factor, as seen in the WKY.LCrgn2 strain, 
and whether adaptation to this change and redundancy within the AP-1 transcription factor 
family might be occurring along with the effect of an acute change in transcription factor 
level. This is a scenario which would be relevant if Jund was directly targeted in a therapeutic 
manner using an antisense or RNA interference-mediated approach.  
 
In addition, there is also evidence of an interaction between the Crgn2 locus and the Crgn1 
locus. A double congenic strain where both Crgn1 and Crgn2 from LEW were introgressed 
onto the WKY genetic background (WKY.LCrgn1,2) was generated. When NTN disease was 
induced, the Crgn2 single congenic had an 8% reduction in glomerular crescents compared to 
WKY and the Crgn1 single congenic had an 18% reduction but the double congenic, 
WKY.LCrgn1,2 had a reduction of 34% showing that an additive effect was occurring when 
both loci were introgressed onto the WKY background (Behmoaras et al., 2010). Of note, this 
additive effect was not seen with either the macrophage infiltration analysis or that of 
proteinuria. However, the mRNA expressions of TNF-α and Nos2 in the double congenic 
strain were both significantly reduced compared to the WKY and the single congenic strains. 
The double congenic strain did not show an additive effect in the Fc-oxyBURST assay and 
isolated BMDMs from the WKY.LCrgn1,2  displayed the same reduction in TNF-α protein 
secretion as the WKY.LCrgn1 and WKY.LCrgn2 single congenic strains. The additive effect 
seen in glomerular crescent formation when both Crgn1 and Crgn2 loci were combined 
suggests a major interaction between the two loci and as a transcription factor, Jund is the 
most likely of the gene candidates that could be exerting effects in trans to alter effector 
genes within the Crgn1 locus that were important mediators of glomerular damage.  
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4.3.1      The roles of AP-1 transcription factor and JunD in inflammation 
AP-1 transcription factor plays an important role in regulating the transcription of early 
response genes. AP-1 activity is known to be induced by multiple physiological stimuli such 
as growth factors, serum and oncoproteins as well as proinflammatory cytokines such as 
TNF-α pointing towards a role in inflammation and innate immune responses (Brenner et al., 
1989; Angel and Karin, 1991; Shaulian and Karin, 2001).  In the immune system, AP-1 has 
been linked with roles in directly activating cytokine production, regulating naïve T-cell 
differentiation, controlling T cell cytokine responses and determining the activation status of 
macrophages (Brenner et al., 1989; Wagner and Eferl, 2005; Behmoaras et al., 2008; Zenz et 
al., 2008).   
 
In macrophages, stimulation with lipopolysaccharide (LPS) through the toll-like receptor 4 
(TLR4) pathway initiates signalling cascades that activate three main families of proteins 
which play key roles in activating inflammatory gene expression (Hu et al., 2007).  Along 
with the NF-κB proteins that are major drivers of the transcriptional activation of 
inflammatory genes and IRF proteins which drive type one interferon production and thereby 
the activation of interferon inducible genes, the MAP kinases are also activated including the 
extracellular signal-regulated kinases (ERKs), c-Jun N-terminal kinases (JNK) and p38 MAP 
kinases. The AP-1 family of transcription factors are the major mediators of the inflammatory 
effects of MAP kinases and the early activation of AP-1 mediates the expression of multiple 
pro-inflammatory cytokine genes such as TNF-α and IL-6. This has led to hypotheses that 
AP-1 could play roles in the pathogenesis of inflammatory diseases and atherosclerosis 
(Newell et al., 1994; Hambleton et al., 1996; Tengku-Muhammad et al., 2000; Zenz et al., 
2008). However, it has been noted that there is a lack of clear evidence for their inflammatory 
role in the responses of primary cells to physiological or microbial factors highlighting a need 
to understand the role of AP-1 proteins in such processes (Hu et al., 2007). 
 
JunD was described as the third member of the Jun gene family in 1989 in the mouse 3T3 
fibroblast cell line (Hirai et al., 1989; Ryder et al., 1989). The relative amounts of Jun protein 
mRNAs were found to vary between different types of cells and tissues and JunD mRNA was 
found to be expressed constitutively at 5-10 fold higher levels than c-Jun mRNA raising the 
possibility of an involvement in the activation of immediate early genes (Ryder et al., 1989). 
This early response function is distinct to that of c-Jun and JunB which are classified as 
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immediate-early genes as their expression can be induced within minutes after exposing cells 
to either serum or different growth factors (de Groot et al., 1991). Unlike c-Jun and JunB 
which are essential for embryonic development, deletion of Jund is not fatal in utero though 
Jund
-/-
 knockout mice do demonstrate reduced postnatal growth, impaired spermatogenesis 
and hormone imbalances (Thepot et al., 2000). In addition they also demonstrate reduced left 
ventricular weights and when their hearts were stressed with pressure overload exhibit 
enhanced cardiomyocyte apoptosis and fibrosis associated with increasing levels of hypoxia-
induced factor 1-α, VEGF, p53 proteins and reduced Bcl-2 protein (Hilfiker-Kleiner et al., 
2005).  
 
JunD is an ‘atypical’ member of the AP-1 family as it can activate or repress gene 
transcription with the result that it has been associated with diverse cell type specific 
functions including roles in regulating cell proliferation and apoptosis and in protecting cells 
from responses to stress stimuli and oxidative stress, whilst in the immune system, JunD has 
previously been associated with the regulation of lymphocyte proliferation, differentiation 
and T helper cell cytokine expression along with macrophage activation (Weitzman et al., 
2000; Mechta-Grigoriou et al., 2001; Lamb et al., 2003; Gerald et al., 2004; Meixner et al., 
2004; Behmoaras et al., 2008; Cook et al., 2011).  
 
Whilst the exact functions of JunD certainly depend on the cell type studied, a general role 
for the factor in cell survival and protecting cells from senescence or apoptotic responses to 
stress stimuli such as TNF-α by modulating pathways including Ras/p53 and the 
MEK1/ERK1/2 signalling pathways has been proposed (Weitzman et al., 2000). In mouse 
fibroblasts exposed to TNF-α, JNK stimulates a survival signal mediated by increased 
expression of JunD which, in collaboration with NF-κB, increases expression of anti-
apoptotic genes such as cIAP-2 (Lamb et al., 2003).  JunD  has been linked with both 
positively and negatively regulating cell-cycle progression that depends on the cellular 
context studied but does not have as potent a pro-proliferative function as c-Jun does 
(Shaulian and Karin, 2002; Eferl and Wagner, 2003). JunD has also been found to protect 
cells from oxidative stress and reduce tumour angiogenesis by limiting the production of 
reactive oxygen species (ROS) (Gerald et al., 2004) though in contrast, in some cells JunD 
may also play a role in mediating oxidative stress as it was found to be a key mediator of 
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androgen-androgen receptor induced ROS production in androgen dependent LNCaP human 
prostate cancer cells (Mehraein-Ghomi et al., 2008).  
 
The genetically determined difference in the expression of Jund between WKY and LEW 
BMDMs presents the opportunity to investigate the effect of how a change in transcription 
factor expression can alter a cell’s transcriptome. The ability to study a congenic rat, where 
the Crgn2 locus from the LEW rat which expresses the lower level of Jund was introgressed 
onto a WKY background, is a unique resource that gives the potential for understanding the 
effects of this altered transcription factor expression in relative isolation and in the context of 
a mammal that is predisposed to immune kidney disease. In addition, the knockout mouse for 
Jund has major abnormalities as discussed above due to the fact that JunD is a constitutively 
expressed transcription factor. Despite this the Jund
-/-
 mouse has given insights into a role for 
JunD in accelerated nephrotoxic nephritis where its deficiency in podocytes caused increased 
oxidative stress, altered VEGFA expression and glomerular injury. Notably no effects were 
seen in the macrophage phenotype (Cook et al., 2011). The advance in technology that has 
enabled the use of zinc finger nucleases to create knockout rats (Geurts et al., 2009) has 
meant that the Jund
-/-
 rat is now being generated on the WKY background and will allow for 
specific investigations of the gene knockout in vivo and in vitro of macrophage phenotypes 
and Crgn susceptibility. However in light of the findings in the knockout mouse, both in the 
effects of the gene knockout overall and in the phenotype seen in the accelerated NTN model, 
a transgenic rat with a lower expression level of Jund rather than a complete knockout on a 
WKY background could potentially give the more relevant and valuable insights. 
 
The analysis of the transcriptomes in both the setting of physiological differences in JunD 
level determined genetically in the comparison of the WKY andWKY.LCrgn2 BMDMs and 
the acute effect of siRNA knockdown could thus give unique and important further insights 
into the role of JunD in macrophages and its potential roles in influencing apoptosis and 
oxidative stress, but could also identify effector genes playing significant roles in mediating 
macrophage damage in Crgn. In addition this would be the first direct investigation, in 
primary cells, of the role of an AP-1 protein in modulating the immune response. 
 
275 
 
4.3.2      The response to LPS stimulation by WKY.LCrgn2 BMDMs 
LPS stimulation induced a major gene expression change in WKY.LCrgn2 BMDMs in all 
timepoints compared to baseline similar to that seen in the WKY and LEW strains (Table 
4.1). As with the comparison between the WKY and LEW strains, the largest number of 
differentially expressed genes was observed at the four hour time point and LPS stimulation 
also caused the majority of genes to be downregulated compared to the basal state. Prior to 
the data analysis, the working hypothesis was that the effect of the LEW Crgn2 locus when 
introgressed on to the WKY background might be to alter the nature of gene response to 
become more like that of LEW BMDMs as the increased numbers of significant genes 
observed in the LEW strain suggested that a release from transcriptional repression could be 
occurring as part of the effect of the Crgn2 locus. In contrast, at each time point, the total 
number of differentially expressed genes was lower in WKY.LCrgn2 BMDMs than in the 
WKY BMDMs suggesting that the effect of introgressing the LEW Crgn2 locus, in effect 
isolating the lower level of Jund in a WKY genetic background, was to attenuate the LPS 
response. The core elements of the LPS response in WKY.LCrgn2 BMDMs were highly 
similar to both WKY and LEW strains and the majority of differentially expressed genes 
were shown to be common between the strains (Figure 4.1). The numbers of genes showing 
robust responses with fold changes more than three-fold in WKY.LCrgn2 BMDMs were also 
similar in number to the other strains, though consistent with the overall lower numbers of 
genes (Table 4.2). Again the similar nature of the LPS response was highlighted by the 
overlap of a common majority of genes amongst these genes with significant fold changes 
(Figure 4.2).  
 
The functional analysis of the gene sets confirmed this common response to LPS with genes 
showing higher expression compared to the basal state following two hours of LPS 
stimulation enriched for the same patterns of enrichment as the WKY and LEW strains. This 
included terms such as the immune response and regulation of cell death and apoptosis whilst 
pathways such as the NOD-like receptor signalling pathway, Toll-like receptor signalling 
pathway and MAPK signalling pathway also showed enrichment (Table 4.3). In the group of 
genes with decreased expression there was enrichment for DNA metabolic and repair 
processes as seen in the WKY and LEW strains and the pathways such as ubiquitin mediated 
proteolysis and cell cycle echoed this similarity (Table 4.4). Motif enrichment analysis of the 
overall set of genes showing differential expression at two hours showed that the same 
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transcriptional drivers played the major role in shaping the inducible gene response including, 
the NF-κB and IRF factor families (Table 4.5).  
 
The set of genes identified as primary response (PRG) and secondary response genes (SRG) 
to LPS stimulation by Ramirez-Carrozzi et al was also investigated to see whether any 
difference was evident in their overall response (Ramirez-Carrozzi et al., 2006; Ramirez-
Carrozzi et al., 2009). As found in the WKY and LEW BMDM analysis, the response in these 
genes was highly similar between the two strains though subtle changes in the LPS response 
of key genes did occur such as Irf1 (Table 4.33 & 4.34). A number of genes, highlighted in 
blue in Tables 4.33 and 4.34 were found to be significantly differentially expressed at a <5% 
FDR threshold over the entire timecourse using EDGE v1.1.291 (Leek et al., 2006) 
demonstrating the influence of Crgn2 and by inference Jund on the expression of early 
response genes which define the overall LPS response. 
 
In conclusion, the overall pattern of LPS response in WKY.LCrgn2 was very similar to the 
WKY and LEW BMDMs with many differentially expressed genes shared in common, if not 
necessarily demonstrating identical fold changes of expression. Notably the total number of  
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Table 4.33 Primary response gene responses in WKY and WKY.LCrgn2 BMDMs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table of primary response genes that require no nucleosome remodelling for their induction 
as classified by Ramirez-Carrozzi et al. (Ramirez-Carrozzi et al., 2009). All fold changes 
given are relative to the basal state BMDM. Grey highlights indicate genes that show 
minimal or no fold change compared to baseline. Blue highlighting indicates gene 
differentially expressed in time course analysis at 5% FDR. 
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Table 4.34 Primary and secondary response gene responses in WKY and 
WKY.LCRgn2 BMDMs 
Table of primary response genes that require no nucleosome remodelling for their induction 
and secondary response genes as classified by Ramirez-Carrozzi et al. (Ramirez-Carrozzi et 
al., 2009). All fold changes given are relative to the basal state BMDM. Grey highlights 
indicate genes that show minimal or no fold change compared to baseline. Blue highlighting 
indicates gene differentially expressed in time course analysis at 5% FDR. 
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genes that were found to be differentially expressed between the basal and LPS stimulated 
state in WKY.LCrgn2 BMDMs was lower than in WKY BMDMs suggesting that the Crgn2 
locus, and therefore by inference the effect of a lower level of Jund expression, attenuated the 
overall LPS response. 
 
4.3.3      The influence of the Crgn2 locus on gene expression in BMDMs following 
LPS stimulation 
The analysis of differential gene expression between WKY and LEW BMDMS identified a 
substantial number of differentially expressed genes between the strains at each time point 
studied. In contrast to this, only a small number of differentially expressed genes were 
identified between WKY and WKY.LCrgn2 BMDMs in an analysis of the static timepoints 
and the majority showed higher expression in WKY.LCrgn2 BMDMs. This finding was 
unexpected as the initial hypothesis for the action of Crgn2 on the macrophage transcriptome, 
based on the phenotypic effects of the locus from the in vivo experiments, was that the Crgn2 
locus, even in the basal state, might have a significant impact on gene transcription and the 
overall macrophage transcriptome. However, as an activator of early response genes, these 
findings suggest that the actual impact of the locus and resulting alteration in Jund levels in 
this in vitro experiment could be centred instead on the way the macrophage responds to LPS 
stimulation in this context. It is also important to note that these conclusions are based on the 
key assumption that there are no retained congenic segments from the donor LEW genome in 
the congenic WKY.LCrgn2 strain. In support of this, recent SNP genotyping experiments in 
the WKY.LCrgn1,2 strain derived from the single congenic WKY.LCrgn1 and 
WKY.LCrgn2 strains, performed as part of a project investigating Crgn3-7 indicate that there 
are no retained donor segments present from the LEW genome in this strain (J. Behmoaras, 
Centre for Complement and Inflammation Research, Imperial College). 
 
The static timepoint analysis did identify differentially expressed genes at each timepoint and 
a number of these have plausible effector actions for both macrophage activation and the 
pathogenesis of crescentic glomerulonephritis. In the basal state, fourteen genes were 
identified at <5% FDR all of which showed increased expression in WKY.LCrgn2 BMDMs. 
Alongside the set of genes located in close proximity to each other on chromosome six, 
putatively linked to immunoglobulin heavy chains, two genes were identified that were 
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located just outside the congenic region on chromosome 16 but their location is such that they 
are likely to be in a recombination zone. Sorting nexin 25 (Snx25) demonstrated 1.38-fold 
higher expression in WKY.LCrgn2 BMDMs and has been linked with a role for negatively 
regulating TGF-β signalling through the degradation of TGF-β receptors via clathrin 
dependent endocytosis pathways (Hao et al., 2011). CCR4-NOT transcription complex, 
subunit 7 (CNOT4) demonstrated 1.46-fold higher expression and  has been linked with a role 
regulating cell proliferation through its deadenylase catalytic activity influencing mRNA 
turnover (Aslam et al., 2009).  
 
At the two hour LPS stimulation time point, the number of differentially expressed genes at 
<5% FDR increased to 25, though 24 genes still showed higher expression in WKY.LCrgn2 
BMDMs. Microfibrillar-associated protein 3-like (Mfap3l) showed 1.59-fold higher 
expression in WKY BMDMS and is located within the congenic interval however it is under 
the influence of Jund expression as demonstrated by the influence of Jund siRNA 
knockdown on its expression compared to scrambled control siRNA transfection (Table 4.31, 
Figure 4.15, 4.16). Whilst its overall function is uncertain, it has been found to be 
overexpressed in metastatic colorectal cancer cells and linked with a role transducing signals 
through the PI3K/AKT pathway (Kang et al., 2008). A number of genes showed higher 
expression in WKY.LCrgn2 BMDMs with links to immune function such as syntaxin 18 
(Stx18) which had 1.8-fold higher expression and has been linked with involvement in 
endoplasmic reticulum mediated phagocytosis where its knockdown reduced the efficiency of 
the overall process (Hatsuzawa et al., 2006). Caveolin 1 (Cav1) was 1.42-fold overexpressed 
and is the primary scaffolding protein for vesicular cellular organelles called caveolae and is 
linked with many diverse functions including an anti-inflammatory role in macrophages 
caused by its regulation of LPS-induced cytokine production involving the MKK3/p38 
MAPK pathway (Wang et al., 2006), Cav1has also been found to co-localise with 
phosphatidylserine at the cell surface of apoptotic macrophages with an increase in its 
expression identified in apoptotic macrophages independent of caspase activation and DNA 
fragmentation (Gargalovic and Dory, 2003).  
 
Sixteen genes were differentially expressed at the four hour timepoint and again only two had 
higher expression in WKY BMDMS (Table 4.11). POU class 2 homeobox 2 (Pou2f2), also 
known as Oct-2, is located on chromosome one and was 1.73-fold higher in WKY BMDMs. 
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Though originally thought to have predominant B cell expression, it is expressed in 
macrophages and, importantly its activation has been shown to be crucial for the 
transcriptional activation of Nos2 in LPS stimulated macrophages (Lu et al., 2009). Slit 
homology 2 (Slit2) is located on chromosome 14 and was 2.13-fold higher in WKY.LCrgn2 
BMDMs. In a rat model of anti-glomerular basement antibody induced Crgn in WKY rats, 
administration of a blocking antibody accelerated the inflammatory process whilst 
administration of Slit2 protein systemically improved disease. Leukocytes harvested from 
these treated rats showed decreased monocyte chemo-attractant protein-1 (MCP)-1 mediated 
migration suggesting endogenous Slit2 inhibited chemo-attractant mediated signals and 
exerted an anti-inflammatory effect in vivo (Kanellis et al., 2004). The higher expression of 
Slit2 demonstrated in NTN-resistant LEW BMDMS would fit with these modes of action. In 
addition, higher expression of transforming growth factor beta 2 (Tgfb2)  was observed at 
1.48-fold which was also observed to be differentially expressed between WKY and LEW 
BMDMs and is an effector protein located in Crgn1. 
 
At eight hours of LPS stimulation, 44 genes were differentially expressed of which 13 
showed higher expression in WKY BMDMs, including previously identified transcripts such 
as Mfap3l and Crtc1, as well as programmed cell death 4 (Pdcd4) on chromosome one whose 
expression has been shown to be increased in apoptosis and has been shown to be part of an 
auto regulatory loop in cancer where, along with the microRNA miR-21, it influences AP-1 
activity. Pdcd4 down regulation is essential for the maximal induction of an AP-1 response to 
RAS oncoprotein transformed cells (Talotta et al., 2008). In addition, Pdcd4 has been found 
to be a pro-inflammatory protein. Pdcd4
-/-
 mice are resistant to the killing effects of LPS 
stimulation linked through the TLR adaptor protein MyD88 and NF-κB leading ultimately to 
increased miR-21 expression and decreased expression of PDCD4 with a post transcriptional 
effect on IL-10 protein expression (Sheedy et al., 2010; Young et al., 2010).  
 
In conclusion, the static timepoint analyses, whilst only identifying a relatively small number 
of differentially expressed genes, did identify at each timepoint plausible effector genes that 
could both influence macrophage activation and link with the pathogenesis of Crgn. In 
addition the pattern of changes and types of genes suggested that the effect of Crgn2 on the 
WKY BMDMs was consistent with a reduction in effector genes linked with activated 
macrophages. However, it is unclear whether only a handful of genes such as those identified 
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would account for the phenotypic differences seen or whether a more subtle coordinated 
change in multiple genes within certain pathways could be mediating the effect.  
 
To investigate this further, gene set enrichment analysis (GSEA) was performed on the sets 
of WKY and WKY.LCrgn2 genes for each time point. Such an approach was complementary 
to the static timepoint analysis approach detailed above. Indeed, in the original publication on 
the analysis method, Subramanian et al identified some limitations with those traditional 
approaches that included the problem that after correcting for multiple hypotheses testing, 
often no genes met the significance threshold as the relevant biological differences were 
modest relative to the noise observed in microarray technology (Subramanian et al., 2005). 
The robust nature of the LPS response that we observe in these BMDMs affecting so many of 
the genes may also preclude the detection of subtle changes between very similar strains such 
as WKY and WKY.LCrgn2. Importantly, Subramanian et al also identified that one 
limitation of single gene analysis is that overall pathway effects could be missed  by a single 
gene approach as a coordinated change in all genes encoding members of a pathway of only a 
small amount could dramatically alter a pathway’s flux more than a single large increase in 
one gene (Subramanian et al., 2005).  
 
The GSEA approach was applied to the data set using the molecular signatures database 
collection of curated pathways and used the recommended and default parameters including 
the gene set permutation correction method, critical due to the relatively low sample size in 
each group. Gene sets were identified as significant, therefore, at the recommended and  more 
stringent 5% FDR threshold (Subramanian et al., 2005; Subramanian et al., 2007). The 
approach revealed some important insights and highlighted that the response to LPS was key 
to understanding the function of the Crgn2 locus and the effect of changes in Jund expression 
level. In the basal state, enrichment was seen only in WKY.LCrgn2 BMDMs for cell cycle 
related processes (Table 4.12). At two hours of stimulation there was striking enrichment for 
multiple cell cycle and DNA replication processes in WKY.LCrgn2 BMDMs suggesting that, 
in contrast to the response to LPS in WKY BMDMs, the down regulation of genes involved 
in these basic core processes which are normally downregulated in the response does not 
occur to the same extent as in WKY BMDMs pointing to an effect of a lack of repression due 
to the lower expression level of Jund (Table 4.13). In comparison, there was enrichment for 
peptide ligand binding receptors and cytokine cytokine-receptor interactions in WKY 
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BMDMs suggesting that processes involving the upregulation of these pathways could result 
in increases in responsiveness of the WKY BMDMS to cytokine signalling and downstream 
processes. This pattern continued at four hours of LPS stimulation (Table 4.14) with the 
additional enrichment of KEGG complement and coagulation cascades seen in WKY 
BMDMs, a pathway where there was leading edge enrichment for a number of serpin 
peptidase inhibitor genes such as serpin peptidase inhibitor, clade E (nexin, plasminogen 
activator inhibitor type 1), member 1 (Serpine1). After eight hours of LPS stimulation the 
previously extensive enrichment in WKY.LCrgn2 BMDMs had reduced with only one term, 
linked to the BioCarta G2 pathway, enriched suggesting the WKY.LCrgn2 BMDMs had now 
responded in a similar manner to WKY BMDMs by down regulating these cellular processes 
in line with the other strain (Table 4.14). In WKY BMDMs in comparison, along with 
enrichment for the complement and coagulation cascades, there was also enrichment for the 
JAK-STAT signalling pathway. The canonical JAK-STAT signalling pathway is initially 
activated by the binding of a peptide ligand such as a cytokine to transmembrane receptors 
(Murray, 2007; Li, 2008; Chuang and He, 2010). The earlier enrichment for cytokine 
cytokine-receptor and peptide ligand binding receptors seen could lead directly to activation 
of this pathway. Binding of cytokines to their receptor activates Janus kinases (JAK), which 
leads to phosphorylation of the intracellular domain of the receptor recruiting and in turn that 
of the STAT proteins which from dimers and then translocate into the nucleus to activate the 
expression of target genes (Murray, 2007; Li, 2008; Chuang and He, 2010). 
 
The initial analyses of differential gene expression using just individual time points only 
identified a handful of significantly expressed genes raising the concern that such an 
approach was missing the overall nature of the response to LPS in the BMDMs which was 
too subtle to capture in the static analysis. To understand better the response, timecourse 
analysis was carried out covering all timepoints used in these experiments. An area under the 
curve (AUC) based analysis was used implemented in SAM v3.0 (Tusher et al., 2001) but 
identified only 44 genes that were differentially expressed between the strains, all of which 
showed higher expression in WKY.LCrgn2 BMDMs compared to WKY BMDMs. The clear 
limitation of such an approach was that it was unable to identify genes that showed a variable 
time profile over the timecourse and whilst the overall AUC may have been similar, the 
kinetics of their response could be different with the peak of expression occurring at different 
times with different implications for the cells. The GSEA approach had demonstrated that 
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subtle effects were occurring between the strains and so a different approach was used based 
on the methodology of Storey et al. (Storey and Tibshirani, 2003; Storey et al., 2005) and 
implemented in the EDGE software package (Leek et al., 2006). This approach identified 830 
genes that demonstrated a different time course profile and though it only identified around 
10% of the genes the 8,510 genes of identified between WKY and LEW BMDMs at the 5% 
FDR threshold, the substantial validation of the results using qRT-PCR demonstrated that it 
had identified important differences in the gene response (Figures 4.8, 4.9 and Appendix B, 
Figures B.1-B.11). One limitation of this statistical method in comparison to the moderated t-
test used in SAM v3.0 (Tusher et al., 2001) was that it was unable to give directionality to the 
change in the response nor an estimate of a fold difference between the strains. 
  
Functional enrichment analysis of the genes for biological processes revealed enrichment for 
multiple terms which at the highest significance were linked with responses to organic 
substance, hormone stimulus, wounding, endogenous stimulus, molecule of bacterial origin 
and LPS. Amongst these terms in addition were cell activation and leukocyte activation, the 
inflammatory response and the regulation of anti-apoptosis, programmed cell death and the 
regulation of cell death (Table 4.17). These terms revealed that the effect of Crgn2 on the 
WKY transcriptome was to alter multiple processes involved in the response to stimulation 
and this large set of genes was likely to contain key effectors for the WKY BMDM over-
activation phenotype. Analysis for enriched KEGG pathways (Table 4.17) identified only 
four pathways that were enriched but these included the Jak-STAT signalling pathway which 
had been identified in the GSEA analysis and leukocyte transendothelial migration, an 
irreversible process for the leukocyte that is essential for progression of the inflammatory 
response in allowing leukocyte migration form the blood into the tissues (Muller, 2011).  
 
The effect of the LEW Crgn2 locus on the WKY NTN phenotype was to decrease the 
severity of disease and identifying gene expression changes that are also present between 
WKY and LEW BMDMs could give useful insights into effector genes in the NTN model. It 
is also important to note that the effect of the Crgn2 locus when introgressed onto the WKY 
background, particularly of a change in Jund expression on a different genetic background 
may not be the same as the effect of the reciprocal congenic segment in LEW BMDMs. In 
addition the extent of the effect may be to only partially normalise a gene’s expression 
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towards that of the LEW strain as exemplified by Mmp8 (Figure 4.19) and Serpinb2 (Figure 
4.9) or even amplify the effect as seen for Slit2 (Figure 4.20).  
 
In total, 573 genes were identified in common between the WKY and LEW EDGE 
timecourse analysis and the WKY and WKY.LCrgn2 analysis. Functional enrichment 
analysis of these genes produced a similar set of enriched biological processes (Table 4.18) 
with a predominance seen for the responses to various stimuli, cell activation and 
programmed cell death and apoptosis. KEGG pathway enrichment was seen for cell adhesion 
molecules and leukocyte transendothelial migration suggesting that one effect of Crgn2 could 
be to alter the ability of macrophages to migrate into the nephritic glomerulus along with the 
Fc gamma R-mediated phagocytosis pathway, central to macrophage function and the likely 
basis of the differences seen in the functional assays between WKY and WKY.LCrgn2 
BMDMs such as the Fc-oxyBURST and bead phagocytosis. The enrichment for the Jak-
STAT signalling pathway was still evident. 
 
A number of candidate effector genes were identified by the timecourse analysis and 
confirmed in the validation experiments. Cysteine dioxygenase 1 (Cdo1) was under the 
influence of the Crgn2 interval (Figure 4.8 and 4.10) and directly affected by siRNA 
knockdown of Jund (Table 4.35) and was differentially expressed between WKY and LEW 
BMDMs during LPS stimulation (Figure 4.10). Cdo1 converts cysteine to cysteine sulphinic 
acid and is one of the key enzymes in the taurine biosynthetic pathway which is linked with a 
role in inhibiting apoptosis (Satsu et al., 2003; Takatani et al., 2004; Dietrich et al., 2010). 
Overexpression has been associated with Sézary syndrome which is an aggressive cutaneous 
T cell lymphoma and its methylation is a strong predictor for metastasis in breast cancer 
(Dietrich et al., 2010). In mice it may regulate antioxidant defence mechanisms through an 
ability to oxidise cysteine residues (Oien and Moskovitz, 2007). Cdo1 has previously been 
shown to be under the influence of Jund in a microarray analysis of Jund
-/-
 cell lines where 
the Jund deficient cells expressed 5.5-fold less Cdo1 compared to wild type cells (Gerald et 
al., 2004). As Cdo1 was associated with protection from oxidants, it was added to the growth 
media of Jund
-/-
 cells and prevented the accumulation of compounds linked to oxidative stress 
such as hydrogen peroxide and HIF-1α (Gerald et al., 2004). As oxidative stress is a potent 
initiator of apoptosis (Buttke and Sandstrom, 1994; Chandra et al., 2000; Avery, 2011), 
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protective influences against oxidative stress associated with higher levels of Jund could 
enhance cell survival of WKY BMDMs in the inflammatory response . 
 
Arg1 was identified as differentially expressed between WKY and LEW BMDMs  with 
WKY BMDMs demonstrating 6.9-fold higher expression in the unstimulated condition and 
14.09-fold higher expression after 24 hours of LPS stimulation (Maratou et al., 2010) and this 
difference was confirmed in this current analysis and validation (Figure 4.10). Arg1 has been 
classically linked as a marker of alternatively activated macrophages leading to multiple 
studies of its role in parasitic and Th2 polarised inflammation and competes for the common 
substrate arginine with Nos2, a marker of classical activation (El Kasmi et al., 2008; Pesce et 
al., 2009). Arg1 has also been shown to be induced in classically activated macrophages 
functioning to suppress nitric oxide production in intracellular infection (El Kasmi et al., 
2008). Understanding the reasons for its upregulation and its actual role in WKY BMDMs 
still remains uncertain. Its increased expression in WKY BMDMs could be seen as a 
passenger effect due to upregulated proinflammatory molecules inducing anti-inflammatory 
pathways within a highly activated macrophage as seen in the WKY strain which could also 
explain the findings for interleukin-10 (IL10) (Figure 4.13). It is interesting to speculate that 
the increase in Arg1 could lead to increased superoxide production as its upregulation has 
been shown to lead to endothelial nitric oxide synthase uncoupling which leads to an 
imbalance in superoxide production (Kim et al., 2009; Chandra et al., 2011). Potentially the 
abnormal levels of Jund could inappropriately alter this balance by driving Arg1 transcription 
leading to the imbalance. In LPS stimulated macrophages the direct or indirect activation of  
C/EBPβ is thought to be responsible for Arg1 induction though no obvious protective or 
pathogenic function has been found for macrophage Arg1 in this setting (El Kasmi et al., 
2008). AP-1 control of Arg1 expression has been identified in cancer where Ron receptor 
tyrosine kinase, involved in the initiation and progression of malignancy, promotes Arg1 
expression in tumour associated macrophages associated with increased tumour growth and 
decreased T cell-mediated immunity thought an AP-1 site in the Arg1 promoter (Sharda et al., 
2011).  
 
Vascular cell adhesion molecule (Vcam-1) was identified in the analysis and its expression 
was modulated by Crgn2 with higher levels observed in WKY BMDMs. Enrichment was 
seen for the cell adhesion molecule KEGG pathway (Table 4.18) for genes differentially 
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expressed between WKY and both LEW and WKY.LCrgn2 BMDMs. VCAM-1 interacts 
with its ligand very late antigen-4 (VLA-4) to regulate leukocyte migration from the vascular 
space into tissues by stimulating endothelial cell NADPH oxidase activity to produce reactive 
oxygen species which leads to the production of endothelial cell matrix metallopeptidases 
facilitating lymphocyte migration (Cook-Mills, 2002). In the rat NTN model, VCAM-1 is 
widely expressed within the endothelium of nephritic glomeruli but was also expressed 
elsewhere in inflamed glomeruli including crescent cells and mesangial cells. Blockade of 
VCAM-1 or VLA-4 in the model did not reduce macrophage infiltration into the inflamed 
glomeruli but blockade of VLA-4 did reduce renal injury (Allen et al., 1999; Khan et al., 
2003). A large component of crescent cells are macrophages but role for this upregulated 
VCAM-1 expression in the macrophage seen previously and at the mRNA level remains 
uncertain. 
 
Serpinb2 is a potential effector molecule identified in both the WKY and LEW BMDM 
comparative analysis and is under the influence of Crgn2 (Figure 4.9). As discussed in 
3.3.5.2, it is induced in inflammation and an array of immune system functions have been 
linked to the gene. It seems clear that it has important regulatory roles in immune responses 
(Schroder et al., 2010; Lee et al., 2011) and is differentially expressed between the NTN-
susceptible WKY and NTN-resistant LEW strains. The functional enrichment analysis of the 
LPS timecourse, just as in the WKY and LEW comparisons, identified enrichment for 
pathways involved in programmed cell death and apoptosis suggesting that these pathways 
could well be playing a key role in the macrophage behaviour seen in the NTN model. This is 
highly relevant because there are suggestions that the progression of innate immune 
responses may be regulated at the level of macrophage survival and this has been suggested 
to be particularly relevant in the context of bacterial infection where bacterial pathogens 
target TLR4-initiated antiapoptotic mechanisms to induce the death of activated macrophages 
and thereby evade detection and destruction by the host immune system (Park et al., 2005). 
Serpinb2 was shown to inhibit TLR4-induced macrophage apoptosis thereby preventing rapid 
macrophage death and premature cessation of the innate immune response. Mechanistically 
this was found to require cooperation of the IKK/NF-κB and p38 MAPK pathways that along 
with the key transcription factor CREB induced the transcription of Serpinb2 (Park et al., 
2005). The striking difference in expression of Serpinb2 between WKY and LEW BMDMs 
suggests that this could be a major effector molecule for the WKY BMDM phenotype and 
288 
 
suggests that antiapoptotic mechanisms could play a role in the NTN disease model. The 
effect of the Crgn2 locus suggests that Serpinb2 is influenced by AP-1 transcription factor 
which along with other genetic loci results in the prolonged survival of WKY BMDMs 
enhancing their ability to cause damage and drive the immune response. In addition, Serpinb2 
is located in Crgn1 and could therefore underlie some of the additive effects of introgressing 
both Crgn1 and Crgn2 from the LEW strain onto the WKY genomic background (Behmoaras 
et al., 2008). 
 
Enrichment for the JAK-STAT pathway was a novel discovery in this analysis and key genes 
within the pathway such as Janus kinase two and three (Jak2, Jak3) along with signal 
transducer and activator of transcription (Stat)-5a and Stat3 demonstrated altered time 
courses of expression. The link between differences in gene expression in elements of the 
signalling pathway and the amount and activity of phosphorylated proteins within this 
pathway remains uncertain but these differences do highlight the potential importance for this 
pathway in the disease model. Signalling through the JAK-STAT pathway is important for 
the kidney's response to injury in disease and there is strong evidence for a role for STAT3 
fibrosis as seen in a number of disease models linked with fibrosis such as diabetic 
nephropathy, unilateral ureteral obstruction and anti-Thy1 glomerulonephritis (Yanagita et 
al., 2001; Chuang and He, 2010; Pang et al., 2010). The pathway is also involved in renal 
ischaemia/reperfusion injury, a model of acute renal failure where JAK2 blockade reduced 
disease by reducing macrophage accumulation and tubular epithelial cell apoptosis (Yang et 
al., 2008) and also in proteinuric glomerular disease where selective JAK2 inhibition reduced 
disesae in Adriamycin nephropathy (Li et al., 2007). Studies in inflammatory glomerular 
disease are more scarce, but the pathway has been found to be active in a mouse model of 
lupus nephritis where inhibition reduced disease (Dong et al., 2007; Wang et al., 2010). 
Activation of STAT3 has also been identified in a number of types of human 
glomerulonephritis including lupus nephritis, IgA nephropathy and vasculitis (Arakawa et al., 
2008).  
 
WKY BMDMs show enhanced Fc mediated oxyBURST activation suggesting that the Fc 
gamma - mediated phagocytosis is enhanced in this strain. The JAK-STAT pathway has long 
been known to be activated by reactive oxygen species (ROS)  (Simon et al., 1998) and 
within the kidney, interferon gamma has also been shown to  stimulate ROS production in 
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mesangial cells via the pathway, as well showing the pathways and functions are closely 
interlinked (Moriwaki et al., 2006). This fits in with the associations of JunD with oxidative 
stress pathways suggesting that there could be a plausible role for the JAK-STAT pathway 
linked with the production of reactive oxygen species in the pathogenesis of NTN such that 
further investigations in vitro and in vivo are needed to understand whether modulation of the 
pathway is a potential therapeutic avenue. 
 
4.3.4      The effect of Jund siRNA knockdown on the BMDM transcriptome 
Along with the investigation of the effect of the Crgn2 locus on the NTN phenotype and 
macrophage activation, the AP-1 transcription factor Jund was associated with 
glomerulonephritis susceptibility at the locus and was a direct determinant of macrophage 
activation (Behmoaras et al., 2008). Therefore, as well as demonstrating the effect of Crgn2 
on the BMDM transcriptome, it was essential to demonstrate similar effects when the 
expression level of Jund was altered in isolation acutely rather than due to a chronic 
genetically determined change. 
 
The result of siRNA knockdown of Jund compared to transfection with scrambled control 
siRNA was to cause major changes in the BMDM transcriptome in both unstimulated and 
eight hour LPS stimulated BMDMs (Table 4.24). Whilst a number of genes showed 
extremely robust fold differences between the two siRNA groups (Table 4.25), it is notable 
that the majority of genes showed only moderate changes in gene expression, particularly less 
than 1.5-fold suggesting that the action of Jund was not as a switch causing major shifts in 
gene expression but as a fine tuning modulator of gene expression altering more subtly the 
transcriptome leading to altered macrophage phenotypes.  
 
Whilst ideally a full time course of siRNA knockdown with additional time points would 
have given even more insight, the eight hour time point was chosen as it overlapped with the 
time point in the comparison between WKY and WKY.LCrgn2 BMDMs following LPS 
stimulation where the largest differences were seen in differential gene expression and had 
proved to be highly valuable. Gene ontology analysis of the groups of genes differentially 
expressed and associated with higher or lower levels of Jund expression confirmed the role of 
Jund in mediating macrophage activation. In unstimulated BMDMs, i.e. prior to LPS 
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stimulation,  genes with higher expression in the scrambled control siRNA transfected group, 
i.e. with higher Jund expression, were associated with responses to LPS and regulation of cell 
activation showing that the ability of the cell to respond to stimulation was fundamentally 
altered by changing the level of Jund expression (Table 4.26). In addition, genes with 
increased expression following Jund knockdown, i.e. with the lower level of Jund, enriched 
for more homeostatic cellular processes such as protein amino acid phosphorylation and 
mRNA processing suggesting also that the level of Jund was fundamentally altering the 
cellular phenotype. Pathway analysis was in line with this (Table 4.27) with enrichment seen 
in scrambled control siRNA transfected BMDMs for the NOD-like receptor signalling 
pathway and apoptosis along with cytokine-cytokine receptor interaction, chemokine 
signalling pathway and cell adhesion molecules suggesting that the BMDM in this state was 
poised and more able to respond to inflammatory stimuli. Of note, Jund siRNA transfected 
BMDMs were associated with Fc gamma R-mediated phagocytosis and MAPK signalling 
pathway suggesting that modulation of key pathways is also part of the functional 
consequence of altering Jund expression levels. It is also possible that the reduction in Jund 
levels, by altering the makeup of AP-1 transcription factor dimers could cause positive effects 
on immune gene expression as well. The gene ontology analysis of genes at eight hours 
showed that by this timepoint only a few terms were enriched in each group (Table 4.28). In 
scrambled control siRNA transfected BMDMs, the biological process terms enriched include 
response to abiotic stimulus along with three terms linked with the regulation of cell death 
and the cellular response to stress whilst in Jund siRNA transfected BMDMs along with 
enrichment for the response to oestradiol stimulus and Golgi vesicle transport, there was 
enrichment for the positive regulation of immune system process again suggesting that 
positive immune functions of AP-1 factor family members were permitted to act now that 
there had been a reduction in Jund expression.   
 
Gene set enrichment analysis confirmed these findings in basal BMDMs (Table 4.29). 
Control siRNA transfected BMDMs enriched for multiple pathways with predominance for 
signalling pathways in line with the gene ontological findings above showing that the cell 
was poised in this state to respond robustly to stimulation. Of note there was also enrichment 
for chemokine receptors that bind chemokines, cytokine and cytokine-receptor interactions, 
peptide ligand binding receptors and class A1 rhodopsin receptors. This is highly similar to 
the findings observed in the LPS stimulated WKY BMDMs at two hours (Table 4.13) and 
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four hours of LPS stimulation (Table 4.14), demonstrating that the ability of the cell to 
respond to extracellular signals was under the influence of Jund. The finding of these 
pathways does also point to the fact that the BMDMs in this basal state are different to that of 
the WKY and WKY.LCrgn2 BMDMs such that the siRNA transfected BMDMs have 
undergone a stress response activating certain pathways explaining the enrichment for 
immune function terms at the basal timepoint. 
 
The nature of the LPS response in the siRNA transfected BMDMs was also investigated to 
ascertain how similar the response was to that seen in WKY and WKY.LCrgn2 BMDMs 
particularly as the serum starvation and siRNA transfection within the siRNA knockdown 
protocol could potentially alter the state of the cells. The LPS response in both control and 
Jund siRNA transfected BMDMs was attenuated markedly compared to normal BMDMs 
(Table 4.32) though fitting with the findings seen between WKY and WKY.LCrgn2 
BMDMs, there were fewer differentially expressed genes in the Jund siRNA transfected 
group confirming that the reduced level of Jund attenuates the transcriptional response to 
LPS. The functional analysis of the genes increasing expression after LPS were similar in 
both scrambled control and Jund siRNA transfected BMDMs to that seen in WKY, 
WKY.LCrgn2 and LEW BMDMs suggesting that despite the reduced numbers of genes that 
changed, the basic responses were similar (Appendix B, Table B.3, B.4). Of note however 
the enriched terms in genes with decreased expression did differ with processes such as 
response to abiotic stimulus and intracellular signalling cascades prominent along with more 
homeostatic cell functions (Appendix B, Table B.5, B.6) suggesting that the basal condition 
and potentially the LPS stimulated state may not be directly comparable with the WKY 
BMDMS.  
 
4.3.5      Comparison of the chronic and acute effects of changes in Jund expression  
The approach used in this chapter aimed to enable a comparison to be made, between WKY 
and congenic WKY.LCrgn2 BMDMs, of the chronic and more physiological effects of a 
genetically determined alteration in transcription factor as seen in the WKY.LCrgn2 strain 
and whether adaptation to this change and redundancy within the AP-1 transcription factor 
family might be occurring along with the effect of an acute change in transcription factor 
level induced by siRNA knockdown of Jund. This is a scenario which would be relevant if 
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Jund is directly targeted in a therapeutic manner using an antisense or RNA interference-
mediated approach.  
 
In the timecourse analysis over the eight hours of LPS stimulation between WKY and 
WKY.LCrgn2 BMDMs, 830 genes were identified that significantly changed. Static 
timepoint analyses only found a relatively small number of genes that were differentially 
expressed between the strains and, at the highest number, 31 genes were observed at the eight 
hour timepoint. The analysis of unstimulated BMDMs following siRNA knockdown of Jund 
identified that 1,672 genes were differentially expressed compared to scrambled control 
siRNA and that 1,476 genes were differentially expressed after eight hours of LPS 
stimulation. These differences suggest that adaptation to the chronic reduction in Jund level 
had occurred in WKY.LCrgn2 BMDMs and that functional redundancy with other AP-1 
transcription factor proteins could be occurring. In addition, adaptation to the effects of the 
other genes located within the Crgn2 congenic interval could also be a factor in the 
differences seen. 
 
The siRNA knockdown of Jund confirmed the widespread effects that altering Jund 
expression has on the BMDM transcriptome. An overlap between the set of genes 
differentially expressed in the timecourse between WKY and WKY.LCrgn2 BMDMs and the 
siRNA knockdown datasets identified that 201 genes were directly controlled by alterations 
in Jund expression and were differentially expressed between WKY and WKY.LCrgn2 
BMDMs. Seven genes were identified that had greater than two-fold differences in 
expression between scrambled control and Jund siRNA transfected BMDMs (Table 4.35) 
and in addition, three were also validated by qRT-PCR (Figure 4.15, 4.16). All were present 
in the unstimulated dataset between scrambled control and Jund siRNA transfected BMDMs. 
Arg1 and Cdo1 have been identified already as prominent effector candidates mediating Jund 
function and are discussed in 4.3.3. Metallothionein 2A (Mt2A) demonstrated 4.58-fold 
higher expression in scrambled control siRNA transfected WKY BMDMs, that is in BMDMs 
with the higher level of Jund expression, compared to Jund siRNA transfected BMDMs. 
Mt2a is an intracellular metal-binding protein whose overexpression is frequently observed in 
invasive human breast cancers (Kim et al., 2011b). Of note, it has been shown to induce 
MMP-9 along with invasion and migration properties of breast cancer cells and that AP-1 
along with NF-κB is required for this process (Kim et al., 2011b). Mt2a has been linked with    
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Table 4.35 Genes under the direct influence of Jund in the timecourse analysis 
between WKY and WKY.LCrgn2 BMDMs 
 
Genes overlapping between the WKY and WKY.LCrgn2 timecourse and were also 
differentially expressed between control and Jund siRNA transfected BMDMs in either basal 
or after LPS stimulation were analysed. These genes all demonstrated greater than two-fold 
changes expression in one of the siRNA datasets. n/a indicates genes that were not 
differentially expressed after LPS stimulation in the siRNA knockdown experiment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
294 
 
protective roles against oxidative stress in a cardiac cell line linked with its role as a heavy 
metal sequestrator and reactive oxygen species (ROS) scavenger (Xue et al., 2009). In 
addition it was also linked to protection against apoptosis following hypoxia and 
reoyxgenation myocardial injury. (Kang et al., 2003; Xue et al., 2009). Mt2a is expressed, 
and has been found to protect against ROS-mediated cell death, in multiple tissues. In human 
lymphoma cells, its expression was shown to be triggered by ROS production where it 
functions as part of the cellular defence mechanism against oxidative stress (Yang and 
Chitambar, 2008) and similarly in HeLa cells, Mt2a protected against the cell death 
consequences of ROS formation following rotenone induced deficiency of 
NADH:ubiquinone oxidoreductase (Reinecke et al., 2006). Mt2a is also upregulated in 
hypoxic human prostate cancer cells promoting the survival of these cells and is 
overexpressed in prostate cancer tissue and residual cancer cells after androgen ablation 
therapy. In addition, its downregulation by siRNA inhibited cell growth and induced cell 
death (Yamasaki et al., 2007). As discussed in 4.3.1, Jund has been associated with protective 
roles against oxidative stress (Gerald et al., 2004) and the finding that it can directly alter the 
expression of Mt2a identifies Mt2a as a potential key effector gene in the WKY BMDM 
overactivation phenotype. 
 
Functional enrichment analysis for the 201 genes overlapping between the transcriptome 
datasets confirmed the role for Jund in modulating the response to stimulation in BMDMs. 
There was significant enrichment for biological processes such as the inflammatory response, 
response to wounding and organic substance and cytokine mediated signalling pathway 
(Table 4.36). However, the stringent significance threshold used did not give enrichment in 
the KEGG pathway analysis for terms linked with cytokine-cytokine receptor interaction, 
apoptosis, JAK-STAT signalling pathway and the MAPK pathway though they were enriched 
below a 10%FDR. The data demonstrates that modulation of Jund levels in acute and chronic 
settings were able to reveal that the core function of JunD are linked with modulation the 
response to stimulation at multiple levels within cell signalling pathways. 
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Table 4.36 Enrichment of biological process and KEGG pathways functional 
annotation terms for genes overlapping EDGE timecourse and siRNA datasets 
 
Genes overlapping between the WKY and WKY.LCrgn2 timecourse and were also 
differentially expressed between control and Jund siRNA transfected BMDMs in either basal 
or after LPS stimulation were analysed. Enrichment for biological process functional 
annotation and KEGG pathway terms used a threshold of <5% FDR and fold enrichment 
>1.5. No enriched KEGG pathway terms were identified at this threshold. 
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4.4 Conclusion 
The data presented in this chapter has shown that the LEW Crgn2 QTL when introgressed on 
to the WKY transcriptome modulates the response to LPS in the WKY strain. The results 
demonstrate that the locus influences macrophage activation by modulating genes involved in 
all steps of the response to stimulation in the macrophage from the cell surface receptor to 
signalling pathways such as the JAK-STAT pathway to transcriptional control of the 
inflammatory response. siRNA knockdown of Jund confirmed a direct role in controlling 
immune pathways that is likely to underlie the major effects of the Crgn2 locus. The data 
analysis identified a number of effector genes influenced by Crgn2 such as Serpinb2 and, by 
combining the transcriptomic data sets, a number of direct Jund targets were confirmed such 
as Cdo1, Arg1 and Mt2a  that merit further study to understand their role in WKY 
macrophage overactivation and potential targets through which to modulate macrophage 
behaviour. 
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Chapter 5. Investigation of the JunD cistrome 
 
5.1 Introduction 
The aim of the work presented in this chapter was to investigate the genome wide binding 
pattern of the activator protein 1 (AP-1) transcription factor JunD in basal and 
lipopolysaccharide (LPS)-stimulated WKY and WKY.LCrgn2 bone marrow-derived 
macrophages (BMDMs). The work aimed to gain insights on how genetically determined 
differences in JunD expression alter its set of cis-acting targets at the genome scale level, 
termed its cistrome (Lupien et al., 2008; Lupien and Brown, 2009). These alterations could 
explain the differences seen in the LPS response in WKY and WKY.LCrgn2 and the 
underlying macrophage overactivation phenotype in WKY BMDMs. 
 
5.1.1      Chromatin immunoprecipitation coupled with high throughput sequencing 
(ChIP-Seq). 
The advent of high throughput (HT) sequencing technologies has revolutionised genomics 
primarily because the vast volumes of data generated by each instrument run now allow 
genome wide analyses to be performed as a matter of routine (Mardis, 2008; Metzker, 2010). 
Chromatin immunoprecipitation (ChIP) is a technique that enriches for the parts of the 
genome where a protein of interest has bound by using formaldehyde to cross-link the protein 
onto the chromatin. Following shearing of the chromatin, the DNA bound fragments are 
immunoprecipitated with specific antibodies (Solomon et al., 1988). This generates a library 
of DNA fragments that can be analysed on a gene by gene basis using polymerase chain 
reaction (PCR)-based techniques. The arrival of array based technologies led to their 
application in the analysis of these ChIP libraries in ChIP-Chip (Blat and Kleckner, 1999; 
Ren et al., 2000). The technological advance brought about by the advent of high throughput 
sequencing technologies has allowed the entire set of DNA fragments to be analysed in a 
ChIP-Seq experiment in an unbiased manner. This was one of the first applications to harness 
the advance in sequencing technology and has lower costs, higher resolution, fewer artifacts, 
greater coverage and a wider dynamic range than the microarray based analysis methods 
(Johnson et al., 2007; Mardis, 2007; Robertson et al., 2007; Park, 2009).  
298 
 
5.1.2      Current limitation of insights into JunD and AP-1 transcription factor 
function 
The genetically encoded differences in JunD expression seen between the WKY and the 
WKY.LCrgn2 and LEW rat strains linked to the Crgn disease model provide a unique 
opportunity to investigate JunD function further (Behmoaras et al., 2008). In the original 
work identifying JunD as a determinant of macrophage activation, a TransAm assay, which is 
a DNA binding ELISA that quantifies the amount of transcription factor binding to a 
consensus sequence, confirmed that specific JunD binding to AP-1 consensus sequence 
nucleotides (5’-TGAGTCA-3’) was significantly higher in nuclear extracts from WKY 
BMDMs compared to both LEW and WKY.LCrgn2 extracts (Behmoaras et al., 2008) 
demonstrating that the increased transcription factor level could have major functional 
consequences in the WKY genome. The ability to interrogate, on a genome wide basis, the 
binding pattern of JunD using ChIP-Seq would therefore increase our understanding of some 
of the mechanisms underlying its influence on macrophage activation.  
 
The current understanding of JunD function as a transcription factor is limited and has only 
been done on a candidate gene or promoter basis (Kuhlmann et al., 2007; Xiao et al., 2007; 
Toualbi-Abed et al., 2008). The Encyclopaedia of DNA elements (ENCODE) project was 
initiated by the National Human Genome Research Institute in the United States with the aim 
to decipher all the functional elements encoded in the human genome sequence (Birney et al., 
2007; Myers et al., 2011). As part of this process, ChIP-Seq has been carried out for JunD in 
a number of human transformed cell lines including H1-hESC, an embryonic stem cell line, 
HepG2 cells, a liver carcinoma cell line and the K562 leukaemia cell line using the same 
antibody as used in this ChIP-Seq project. The data does include a genome wide binding 
pattern for JunD in theses cell lines. However such results are not directly applicable as the 
early analyses from the project demonstrated that the cistrome of a number of factors, and 
specifically JunD, is highly cell specific and no macrophage cell lines have been studied to 
date in the project (Farnham, 2009).  Apart from a ChIP-Seq experiment for c-JUN in the 
K562 cell line (Li et al., 2011), no other investigations have been carried out at the genome 
wide level for AP-1 transcription factors nor in primary cells linked to a model of complex 
human disease. Bioinformatics surveys of the frequency and distribution of AP-1 consensus 
binding sites, such as the 5’-TGAGTCA-3’ motif, in the human genome have found that 
around one third of genes in the human genome have putative AP-1 recognition sites, which 
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rises to over half if variants of this consensus sequence are used (Zhou et al., 2005). These 
pieces of evidence gave confidence that ChIP-Seq for JunD could reveal a genome wide 
distribution of binding events linked to binding to the AP-1 consensus motif. In addition, as 
AP-1 proteins have long been recognised to interact widely with other factors, its binding at 
additional sites that do not necessarily contain a canonical AP-1 binding site could also be 
revealed (Chinenov and Kerppola, 2001). 
 
5.2 Results 
5.2.1      Methodological development of ChIP and ChIP-Seq 
5.2.1.1 ChIP methodology 
Initial methodological development of ChIP was carried out to ensure that 
immunoprecipitation could be successfully performed. As demonstrated in Figure 1.4, and 
detailed in Chapter 2 Methods 2.9, the process of ChIP contains a number of steps critical to 
the successful enrichment of transcription factor bound chromatin. Efficient shearing of the 
chromatin to produce fragments between 200 and a maximum of 700 base pairs in size is 
needed to give the accurate resolution for ChIP-Seq and reliable assessment of the DNA 
using polymerase chain reaction (PCR) and quantitative PCR (qPCR) based methods. Initial 
shearing of chromatin was performed using an enzymatic digestion based method but 
banding seen in quality control groups raised concerns regarding shearing biases and, along 
with problems in the reproducibility of shearing between batches (Figure 2.4), a sonication 
based method was implemented. This used the non-probe based approach of the Covaris S2 
(Covaris Inc., Woburn, Massachusetts, USA) which uses focused acoustic energy waves and 
has become an essential tool in library preparation for high-throughput sequencing 
technologies. Compared to probe and bath-based sonicators it allows for isothermal and non-
contact processing of the samples (Figure 5.1).  
 
The immunoprecipitation process relies on the use of a specific antibody. The antibody 
against JunD used in this experiment is the same as that used for the ChIP-Seq of JunD in 
three different cell lines by the ENCODE project and its specificity for JunD has been 
demonstrated previously (Behmoaras et al., 2008). Alongside immunoprecipitation with the 
antibody specific to the transcription factor of interest, two important additional controls are  
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Figure 5.1 Chromatin shearing results 
2% TAE agarose gels showing size range of sheared chromatin. Each lane represents a 
different preparation of chromatin subjected to identical shearing conditions. (A) Enzymatic 
digestion was used, resulting in sheared chromatin but with banding occurring every 150 base 
pairs. (B) Sonication using the Covaris S2 was performed resulting in sheared chromatin in 
the desired size range without evidence of bias or banding. 
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implemented at this point (Figure 1.4). The first control is an antibody control where a non-
specific immunoglobulin G (IgG) is used, alongside the specific antibody, in the 
immunoprecipitations to demonstrate the background levels of non-specific protein binding. 
This is used in PCR and qPCR based analysis of immunoprecipitated chromatin. The second 
control is the ‘input’ control which is chromatin that is not exposed to the 
immunoprecipitation process but undergoes all other processing steps. This input control 
contains the theoretical maximum of all potential binding sites in the genome. PCR and 
qPCR based analysis of enriched chromatin was used to demonstrate that successful 
enrichment for Jund had occurred prior to library preparation for ChIP-Seq. Figure 5.2  
demonstrates the PCR result for a putative AP-1 binding site in the promoter of interleukin-6 
(Il-6) demonstrating enrichment for JunD compared to the IgG control lane. Primers were 
designed to compass the AP-1 binding site with an amplicon size between 100 and 150 base 
pairs. The input lane demonstrates the maximum signal that could have been achieved if 
JunD had bound to every available DNA copy containing this genomic locus. 
 
5.2.1.2 ChIP-Seq methodology 
ChIP-Seq was performed in BMDMs from WKY and WKY.LCrgn2 in both the basal state 
and following two hours of LPS stimulation. The WKY.LCrgn2 congenic strain contains the 
Crgn2 QTL locus introgressed from the LEW strain onto the WKY genomic background. 
The AP-1 transcription factor Jund is one of the genes located within this interval and the 
WKY strain demonstrates marked overexpression of Jund in comparison to WKY.LCrgn2 
BMDMs (Figure 4.6). The WKY.LCrgn2 strain was used in preference to the LEW strain 
because in the LEW genome, differences in the expression of other transcription factors and 
sequence variants could alter JunD binding to a significant extent and create uncertainties 
about the peak calls 
 
BMDMs from one biological replicate from each of the WKY and WKY.LCrgn2 strains 
were cultured in four separate petri dishes. Two petri dishes were used for each condition, 
basal and two hours LPS stimulation, from which, following fixation with formaldehyde, the 
BMDMs were pooled for further processing in the ChIP protocol. The ChIP-Seq DNA 
libraries were generated from a pool of five technical immunoprecipitation replicates both to  
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Figure 5.2  PCR assessment of chromatin immunoprecipitation 
2% TAE agarose gel demonstrated the results of the PCR assessment of chromatin 
immunoprecipitation for JunD in WKY BMDMs. The PCR products were loaded in duplicate 
in adjacent lanes. Lane 1 and lane 2 demonstrate the PCR result for JunD ChIP. Lane 3 and 
lane 4 demonstrate the negative control antibody, IgG, result which is blank. Lane 5 and lane 
6 contain the input control lane which represents the theoretical maximum enrichment signal 
for this locus. Lane 8 contains the PCR negative control water blank. 
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minimise variability between each technical immunoprecipitation and to generate sufficient 
yield (10ng) for the library preparation. 
 
The controls used for ChIP-Seq are very important (Park, 2009). Though the use of negative 
antibody control IgG has been advocated, an immunoprecipitation with such an antibody 
pulls down minimal amounts of DNA and, as a consequence, yields minimal sequence 
output. In addition, the low immunoprecipitation yield can lead to a high percentage of clonal 
sequencing reads being introduced during the PCR amplification stage of the library 
preparation (Northrup and Zhao, 2011). Input control chromatin has been used as the control 
sample in nearly all ChIP-Seq studies and was also used in this study as it generates a more 
accurate estimation of the biases that can result from the chromatin shearing processes and 
the sequencing itself (Park, 2009; Northrup and Zhao, 2011). In addition, each strain and 
condition, for example the WKY basal DNA library, had its own relevant input chromatin 
library sequenced to further remove the potential for bias both from the effect of LPS 
stimulation on the cell and between the WKY and WKY.LCrgn2 strains. This input control 
chromatin library is not used to generate a specific set of background peaks but is 
incorporated into the analysis algorithms to allow for the significance of a potential peak to 
be assessed. 
 
5.2.2      Sequencing of ChIP-enriched DNA fragments 
Sequencing of ChIP-enriched DNA fragments was successfully carried out on the Illumina 
Genome Analyzer IIx producing between 1,861 and 2,375 megabases of raw sequence per 
strain and condition. The Burrows Wheeler Alignment tool v0.5.9 (Li and Durbin, 2009) was 
used to map the sequenced reads to the Brown-Norway rat reference genome (RN4) (Table 
5.1). This analysis was carried out by Mr Santosh Atanur, Physiological Genomics and 
Medicine (PGM) Group. Duplicate reads introduced by the PCR amplification step of the 
ChIP-Seq were removed and only uniquely mapped reads were taken forward for the 
identification of JunD binding sites.  
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Table 5.1 Sequencing and mapping statistics 
 
 
Total sequence yield per sample lane are shown with numbers of mapped and non-duplicate 
mapped reads using Burrows-Wheeler algorithm v0.5.9 (Li and Durbin, 2009). 
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5.2.3      Identification of ChIP-enriched regions in the genome 
ChIP-enriched regions in the genome, or peaks, in each group were identified using 
BayesPeak v1.1.3 (Spyrou et al., 2009; Cairns et al., 2011) using a posterior probability 
threshold of 0.9. This analysis was performed by Dr Prashant Srivastava, PGM Group as 
detailed in 2.17.8.3. The algorithm uses a hidden Markov model to identify enriched regions 
of the genome. This resulted in a set of enriched regions with a narrow mean peak width 
ranged from 185 to 251 base pairs with a maximum identified peak width in any of the 
groups of 7,199 base pairs (Figure 5.3).  
 
The analysis of the JunD cistrome in WKY BMDMs identified 27,124 peaks in WKY basal 
BMDMs and 36,687 in WKY LPS stimulated BMDMs (Table 5.2). In comparison, in 
WKY.LCrgn2 BMDMs which have lower JunD expression levels, only 16,593 peaks in 
WKY.LCrgn2 basal and 8,869 peaks in LPS stimulated BMDMs were identified. Peaks were 
found to be distributed throughout the genome. The distribution of peaks in relation to 
Ensembl transcriptional start sites (TSS) was analysed using the gene intervals notator within 
the CARPET suite (Cesaroni et al., 2008). Increased numbers of peaks in both the basal and 
two hour LPS stimulated condition in the WKY strain were evident for each of the annotation 
categories used (Table 5.3).  Whilst the overall numbers of peaks in each annotation category 
were increased in the WKY BMDMs, the proportion of peaks for each annotation category 
shared a similar distribution pattern across the strains and conditions (Figure 5.4). In each 
data set, the largest proportion of peaks was located in intergenic regions. There was an 
increased proportion of peaks in this region in WKY.LCrgn2 BMDMs, 44% in the basal and 
43% in two hour LPS stimulated, compared to WKY BMDMs, 39% in basal and 35% in two 
hours LPS stimulated BMDMs. WKY BMDMs demonstrated higher proportions of peaks 
within the intron and exon annotation categories compared to WKY.LCrgn2 BMDMs whilst 
the proportion of peaks in the promoter region was similar, ranging from 21% in WKY basal 
and two hour LPS stimulated BMDMs to 22% in WKY.LCrgn2 BMDMs. There was an 
increase to 25% for promoter peaks in WKY.LCrgn2 BMDMs stimulated for two hours with 
LPS. Peaks were preferentially located near to the TSS in the WKY and WKY.LCrgn2 
strains in each condition (Figure 5.5). Peaks located within 100 kilobases of the TSS 
demonstrated a gradual rise in the numbers of peaks at each point approaching the TSS with a 
more marked rise occurring after five kilobases from the TSS (Figure 5.5).  
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Figure 5.3 Width of peaks identified using BayesPeak algorithm 
Peaks were filtered into (A) 500 base pair width bins for all identified peaks and (B) 100 base 
pair bins for all peaks under 1000 base pairs in width. JunD binding peaks were identified 
using BayesPeak v1.1.3 with a posterior probability threshold of 0.9 (Spyrou et al., 2009; 
Cairns et al., 2011).  
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Table 5.2 Numbers of ChIP-Seq Peaks identified with BayesPeak  
 
 
 
 
 
 
JunD binding peaks were identified using BayesPeak v1.1.3 with a posterior probability 
threshold of 0.9 (Spyrou et al., 2009; Cairns et al., 2011).  
 
 
 
Table 5.3 Annotation of JunD peak locations  
 
The genomic location of peaks relative to the transcriptional start sites (TSS) of Ensembl 
transcripts was assessed using the gene intervals notator within the CARPET  suite (Cesaroni 
et al., 2008). Promoter region was defined as 20 kilobases (kb) upstream of the TSS and the 
upstream region was defined as the region between 20kb and 50kb from the TSS. 
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Figure 5.4 Genomic distribution of JunD peaks  
The proportion of peaks in each genomic location annotation category is displayed. The 
genomic location of peaks relative to the transcriptional start sites (TSS) of Ensembl 
transcripts was assessed using the gene intervals notator within the CARPET  suite (Cesaroni 
et al., 2008). Promoter region defined as 10 kilobases (kb) upstream of the TSS, upstream 
region between 10kb and 50kb upstream from TSS. 
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Figure 5.5 Distance of peaks from transcriptional start site (TSS) 
Distribution of peaks within 100 kilobases (A) and 20 kilobases (B) of the TSS of Ensembl 
transcripts. 
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JunD binding peaks were associated with a gene if the peak was located within the 20kb 
upstream region of the TSS, which could therefore include any potential promoter or 
enhancer areas, as well as within the gene body itself. The gene body encompassed all the 
introns and exons of the gene (TSS to transcription termination site). This approach identified 
that 46.2% of all the peaks (12,522 peaks) in basal WKY BMDMs and 49.4% (18,124 peaks) 
in two hour LPS stimulated WKY BMDMs were associated with a gene. In WKY.LCrgn2 
BMDMS, 38.6% of peaks (6,408 peaks) in the basal state and 38.7% (3,361 peaks) in the 
LPS stimulated state were associated with a gene.  
 
5.2.4      Gene ontology analysis of JunD-bound genes in basal BMDMs 
In basal WKY BMDMs, 12,522 peaks were associated with 5,339 unique JunD-bound genes. 
In comparison to basal WKY BMDMs, there were only 6,408 peaks associated with 2,606 
unique JunD-bound genes in basal WKY.LCrgn2 BMDMs reflecting the consequences of the 
marked overexpression of Jund in WKY BMDMs compared to WKY.LCrgn2 BMDMs.  
 
The gene ontology analysis of the Jund-bound genes in WKY basal BMDMs identified 
enrichment for genes associated with macrophage immune function such as cell-cell 
signalling and antigen processing and presentation (Table 5.4). There was also enrichment 
for multiple developmental processes such as ectoderm development, epithelium 
development and reproductive developmental processes. The pathway associated terms from 
the KEGG database that were significantly enriched included multiple immune and 
autoimmune diseases such as type 1 diabetes mellitus, graft versus host disesae, allograft 
rejection and autoimmune thyroid disease along with core macrophage linked functions such 
as antigen processing and presentation (Table 5.4). Gene ontology analysis of the JunD-
bound genes in WKY.LCrgn2 BMDMs identified significant enrichment for macrophage 
associated functions such as antigen processing and presentation and transmembrane receptor 
protein tyrosine kinase signalling pathways (Table 5.5) but, unlike the Jund-bound genes in 
WKY BMDMs, no enrichment for developmental processes was evident. Pathway analysis 
using the KEGG database identified enrichment for the same set of autoimmune disease 
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Table 5.4  Gene ontology analysis of JunD-bound genes in WKY basal BMDMs 
 
This table details the significantly enriched biological process functional annotation terms 
and KEGG pathways from DAVID for JunD-bound genes  in WKY basal BMDMs. 
Enrichment for biological process functional annotation terms and KEGG canonical 
pathways used a threshold of <5% FDR and fold enrichment >1.5.  
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Table 5.5 Gene ontology analysis of JunD-bound genes in WKY.LCrgn2 basal 
BMDMs 
 
This table details the significantly enriched biological process functional annotation terms 
and KEGG pathways from DAVID for JunD-bound genes in WKY.LCrgn2 basal BMDMs. 
Enrichment for biological process functional annotation terms and KEGG canonical 
pathways used a threshold of <5% FDR and fold enrichment >1.5.  
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terms and core macrophage functions (Table 5.5) as was identified in WKY basal BMDMs 
(Table 5.4) suggesting that JunD could have similar core roles in each strain independent of 
the different expression levels of the transcription factor.  
 
There were 919 JunD-bound genes in common between the WKY basal and WKY.LCrgn2 
basal BMDMs whilst there were 4,420 JunD-bound genes unique to WKY basal BMDMs 
and 1,687 genes unique to WKY.LCrgn2 BMDMs (Figure 5.6). Gene ontology analysis 
associated the 4,420 unique JunD-bound genes in WKY basal BMDMs with cell-cell 
signalling along with multiple developmental processes whilst only protein deubiquitination 
was associated with the 1,687 unique JunD-bound genes in WKY.LCrgn2 BMDMs. The 
JunD-bound genes in common enriched for antigen processing and presentation linked terms, 
the immune response and cell motion (Table 5.6). This common set of JunD-bound genes in 
basal BMDMs also enriched for multiple autoimmune disease pathways (Table 5.7), as had 
been observed in the analysis of the individual JunD-bound gene sets (Table 5.4, 5.5), along 
with the antigen processing and presentation pathway. This highlights that in the basal state, 
despite the differences in the expression level of Jund between the WKY and WKY.LCrgn2 
strains, JunD interacts with gene sets linked to basic macrophage functions. 
 
5.2.5      Gene ontology analysis of JunD-bound transcripts in two hour LPS 
stimulated BMDMs 
Following two hours of LPS stimulation, there were 18,124 peaks associated with 7,612 
unique JunD-bound genes in WKY BMDMs compared to only 3,361 peaks associated with 
1,022 unique JunD-bound genes in WKY.LCrgn2 BMDMs. Gene ontology analysis of the 
JunD-bound genes in LPS-stimulated WKY BMDMS identified enrichment for protein 
kinase cascades, regulation of responses to external stimuli as well as second messenger 
mediated signalling and the MAPKKK cascade. There was also enrichment for multiple 
autoimmune disease pathways (Table 5.8). The JunD-bound genes in WKY.LCrgn2 
BMDMs (Table 5.9) were associated with core macrophage functional terms such as antigen 
processing and presentation, the immune response and cell-cell signalling. Multiple 
autoimmune disease associated pathways were also enriched along with the antigen 
processing and presentation pathway as had been observed in basal WKY and WKY.LCrgn2 
BMDMs (Table 5.4, 5.5).  
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Figure 5.6 Unique and common JunD-bound genes between basal WKY and 
WKY.LCrgn2 BMDMs 
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Table 5.6 Functional annotation of the unique and common JunD-bound genes 
between basal WKY and WKY.LCrgn2 BMDMs 
 
This table details the significantly enriched biological process functional annotation terms 
from DAVID for the unique and common JunD-bound genes between  basal WKY and 
WKY.LCrgn2 BMDMs. Enrichment for biological process functional annotation terms used 
a threshold of <5% FDR and fold enrichment >1.5.  
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Table 5.7 Pathway enrichment analysis for the unique and common JunD-bound 
genes between basal WKY and WKY.LCrgn2 BMDMs  
 
This table details the significantly enriched KEGG pathway terms from DAVID for the 
unique and common JunD-bound genes between  basal WKY and WKY.LCrgn2 BMDMs. 
Enrichment for biological process functional annotation terms used a threshold of <5% FDR 
and fold enrichment >1.5.  
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Table 5.8 Gene ontology analysis of JunD-bound genes in two hour LPS-stimulated 
WKY BMDMs 
 
This table details the significantly enriched biological process functional annotation terms 
and KEGG pathways from DAVID for JunD-bound genes in two hour LPS-stimulated WKY  
BMDMs. Enrichment for biological process functional annotation terms and KEGG 
canonical pathways used a threshold of <5% FDR and fold enrichment >1.5. The top 20 
enriched functional annotation terms are listed in this table. The full list of enriched terms is 
detailed in Appendix C, Table C.1.  
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Table 5.9 Gene ontology analysis of JunD-bound genes in two hour LPS-stimulated 
WKY.LCrgn2 BMDMs 
 
This table details the significantly enriched biological process functional annotation terms 
and KEGG pathways from DAVID for JunD-bound genes in two hour LPS-stimulated WKY  
BMDMs. Enrichment for biological process functional annotation terms and KEGG 
canonical pathways used a threshold of <5% FDR and fold enrichment >1.5.  
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When the JunD-bound genes between BMDMs from LPS-stimulated WKY and 
WKY.LCrgn2 BMDMs were compared, 636 JunD-bound genes were found to be in common 
between these two groups. There were 6,976 unique JunD-bound genes in LPS-stimulated 
WKY BMDMs and only 386 unique JunD-bound genes in LPS-stimulated WKY.LCrgn2 
BMDMs (Figure 5.7). JunD-bound genes unique to WKY LPS-stimulated BMDMs were 
associated with immune function related terms such as protein kinase cascade, cell activation, 
regulation of response to external stimulus and second messenger mediated signalling as well 
as immune system development (Table 5.10). No enriched terms were found for the 386 
unique JunD-bound genes in WKY.LCrgn2 LPS stimulated BMDMs. The JunD-bound genes 
common between WKY and WKY.LCrgn2 BMDMs enriched for core macrophage functions 
such as antigen processing and presentation and the immune response (Table 5.10). Pathway 
enrichment analysis associated the unique JunD-bound genes in WKY LPS-stimulated 
BMDMs with the MAPK signalling pathway whilst the genes common between the strains 
enriched with high significance for autoimmune disease pathways and antigen processing and 
presentation (Table 5.11). These analyses demonstrate that JunD-bound genes in WKY 
BMDMs after LPS stimulation are associated with responses to stimulation and signalling 
pathways whilst there are common functions for JunD shared between WKY and 
WKY.LCrgn2 linked with basic macrophage activities such as antigen processing and 
presentation. 
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Figure 5.7 Unique and common JunD-bound genes between two hour LPS-
stimulated WKY and WKY.LCrgn2 BMDMs  
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Table 5.10 Functional annotation of the unique and common JunD-bound genes 
between two hour LPS-stimulated WKY and WKY.LCrgn2 BMDMs 
 
This table details the significantly enriched biological process functional annotation terms 
from DAVID for the unique and common JunD-bound genes between  basal WKY and 
WKY.LCrgn2 BMDMs. Enrichment for biological process functional annotation terms used 
a threshold of <5% FDR and fold enrichment >1.5. The top 20 enriched functional annotation 
terms are listed in this table. The full list of enriched terms is detailed in Appendix C, Table 
C.2. 
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Table 5.11 Pathway enrichment analysis for the unique and common JunD-bound 
genes between basal WKY and WKY.LCrgn2 BMDMs  
 
This table details the significantly enriched KEGG pathway terms from DAVID for the 
unique and common JunD-bound genes between  basal WKY and WKY.LCrgn2 BMDMs. 
Enrichment for biological process functional annotation terms used a threshold of <5% FDR 
and fold enrichment >1.5.  
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5.2.6      JunD-peaks underlying the WKY macrophage overactivation phenotype 
As detailed in 5.2.2, there were 5,339 JunD-bound genes in the basal state and 7,612 JunD-
bound genes identified following two hours of LPS stimulation in WKY BMDMs. There 
were 1,900 genes only present in basal WKY BMDMs whilst 3,439 of these genes were 
always bound by JunD and 4,173 of JunD-bound genes were unique to the LPS stimulated 
state in WKY BMDMs and were therefore induced during LPS stimulation (Figure 5.8). The 
1,900 JunD-bound genes unique to the basal state enriched weakly for only the citrulline 
biosynthetic process and peptidyl-citrulline biosynthetic process from peptidyl-arginine terms 
(Table 5.12).  The 3,439 JunD-bound genes common to both states enriched for multiple 
developmental processes as well as cell-cell signalling, cell motion and antigen processing 
and presentation along with autoimmune disease pathways (Table 5.13). These terms 
indicate some of the potential constitutive functions of JunD in macrophages. Following LPS 
stimulation, the 4,173 inducible JunD bound genes associated with terms including the 
response to wounding, the regulation of response to external stimulus and second messenger 
mediated signalling as well as the MAPK signalling pathway (Table 5.14).  
 
LPS stimulation rapidly induces a transcriptional response in WKY and WKY.LCrgn2 
BMDMs with 7,509 differentially expressed genes compared to the basal state in WKY 
BMDMs and 6,217 differentially expressed genes compared to the basal state in 
WKY.LCrgn2 BMDMs identified after two hours of LPS stimulation (Table 4.1). 
Differences in the overall numbers of genes that demonstrated significant differential 
expression compared to baseline was observed at each of the timepoints when comparing 
WKY and WKY.LCrgn2 BMDMs (Table 4.1). The effect of introgressing the LEW Crgn2 
QTL onto the WKY genomic background resulted in the identification of 830 genes that 
showed a significantly different LPS response over the eight hour timecourse between WKY 
and WKY.LCrgn2 BMDMs (see 4.2.3.2). As JunD was identified as the positional candidate 
within Crgn2 determining macrophage activation, it is likely that JunD-bound genes in WKY 
BMDMs that are unique in comparison to WKY.LCrgn2 BMDMs could play an important 
role in determining the differences seen in gene expression between the WKY and 
WKY.LCrgn2 strains.  
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Figure 5.8 Unique and common JunD-bound genes between basal and two 
hour LPS-stimulated WKY BMDMs 
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Table 5.12 Gene ontology analysis of JunD-bound genes unique to basal WKY 
BMDMs 
 
This table details the significantly enriched biological process functional annotation terms 
and KEGG pathway terms from DAVID for the JunD-bound genes unique to the basal state 
in WKY BMDMs. Enrichment for biological process functional annotation terms used a 
threshold of <5% FDR and fold enrichment >1.5.   
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Table 5.13 Gene ontology analysis of the Jund-bound genes common between basal 
and LPS-stimulated WKY BMDMs 
 
This table details the significantly enriched biological process functional annotation terms 
and KEGG pathway terms from DAVID for the common JunD-bound genes between basal 
and LPS-stimulated WKY BMDMs. Enrichment for biological process functional annotation 
terms used a threshold of <5% FDR and fold enrichment >1.5. The top 20 enriched functional 
annotation terms are listed in this table. The full list of enriched terms is detailed in 
Appendix C, Table C.3. 
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Table 5.14 Gene ontology analysis of the Jund-bound genes unique to LPS-
stimulated WKY BMDMs compared to basal WKY BMDMs 
 
This table details the significantly enriched biological process functional annotation terms 
and KEGG pathway terms from DAVID for the JunD-bound genes unique to LPS-stimulated 
WKY BMDMs compared to basal WKY BMDMs. Enrichment for biological process 
functional annotation terms used a threshold of <5% FDR and fold enrichment >1.5. The top 
20 enriched functional annotation terms are listed in this table. The full list of enriched terms 
is detailed in Appendix C, Table C.4.  
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The JunD-bound genes that were unique to the WKY BMDM ChIP-Seq datasets were further 
filtered to exclude any JunD-bound genes identified in WKY.LCrgn2 BMDMs in either the 
basal or LPS stimulated state. There were 1,711 genes unique to the WKY basal state and not 
present in WKY.LCrgn2 BMDMs whilst there were 2,516 unique to WKY that were JunD-
bound regardless of stimulation. There were 3,879 JunD-bound genes that were uniquely 
induced in WKY BMDMs after two hours of LPS stimulation. Functionally the 1,711 genes 
unique to WKY basal BMDMs were still associated with the same terms as before (Table 
5.12) suggesting that functionally these genes may not play a major role in macrophage 
function. The 2,516 core JunD-core genes that are bound regardless of stimulation, in 
comparison still enriched for multiple developmental pathways as before as well as cell-cell 
signalling (Appendix C, Table C.5). KEGG pathway analysis did not find the strong 
enrichment for immune and autoimmune pathways that had been observed previously (Table 
5.13) confirming that these genes are common to WKY and WKY.LCrgn2 BMDMs and 
represent core functions of JunD in these rat BMDMs. The 3,879 unique inducible JunD-
bound genes were still associated with terms such as response to wounding and regulation of 
the response to external stimulus and the MAPK signalling pathway (Appendix C, Table 
C.6). This demonstrates that the function of JunD in WKY BMDMs, due to its increased 
expression in comparison to WKY.LCrgn2 BMDMs, is to alter the way the BMDMs respond 
to stimulation. 
 
Within the set of 830 effector genes with differential timecourse gene expression patterns 
between WKY and WKY.LCrgn2 BMDMs, caused by the introgression of LEW Crgn2 onto 
the WKY background, JunD-bound genes could indicate direct targets influenced by JunD. 
There were 64 unique JunD-bound genes present in WKY BMDMs regardless of stimulation 
state that were within the set of 830 genes identified as having differential time courses of 
expression between WKY and WKY.LCrgn2 BMDMs (Table 5.15). These core genes were 
functionally linked with cell projection organisation, neuron development and the regulation 
of cell motion (Table 5.16). Genes that were also differentially expressed between WKY and 
LEW Crgn2 are likely to have more direct relevance for the NTN model. Of the 64 genes 
identified, 48 genes also showed differential expression between WKY and LEW BMDMs. 
These were associated functionally with a similar set of processes (Table 5.16). Such terms 
may allow for BMDMs from the WKY strain to infiltrate glomeruli or interact with the 
inflammatory milieu in a different manner to WKY.LCrgn2 BMDMs but also the lack of  
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Table 5.15 Unique core JunD bound genes that are differentially expressed genes 
over the LPS timecourse between WKY and WKY.LCrgn2 BMDMs  
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Table 5.15 continued 
  
This table details the unique core JunD-bound genes that are differentially expressed in 
timecourse analyses between WKY and WKY.LCrgn2 BMDMs. 
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Table 5.16 Gene ontology analysis of unique core JunD bound genes that are also 
differentially expressed genes over the LPS timecourse between WKY and 
WKY.LCrgn2 BMDMs 
 
 
This table details the significantly enriched biological process functional annotation terms 
from DAVID for the unique core JunD-bound genes that are differentially expressed in 
timecourse analyses between WKY and WKY.LCrgn2 BMDMs. Enrichment for biological 
process functional annotation terms used a threshold of <5% FDR and fold enrichment >1.5.  
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functional annotation means that the ultimate functions of these genes in WKY BMDMs 
uncertain. 
 
There were 112 unique LPS-inducible JunD-bound genes within the set of 830 genes 
identified as having differential time courses of expression between WKY and WKY.LCrgn2 
BMDMs (Table 5.17). Functionally these were associated with response to molecules of 
bacterial origin, organic substances and the response to LPS along with a number of 
metabolic process linked terms including generation of precursor metabolites and energy and 
carbohydrate catabolic process suggesting that JunD-bound genes in this context could alter 
how the cell responds to stimulation and influences the homeostatic cell processes that enable 
the macrophage to maintain this response (Table 5.18). Genes that were also differentially 
expressed between WKY and LEW Crgn2 are likely to have more direct relevance for the 
NTN model. Of the 112 genes identified above, 76 also showed differential expression over 
the LPS timecourse in a comparison between WKY and LEW BMDMs (Table 5.18). These 
genes were all associated with responses to stimulation particularly centred on the response to 
LPS, consistent with the mode of stimulation used in the experiments. The results 
demonstrate that JunD interacts with genes that determine how BMDMs are able to respond 
to LPS. 
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Table 5.17 Unique LPS-inducible JunD bound genes that are differentially expressed 
genes over the LPS timecourse between WKY and WKY.LCrgn2 BMDMs 
 
334 
 
Table 5.17 continued 
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Table 5.17 continued 
 
This table details the unique LPS-inducible JunD-bound genes that are differentially 
expressed in timecourse analyses between WKY and WKY.LCrgn2 BMDMs. 
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Table 5.18  Gene ontology analysis of unique LPS-inducible JunD bound genes that 
are also differentially expressed genes over the LPS timecourse between WKY and 
WKY.LCrgn2 BMDMs  
 
This table details the significantly enriched biological process functional annotation terms 
from DAVID for the unique LPS-inducible JunD-bound genes that are differentially 
expressed in timecourse analyses between WKY and WKY.LCrgn2 BMDMs. Enrichment for 
biological process functional annotation terms used a threshold of <5% FDR and fold 
enrichment >1.5.  
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The siRNA knockdown of Jund confirmed that Jund directly alters the expression of genes 
involved in how the macrophage responds to stimulation (Table 4.22-4.24). There were 187 
unique core JunD-bound peaks that were directly influenced by siRNA knockdown of Jund 
in either unstimulated or LPS-stimulated WKY BMDMs. These were functionally associated 
with two developmental processes, namely midgut development and regulation of organelle 
organisation along with cell activation (Table 5.19). There were 343 unique LPS-inducible 
JunD-bound genes that were directly influenced by siRNA knockdown of Jund. Functionally 
these were linked with the responses to organic substance, the intracellular signalling cascade 
and cell activation along with the MAPK signalling pathway (Table 5.20). 
 
Combining these sets of genes identified 12 genes that were unique core JunD-bound genes 
and were differentially expressed between WKY and WKY.LCrgn2 BMDMs and were 
directly influenced by siRNA knockdown of Jund in either the unstimulated or LPS 
stimulated states (Table 5.21). There were 36 genes that were unique inducible JunD-bound 
genes that also fitted these criteria (Table 5.22). Within this set of genes are some of the 
likely main candidates for how Jund is able to mediate the differences seen in macrophage 
activation between the WKY and WKY.LCrgn2 BMDMs. Of note Jund itself is identified 
within this list as it has an associated LPS-inducible JunD peak demonstrating that a feedback 
loop could enhance its expression level within WKY BMDMs.  
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Table 5.19 Gene ontology analysis of unique core JunD bound genes that are also 
differentially expressed following siRNA knockdown of Jund in unstimulated and LPS 
stimulated WKY BMDMs  
 
 
 
This table details the significantly enriched biological process functional annotation terms 
and KEGG pathway terms from DAVID for the JunD-bound genes unique to LPS-stimulated 
WKY BMDMs compared to basal WKY BMDMs. Enrichment for biological process 
functional annotation terms used a threshold of <5% FDR and fold enrichment >1.5.   
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Table 5.20 Gene ontology analysis of unique LPS-inducible JunD bound genes that 
are also differentially expressed following siRNA knockdown of Jund in unstimulated 
and LPS stimulated WKY BMDMs 
 
This table details the significantly enriched biological process functional annotation terms 
and KEGG pathway terms from DAVID for the JunD-bound genes unique to LPS-stimulated 
WKY BMDMs compared to basal WKY BMDMs. Enrichment for biological process 
functional annotation terms used a threshold of <5% FDR and fold enrichment >1.5.   
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Table 5.21 Differentially expressed genes between WKY and WKY.LCrgn2 BMDMs 
under the direct influence of JunD 
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Table 5.22 Differentially expressed genes between WKY and WKY.LCrgn2 BMDMs 
under the direct influence of JunD 
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5.2.7      Validation of ChIP enriched peaks 
JunD-associated peaks in both the WKY and WKY.LCrgn2 datasets were selected for 
validation from the sets of JunD-bound genes that overlapped with genes under the influence 
of Crgn2 and following siRNA knockdown of Jund in the transcriptome analyses, along with 
a number of randomly selected peaks. The validations were performed in three separate 
biological replicates from each of which two separate cultures of BMDMs were pooled. The 
results were expressed as fold change over IgG of the individual percentage input values from 
each replicate. The percentage input is a measure of the overall binding of the transcription 
factor at a locus compared to the input chromatin sample which represents the theoretical 
maximum (100%) of all the potential enriched binding sites for that locus. Paired one-tailed t-
tests were performed to compare each pair of input values for each gene from the three 
biological replicates and the significance is demonstrated above each bar (Figure 5.9, 5.11, 
5.12). 
 
The validation of peaks in the WKY strain was performed for six peaks in the basal state 
(Figure 5.9). All the assays showed at least two-fold enrichment for JunD over the 
background IgG and five out of the six demonstrated significant differences between the 
JunD percentage input results and the IgG percentage input results, analysed using a paired 
one-tailed t-test. Twelve JunD peaks were validated in WKY LPS stimulated BMDMs. All 
the peaks showed enrichment of at least two-fold over background. In three of the peaks, 
however, this was not found to be significant using a paired one-tailed t-test when the three 
biological replicates were analysed together. The reduced level of JunD expression in the 
WKY.LCrgn2 was reflected in the lower levels of enrichment in the validation results. Six 
peaks did demonstrate enrichment above background levels though only one reached 
significance when the percentage inputs were analysed together using a paired one-tailed t-
test.  
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Figure 5.9 ChIP-Seq validation in basal WKY BMDMs 
Six ChIP-Seq peaks identified by BayesPeak at a posterior probability threshold of 0.9 (A) 
were validated by qPCR. Grey highlights indicate identified JunD-peaks. The aligned reads 
comprising a peak for each JunD-bound gene are shown with genome browser views. Results 
expressed as mean fold change over IgG from biological triplicates, each amplified in 
triplicate. **P<0.01, *P<0.05, ns; non-significant using a paired t-test (one-tailed) to compare 
whether % input for the JunD ChIP qPCR was significantly different to % input for IgG.  
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Figure 5.10 ChIP-Seq peaks validated in LPS-stimulated WKY BMDMs 
Ten additional ChIP-Seq peaks identified by BayesPeak at a posterior probability threshold of 
0.9 were validated by qPCR as detailed in Figure 5.11. The aligned reads comprising a peak 
for each JunD-bound gene are shown with genome browser views. Grey highlights indicate 
significant JunD-peaks identified using BayesPeak. 
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Figure 5.11 ChIP-Seq validation in LPS-stimulated WKY BMDMs 
ChIP-Seq peaks identified by BayesPeak at a posterior probability threshold of 0.9 were 
validated by qPCR. The genome browser views of the peaks are illustrated in Figure 5.10 
and 5.11. Results expressed as mean fold change over IgG from biological triplicates, each 
amplified in triplicate. The solid red line indicates threshold over which enrichment above 
background has occurred. **P<0.01, *P<0.05, ns; non-significant using a paired t-test (one-
tailed) to compare % input for the JunD ChIP qPCR against % input for IgG for the gene 
tested. 
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Figure 5.12 ChIP-Seq validation in basal and LPS stimulated WKY.LCrgn2 
BMDMs 
Seven ChIP-Seq peaks identified by BayesPeak at a posterior probability threshold of 0.9 (A) 
were validated by qPCR. The aligned reads comprising a peak for each JunD-bound gene are 
shown with a genome browser view. The genome browser images for Ctss, Prodh2 and 
Snapc2 are contained within Figures 5.9 and 5.10. Results expressed as mean fold change 
over IgG from biological triplicates, each amplified in triplicate. The solid red line indicates 
threshold over which enrichment above background has occurred. **P<0.01, *P<0.05, ns; 
non-significant using a paired t-test (one-tailed) to compare whether % input for the JunD 
ChIP qPCR was significantly different to % input for IgG.  
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5.2.8      Motif analysis 
Motif analysis was performed to test whether enrichment within the binding peaks for an AP-
1 transcription factor consensus motif had occurred. Two approaches were used; de novo 
motif identification and scanning peak sequences for instances of known AP-1 motifs. 
Multiple binding motifs have been observed for the AP-1 binding motif which are all 
variations of the classical binding site palindrome for AP-1 which is the seven base pair 5’-
TGA[G/C]TCA-3’ TPA response element (TRE) sequence (Angel et al., 1987; Lee et al., 
1987) and the lower affinity eight base pair 5’-TGAGCTCA-3’ cAMP responsive element 
(CRE) (Nakabeppu et al., 1988; Rauscher et al., 1988). The different motifs demonstrate 
different levels of conservation for the different nucleotides making up these seven or eight 
base pair palindromes. This means that scanning for known motifs has relatively low power 
as multiple annotated variations of the same motif may be called as enriched rather than if 
one unifying motif for AP-1 transcription factor existed. 
 
De novo motif analysis was performed on all the peak sets using Homer (Barish et al., 2010; 
Heinz et al., 2010). De novo motifs were classed as enriched according to criteria defined by 
the algorithm authors namely that the motif frequency should be greater than 5% in the 
dataset and a P-value <1.0E-50 should be the criteria for significance. Identified motifs were 
also inspected to check for their alignment to the known motifs identified by the algorithm 
and were scanned using TOMTOM (Gupta et al., 2007) on its default settings, to confirm 
their assignment to a known transcription factor and therefore increase confidence about the 
accuracy of the matches to identified motifs. 
 
Motif analysis in WKY LPS stimulated BMDMs identified a number of enriched motifs. A 
12 base pair motif that was present in 63% of all the peaks (Figure 5.13) was found that 
showed strong similarities to the consensus AP1 motif with strong conservation of the 
‘TGAG’ part at the start of the canonical sequence. Homer analysis associated the motif with 
the V$AP1_01 Transfac motif whilst TOMTOM analysis associated it most strongly with the 
V$AP1_Q4 motif. In addition, there were also similarities with multiple other AP-1 motifs 
(Figure 5.13). Of note the commonality of such a simple sequence also means that scanning 
for known motifs produces multiple hits for all the known motifs in control sets lowering the 
significance of any motif matching in the sample set studied (Table 5.18). Despite this, 
scanning for known motifs using Homer found that around 50% of all the peaks contained the  
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Figure 5.13 Identification of AP-1 transcription factor motif in JunD-bound 
peaks in WKY LPS-stimulated BMDMs 
De novo motif analysis identified a 12 base pair motif present in 63% peaks (A). Matching of 
the motif with known motifs matched the de novo motif (bottom motif displayed) with the 
consensus AP-1 motif from Transfac database (top motif displayed).  A match with AP-1 
motifs was confirmed using TOMTOM (A) and listed in the table (B). 
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Table 5.23 Enrichment of known AP-1 motifs in JunD-bound peaks in basal and LPS 
stimulated ChIP-Seq data sets from WKY and WKY.LCrgn2 BMDMs 
 
Enrichment for known AP-1 motifs was confirmed in each of the strain and condition data 
sets. Motifs are listed in the order of significant matching to the de novo motif detailed in 
Figure 5.13.  
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V$AP1_Q4 motif with significant enrichment seen in both WKY data sets. Multiple other 
instances of the motif were also present in a high percentage of peaks. Significant enrichment 
was also seen for other AP-1 motifs in WKY.LCrgn2 datasets. 
 
The large size of the WKY LPS stimulated dataset allowed for a number of other de novo 
motifs to be identified. A ten base pair motif present in 68.9% peaks was identified at very 
high significance that was associated with the consensus motif for Ascl2 (Figure 5.14A) and 
this was confirmed in TOMTOM analysis. There was also enrichment noted for a de novo 
motif matching CACCC-binding factor (Figure 5.14B) present in 65.6% peaks, for an Eomes 
matching motif in 27.1% of peaks (Figure 5.14C) and an Ets like motif occurred in 17.3% 
peaks (Figure 5.14D). De novo motif analysis in the WKY basal peak dataset identified 
strong enrichment for a 12 base pair motif present in 87.6% peaks that showed similarities to 
the CAC binding protein motif in Homer analysis and TOMTOM analysis (Figure 5.15A). 
The de novo analysis also identified a ten base pair motif present in 69.1% of peaks that 
associated with a REST-NRSF ChIP-Seq motif (JunD-bound peaks in WKY LPS-stimulated 
BMDMs (Figure 5.15B) 
 
 
 
 
 
 
 
 
 
 
 
 
  
351 
 
 
Figure 5.14 Motif analysis results for de novo motifs in JunD-bound peaks in 
WKY LPS-stimulated BMDMs  
De novo motif analysis using HOMER (Barish et al., 2010; Heinz et al., 2010) identified four 
de novo motifs that matched the known transcription factor consensus binding motifs for 
Ascl2 (A), CACCC-binding factor (B), Eomes (C) and Ets (D). The match to a known 
consensus binding motif was confirmed using TOMTOM (Gupta et al., 2007). The de novo 
motif identified is displayed on the bottom of each the pair of motifs, the matched consensus 
motif for a transcription factor on the top.   
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Figure 5.15 Motif analysis results for de novo motifs in WKY basal BMDM 
JunD 
De novo motif analysis using HOMER (Barish et al., 2010; Heinz et al., 2010) identified two 
de novo motifs that matched the known transcription factor consensus binding motifs for 
CACCC-binding factor (A) and Rest-NRSF (B). The match to a known consensus binding 
motif was confirmed using TOMTOM (Gupta et al., 2007). The de novo motif identified is 
displayed on the bottom of each the pair of motifs, the matched consensus motif for a 
transcription factor on the top. 
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5.3 Discussion 
The analysis of the JunD cistrome in WKY and WKY.LCrgn2 BMDMs aimed to identify the 
key elements within the genome that JunD interacted with in each strain and to understand 
how the marked differences in the expression of the JunD altered gene expression in the LPS 
response in WKY and WKY.LCrgn2 BMDMs. This investigation of the cistrome was carried 
out using ChIP-Seq. The first ChIP-Seq studies were published in 2007 and focused on the 
basic application of the sequencing and analysis techniques. Johnson et al. led the way 
publishing the first major report on ChIP-Seq for a transcription factor focusing on the 
binding pattern of the neuron-restrictive silencer factor, NRSF or REST (repressor element-1 
silencing transcription factor) in a Jurkat T cell line (Johnson et al., 2007) whilst Barski et al. 
did the same for the study of histone methylation, mapping twenty histone lysine and arginine 
methylations throughout the genome in primary human CD4
+ 
cells along with the profile for 
transcription factor CTCF (Barski et al., 2007). Soon after,  Robertson et al. investigated the 
targets of STAT1 in human HeLa S3 cells stimulated with interferon gamma (Robertson et 
al., 2007). The ENCODE project, in addition, quickly took advantage of the technology in 
cell lines giving key insights into transcription factor function in general (Birney et al., 2007).  
 
The rapid application of these advanced sequencing techniques quickly gave new ideas about 
how genes are transcriptionally activated (Farnham, 2009). Whilst the overriding principles 
still hold true that it is the promoters and enhancer regions of the genome, the cis-regulatory 
elements, in conjunction with the proteins that bind them that control the different levels of 
transcription of genes, the overall binding pattern of transcription factors in the genome was 
found to be much more complex. Transcription factors that bind exclusively to the proximal 
promoter of a gene were concluded to be the exception not the rule, with many factors 
binding to diverse regions of the genome (Birney et al., 2007; Sandelin et al., 2007; Farnham, 
2009). The sheer number of site specific transcription factors that function in the genome, 
around 1,391 at least in humans, adds greatly to the complexity of transcriptional regulation 
(Vaquerizas et al., 2009). It is clear however that understanding the roles of transcription 
factors in specific tissues and cells is critical not least because of the association of 
transcription factors with causing diseases such as cancer and developmental syndromes. In 
one survey, 164 factors were shown to be directly responsible for 277 diseases or syndromes 
in Mendelian-inherited monogenic diseases and the mis-regulation of other factors was also 
found to have important implications for more complex or multigenic diseases (Vaquerizas et 
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al., 2009). In such a context, the value of a disease model such as the rat where misregulation 
of at least one identified transcription factor associates with disease susceptibility and also 
alters the phenotype of a key disease effector cell is clear (Behmoaras et al., 2008).  
 
5.3.1      Peak calling in ChIP-Seq 
Peak calling is a key part of the ChIP-Seq data analysis pathway and its methodology was 
quickly the subject of reviews particularly as the computational analysis was the most 
substantial early challenge for the approach (Park, 2009; Pepke et al., 2009).  In essence, they 
all share the same simple principles of identifying the regions of binding in the genome 
which are marked by the aggregation of sequencing reads. This allows for binding events to 
be called on the basis of quality and signal criteria and to be statistically analysed and graded. 
A key challenge and factor in the analysis is that as ChIP is an enrichment process, the 
majority of DNA fragments in a ChIP reaction (and therefore the reads sequenced) are 
background whilst the minority, although enriched, are fragments to which the transcription 
factor has bound (Pepke et al., 2009). The approach used in this analysis performed by Dr 
Prashant Srivastava, PGM Group, was implemented in the Bayesian analysis programme 
BayesPeak (Spyrou et al., 2009; Cairns et al., 2011).  This algorithm uses a fully Bayesian 
hidden Markov model to detect enriched locations in the gnome as well as allowing for 
control samples to be incorporated into the analyses. The authors proposed that its advantage 
was its essential Bayesian approach and within that the algorithm produced posterior 
probabilities as the measure of how certain a peak was. Regions were called enriched when 
they looked more like a peak than background (Spyrou et al., 2009). In addition the 
programme was previously shown to perform well in comparison to a number of commonly 
used algorithms  (Spyrou et al., 2009) including the commonly used algorithm MACS which 
uses the Poisson distribution to identify the peak regions (Zhang et al., 2008). 
 
5.3.2      The use of ChIP-Seq in the study of macrophage function 
Whilst the epigenome of CD4
+
 T cells has been the most well characterised thus far in the 
immune system (Northrup and Zhao, 2011), a number of publications have centred on the 
study of transcription factors within LPS stimulated primary macrophages looking both at 
key factors that determine the macrophage lineage and enhancer activity as well as 
modulators of the immune response. The evidence produced by these studies on macrophage 
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function has shown how a context dependent response within a cell type is due to the 
existence of cell type specific cistromes that are the direct result of interactions between sets 
of lineage determining factors causing alterations in the overall chromatin landscape. 
(Ghisletti et al., 2010; Heinz et al., 2010; Natoli et al., 2011).  
 
Enhancer regions are critical to the LPS response in macrophages and studies have found that 
there are between 35,000 and 45,000 regions in the genome that can be classified as 
enhancers on the basis of a combination of histone marks, p300 binding sites and conserved 
TF binding sites (Natoli et al., 2011). Ghisletti et al. deciphered the organisational principles 
of enhancers that control the LPS induced gene expression response in mouse primary 
macrophages (Ghisletti et al., 2010). They detailed the LPS inducible binding pattern of p300 
and used it to identify enhancers associated with inducible genes. At these enhancers there 
was a common regulatory system that consisted of combined binding sites for cell type 
specific constitutive transcription factors in particular the Ets protein PU.1 as well as MAFB 
and RUNX1 along with binding sites for more ubiquitous and stimulus activated factors such 
as NF-κB, IRF and AP-1. This regulatory system that was created allowed for the response 
induced by inflammatory stimuli to be adapted to the specific cellular context in which it was 
being elicited. This could therefore explain how, and why, the responses to a given stimulus, 
for example LPS, would differ between T cells and macrophages. Central to this activity of 
enhancers was the Ets protein PU.1. It was the key factor essential for maintaining Histone 
H3 mono-methyl K4 (H3K4me1) at enhancers suggesting that it was required to make 
genomic regions behave as enhancers and could even contribute to, and shape, the three-
dimensional landscape of the macrophage genome acting as a global genome organiser. 
Indeed in macrophages, AP-1 and C/EBP motifs were found to be highly enriched in PU.1 
peaks in comparison to  B cells where there was enrichment for E2A, EBF, Oct and NFκB 
motifs (Heinz et al., 2010). The linking of AP-1 with the functions of PU.1 in creating 
functionally active enhancers capable of contributing to cell type specific and/or signal 
dependent gene expression in these studies (Ghisletti et al., 2010; Heinz et al., 2010) is 
exciting in the context of WKY BMDMs where the over expression of JunD could plausibly 
significantly alter the nature of these interactions compared to WKY.LCrgn2 BMDMs and 
LEW BMDMS with their lower level of JunD expression. This could potentially give a 
mechanistic insight into how the altered level of JunD drives macrophage activation.  
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The roles of transcription factors that have more of a regulatory or modulatory effect on the 
innate immune response have also been studied in macrophages. Barish et al. found that the 
Bcl-6 and NF-κB cistromes mediate opposing regulation of the innate immune response 
(Barish et al., 2010). Bcl-6 is a transcriptional repressor and was found to prevent the 
exaggerated activation of LPS inducible genes. Bcl-6
-/-
 mice showed a broad hypersensitive 
response to LPS which was exaggerated compared to the response in normal Bcl6
+/+
 mice. 
ChIP-Seq for Bcl-6 revealed that the majority of its binding sites were not at gene promoters 
but in distant intragenic and intronic sites (Barish et al., 2010). Motif analysis of these peaks 
identified PU.1 and NF-κB binding sites which suggested to the authors that the functional 
effects of these differences in Bcl-6 expression were occurring at PU.1 bound enhancers and 
that Bcl-6 functioned to actively repress proximal PU.1 marked enhancers. Their further 
functional analysis found that Bcl-6 restricted the activating factor NF-κB by limiting basal 
and TLR-inducible histone acetylation (Barish et al., 2010). This work found one of the key 
factors that limits the LPS response in macrophages with the knockout for Bcl-6 showing 
how critical the combinations and expression levels of factors present in a cell are for 
maintaining and controlling normal immune responses. 
 
Not all factors, however, have such a major effect on the innate immune response. The JmjC 
family histone demethylase, Jmjd3, in contrast, was found to be preferentially recruited to 
70% of LPS inducible genes but its deletion left most of its target genes unaffected (De Santa 
et al., 2009). A few hundred genes were altered in that they had moderately impaired RNA 
polymerase II recruitment and transcription showing it did have some effect but certainly not 
at the scale seen with Bcl-6. The factor was thought therefore to fine tune the transcriptional 
response of LPS stimulated macrophages (De Santa et al., 2009). Such findings highlight 
some important aspects of the regulation of the transcriptional response that ChIP-Seq has 
found. In this article investigating Jmjd3 function, the lack of effect in Jmjd3
-/-
 macrophages 
on known Jmjd3 targets suggested to the authors that functional redundancy proceeded by 
other coregulators may prevent the occurrence of transcriptional defects. Alternatively, in the 
explanation favoured by the authors, the small magnitude of transcriptional changes coupled 
with the stability of mature mRNA may have masked the changes occurring as the result of 
the deletion (De Santa et al., 2009). One answer to why the biological impact of such a 
regulator was so small was that its impact reflected the combination of a large amount of 
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simultaneous small changes i.e. a fine tuning role rather than a limited number of effects of 
high intensity such as those seen with sequence specific factors (De Santa et al., 2009). 
 
Such functional redundancy in binding sites leading to the poor coordination of transcription 
factor binding and transcriptional output is well recognised and the overlap of genes that are 
bound and differentially regulated by a factor can be in the order of only 1% to 10% or 20% 
(Farnham, 2009; Northrup and Zhao, 2011). A number of potential explanations have been 
proposed including that not all binding events are functional (Farnham, 2009). Such a 
simplistic view does not fully account for the differences, however, and it is clear that the 
assignment of binding sites to target genes, whilst the best approach that can be currently 
employed, does not capture the full complexity or relationships of binding sites and their 
regulation of target genes. Indeed long range regulation of genes by a binding site is not 
considered by such an approach.  
 
The concept of functional redundancy is very important and it means simply that closely 
related factors can bind to the same sites and have the same function. Eliminating one 
member could allow for a higher level of binding of another, in effect replacing the other 
factor in functional terms (Farnham, 2009). Compensation for a factor in knockout models 
during development could also result in related proteins being able to regulate the target 
genes. Functional redundancy within clusters might also be a major factor to consider as it 
may be incorrect to assume a factor acts at a binding site solely as an individual. It is more 
likely to bind with other factors  thus loss of one factor may not affect transcription whereas 
the loss of many could have a large effect (Farnham, 2009). Binding events may also have 
other functions within the genome particularly those in intergenic regions such as controlling 
alternative promoter usage or splicing. Binding events may also influence the transcription of 
microRNAs, other non-coding RNA species and unannotated genes (Northrup and Zhao, 
2011).  
 
5.3.3      The JunD cistrome in WKY and WKY.LCrgn2 BMDMs 
The data presented in this chapter demonstrates how the difference in JunD expression 
between the WKY and WKY.LCrgn2 strains alters the JunD cistrome. In WKY BMDMs, 
27,124 peaks in the basal condition and 36,687 peaks after LPS stimulation were identified 
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compared to the 16,593 basal and 8,689 peaks following LPS stimulation identified 
respectively in the WKY.LCrgn2 groups. This shows that the major effect of altering JunD 
expression is to significantly alter its binding profile in the genome. The numbers of peaks 
after LPS stimulation increased which may reflect the small increase in mRNA level of the 
factor seen after LPS stimulation or that the binding ability of JunD increases after LPS 
stimulation which could be linked to a change in chromatin structure that had occurred 
allowing better access to binding sites. It is interesting to note the marked reduction in peaks 
after LPS stimulation in WKY.LCrgn2 BMDMs may reflect a more closed or unfavourable 
chromatin environment fitting in with the reduced numbers of transcripts that change 
compared to WKY BMDMs. 
 
The overall distribution of the peaks with reference to genomic features was very similar 
between the strains and conditions though there was an increase in intronic peaks seen in 
WKY BMDMs (Figure 5.3) demonstrating that the overall pattern of JunD binding is not 
altered, just the overall numbers of peaks, by the change in factor expression between the 
WKY and WKY.LCrgn2 strains. The overall genomic distribution shared similarities but also 
differences with other data sets. Ghisletti et al. identified that for p300, 14% of peaks were 
located in a 5 kilobase area around the TSS, 3% were located in exons and 27% in introns. 
The distribution within the gene body is similar to that identified in this data set (Figure 5.4). 
Whilst similar overall, they did find a higher frequency of peaks in the upstream 20 kilobase 
region from the TSS (Ghisletti et al., 2010). The genomic distribution of PU.1 that was 
identified in the study by Ghisletti et al. was very different and whilst 4% of peaks were in 
exons, 39% were intronic and 20% were within 2.5 kilobases of the TSS.  Barish et al. found 
that for the p65 cistrome (NF-κB) , 5% of peaks were located in exons and 39% were in gene 
introns with only 10% in promoters though a definition for the promoter region was not made 
(Barish et al., 2010).  De Santa et al. found that Jmjd3 was preferentially located close to the 
TSS with 54% of peaks located within 500 base pairs of the TSS (De Santa et al., 2009). The 
35% of intergenic peaks in LPS-stimulated WKY BMDMs, rising to 44% of peaks in basal 
WKY.LCrgn2 BMDMs is comparable to other data sets which found between 37% for PU.1 
and 56% of p300 peaks lying in intergenic regions in the study by Ghisletti et al. (Ghisletti et 
al., 2010) to 48% of p65 NF-κB and 56% of Bcl-6 peaks lying in those regions in the study 
by Barish et al. (Barish et al., 2010). Of note, both studies were on LPS stimulated mouse 
macrophages. Whilst the overall pattern of distribution does vary depending on the factor 
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studied, the proportions do show how intergenic binding forms an important proportion of the 
overall binding of a transcription factor and that promoter binding is still critically important 
for the function of a transcription factor.  
 
A number of different approaches have been used to associate peaks with genes, depending 
on the context studied, but all include an element of arbitrary selection and are sometimes not 
explicit in the definition used of a promoter, leading to the variation in the locations of peaks 
as shown above. Unfortunately no standard definitions or criteria have been published and are 
currently in use. In this analysis a region 20 kilobases upstream of the TSS was used along 
with the entire gene body to define a peak associated gene. This aimed to encompass binding 
events in nearby enhancer and promoter regions similar to the enhancer based approach of 
Ghisletti et al. who used the 20 kilobase region around the TSS apart excluding 5 kilobases 
around the TSS as the focus was not on proximal promoter function (Ghisletti et al., 2010). 
JunD could be active at either type of region hence the whole region was included in our 
analysis. Wei et al. associated peaks with genes if they lay within 10 kilobases upstream of 
the promoter or were situated within the gene body up to the transcriptional end site (Wei et 
al., 2010) whilst De Santa et al. associated all peaks that were located within 100 kilobases of 
a TSS (De Santa et al., 2009).  
 
The JunD cistrome data sets do show that peak frequency increases as the distance towards 
the TSS decreases with particular rises in number seen from 20 kilobases upstream with a 
sharp rise within 5 kilobases fitting with the findings of others (Figure 5.5).  Ghisletti et al. 
found that whilst 44% of peaks lay between 20 and 100 kilobases upstream of the TSS, 29% 
were located within 2.5 to 20 kilobases upstream (Ghisletti et al., 2010). In this data set 
20.5% of peaks lay within 20 kilobases upstream of the TSS in WKY basal BMDMs, 29.0% 
in LPS-stimulated WKY BMDMs whilst 22.1% of peaks in basal and 24.9% in LPS-
stimulated WKY.LCrgn2BMDMs were within this distance. 
 
The association of peaks with the nearest gene using the criteria specified above identified 
that 5,339 unique transcripts were associated with a peak in WKY basal BMDMs and 7,612 
transcripts in WKY LPS stimulated BMDMs. In contrast there were considerably fewer 
genes in WKY.LCrgn2 BMDMs that were linked, with 2,606 linked transcripts in the basal 
state and 1,022 in the LPS stimulated state. Putting this into context with the transcriptomic 
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data, after two hours of LPS stimulation in WKY BMDMs, 7509 transcripts were 
differentially expressed rising to 11,616 at four hours of LPS stimulation and 9,807 after 
eight hours (Table 4.1). This shows that in comparison to the overall numbers of genes 
responding to LPS, JunD, even in WKY BMDMs, only binds to a proportion of transcripts 
showing that it has specific functions and not a global role as seen for factors such as PU.1 
(Ghisletti et al., 2010). Timecourse analysis between WKY and WKY.LCrgn2 BMDMs 
revealed that 830 genes were differentially expressed with small changes between the two 
strains (Table 4.8) which, in comparison to the number of peaks that differ, is much less and 
suggests clearly that functional redundancy could well be occurring within the BMDMs from 
different strains. There was still a difference seen in these effector genes suggesting that JunD 
does influence gene expression however, it is focused specifically on distinct pathways and 
processes rather than having an overall modulatory effect as seen for Bcl-6 in the LPS 
response (Barish et al., 2010).  
 
JunD is a constitutively expressed transcription factor and the knockout mouse shows a 
number of key phenotypes. Jund
-/-
 knockout mice are viable unlike the knockouts for the 
other Jun family proteins but they do demonstrate reduced postnatal growth, impaired 
spermatogenesis and hormone imbalances (Thepot et al., 2000). They also demonstrate 
reduced left ventricular weights and functionally respond poorly to pressure overload in the 
heart (Hilfiker-Kleiner et al., 2005). The knockout is also susceptible to accelerated 
nephrotoxic nephritis where the functional consequences of the reduced level of JunD is seen 
primarily in podocytes not macrophages (Cook et al., 2011). This demonstrates how the 
functional role of a transcription factor is both cell-specific and strain or species-specific 
echoing the evidence suggested from the ENCODE project for JunD (Farnham, 2009).  
 
Understanding the basic functions of JunD are highly relevant to the WKY disease model 
because of its potential for use as the genetic background for a Jund
 
 knockout rat, a project 
enabled by the application of zinc finger nuclease technology (Geurts et al., 2009). In the 
basal state, 4,420 unique JunD-bound genes were found in WKY basal BMDMs in 
comparison to only 1,687 unique JunD-bound genes in WKY.LCrgn2 BMDMs. The 919 
genes in common were associated with core macrophage functions such as antigen processing 
and presentation and the immune response (Table 5.6) and autoimmune disease pathways 
(Table 5.7). The higher number of JunD-bound genes in WKY basal BMDMs associated 
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with a number of developmental processes (Table 5.6) and only cell-cell signalling and 
second-messenger-mediated signalling are linked to possible LPS response functions 
 
Regardless of the stimulation or activation state, JunD peaks were associated in WKY 
BMDMs with multiple developmental functions fitting with its role as a constitutive 
transcription factor including ectoderm and epithelium development, cardiac and 
reproductive developmental processes which are highly relevant because of the impaired 
fertility seen in the knockout mouse (Table 5.13). In WKY BMDMs, this suggests that a 
fundamental part of JunD function is not simply in macrophage activation but as a 
determinant, potentially, of more fundamental cellular phenotypes (Table 5.13).  
 
The cistrome evidence presented suggests that the overexpression of JunD in WKY rats 
enables it to bind to an increased number of genes with the potential to influence multiple 
processes. The genes associated with peaks in the WKY and WKY.LCrgn2strains 
demonstrated core functions for JunD in the macrophage with enrichment seen for antigen 
processing and presentation (Table 5.4, 5.5, 5.8 and 5.9). These functions were evident in all 
the KEGG pathway analyses amongst the strains where multiple terms associated with 
immune and autoimmune diseases along with antigen processing and presentation. As might 
be expected, there was a strong overlap between the associated genes within the strains, 
regardless of condition, showing the conservation of JunD binding and highlighting the 
reliability of the dataset. The commonality observed also gave confidence to the validity of 
the experimental approach, as in four separate data sets in macrophages, core JunD functions 
were the same. 
 
The analysis of the JunD cistrome ultimately aimed to understand how the binding pattern of 
JunD in the WKY and WKY.LCrgn2 resulted in the differences seen in the LPS response 
over an eight hour timecourse between WKY and WKY.LCrgn2 BMDMs. The analysis of 
the effect of siRNA knockdown of Jund in WKY BMDMs confirmed that JunD is able to 
alter the expression of genes in BMDMs both in the unstimulated and LPS stimulated state 
(Table 4.20). Whilst multiple genes are present in the Crgn2 congenic interval, the fact that 
Jund, as a major determinant of macrophage activation and the positional candidate within 
the Crgn2 QTL (Behmoaras et al., 2008), is a transcription factor suggests that JunD-bound 
genes could underlie many of the differences in gene expression seen between WKY and 
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WKY.LCrgn2 BMDMs in the stimulation time course. There were 6,976 unique JunD-bound 
genes in LPS stimulated WKY BMDMs compared to only 386 in LPS stimulated BMDMs 
from the WKY.LCrgn2 strain. The JunD-bound genes in the LPS-stimulated WKY BMDMs 
associated with multiple immune processes including the protein kinase cascade, cell 
activation and the regulation of responses to external stimulus and the MAPK signalling 
pathway (Table 5.14). This demonstrates that the increased expression of JunD in WKY 
BMDMs compared to WKY.LCrgn2 BMDMs results in JunD interacting with multiple genes 
that determine how the macrophage responds to the LPS stimulus.  
 
In this ChIP-Seq study, an early timepoint (two hours of LPS stimulation) in the LPS 
response was analysed in order to understand how interactions of JunD with the genome at 
this timepoint could lead on to the differences seen in gene expression after this time. Such a 
view has been used in other studies linking the two hour timepoint with gene expression 
changes at eight hours of LPS stimulation in mouse macrophages stimulated with LPS 
(Ghisletti et al., 2010). It is therefore pertinent that the major transcriptomic differences 
between WKY and WKY.LCrgn2 BMDMs occurred later in the timecourse, mostly at eight 
hours of stimulation (see Chapter 4). Whilst these changes in effector gene expression may 
not be the same as the genes bound by JunD earlier in the timecourse, genes that were bound 
by JunD and were differentially expressed could be some of the main mediators through 
which JunD is able to alter macrophage activation. Of the 830 genes that showed differential 
expression over the timecourse of LPS stimulation between WKY and WKY.LCrgn2 
BMDMs, 64 genes were unique core JunD-bound genes, defined as genes bound regardless 
of stimulation state and 48 genes were also differentially expressed between WKY and KEW 
BMDMs, relevant as the Crgn2 from the NTN-resistant LEW strain is introgressed onto the 
WKY background in the WKY.LCrgn2 congenic strain. Analysis of the unique LPS-
inducible JunD-bound genes found that 112 genes were also differentially expressed between 
WKY and WKY.LCrgn2 BMDMs over the timecourse and 76 were also differentially 
expressed between WKY BMDMs and LEW BMDMs. The core JunD-bound genes 
demonstrated enrichment for cell projection development, neuron development and 
regulation of cell motion (Table 5.16). Whilst not directly associated with macrophage 
function, conceivably these processes could influence the ability of the BMDMs to infiltrate 
the glomerulus. However, the lack of functional annotation in this relatively large gene set 
suggests that the genes as a group have unknown functions and further study could identify 
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novel macrophage activation effector genes. The unique inducible JunD-bound genes in 
comparison showed enrichment for functions linked to the response to molecules of bacterial 
origin, organic substances and LPS (Table 5.18). These results demonstrate that JunD 
interacts with genes that determine how BMDMs are able to respond to LPS following 
stimulation with LPS and these genes are likely to underlie the macrophage activation 
phenotype. 
 
These findings between the WKY and WKY.LCrgn2 strains reflect how the chronic 
difference in JunD expression could alter the LPS response and by inference how the WKY 
BMDMs in the NTN-model could respond differently when infiltrating the inflammatory 
glomeruli. In this chronic setting, redundancy within the AP-1 transcription factor could limit 
the effect the difference in Jund expression had on macrophage behaviour. An acute change 
in Jund expression was examined by siRNA knockdown. Amongst the differentially 
expressed genes between scrambled control and Jund siRNA transfected WKY BMDMs in 
either the unstimulated or LPS stimulated state, 187 had core JunD-peaks. Functionally these 
were associated with midgut development and organelle organisation processes and cell 
activation (Table 5.19). There were 343 genes that were differentially expressed between 
scrambled control and Jund siRNA transfected WKY BMDMs in either the unstimulated or 
LPS stimulated state that had inducible JunD-binding peaks. Confirming the findings 
observed between the WKY and WKY.LCrgn2 BMDMs, these 343 genes were functionally 
associated to the response to organic substance, intracellular signalling cascades and cell 
activation showing that Jund could be a determinant of macrophage activation by altering 
how the BMDMs are able to respond to stimulation (Table 5.20).  
 
Combining these sets of genes identified 12 genes that had a core JunD peak (Table 5.21) 
and  35 genes, apart from Jund itself that had a LPS-inducible JunD-peak (Table 5.22) that, 
in both groups, were differentially expressed between WKY and WKY.LCrgn2 BMDMs and 
were directly influenced by siRNA knockdown of Jund in either the unstimulated or LPS 
stimulated states. Within this set of genes could lie some of the key mediators of how Jund 
functions to determine macrophage activation. Amongst the core JunD-bound genes (Table 
5.21), v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian) (Mafb) is a 
transcription factor expressed in the myeloid lineage of the haemopoeitic system. Mafb is 
essential for the induction of monocyte and macrophage differentiation (Kelly et al., 2000) 
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and interacts with PU.1 to determine whether progenitor cells differentiate into macrophages 
or dendritic cells. High levels of PU.1 inhibit the activity of Mafb, driving the progenitors to 
differentiate into dendritic cells rather than macrophages  (Bakri et al., 2005). Functionally, 
Mafb has been identified as a part of a core macrophage response module in macrophage 
activation linked with TLR stimulation along with the transcription factor AP-1 and 
Egr1(McDermott et al., 2011). Egr1 is differentially expressed between WKY and 
WKY.LCrgn2 BMDMs and is an inducible JunD-bound gene (Table 5.17). In an 
experimental mouse model of cigarette exposure, Mafb was upregulated in alveolar 
macrophages as a consequence of the induced oxidative stress and inhibits apoptosis resulting 
in the enhanced survival of the alveolar macrophages (Machiya et al., 2007). Il20rb is a core 
JunD-bound gene and forms part of the heterodimer that makes up the receptor for the 
cytokine Il20 which is a member of the Il-10 family and is preferentially expressed by 
monocytes (Wolk et al., 2002). It is has been implicated in the pathogenesis of lupus 
nephritis, where its production by macrophages stimulates mesangial cells to produce a 
number of proinflammatory mediators including MCP-1, IL-6, reactive oxygen species and 
iNOS (Li et al., 2008). The set of inducible JunD-bound genes (Table 5.22) also includes 
potential mediators of macrophage activation such as tumour necrosis factor receptor 
superfamily, member 1A (Tnfrsf1a) which is one of the main receptors mediating TNF-α 
signalling and can activate NF-κB as well as mediate apoptosis and regulate inflammation. 
Mutations in the gene cause the autosomal dominant multisystem auto-inflammatory disorder 
tumour necrosis factor receptor (TNFR) associated periodic syndrome (TRAPS) (Stojanov 
and McDermott, 2005). Blockade of TNF-α has been shown previously to reduce 
inflammation and scarring in the NTN model (Khan et al., 2005). A further example is 
mitogen-activated protein kinase kinase 3 (Map2k3) which participates in the MAP kinase-
mediated signalling pathway to activate p38-MAPK and blockade of p38-MAPK has been 
shown previously to reduce Crgn in the NTN model (Sheryanna et al., 2007).  
 
Motif analysis identified a de novo motif matching a consensus AP-1 binding site motif in 
63% of peaks (Figure 5.10) comparable to other data sets where the studied factor was 
identified in 74% of peaks (Barish et al., 2010) and between 55.8% at the highest stringency 
to 96.7% at more relaxed thresholds (Ghisletti et al., 2010). Scanning for known motifs of 
AP-1 within the ChIP-Seq peaks identified a frequent occurrence of the motifs within the 
peaks (Table 5.17). This de novo variant AP-1 motif has been recognised previously and has 
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been shown to be functionally active (Xiao et al., 2007). As part of an in vitro study on how 
cyclin-dependent kinase 4 (CDK4) controls how cells enter and progress through the cell 
cycle, JunD was found to inhibit Cdk4 expression through a critical AP-1 binding site 
consisting of the TGAGACA sequence in its promoter. Deletion of the sequence from the 
promoter prevented repression of transcription after overexpression of JunD, gel shift assays 
and ChIP assays demonstrated JunD binding occurred at the site and when the AP-1 site was 
mutated, repression of the gene was prevented (Xiao et al., 2007).  
 
Binding motifs have been traditionally defined using in vitro studies and bioinformatics 
approaches and scanning the genome with consensus motifs or position weight matrices has 
identified the potential binding region for multiple transcription factors (Farnham, 2009). 
Such studies have shown that there is a high degree of complexity and diversity in how 
transcription factors recognise DNA (Badis et al., 2009). Transcription factors are able to 
recognise distinctly different DNA sequences and the existence of secondary motifs is a 
general phenomenon of transcription factors and can be bound just as well as the primary 
motifs, increasing the overall complexity of transcriptional regulation (Badis et al., 2009). 
Transcription factors can even bind to regions lacking a consensus motif (Rabinovich et al., 
2008) though many studies do show that many transcription factors in general do need to use 
a specific or recognisable motif (Johnson et al., 2007; Robertson et al., 2008; Badis et al., 
2009; Barish et al., 2010; Ghisletti et al., 2010). A number of mechanisms have been 
proposed that explain how a transcription factor can bind to a region in the absence of a 
consensus motif, including binding away from the motif with chromatin looping bringing it 
close to the site, so called ‘piggyback’ binding which is mediated by protein-protein 
interactions with another factor that does not involve the DNA binding domain of the factor 
studied or assisted binding to a sequence with a low match to the classic motif from another 
factor that anchors it on to the genome (Farnham, 2009). Indeed the inherent difficulty overall 
is that the motif finding approaches used assume that transcription factors are recruited to the 
genome in vivo by motifs similar to those identified in vitro, a clear limitation when studying 
a largely unexplored, in genomic terms, primary rat cell type. 
 
De novo motif analysis identified a number of motifs for other transcription factors 
suggesting potential collaborative roles in complexes with AP-1 transcription factor and JunD 
(Figure 5.11-5.12). These were unique to the WKY strain suggesting that the increased levels 
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of JunD expression facilitated new partnerships with other transcription factors that were not 
seen in WKy.LCrgn2 BMDMs. A ten base pair motif found in 68.9% of peaks was associated 
the motif with the Ascl2 transcription factor. Ascl2 is a basic helix-loop-helix transcription 
factor that binds classically to the E-box (5’CANNTG-3’) and has been associated previously 
with developmental processes in the nervous system as well as its overexpressed in colorectal 
cancer linked with a role in promoting cell proliferation (Jubb et al., 2006). The Krüppel-like 
family (KLF) of transcription factors bind to the CACCC-binding domain identified in 
Figure 5.11B which was found in 65% of peaks. The KLF family is made up of seventeen 
proteins in mammals and have been found to regulate multiple biological processed including 
proliferation, differentiation, development, programmed cell death and responses to external 
stress as well as being linked with multiple diseases including cancer and cardiovascular 
disease (McConnell and Yang, 2010). Within the immune system they have been found to 
regulate signalling following activation of macrophages and are associated with 
monocyte/macrophage differentiation (Cao et al., 2010; McConnell and Yang, 2010). KLF4, 
for example, has been found to mediate macrophage signalling in response to inflammatory 
cytokines and along with the p65 subunit of NF-κB induces NOS2 whilst other factors such 
as KLF2 negatively regulate activation implicating an involvement for the factors in 
autoimmunity and acute and chronic inflammatory disease states (Feinberg et al., 2005; Cao 
et al., 2010; McConnell and Yang, 2010). Eomes (Figure 5.11C) is a paralogue of the T cell 
transcription factor T-bet associated with functions in CD8
+
 T cells and NK cells to induce 
cytokine secretion and cytotoxic capabilities (Intlekofer et al., 2005; Kinjyo et al., 2010). Ets 
transcription factors are well known to play key roles in macrophages with prominent 
members of the family such as PU.1 linked with key roles in determining macrophage 
responses in the innate immune response (Ghisletti et al., 2010; Natoli et al., 2011) whilst 
Ets-1, the founding member of the family and the likely best match found for the identified 
motif (Figure 5.11D) controls the expression of cytokine and chemokine genes in a wide 
variety of cells (Russell and Garrett-Sinha, 2010). NRSF/REST type motifs were enriched in 
basal WKY BMDMs  (Figure 5.12A) and NRSF is a repressive factor of a large number of 
terminal neuronal differentiation genes in non-neuronal cells (Majumader, 2006). Other 
functions within the  macrophage in this context are clearly less certain though the occurrence 
of the motif in 69.1% of basal WKY peaks suggests it could have a more fundamental 
developmental role in differentiating macrophages. 
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5.4 Conclusion 
In conclusion, the data presented in this chapter shows how a genetically determined 
difference in the level of the AP-1 transcription factor JunD, previously associated with 
macrophage activation, dramatically alters its genome wide binding pattern, its cistrome. The 
higher expression in WKY BMDMs results in JunD associating with genes that are 
differentially expressed between WKY and WKY.LCrgn2 BMDMs during LPS stimulation 
and are directly altered by acute changes in Jund expression and are also linked with 
functions mediating the response to stimulation. The data presented, therefore, defines the 
cistromic basis and the gene expression differences that result in the over-activation 
phenotype observed in WKY BMDMs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
368 
 
Chapter 6. Histological investigations and genetic studies in 
patients with crescentic glomerulonephritis 
6.1 Introduction 
The aims of the work presented in this chapter were firstly to investigate JUND expression in 
human renal biopsy sections to investigate if the expression pattern of JUND was linked to 
the type or severity of glomerular disease and to use a novel histological technique to 
investigate the pattern of activator protein-1 (AP-1) transcription factor binding and activity 
in glomerular disease. Secondly by using two different approaches, namely Sanger 
sequencing of the JUND locus and a tagging single nucleotide polymorphism (SNP) study, 
the work aimed to investigate whether any genetic polymorphisms at the JUND locus were 
associated with the risk of developing antineutrophil cytoplasmic antibody (ANCA)-
associated vasculitis and crescentic glomerulonephritis (Crgn). 
 
6.1.1      AP-1 transcription factor in human renal inflammatory disease 
Multiple lines of evidence suggest that the AP-1 transcription factor may be an important 
transcription factor as part of immune signalling in inflammatory processes that can affect the 
kidney. AP-1 transcription factor activity can be induced by multiple physiological stimuli 
including pro-inflammatory cytokines (Brenner et al., 1989; Angel and Karin, 1991; Shaulian 
and Karin, 2001) whilst in the immune system, AP-1 transcription factor has been linked with 
roles in directly activating cytokine production, regulating naïve T-cell differentiation, 
controlling T cell cytokine responses and determining the activation status of macrophages 
(Brenner et al., 1989; Wagner and Eferl, 2005; Behmoaras et al., 2008; Zenz et al., 2008). 
AP-1 transcription factor may play an important role in initiating and modulating 
inflammatory processes in autoimmune diseases such as rheumatoid arthritis and psoriasis 
through a number of mechanisms, which raises the potential for it to be a drug target for such 
conditions (Wagner and Eferl, 2005; Zenz et al., 2008) and to have roles in other autoimmune 
and inflammatory conditions. In animal models of renal disease it has been shown to be 
active in nephritic glomeruli of the WKY rat in an NTN model from day 1 after NTS 
injection and was proposed to have a regulatory role in the expression of pro-inflammatory 
factors in nephritic glomeruli (Sakurai et al., 1997; Sakurai and Sugita, 1998).  In addition, 
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AP-1 has been shown to be active in human inflammatory renal disease (Zheng, 2006; Zheng 
et al., 2008).  
 
6.1.2      Histological analysis of renal biopsies 
The renal biopsy is an essential procedure within nephrology for the diagnosis, prognosis and 
treatment of renal disease. The first percutaneous renal biopsy was described in 1951 by 
Iverson and Brun who used intravenous pyelography to map the location of the kidney and a 
needle, to which vacuum suction had been applied, to remove a core of renal tissue (Iversen 
and Brun, 1951).  Even then its value in acute renal failure was noted as the authors believed 
it could inform about the nature and degree of renal injury and help to decide the method of 
treatment.  The clear benefit they saw was to solve the problems connecting the mechanism 
of origin of renal disorders and their pathophysiology. Histological analysis of renal biopsy 
material has become the central diagnostic tool in renal disease with histological 
classifications developed to aid the management of patients with a wide spectrum of renal 
disease, including diseases that are associated with crescentic glomerulonephritis such as 
ANCA-vasculitis (Berden et al., 2010), SLE (Weening et al., 2004) and IgA nephropathy 
(Roberts et al., 2009). 
 
6.1.3      Histological techniques for investigating a role for JUND and AP-1 in renal 
disease 
6.1.3.1 Immunohistochemical techniques 
As well as being the major modality for diagnosis in human renal disease driving patient 
management, the analysis of human renal biopsies from surplus patient diagnostic material is 
able to give important insights into disease pathogenesis. Staining for the presence of 
macrophages is widely performed and the predominant marker CD68, a 110-kD 
transmembrane glycoprotein highly expressed by human monocytes and tissue macrophages, 
has been used since the development of antibodies against it in 1989 to identify macrophages 
in paraffin embedded tissue (Nilsson et al., 2006). Immunohistochemical staining for JUND 
and CD68 in human biopsies was used to see whether the pattern and intensity of staining of 
JUND may correlate with the type and severity of renal disease present and whether it was 
associated with key inflammatory cells such as the macrophage. Standard 
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immunohistochemical methodologies were used in collaboration with the Department of 
Histology as described in 2.16.2.  
 
6.1.3.2 Southwestern histochemistry (SWH) 
As discussed in 6.1.1 and with JUND being one of the JUN protein members of the AP-1 
transcription factor family, understanding the binding pattern following activation of AP-1 
could give insights into the role of the transcription factor family in glomerular disease. 
Consequently, a technique that could investigate the DNA binding pattern of the transcription 
factor in biopsies was identified called Southwestern histochemistry. This method of in situ 
transcription factor detection, first described in 1999 in a rat model of immune complex 
glomerulonephritis, uses non-radioactive probes in paraffin wax embedded tissue to detect 
DNA bound transcription factors (Hernandez-Presa et al., 1999). The probes used are double 
stranded oligonucleotide probes that contain the AP-1 consensus binding motif (5’-
TGAGTCA-3’). In the protocol, a paraformaldehyde fixation is used to fix the proteins in situ 
where they are bound to DNA which is then removed in a DNase digestion. This allows for 
the digoxigenin labelled probes to bind to the AP-1 transcription factor dimer because they 
contain a matching AP-1 transcription factor motif. Detection of the labelled probe allows for 
the localisation of the bound transcription factor to be achieved in the renal section 
(Hernandez-Presa et al., 1999). The protocol has been subsequently used, with minor 
modifications, in six other publications investigating both proteinuric renal disease and 
inflammatory renal disease for AP-1 and NF-κB transcription factors (Mezzano et al., 2001; 
Mezzano et al., 2004; Zheng, 2006; Mezzano et al., 2007; Zheng et al., 2008). Before using 
this technique on the limited resource of human paraffin embedded renal biopsies, the 
optimisation of the protocol was carried out using the NTN rat model of crescentic 
glomerulonephritis. 
 
6.1.4      Genetic studies in patients with crescentic glomerulonephritis 
Genetic studies in human patients with Crgn have been mostly limited to candidate gene 
study approaches. To date, no genome wide association studies (GWAS) have been published 
for the ANCA associated systemic vasculitides or to investigate specifically SLE with renal 
involvement (Hindorff et al., 2011), though candidate genes and loci have been investigated 
in a number of studies in the ANCA vasculitides and, in particular, Wegener’s 
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granulomatosis (Monach and Merkel, 2010). In the absence of published genome-wide data 
sets in a suitable population, I undertook a candidate gene approach to investigate whether 
there were any links between polymorphisms at the JUND locus and disease susceptibility 
using two main strategies. Sequencing of the coding sequence of JUND and its proximal 
promoter was carried out in a cohort of French vasculitis patients to investigate whether any 
novel variants were present in the coding region of the gene or in the proximal promoter that 
could influence susceptibility to disease and to investigate whether variation was occurring at 
known single nucleotide polymorphisms (SNP identified by dbSNP (Sherry et al., 2001). The 
role for common polymorphisms at the JUND locus in disease susceptibility was investigated 
using a tagging SNP study in a larger cohort of patient samples from 375 vasculitis cases 
(MRC/Kidney Research UK Glomerulonephritis DNA Bank (MRCGN) cohort consisting of 
patients aged 18 to 70 years with histological evidence of necrotising glomerulonephritis with 
epithelial crescent formation and the presence of circulating anti-neutrophil cytoplasmic auto-
antibodies (ANCA) courtesy of Professor T Vyse, King’s College, London) and 959 control 
samples (Panel 1 of UK Blood Services collection of common controls) used by the 
Wellcome Trust Case Control Consortium (WTCCC, 2007).  
 
Tagging SNP based approaches rely on the fact that global patterns of DNA sequence 
variation are inherited in blocks called haplotypes and SNPs have been identified, largely 
from the work of the HapMap project, that ‘tag’ these blocks allowing a researcher to 
characterise the genetic variation at a given locus by genotyping only a subpopulation of the 
total number of polymorphisms that occur there (Johnson et al., 2001; Patil et al., 2001; 
Gabriel et al., 2002). The International HapMap project was launched in 2002 and was 
conceived as a response to the challenges posed in investigating the genetic basis of common 
diseases, largely due to the low power of family based linkage studies and the limitations of 
candidate gene approaches compared to the success and progress made in rare, highly 
heritable ‘Mendelian’ diseases. (Risch and Merikangas, 1996; International HapMap 
Consortium, 2005; International HapMap Consortium, 2007). The original objective of the 
HapMap project was to genotype at least one common SNP every 5 kilobases (kb) across the 
genome in 270 individuals from 4 diverse populations and by phase II of the project, 3.1 
million human SNPs had been genotyped and which included 25-35% of common SNP 
variation in the populations studied. Most importantly, this use of the HapMap data set has 
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been central to the development of genome-wide association studies and a shift in focus away 
from candidate gene approaches (International HapMapConsortium, 2007).   
 
6.2 Results 
6.2.1      Immunohistochemical investigation of the relationship of JUND with human 
renal disease 
Patient samples were identified from the existing collection of diagnostic samples held by 
Professor H. Terence Cook of the Department of Pathology at Hammersmith Hospital. 
Ethical approval for this study of human renal biopsies was obtained by Dr Richard Hull and 
Professor H. Terence Cook from the St Mary’s Hospital Research Ethics Committee 
(Reference number: 09/H0712/15). Patients with class IV systemic lupus erythematosus 
(SLE) as defined by the ISN/RPS classification of 2003 (Weening et al., 2004) were selected 
as the disease group for investigation as this disease class exhibits an active, often 
proliferative, glomerulonephritis with crescent formation and macrophage infiltration. Two 
control groups which show no inflammatory features or macrophage infiltration namely 
minimal change disease (MCD) and thin basement membrane nephropathy (TBM) were 
selected (Tryggvason and Patrakka, 2006; Mathieson, 2007). It is important to note that renal 
biopsies are only performed for abnormal clinical indices hence the need to select two control 
groups that contrasted with the SLE disease group. MCD is the histopathological description 
of the changes seen on biopsy of patients who present with heavy proteinuria and its related 
clinical condition nephrotic syndrome (Mathieson, 2007). TBM nephropathy is the most 
common cause of persistent haematuria in children and adults and is one of the most common 
disorders of the kidney, affecting 1% of the population (Tryggvason and Patrakka, 2006).  
The name refers to the characteristic finding of uniform thinning of the glomerular basement 
membrane on electron microscopic analysis of the kidney. TBM nephropathy has an 
excellent prognosis and, though it may not be just a benign finding in all cases, its clinical 
course has led some authors to state that it should not really be considered a ‘true’ disease of 
the kidney (Tryggvason and Patrakka, 2006). It thus formed a useful control group for this 
study. Immunohistochemical staining for CD68 and JUND was carried out by the 
Department of Histology, Hammersmith Hospital using their established protocols in 
collaboration with Ms Sarah Horton, Senior Biomedical Scientist.  
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Representative images of the typical morphology of the human renal sections examined are 
shown in Figure 6.1. The H&E (hematoxylin and eosin stain) sections shown for MCD 
(Figure 6.1A) and TBM (Figure 6.1D) demonstrate normal glomerular architecture whilst a 
crescentic glomerulus with widespread proliferative changes in the remaining area of normal 
tuft is demonstrated for a case of SLE (Figure 6.1G). Both the control groups show none or 
only one or two macrophages (a normal finding) in the glomeruli (Figure 6.1B, E). In the 
sections from the SLE case, a number of macrophages are visible within the glomerulus and 
surrounding tubular capillaries (Figure 6.1H). Immunohistochemical staining for JUND 
demonstrated positive staining in all three groups with widespread positive staining in 
glomerular nuclei and tubular nuclei and cytoplasmic staining evident in the MCD group 
(Figure 6.1C), some positive staining of glomerular nuclei and tubular nuclei seen in the 
TBM group (Figure 6.1F) and widespread positive staining in the glomerular and 
tubulointerstitial compartment evident in the SLE group (Figure 6.1I).  
 
To understand better whether any differences in JUND expression were present between the 
three groups, quantitative analyses of cell counts and semi-quantitative analyses of staining 
area and staining intensity were performed. Samples were scored by two observers, Dr 
Richard Hull and Ms. Sarah Horton, Senior Biomedical Scientist, Department of Histology, 
Hammersmith Hospital, for the number of macrophages, JUND positive cells, percentage of 
positive cells and intensity of staining within each glomerular cross section (GCS) and 
percentage of affected cells and staining intensity for the tubulointerstitial compartment. The 
semi-quantitative analyses were scored using a scale from 0-3 for amount or proportion of 
positive staining; 0= <25%, 1= 26-50%, 2= 51-75% and 3= 76-100 whilst intensity was rated 
using a similar scale; 0= no staining, 1= mild, 2=moderate and 3=marked. Results were 
analysed using GraphPad Prism v5.02 using parametric and non-parametric analyses of 
variance to explore the differences between the disease groups.  
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Figure 6.1 Immunohistochemical staining of human renal biopsies. 
Representative images are shown from cases of minimal change disease (MCD) (a, b, c), thin 
basement membrane (TBM) disease (d, e, f) and class IV lupus nephritis (g, h, i). H&E 
sections (a, d) demonstrate the normal glomerular morphology seen in MCD and TBM 
respectively whilst a crescentic glomerulus with proliferative change within the remaining 
area of glomerular tuft is demonstrated in (g). Staining for macrophages (CD68) 
demonstrates minimal numbers of CD68 positive cells in MCD (b) and TBM (e) whilst 
increased numbers are seen in class IV lupus (h) both within the glomerulus and interstitium. 
Staining for JUND (c, f, i) demonstrates widespread nuclear and cytoplasmic JUND staining 
in all three disease groups. 
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Cases of SLE demonstrated significantly higher average numbers of macrophages per GCS 
than both the TBM and MCD groups (Figure 6.2A). No difference was observed between the 
TBM and MCD groups. In addition, significantly higher numbers of JUND positive cells per 
GCS were demonstrated in the SLE group compared to the MCD and TBM groups with 
again, no difference demonstrated between the MCD and TBM groups (Figure 6.2B). On 
average, there were higher numbers of positive JUND staining cells in each GCS than there 
were macrophage numbers indicating that cells other than macrophages stained positive for 
JUND which is evident from the representative images in Figure 6.1. There was a minor 
trend for a higher score in the SLE group but no significant difference between groups for the 
percentage of JUND positive cells per GCS (Figure 6.2C) and similarly there was a non-
significant trend for higher staining intensity in the SLE group compared to the two other 
renal disorder groups (Figure 6.2D).  
 
The tubulointerstitial compartment was examined to see whether any differences in JUND 
staining could be identified between the disease groups (Figure 6.3). No difference was seen 
between groups for the mean proportion of tubular nuclei positive for JUND though there 
was a suggestion of higher scores in the MCD group (Figure 6.3A) and there was no 
significant difference in the intensity of nuclei staining (Figure 6.3B). Of note, cytoplasmic 
staining for JUND was seen in both glomerular and tubular cells and the overall impact of 
this in the tubulointerstitial compartment in general was assessed and no differences were 
seen between disease groups in both the percentage of tubules staining positive (Figure 6.3C) 
or for the intensity of the staining (Figure 6.3D). 
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Figure 6.2  Quantitative and semi-quantitative analysis of macrophage count 
and JUND staining of human renal biopsies. 
Mean macrophages per glomerular cross section (GCS) (A) and mean JUND positive cells per 
GCS (B) were analyzed using one-way ANOVA and Bonferonni’s Multiple Comparison Test for 
each group. Glomeruli were semi-quantitatively scored by Dr Richard Hull and Ms. Sarah 
Horton, Senior Biomedical Scientist, Department of Histology, Hammersmith Hospital on a scale 
from 0-3 for the percentage of positive JUND staining cells per glomerulus (C) and intensity of 
JUND staining in each glomerulus (D). Data was analyzed using the Kruskal-Wallis test and 
Dunn's Multiple Comparison Test to compare amongst groups. ***P<0.001, **P<0.01, ns=non-
significant.  
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Figure 6.3  Quantitative and semi-quantitative analysis of tubulointerstitial 
compartment for JUND staining in human renal biopsies. 
The tubulointerstitial compartment for tubular nuclei with JUND positivity (A) and the intensity of 
JUND staining (B) and for the overall proportion of tubules positive for JUND (C) and the overall 
staining intensity (D) were scored. Samples were scored on a scale from 0-3 for the proportion of 
positive staining (0= <25%, 1= 26-50%, 2= 51-75% and 3= 76-100%) and the intensity (0= no 
staining, 1= mild, 2=moderate and 3=marked). Data was analyzed using the Kruskal-Wallis test and 
Dunn's Multiple Comparison Test to compare amongst groups; ns=non-significant.  
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6.2.2      Southwestern histochemistry 
The methodology of the Southwestern histochemistry technique was optimised on renal 
sections from the WKY NTN model. Figure 6.4 demonstrates the value of the NTN model in 
this optimisation process as there are distinct differences observed in histological appearance 
between the rat kidney at Day 0 of NTN induction (Figure 6.4A) and at Day 8 after NTN 
induction with crescent formation observed in the majority of glomeruli (Figure 6.4B, C). 
Immunohistochemical staining for JUND was also different between the two timepoints with 
low intensity glomerular staining evident at day 0 (Figure 6.4D) and widespread positivity of 
nuclei particularly within the crescentic glomeruli seen on day 8 (Figure 6.4E). 
 
In total, eight separate trials of the Southwestern histochemistry were performed in order to 
optimise the technique and the results of three example runs are shown (Figures 6.5, 6.6 and 
6.7).  A range of AP-1 probe concentrations were trialled ranging from the 100pM used in 
early published accounts of the technique (Hernandez-Presa et al., 1999) to 20,000pM. A 
range of negative controls as used in published accounts were used including the absence of a 
probe, probes with a mutated AP-1 binding site and a competition assay (Hernandez-Presa et 
al., 1999; Mezzano et al., 2001; Mezzano et al., 2004). 
 
Figure 6.5 demonstrates the results of an early optimisation run. Negative staining was 
observed in Day 0 NTN sections at probe concentrations of 1000pM (Figure 6.5A) and 
5000pM (Figure 6.5B) and in the negative control section (Figure 6.5C). Positive nuclear 
staining was demonstrated on day 8 sections at probe concentrations ranging from 1000pM to 
10000pM (Figure 6.5 D, E, F) though a technical replicate of the 1000pM concentration 
showed a lower level of positive staining (Figure 6.5G). Negative controls using mutated 
probes at 1000pM were able to show only very mild staining in day 0 and day 8 sections 
(Figure 6.5 H, I) though at a high probe concentration of 10000pM, strong staining was 
demonstrated indicating non-specific binding was occurring (Figure 6.5J). The example run 
in Figure 6.6 demonstrates difficulties in the probe concentration reproducibility of the 
technique as after a number of negative runs, only a low level of positive staining is seen with 
a probe concentration of 5000pM in a day 8 section (Figure 6.6A). Negative controls were 
again satisfactory with the mutated probe at a concentration of 5000pM showing minimal 
staining (Figure 6.6E) but again more positive staining was seen at a higher concentration 
(Figure 6.6F). 
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Figure 6.4  Immunohistochemical staining of rat renal histology sections. 
Representative images from WKY rat renal histology sections demonstrating normal 
glomerular appearance at day 0 of NTN induction in a Periodic acid-Schiff (PAS) stained 
section (A), and crescent formation on day 8 after NTN induction in a PAS stained section 
(B) and H&E stained section (C). Immunohistochemical staining for JUND demonstrates low 
intensity staining in the glomerulus at day 0 (D) and more intense JUND staining at day 8 
post NTN induction (E). 
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Figure 6.5  Southwestern histochemistry of WKY rat renal histology sections 
for example run 1. 
Day 0 post NTN sections (A, B, C) demonstrate no positive nuclear staining at 1000pm dose 
of probe (A), 5000pm dose (B) and no staining in the absence of probe (C). Positive nuclear 
staining was demonstrated on sections from a WKY rat day 8 post NTN induction at a probe 
dosage of 1000pM (D), 5000pM (E) and 10000pM (F). A technical replicate from the 
1000pM dosage is demonstrated (G) showing a low level of positive staining. Negative 
controls using mutated probes demonstrate mild staining at 1000pM from day 0 sections (H) 
and day 8 sections (I) and strong positive staining at high dose 10000pM (J). 
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Figure 6.6  Southwestern histochemistry of WKY rat renal histology sections 
day 8 after NTN induction for example run 2. 
Weak positive staining is demonstrated at a probe dosage of 5000pM (A) with widespread 
positive staining demonstrated at a dosage of 10000pM (B) and 20000pm (C). Negative 
controls show negative staining with absence of probe (D) and with a mutated probe at 
5000pM (E) but positive staining was demonstrated with a mutated probe concentration of 
10000pM (F). 
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Further optimisation allowed for the demonstration of positive staining at probe 
concentrations more akin to the published reports (Figure 6.7A) with clear negative controls 
in evidence at the comparable concentrations for the mutated probe (Figure 6.7H) and with a 
competition assay (Figure 6.7I). Whilst positive staining could be demonstrated in rat renal 
sections, the overall consistency and reproducibility of the technique fell below an acceptable 
quality level such that it was felt that the technique could not be translated to human renal 
sections. 
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Figure 6.7  Southwestern histochemistry of WKY rat renal histology sections 
day 8 after NTN induction for example run 3. 
Weak positive staining is demonstrable at a probe dosage of 100pm (A) and more positive 
staining at higher dosages of 1000pm replicate 1 (B) and replicate 2 (C), 5000pm (D) and 
10000pm (E). Negative controls demonstrate no staining in the absence of a probe (F) and 
very minimal staining for mutated probes (G, H) and with a competition assay (I). 
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6.2.3      Genetic studies in human patients with Crgn 
The second part of the strategy, as detailed in 6.1.4, was to investigate whether there was a 
link between genetic variation at the JUND locus and susceptibility to Crgn, in particular 
ANCA vasculitis. JUND in humans is located on chromosome 19 (19p13.2) and is 1,870 base 
pairs (bp) in length with a high GC content of 69.7% and the protein coding sequence 
consists of a single exon, 1,044bp in length. Figure 6.8 illustrates the gene with its main 
features and polymorphisms within the coding sequence and the proximal promoter.   
 
6.2.3.1 Sequencing of the JUND locus 
Six sets of primers spanning the genomic sequence of JUND and 1000 base pairs of its 
proximal upstream promoter region were designed as detailed in 2.17.1 using NCBI build 36 
of the human genome. Ninety-nine vasculitis samples and ninety matched controls (Cochin 
Hospital, Paris, France) were analysed. 100ng of genomic DNA was amplified for each 
amplicon using KOD Hot start polymerase as per 2.11.1. 
  
Resequencing of the JUND locus in vasculitis cases, including the coding sequence of the 
gene and 1000 base pairs of the proximal promoter, identified two novel polymorphisms in 
the proximal promoter region of the gene, novel SNP1 and novel SNP2, Table 6.1, one of 
which (Novel SNP 2) was present in both a control and a disease patient.  No differences in 
the frequency of the three known SNPs in the coding region of the gene itself (rs10401251, 
rs1478151 and rs12979029) or in its 3’UTR region were seen between patients and controls. 
Allelic frequencies for the polymorphisms in the promoter region of the gene were generated 
from analysis of the sequencing reads using Sequencher software v4.8 (Gene Codes 
Corporation, Ann Arbor, Michigan, USA). Table 6.1 shows the allelic frequencies of SNPs 
found in the promoter region of the gene. The data was analysed for basic quality and 
association tests in Haploview v4.2 (Barrett et al., 2005) including testing for Hardy-
Weinberg equilibrium (Table 6.2). This demonstrated that there was no significant deviation 
from the Hardy-Weinberg equilibrium in any of the SNPs investigated (Table 6.2). 
Association tests between the two groups were performed and the results are detailed in 
Table 6.3. Two SNPs, rs41374745 and rs7247222, showed an initial weak association with 
disease after initial χ2 analysis (P- value=0.019 and 0.012 respectively) which, after correction 
by permutation testing to account for multiple testing biases, were not significant.  
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Figure 6.8  JUND locus on chromosome 19.   
Illustration of the position of known and novel single nucleotide polymorphisms (SNPs) 
found by Sanger sequencing of a cohort of French vasculitis patients and controls in relation 
to the coding sequence of the gene. The clear boxed area indicates the location of the 5’ and 
3’ untranslated regions (UTR) and the black box indicates the location of the single coding 
exon. 
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Table 6.1  Allelic frequencies of SNPs in JUND promoter region 
Sanger sequencing of the JUND promoter region was performed and analysed using 
Sequencher software to analyse the electropherograms. Allelic frequencies were determined 
for each SNP. Both absolute numbers and frequencies are shown for each allele. 
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Table 6.2  Minor allele frequency and Hardy-Weinberg P-value 
 
Result of basic data quality checks from Haploview 4.2 demonstrating minor allele frequency 
and Hardy-Weinberg equilibrium P-value.  
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Table 6.3  Association testing result 
 
Association testing results demonstrating chi square and P-value for the frequencies in cases 
v controls and p value obtained after 100,000 permutations to correct for multiple testing 
biases.  
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value=0.019 and 0.012 respectively) which, after correction by permutation testing to account 
for multiple testing biases, were not significant.  
 
Two haplotype blocks were identified using the linkage disequilibrium (LD) D’ chart 
generated using the algorithm implemented in Haploview v4.2 (Figure 6.9) which did not 
alter with or without the inclusion of the novel SNPs. The default implementation in 
Haploview was used which is based on the algorithm of Gabriel et al (Gabriel et al., 2002). 
This uses a 95% cut off of D’, the normalised measure of allelic association, to define LD 
blocks. This implementation uses confidence bounds rather than exact estimates because the 
authors felt that D’ values could fluctuate when a small number of samples or rare alleles 
were investigated. Pairs of alleles were defined as being in ‘strong LD’ where the one sided 
upper confidence of 95% for D’ was >0.98, meaning no historical recombination had 
occurred. ‘Strong evidence for historical recombination’ was defined when the D’ was less 
than 0.9 (Gabriel et al., 2002). Table 6.4 illustrates the analysis of the association test results 
of the haplotypes. An initial χ2 analysis suggested a weak association of two haplotypes in 
block 2 might be associated with disease but after multiple tests correction only the ‘GGT’ 
haplotype had a weak associated P-value of 0.037 which was linked to the G allele of the 
weakly associated SNP rs7247222.  
 
6.2.3.2 Tagging SNP study of the JUND locus 
A tagging SNP study of the JUND locus was performed to test for the association of common 
SNPs in of close to the JUND gene with glomerulonephritis. The study populations were a 
cohort of focal necrotising glomerulonephritis cases from the MRCGN cohort, and panel 1 of 
the UK Blood Service common controls, used in the Wellcome Trust Case Control 
Consortium studies. The then most up to date version of HapMap (version 2, release 24) was 
used to identify tagging SNPs that covered the JUND locus (Figure 6.10) and upstream from 
the gene’s transcriptional start site to the end of the LD block. The Tagger algorithm 
implemented in Haploview (de Bakker et al., 2005) was used to identify the minimum 
number of these SNPs that could be used to survey the region. Using an r
2
 threshold of 0.9 
and pairwise tagging, five SNPs were identified that adequately covered the region at a mean 
max r
2
 of 0.992 and are highlighted with black rings in Figure 6.10. The five tagging SNPs 
were able to cover all seven alleles  
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Figure 6.9 Linkage disequilibrium and haplotype result 
Linkage disequilibrium (LD) D’ chart generated from Haploview using the algorithm as per 
Gabriel et al summarizing the pattern of LD in the genotyped cohorts from the vasculitis and 
control samples to include novel SNPs (A) and without (B). The numbers in the boxes are the 
pairwise D’ values below 100.  Two LD blocks have been defined named block 1 and block 
2. The presence of absence of the novel SNPs does not affect the haplotype blocks which are 
summarized with their frequencies in (C). Dark lines indicate >10% of haplotypes in total, 
light grey lines indicate >1% of all haplotypes.   
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Table 6.4  Haplotype association testing result 
 
Association testing results of haplotypes demonstrating chi square and p values for the 
haplotype frequency and permutations (n=100,000) corrected P-value.   
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Figure 6.10  Linkage disequilibrium (LD) plot with HapMap track of JUND 
locus. 
This plot shows the location of the JUND gene in relation to known HapMap tagging SNPs 
upstream and downstream to the next nearby gene locus.  Linkage disequilibrium (LD) D’ 
chart of genotypes is generated from the CEPH (Utah residents with ancestry from northern 
and western Europe) panel downloaded from the HapMap project server into Haploview 4.2. 
The LD plot shown is the default D’ chart generated as per Gabriel et al. Tagging SNPs used 
to survey the JUND locus are indicated by black circles. This data uses HapMap Version 2, 
release 24. 
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identified (rs10419232 was captured by rs6512255 and rs12608504 by rs11086102). There 
was redundancy in this capture as using a more aggressive tagging approach with two marker 
haplotypes; only three SNPs were needed to cover the region (rs11086102 rs6512255 and 
rs4254438 with a mean max r
2
 of 0.987). Subsequent to the completion of the tagging SNP 
study, a further release of HapMap occurred identifying more tagging SNPs (rs4393694 and 
rs11086103) in the region (Figure 6.11). The locus was thus reassessed using Tagger and 
both additional SNPs were captured by the five tagging SNPs used in the original study. 
 
Genotyping of five tagging SNPs covering the JUND locus was successfully performed in 
375 cases of focal necrotising glomerulonephritis from the MRCGN cohort and 959 control 
DNA samples from panel 1 of the UKBS panel of common controls. Alleles were called in 
the amplified samples using the allelic discrimination programme incorporated into SDS v2.3 
(Applied Biosystems) and only clear unambiguous calls were used for further analysis 
(Figure 6.12). Table 6.5 details the summarised genotyping results for the 5 tagging SNPs 
and Table 6.6 details the basic data quality checks implemented in Haploview showing that 
all the genotypes at each SNP were in Hardy-Weinberg equilibrium (HWE), tested with the 
χ2 test with a significant P-value cut-off of 0.05.  
 
Association testing was carried out for each SNP between the cases and controls and no 
significant differences were observed either before or after permutation based multiple test 
corrections were performed (Table 6.7). Haplotype analysis was performed using both the 
default algorithm based on the methodology of Gabriel et al (Gabriel et al., 2002) (Figure 
6.13A) and the Solid Spine of LD method implemented in Haploview (Figure 6.13B) in an 
attempt to capture the full scope of the potential for haplotype analysis. This latter method 
identifies a ‘spine’ of strong LD running from one marker to another along the sides of the 
triangle in the LD chart allowing links to be made between the first and last markers in the 
block which are in strong LD with the other intermediate markers but accounts for the fact 
that not all markers may be in strong LD with another (rs12610691 in Figure 6.13B). No 
associations were found with haplotypes identified with the Gabriel et al methodology (Table 
6.8) or the Solid Spine of LD methodology (Table 6.9) and disease risk. 
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Figure 6.11 Linkage disequilibrium (LD) plot of JUND locus using the latest 
HapMap version 3, release R2. 
LD plot of the JUND locus using HapMap version 3, release R2. The LD plot shown is the 
default D’ chart generated as per Gabriel et al. Tagging SNPs used to survey the JUND locus 
are indicated by black circles. New tagging SNPs identified by this HapMap release are 
located in positions 3 and 8. 
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Figure 6.12  Allelic discrimination plots showing the genotyping results for 
each of the tagging SNPs for MRCGN vasculitis cases and UKBS control cases 
These plots demonstrate the distribution of genotyped alleles, non-template controls and 
failed samples. Each plot is the summarised output data for the allelic discrimination calls 
generated by SDS v2.1 for each tagging SNP analysed; rs11086102 for MRCGN cohort (A) 
and UKBS cohort (B), rs12610691 for MRCGN cohort (C) and UKBS cohort (D), rs4254438 
for MRCGN cohort (E) and UKBS cohort (F), rs6512255 for MRCGN cohort (G) and UKBS 
cohort (H) and rs12461701 for MRCGN cohort (I) and UKBS cohort (J). 
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Table 6.5 Summary of genotyping results for 5 tagging SNPS covering JUND 
locus. 
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Table 6.6 Result of basic data quality checks from Haploview demonstrating minor 
allele frequency and Hardy-Weinberg equilibrium P-value 
 
 
 
 
Table 6.7 Association testing results demonstrating chi square and P-value results 
for allelic associations in cases versus controls and P-value obtained after 100,000 
permutations to correct for multiple testing bias. 
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Figure 6.13 Linkage disequilibrium chart of tagging SNP data for JUND locus 
Linkage disequilibrium (LD) D’ prime chart generated from Haploview using the algorithm 
as per Gabriel et al summarizing the pattern of LD in the genotyped cohorts from MRCGN 
and UKBS samples (A). The numbers in the boxes are the pairwise D’ values below 100. The 
LD pattern obtained is similar to the pattern for the CEPH HapMap samples demonstrated in 
Figures 6.10 and 6.11. The LD plot generated using the Solid Spline of LD algorithm 
implemented in Haploview shows a similar finding (B). The dotted line indicates a marker 
removed from the haplotype analysis because of its low LD with all the other markers. 
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Table 6.8 Association testing results of haplotypes demonstrating chi square and P-
values for the haplotype frequency and permutation (n=100,000) corrected P-value 
 
 
Table 6.9 Association testing results of haplotypes defined using Solid Spine of LD 
method 
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Table 6.10 Power calculation for tagging SNP study at varying relative risk of  
associated genotype 
 
Percentage power given for varying degrees of relative risk (RR) using associated allelic 
frequency from HapMap Ceph population published in dbSNP.  
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6.3 Discussion 
Two methods were used to investigate whether the pattern of JUND expression and AP-1 
transcription factor was associated with crescentic glomerulonephritis and in which cells 
within the kidney it was predominantly expressed. The first methodology used standard 
immunohistochemical techniques to investigate the pattern of JUND protein expression. The 
presence of high numbers of macrophages in crescentic lesions has long been recognised 
(Atkins, 1998) and this was confirmed in the SLE group (Figure 6.1 & Figure 6.2). The 
interest in JUND and AP-1 expression in the kidney arises from the fact that JUND is a 
determinant of macrophage activation in rat macrophages associated with susceptibility to 
crescentic glomerulonephritis and is also a determinant of macrophage activation in human 
macrophages (Behmoaras et al., 2008) and the finding of increased macrophage numbers in 
the SLE case validated our strategy of using this disease group as an example of active 
glomerulonephritis for the investigation of JUND protein and AP-1 transcription factor 
distribution. The low macrophage counts and the normal structural appearance on both MCD 
and TBM show their value as negative control groups for the study. JUND is a constitutive 
transcription factor and because of this, prior to commencing the study, it was hypothesised 
that a low level widespread expression of the protein might occur in all three types of 
glomerular disease with increased staining seen in any inflammatory lesions particularly in 
association with macrophage infiltration. It was thus unexpected to see such a widespread and 
intense staining for JUND in the MCD and particularly the TBM groups which, apart from a 
thinned basement membrane, is essentially a normal kidney as well as in the SLE group. In 
this latter group, the majority of cells stained intensely for JUND and this included both 
infiltrating immune cells and intrinsic cells in the glomerulus (Figure 6.1I & Figure 
6.2C&D) as well as in the tubulointerstitial compartment (Figure 6.3). The high numbers of 
JUND positive cells were a reflection, in part, of the significant macrophage infiltration that 
had occurred in these active lesions (Figure 6.2A) but also of the proliferation of glomerular 
cells as part of the inflammatory response. The MCD group showed widespread staining in 
both the glomeruli and within tubules and its intensity in both compartments was comparable 
to the SLE group (Figure 6.2, Figure 6.3). MCD is a common cause of nephrotic syndrome 
with levels of proteinuria being a major feature of the disease (Hull and Goldsmith, 2008).  
There is a large body of indirect evidence supporting a role for the immune system in the 
pathogenesis of the disease and in particular a key role for T cells as part of Th2 biased 
responses (Mathieson, 2007) notwithstanding the widespread use and efficacy of 
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immunosuppressive agents in its treatment. Therefore the widespread changes seen in the 
MCD disease group (Figure 6.1C) could be a reflection of an underlying immune process 
driving the disease or a response by the cells to proteinuria or indeed could be a feature 
simply of normal renal tissue. Southwestern histochemistry has been used to show that 
tubular over activation of AP-1 and NF-κB occurs in patients with MCD linked to the 
simultaneous upregulation of proinflammatory and profibrogenic genes. Increased activation 
of the transcription factors alone was thought to potentially indicate the response of tubular 
renal cells to injury (Mezzano et al., 2001). The finding of staining in glomerular and tubular 
cells in TBM does challenge this hypothesis as this disorder has no immune links and its 
central feature of persistent microscopic haematuria is due to a uniformly thinned glomerular 
basement membrane with light microscopy showing normal glomerular histology 
(Tryggvason and Patrakka, 2006). In conclusion this work demonstrates that JUND, as a 
constitutive transcription factor, is widely expressed in the kidney in both the glomerulus and 
the tubulo-interstitial compartment in nephritic kidneys and that whilst JUND is expressed 
intensely in macrophages it may still have functional roles to play in intrinsic renal cell 
function. Indeed it has been recently shown that in Jund-deficient (Jund
-/-
) mice, it is the 
deficiency of JUND in podocytes as opposed to a functional difference caused in macrophage 
behaviour that led to increased oxidative stress in podocytes which resulted in increased 
glomerular injury in a mouse model of NTN (Cook et al., 2011). 
 
JUND as a JUN family protein is a member of the AP-1 transcription family and forms 
homodimers or heterodimers with other family members such as the other JUN proteins (C-
JUN, JUNB), FOS and ATF proteins (Shaulian, 2010). We believed therefore that 
understanding the role of AP-1 transcription factor overall in glomerulonephritis could help 
give insights into JUND function. Southwestern histochemistry was therefore an ideal 
methodology to use in investigating glomerulonephritis as it uses oligonucleotide probes 
containing the consensus sequence of the transcription factor which are also 3’labelled with 
digoxigenin to probe the location of AP-1 complexes bound to the genome in formalin fixed 
paraffin embedded tissues (Hernandez-Presa et al., 1999; Mezzano et al., 2004). The method 
can also be combined with standard immunohistochemistry to identify cell type specific 
localization of the DNA binding factors and the intention would be therefore to combine it 
with JUND and CD68 macrophage staining to gain further insights into its function.  
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Publications on the field, though few in number, do suggest the technique has the potential 
for reproducible results for AP-1 transcription factor (Hernandez-Presa et al., 1999; Mezzano 
et al., 2001; Zheng, 2006). Hernandez-Presa et al published their first account of the 
technique in 1998 in atherosclerotic arterial sections in a rabbit model (Hernandez-Presa et 
al., 1998) applying it to immune complex glomerulonephritis in rats in the following year to 
investigate the link between the activation of both NF-κB and AP-1 with inflammation in 
vivo (Hernandez-Presa et al., 1999). They showed in this methodological account that control 
rats without disease showed no nuclear staining for AP-1 whilst there was a widespread 
staining for positive cells in the kidney sections of rats with the immune complex 
glomerulonephritis (Hernandez-Presa et al., 1999). The positive cells were distributed 
throughout the glomeruli and tubulointerstitial areas with almost every nucleus, it seemed, 
staining positive. They were able to show satisfactory negative controls with weak or 
negative staining with a competition assay and the mutant probe though they did not show the 
result obtained from the absence of the probe (Hernandez-Presa et al., 1999). Mezzano et al. 
published the next report using the technique (Mezzano et al., 2001) investigating proteinuria 
renal disease in patients with MCD and idiopathic membranous nephropathy (MN) and used 
a staining score to quantify the results. They demonstrated that patients from both disease 
groups had higher NF-κB activation than controls with IgA nephropathy with MCD patients 
having the highest scores. AP-1 was found to be activated in MCD though the extent was not 
correlated with the degree of proteinuria and was also activated in membranous nephropathy 
in the cortical tubular epithelial cells with the level of activation correlating this time with the 
degree of proteinuria. The results that they presented did show positive NF-κB staining and 
improved background compared to Hernandez-Presa et al.in the NF-κB staining though there 
was a lower level of AP-1 staining seen than for both NF-κB in this study and the staining 
demonstrated by Hernandez-Presa et al. (Hernandez-Presa et al., 1999; Mezzano et al., 2001). 
The differences seen between NF-κB and AP-1 staining could be a reflection of the relative 
abundances of the proteins in the tissue and this data would therefore imply a higher 
expression of NF-κB than AP-1. Ashizawa et al. (Ashizawa et al., 2003) used a slightly 
different published methodology of SWH to investigate a role for NF-κB in IgA nephropathy. 
They showed the presence of weak but significant positive signals for NF-κB in normal 
kidneys both in glomerular cells and in the interstitial compartment and showed only weak 
but significant signals in both minimal change disease and membranous nephropathy. They 
were, however, unable to show any correlations with proteinuria which is in contrast to the 
findings of Mezzano. They did show prominent NF-κB activation in glomerular cells 
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particularly in areas of mesangial cell proliferation in IgA nephropathy. Whilst the 
methodology did differ between the two groups, the differences in staining seen especially 
with a prominent transcription factor such as NF-κB raises concerns about the reproducibility 
of the technique. 
 
Southwestern histochemistry has also been used to investigate the role of NF-κB in in cases 
of SLE using the methodology of Hernandez-Presa et al. (Zheng, 2006; Zheng et al., 2008). 
Expression of activated NF-κB was shown to be widespread in glomeruli from patients with 
class IV lupus involving glomerular endothelial cells, mesangial cells and parietal epithelial 
cells as well as in inflammatory infiltrates in a crescentic glomerulus (Zheng, 2006). Cases of 
class V lupus were also studied in which activation was predominantly seen in podocytes 
fitting in with the membranous like changes that occur in this disease subgroup whilst there 
was only limited staining in cases of MCD. In their subsequent study published in 2008 they 
studied NF-κB in the tubulointerstitial compartment in lupus nephritis and also performed 
SWH for AP-1 though this was a more minor component of the work. They saw extensive 
and widespread upregulation of NF-κB in renal tubular and interstitial cells along with AP-1 
compared to normal controls which showed no staining and cases of MCD which showed 
weaker but positive staining. Zheng et al were able to show that normal controls did show 
minimal staining but did not show the full gamut of negative controls seen in other 
publications for the disease groups (Zheng et al., 2008). 
 
In summary the published literature showed that the SWH technique had the potential to 
show positive staining results in human renal biopsy sections though at times some of the 
published figures, when showing positive staining, showed every nuclei being positive rather 
than a range of intensities or at least some negative cells raising questions about the 
specificity of the technique. In addition there were conflicting results between groups 
studying proteinuria renal diseases and the question of how reproducible the technique could 
be has not been addressed. Nevertheless we felt that the technique could offer a useful way of 
further investigating a role for AP-1 in crescentic glomerulonephritis. The widespread 
investigation of proteinuria diseases by Mezzano and Ashizawa would be able to give us a 
positive control reference whilst the work of Zheng would give some guidance regarding any 
consistency of the SLE results. It is worth noting that Zheng only investigated AP-1 in the 
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context of tubulointerstitial lesions in SLE and not in the glomerulus thus our work would 
also be novel in investigating this aspect of AP-1 function. 
 
The application of SWH to the rat model of NTN, despite some technical issues, does allow 
for some conclusions to still be drawn. Negative staining was evident in the day 0 NTN 
sections at a range of doses whilst at the same doses positive staining for AP-1 was seen in 
the day 8 NTN section (Figure 6.5) suggesting that AP-1 is activated after NTN induction 
fitting in with our previous data (Behmoaras et al., 2008). The negative controls in Figure 6.5 
whilst showing some weak positivity clearly show that AP-1 transcription factor could be 
identified in the renal sections. Figure 6.6 again shows that positive staining for AP-1 can be 
demonstrated albeit at higher doses with the negative controls showing clear differences. 
Whilst the ability to easily replicate staining at equivalent doses can be questioned, as has 
been demonstrated, positive identification of AP-1 staining with evidence to suggest that its 
activation was tied in with the stage of NTN was demonstrated. 
 
The SWH technique was extremely difficult to optimise and its poor reproducibility and 
seeming lack of specificity meant that we were unable to translate the work from the rat into 
the limited resource of human renal biopsy tissue. The majority of steps within the protocol 
had the potential to impact on the final outcome of the technique. In the methodology by 
Hernandez-Presa et al. and Mezzano et al. (Hernandez-Presa et al., 1999; Mezzano et al., 
2001) the oligonucleotide probes are enzymatically labelled at their 3’ end with terminal 
transferase by incorporation of a single digoxigenin labelled dideoxyuridine-triphoshate 
(DIG-ddUTP). Paraformaldehyde fixation is used to fix the proteins in situ where they have 
bound to the chromatin prior to a DNase digestion which removes. The preparations are then 
incubated with the labelled probes that contain the AP-1 binding motif overnight which bind 
to the AP-1 transcription factor complexes. An anti-digoxigenin antibody conjugated with 
alkaline phosphatase is used to allow colorimetric detection of the probe. The oligonucleotide 
probes contain the consensus sequence of the transcription factor of interest. To investigate 
AP-1 transcription factor, I used an oligonucleotide containing a consensus sequence for AP-
1, ‘TGAGTCA’, as used in previous publications (Hernandez-Presa et al., 1999; Mezzano et 
al., 2004). Negative controls form an essential part of all the published studies. In this work, 
the same types of negative controls were used, namely the absence of the probe, a mutant AP-
1 sense probe labelled with digoxigenin at the same concentration as the labelled probe and 
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competition assays with a 100-fold excess of unlabelled AP-1 probes followed by incubation 
with its respective labelled probe. 
 
As described in 2.16.3, the technique involves a number of incubations with key reagents and 
wash steps. The levamisole incubation quenches endogenous alkaline phosphatase and the 
incubation was trialled and set to 30 minutes to minimise any background or cytoplasmic 
staining with alkaline phosphate. At time lengths shorter than 30 minutes, there was an 
unacceptable level of background staining. Paraformaldehyde fixation was another critical 
stage in order to fix the transcription factor protein to DNA and along with the pepsin A 
digestion was optimised using different time lengths of incubation. A technical report on the 
methodology also noted the significance of this latter step finding that incubations less than 
30 minutes or more than 40 minutes resulted in a lack of staining (Hernandez-Presa et al., 
1999). An important issue was the concentration of probe used and volume. Due to the size of 
the rat kidney sections, some 10 times the area of a human renal biopsy, an increased 
concentration of probe was used to allow physically more labelled probe to be present and 
attach to AP-1 binding sites. Weak staining was achieved at the 100pM concentration used by 
the majority of studies but the technique worked better with probes at 1000pM or 2500pM 
which gave good nuclear staining without the non-specific staining and background that 
occurred at high doses. 
 
The genetic work in this chapter aimed to investigate whether any association with 
polymorphisms at the JUND locus could be associated with risk of disease and used two 
different approaches; resequencing of the coding region of the gene and 1000bp upstream in 
one cohort of patients to identify whether any known variants as well as any novel variants 
could be associated with disease in one cohort and a tagging SNP study in a second cohort to 
explore a wider view of the region. JUND itself is a small single exon gene of 1,870 base 
pairs located on chromosome 19 in humans. The two approaches also aimed to capture 
different types of variants that could be linked with increased disease risk, both common 
variants, in the case of the tagging SNP study, and rarer variants in the case of the 
resequencing project which did indeed identify two novel polymorphisms (6.2.3.1).  
 
No difference in frequency was observed at any of the three SNPs located in the protein 
coding region of the gene. Two of the SNPs (rs41478151 and rs12979029) are non-
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synonymous coding SNPs and as JUND is a constitutively expressed transcription factor it is 
not unsurprising that there would be a selection pressure against deleterious mutations 
occurring in the population. As it had been found in the NTN model that a promoter 
polymorphism accounted for some of the expression differences in JUND  mRNA seen 
between WKY and LEW rats, I also surveyed the proximal promoter region of the JUND 
gene to assess whether any polymorphisms in this region could be linked with disease 
(Behmoaras et al., 2008). Such an expression SNP (eSNP) could alter a transcription factor 
binding site or the activity of the promoter and such alterations, leading to changes in JUND 
expression, could conceivably be linked with disease risk. However in this relatively small 
study of only 99 patients and 90 controls no significant associations were found between any 
of the 6 previously identified SNPs or the 2 novel SNPs. Haplotype analysis (Table 6.4) did 
identify a weak association of the ‘GGT’ haplotype with disease (P-value=0.037) which was 
linked to the G allele of the weakly associated SNP rs7247222. The size of the patient and 
control cohorts used means that the greater significance could not be reached as the power to 
detect small gene effects in this case was low but highlights the potential for the study of this 
region in a large patient cohort. One of the challenges of investigating such a relatively 
uncommon disease is the limited size of cohorts. Indeed, the cohort of disease patients in a 
GWAS study in ANCA-associated systemic vasculitis consisted of only 911 patients 
(Trivedi, 2011).  
 
The tagging SNP study took a different approach in trying to survey a wider area of the 
JUND locus. As detailed in 6.2.3.2, 5 SNPS were selected that covered the JUND locus and 
areas downstream and particularly upstream of the gene. With the successful genotyping of 
275 cases and 959 controls, a basic power calculation based on the reported Ceph frequencies 
from the HapMap project of the alleles, found that for a relative risk of 1.5 there was a greater 
than 90% power to detect a link with disease risk (Table 6.10) but at a lower levels of 
relative risk of 1.2, this power did decrease significantly (Skol et al., 2006). However, the 
striking finding of the results is that there were minimal differences between the control and 
case groups for any of the alleles (Table 6.7) and none met a corrected P-value threshold for 
surveying these 5 polymorphisms of 0.01 or even an uncorrected basic P-value threshold of 
0.05. Both sample populations were Caucasian and the strength of the samples was their 
robust phenotyping. The cases were from the MRCGN cohort of ANCA vasculitis which has 
a strict entry criteria consisting of patients aged 18 to70 years with histological evidence of 
409 
 
necrotising glomerulonephritis with epithelial crescent formation and the presence of 
circulating anti-neutrophil cytoplasmic auto-antibodies (ANCA). The control cohort is from 
the UK Blood Service Panel of Controls which used healthy Caucasian blood donors and has 
been widely used since its first application in GWAS studies (WTCCC, 2007). In conclusion 
therefore no genetic variants at the JUND locus were found that could be associated with 
disease risk in the two cohorts that were studied. Whilst these results do not exclude a 
functional role for JUND in macrophages in humans, it does suggest that cis-acting genetic 
polymorphisms at the JUND locus do not contribute to disease risk. 
 
The potential of genetic studies in human complex disease was dramatically altered by the 
publication of the first GWAS study in 2005 and as of the 9
th
 September 2011, the catalogue 
of published GWAS studies reports that 1003 such studies have been published identifying 
4978 SNPs to be significantly associated with disease risk at a P<1.0x10
-5
 (Hindorff et al., 
2011). The GWAS studies harnessed the data from the international HapMap project and the 
development of whole genome genotyping arrays to achieve these successes (Ku et al., 2010). 
However the majority of disease associated risk alleles that the studies have captured are 
linked with small effect sizes with odds ratios less than 1.5 (Altshuler et al., 2008; Hindorff et 
al., 2009) and this means they account for only a minor proportion of the total inherited risk 
(Manolio et al., 2009).  This has led authors to discuss whether the value of GWAS lies not as 
a tool for identifying an individual’s risk of disease but rather as a tool for identifying the 
biological pathways that underlie a disease (Hirschhorn, 2009) or even that the focus should 
move away from trying to find new variants through ever increasing sample sizes to 
identifying rare variants with larger effects that can explain disease heritability (Goldstein, 
2009). One of the limitations of the GWAS approach is that lower frequency alleles less than 
5% are not well surveyed by the genotyping arrays and that most GWAS studies have lower 
power to detect the common alleles that have low effect sizes (odds ratios <2) leading to ever 
growing sample sizes in consortium based studies and meta-analyses (Ku et al., 2010). 
Targeted resequencing approaches may have real value in investigating the regions identified 
by GWAS made possible by the advance in high throughput sequencing technologies and 
they quickly began to bear fruit as exemplified by the association of rare variants in IFIH1 
with protection against type 1 diabetes (Nejentsev et al., 2009). Other approaches that focus 
on cohorts with extreme phenotypes such as severe early onset obesity may have improved 
power for discovering rare variants particularly when combined with follow up studies in 
410 
 
case-control and population cohorts (Bochukova et al., 2010; Walters et al., 2010). The 
integration of GWAS data with systems genetics approaches to analyse gene networks in 
animal models may also give insights into novel disease associated pathways and variants of 
lower effect sizes as seen in the link between a trans-acting interferon regulatory factor 7 
(IRF7)-driven inflammatory network (IDIN) and type 1 diabetes risk (Heinig et al., 2010). 
 
Genetic studies in human patients with the main Crgn associated diseases such as ANCA-
associated vasculitis (Tarzi et al., 2011) have been mostly limited to candidate gene studies. 
The rarity of vasculitis cases in the population and the resulting lack of family data has 
previously raised questions by authors as to whether there is enough evidence of a genetic 
contribution to the risk of disease to carry out genetic studies though these concerns have 
been addressed by studies showing increased risks of Wegener’s granulomatosis in first 
degree relatives of cases (Knight et al., 2008; Monach and Merkel, 2010). To date, no 
genome wide association studies (GWAS) have been formally published for the ANCA 
associated systemic vasculitides or to investigate specifically SLE with renal involvement 
(Hindorff et al., 2011) although there have been GWAS studies for SLE in general (Graham 
et al., 2008; Harley et al., 2008; Hom et al., 2008; Han et al., 2009) and for Behçet’s disease 
in cohorts of Japanese patients (Mizuki et al., 2010) and Turkish patients (Remmers et al., 
2010) both of which found associations with IL23R-IL12RB2 and IL10 loci. The majority of 
studies have been candidate gene studies and these have continued to be published since the 
beginning of the GWAS era possibly reflecting the challenges of finding adequate sample 
sizes in rare disease populations. These studies have given important insights into the 
diseases such as the linking of a number of associations with the HLA region in particular the 
HLA-DPB1 region (Heckmann et al., 2008; Stassen et al., 2009) as well as with CD226 in a 
large study of Wegner’s patients (Wieczorek et al., 2009) and copy number variation in 
FCGR3B (Fanciulli et al., 2007). There have been GWAS studies performed for other 
autoimmune diseases that can cause crescentic glomerulonephritis in particular, SLE though 
none of the studies have specifically looked at lupus nephritis, tending to look at the disease 
group in general (Graham et al., 2008; Harley et al., 2008; Hom et al., 2008; Han et al., 
2009). It has been investigated as a subphenotype in two studies by Yang et al with a 
marginally significant association (Odds ration= 1.25, P-value = 0.02) found in a SNP linked 
with the gene Elf1 in patients from Hong Kong  in one of the studies (Yang et al., 2010; Yang 
et al., 2011).  
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A GWAS in ANCA-associated systemic vasculitis has been undertaken by the European 
Vasculitis Genetics Consortium but thus far has only been presented in abstract form 
(Trivedi, 2011). The abstract reports the successful genotyping of 911 samples from 
Caucasian patients with clinical serological and histological evidence of Wegener’s 
granulomatosis or microscopic polyangiitis and 6000 controls from the Wellcome Trust Case 
Control Consortium. The authors reported that 190 SNPs were associated with disease 
susceptibility at a P-value<5x10
-8
. A replication experiment has also been undertaken in 140 
SNPs in DNA samples from continental Europe. The strongest reported association is to the 
major histocompatibility complex (MHC) region (P=4.5x10
-81
) and the authors report 
confirming two previously reported associations and have identified 6 novel ones.  
 
The potential to investigate further the rarer polymorphisms at the JUND locus identified by 
sequencing the JUND locus in a cohort of French vasculitis patients as detailed in 6.2.3.1 was 
explored for the larger patient cohort used in 6.2.3.2 but the high GC content of the proximal 
promoter of JUND meant that customized tagging SNP assays or ARMS (amplification-
refractory mutation system) assays could not be designed or performed for the larger patient 
cohort. The more recent technological advances in high throughput sequencing do give the 
potential for future and further studies of the locus (Mardis, 2008). With rarer diseases such 
as ANCA vasculitis and crescentic glomerulonephritis, approaches such as those discussed 
above in investigating extreme phenotypes such as severe relapsing or treatment resistant 
cases or leveraging the power of animal models may be well placed to give insights in the 
future into the biological pathways underlying disease risk. 
 
6.4 Conclusions 
In conclusion the histological analyses in this chapter demonstrate that JUND is widely 
expressed in human renal tissue including diseased glomeruli and macrophages though no 
differences in its expression can be detected between inflammatory and non-inflammatory 
disease processes. In the rat NTN model, Southwestern histochemistry confirmed that AP-1 is 
activated in nephritic glomeruli compared to controls fitting in with previous findings in the 
NTN model. The genetic studies in humans demonstrated that, within their limitations of 
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sample size, no genetic variants at the JUND locus were associated with the risk of 
developing ANCA-associated vasculitis. 
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Chapter 7. General Discussion 
 
The aim of the work presented in this PhD project was to investigate the mechanisms 
underlying the regulation of macrophage activation and glomerular inflammation by Jund in 
both the nephrotoxic nephritis (NTN)-susceptible WKY rat strain and in human patients with 
crescentic glomerulonephritis (Crgn). The major objectives were to identify the key genes 
and pathways underlying JunD-mediated activation of macrophages by utilising state-of-the-
art genomic technologies including the combined use of high throughput sequencing with 
genome-wide expression analysis and whether genetic variation at the JUND and other AP-1 
member loci in patients with renal disease is linked with susceptibility to glomerular disease.  
 
Macrophages are the predominant immune effector cell in Crgn as demonstrated by multiple 
studies in animal models of Crgn (Holdsworth et al., 1981; Tang et al., 1996; Isome et al., 
2004; Duffield et al., 2005). The investigation of Crgn in animal models has been able to give 
insights into the pathogenesis of crescent formation linked with macrophage effector function 
along with insights into genetic factors underlying disease susceptibility. The NTN model in 
the WKY rat strain, in particular, has enabled the role of cell-mediated innate immunity, 
particularly of macrophages, in crescent formation to be studied (Cook et al., 1999; Tam et 
al., 1999). WKY rats are uniquely susceptible to NTN, developing progressive proteinuria 
and proliferative necrotising crescentic glomerulonephritis at doses of NTS that are sub-
nephritogenic in the other rat strains (Kawasaki et al., 1992; Aitman et al., 2006). This unique 
susceptibility demonstrated by the WKY rat compared to the Lewis rat (LEW), with which it 
shares the same MHC haplotype led to the study of its underlying genetic determinants 
(Aitman et al., 2006). Seven quantitative trait loci underlying the unique susceptibility of the 
WKY strain have been identified (Crgn1-7) (Aitman et al., 2006). Copy number variation in 
the Fc receptor Fcgr3 was linked to NTN susceptibility at Crgn1(Aitman et al., 2006) whilst 
the AP-1 transcription factor JunD was identified as a determinant of macrophage activation 
associated with NTN susceptibility at Crgn2 (Behmoaras et al., 2008). The two loci influence 
the NTN disease model by altering the level of macrophage activation as demonstrated by 
functional assays including antibody mediated cytotoxicity assays, Fc-oxyBURST and 
opsonised bead phagocytosis (Aitman et al., 2006; Behmoaras et al., 2008; Behmoaras et al., 
2010). Jund was found, using siRNA knockdown experiments. to also directly modulate 
macrophage activation in functional assays (Behmoaras et al., 2008). Gene expression studies 
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have also identified that a large number of genes are differentially expressed between the 
bone marrow derived macrophages (BMDMs) from the WKY and LEW strains both in a 
serum starved basal condition and following 24 hours of prolonged lipopolysaccharide (LPS) 
stimulation (Maratou et al., 2010).  
 
The use of LPS stimulation is an in vitro approach for activating the innate immune response 
in macrophages via Toll-like receptor signalling pathways. This initiates a now well 
characterised and robust response in the macrophage and LPS activated signalling pathways 
intersect with many critical pathways controlling cellular proliferation, apoptosis, endocytosis 
and secretion (Nilsson et al., 2006). Investigating the response to LPS in macrophages has 
wide implications for macrophage biology as a way of gaining insights into the mechanisms 
that underlie the complex responses to infection and tissue injury and has become the 
favoured approach in investigating the function of transcription factors in shaping the LPS 
response (Gilchrist et al., 2006; Foster et al., 2007; Hargreaves et al., 2009; Barish et al., 
2010; Ghisletti et al., 2010).  
 
The response to LPS stimulation at the transcriptome level in BMDMs from the WKY and 
LEW strains and the congenic WKY.LCrgn2 strain where the Crgn2 QTL from the LEW 
strain was introgressed onto the WKY genetic background were examined using microarrays 
and the results are detailed in Chapter 3 and Chapter 4. The BMDMs from four biological 
replicates per strain were cultured simultaneously and the RNA harvested in the basal state 
and after two, four and eight hours of LPS stimulation. This allowed for a number of different 
detailed comparisons to be made of the resulting microarray data. The first comparisons 
detailed in Chapter 3 were made between the parental strains which are the NTN-susceptible 
WKY and the NTN-resistant LEW strains in order to understand how the early LPS 
responses differ between the strains and to identify the key effector genes mediating the 
macrophage activation response along with potential positional candidates for the Crgn3-7 
QTLs. Chapter 4 detailed the second comparison that was made investigating the differences 
between the WKY and WKY.LCrgn2 congenic strain during the LPS response. 
 
Stimulation with LPS induced major changes in the BMDM transcriptome which occurred 
rapidly, so that even by two hours of LPS stimulation, 7,509 genes were differentially 
expressed in WKY BMDMs and 10,234 genes were differentially expressed in LEW 
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BMDMs compared to their basal states (Table 3.1). The LPS response was markedly similar 
in the WKY, LEW and WKY.LCrgn2 strains with a substantial component common to all 
strains (Table 4.1, Figure 4.1). Whilst LPS induced the upregulation of genes, the majority 
of genes were actually downregulated which is consistent with the literature (Hume et al., 
2002; Nau et al., 2002; Ravasi et al., 2007; Ramsey et al., 2008). The differential expression 
of key early response genes identified by other studies (Ramirez-Carrozzi et al., 2006; 
Ramirez-Carrozzi et al., 2009) was also observed (Table 3.32). 
 
Whilst there were commonalities in the LPS response, the data analysis presented in Chapter 
3 also demonstrated that there were differences in gene expression between the BMDMs of 
the WKY and LEW strains. The static timepoint analysis between the WKY and LEW 
discovered that a large number of genes were differentially expressed between the two strains 
at each LPS stimulation timepoint investigated (Table 3.9). At each timepoint, a number of 
genes demonstrated robust fold differences greater that five-fold between WKY and LEW 
BMDMs. However, only a minority were located within a Crgn QTL suggesting that the 
majority of the genes identified as differentially expressed between the strains had effector 
functions. Whilst intrinsic cell factors do account for some of the susceptibility seen to NTN 
in the WKY strain (Smith et al., 2007), it is likely that genes identified with robust or 
consistent differential gene expression across the timepoints could be positional candidates 
for Crgn QTLs underlying BMDM driven Crgn susceptibility. Cytochrome P450, family 2, 
subfamily j, polypeptide 4 (Cyp2j4) was a prominent example of this located in Crgn5. It 
demonstrated robust differences in expression across all four timepoints between the WKY 
and LEW strains (Figure 3.5). Cyp2j4 metabolises arachidonic acid to produce 
epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE) (Zhang et 
al., 1997). Its function in macrophages is uncertain but, as discussed in 3.3.4.1, there are 
potential links to roles promoting cell proliferation and inhibiting apoptosis in leukaemia cells 
(Chen et al., 2011a). Notably it is not differentially expressed between mesangial cells from 
WKY and LEW BMDMs (J Behmoaras, CCIR, Imperial College, personal communication). 
Such a finding means that Cyp2j4 is an attractive candidate for further study in macrophage 
function and the NTN model as a candidate gene for the Crgn5 QTL and a target gene for 
knockout in the WKY rat.  
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A number of other genes located in Crgn QTL regions are potential positional candidates for 
the loci though none demonstrate the same robust level of differential expression as Cyp2j4. 
Of note, most have uncertain functions and only a minority have known functions in 
macrophages but their potential roles in other cell types suggest that they could play a role in 
shaping the WKY BMDM phenotype, meriting further investigation. Crgn4 contained a 
number of positional gene candidates including breast cancer anti-estrogen resistance 3 
(Bcar3) which was 2.5-fold overexpressed in basal WKY BMDMs and is known to regulate 
the non-receptor protein-tyrosine kinase c-Src in breast cancer cells with functions in in cell 
proliferation, survival and migration (Schuh et al., 2010). In addition Crystillin zeta (Cryz) 
was 1.9-fold overexpressed in basal WKY BMDMs and causes the higher stability and 
expression of the anti-apoptotic gene Bcl-2 in leukaemic cells (Lapucci et al., 2010). In 
Crgn6, Mediterranean fever (Mefv) demonstrated differential expression during the 
timecourse at two and eight hours of LPS stimulation. Mefv is also known as pyrin and 
associated with inflammasomes, which are key regulators of the innate immune response 
linked to multiple autoinflammatory disorders (Lamkanfi, 2011). Assembly of the 
inflammasome results in the activation of caspase 1 which is a cysteine proteinase that 
matures the proinflammatory forms of interleukin-1β (Il-1β) and IL-18 (Lamkanfi, 2011). 
Mefv regulates caspase-1 and, as a consequence, has been linked with both pro and anti-
inflammatory roles (Chae et al., 2003; Yu et al., 2005; Chae et al., 2006; Papin et al., 2007; 
Seshadri et al., 2007). It may be that the regulation of IL1-β processing is not its main 
function (Seshadri et al., 2007) and, for example, mice with mutated forms of the protein also 
show heightened sensitivity to endotoxin and a defect in macrophage apoptosis through an Il-
1-independent pathway (Chae et al., 2003).   
 
The identification of effector gene candidates in the LPS response in WKY BMDMs was an 
important finding in the dataset as was the confirmation of previously identified effector 
genes for the NTN model. One such example is the purinergic receptor P2X, ligand-gated ion 
channel, 7 (P2rx7) which has a well-recognised proinflammatory role in immune-mediated 
renal injury (Turner et al., 2007; Taylor et al., 2009). MCP-1 has chemotactic activity for 
monocytes and anti-MCP-1 antibodies reduce crescent formation in WKY NTN disease by 
reducing the numbers of macrophages within the glomerulus (Wada et al., 1996). Mesangial 
cells from the glomeruli of WKY rats along with their BMDMs produce significantly higher 
levels of monocyte chemoattractant protein 1 (MCP-1) than the LEW strain (Smith et al., 
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2007). It is notable, therefore, that the receptor for MCP-1, chemokine (C-C motif) receptor 2 
(Ccr2) is also overexpressed in WKY BMDMs after four hours of LPS stimulation (Table 
3.33 and Appendix A, Figure A.7) suggesting that its upregulation could contribute to the 
increased infiltration of macrophages to the glomerulus seen in WKY NTN.  
 
Chapter 4 detailed the second comparison that was made investigating the differences 
between the WKY and WKY.LCrgn2 congenic strain during the LPS response. Functionally 
the congenic strain exhibits a reduced level of activation in comparison to the WKY rat and 
demonstrates a reduced level of disease demonstrating that genes within the Crgn2 QTL 
influence key response pathways in the macrophage (Behmoaras et al., 2008). The analysis of 
static timepoints between WKY and WKY.LCrgn2 BMDMs, whilst only identifying a 
relatively small number of differentially expressed genes in comparison to the analyses 
between the WKY and LEW strains, did identify possible effector genes that could influence 
macrophage activation and link with the pathogenesis of Crgn. Caveolin 1 (Cav1) which 
demonstrated 1.42-fold overexpression in WKY.LCrgn2 BMDMs after two hours of LPS 
stimulation has been linked with anti-inflammatory roles in macrophages (Wang et al., 2006) 
and is overexpressed in apoptotic macrophages (Gargalovic and Dory, 2003). After four 
hours of LPS stimulation, POU class 2 homeobox 2 (Pou2f2, also known as Oct2) was 1.73-
fold overexpressed in WKY BMDMs. Its activation is crucial for the transcriptional 
activation of Nos2 in LPS stimulated macrophages (Lu et al., 2009). At the same timepoint, 
slit homology 2 (Slit2) was 2.13-fold higher in WKY.LCrgn2 BMDMs. In a rat model of 
Crgn, administration of an anti-Slit2 antibody accelerated disease whilst Slit2 administration 
improved disease through inhibiting chemo-attractant mediated signals for macrophages 
(Kanellis et al., 2004).   
 
Analysis of the overall timecourse between WKY and WKY.LCrgn2 BMDMs identified that 
830 genes demonstrated a different expression profile between the strains at a 5% FDR 
threshold. Overall, this set of genes, in gene ontological analyses, were involved in functional 
processes linked to how the cell responds to simulation such as the response to organic 
substance, wounding and LPS as well as overall cell activation, the regulation of anti-
apoptosis and programmed cell death and the Jak-STAT signalling pathway (Table 4.17). 
These terms suggested that the effect of Crgn2 on the WKY transcriptome was to alter 
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multiple process in the response to stimulation and this large gene set contained key effectors 
for the WKY BMDM phenotype.  
 
Within this set of 830 genes, a number of candidates were identified, and were validated by 
qRT-PCR, that could play important inflammatory effector roles in the WKY BMDMs and 
were relevant to the NTN model as a whole. Such candidates merit prioritisation for 
confirmatory studies for the identified difference in mRNA expression at the protein level 
between WKY and WKY.LCrgn2 BMDMs and for further functional studies in WKY 
BMDMs and the NTN model overall. Cysteine dioxygenase 1 (Cdo1) was under the 
influence of the Crgn2 interval (Figure 4.10) and directly affected by siRNA knockdown of 
Jund (Table 4.31). Cdo1 has previously been shown  to be under the influence of Jund  in a 
microarray analysis of Jund
-/-
 cell lines associated with protection from oxidative stress 
(Gerald et al., 2004). Serpinb2 is a potential effector molecule identified in both the WKY 
and LEW BMDM comparative analysis and is under the influence of Crgn2 (Figure 4.9). 
Serpinb2 is able to inhibit TLR4-induced macrophage apoptosis thereby preventing rapid 
macrophage death and premature cessation of the innate immune response (Park et al., 2005). 
The striking difference in expression of Serpinb2 between WKY and LEW BMDMs suggests 
that this could be a major effector molecule for the WKY BMDM phenotype and suggests 
that antiapoptotic mechanisms could play a role in the NTN disease model. The effect of the 
Crgn2 locus suggests that Serpinb2 is influenced by AP-1 transcription factor which along 
with other genetic loci results in the prolonged survival of WKY BMDMs enhancing their 
ability to cause damage and drive the immune response. 
 
Enrichment for the JAK-STAT pathway was a novel discovery in this analysis and key genes 
within the pathway such as Janus kinase two and three (Jak2, Jak3) along with signal 
transducer and activator of transcription (Stat)-5a and Stat3 demonstrated altered time 
courses of expression (Table 4.19). The link between differences in gene expression in 
elements of the signalling pathway and the amount and activity of phosphorylated proteins 
within this pathway is uncertain but these differences do highlight the potential importance 
for this pathway in the disease model. Signalling through the JAK-STAT pathway is 
important for the kidney's response to injury in disease and there is evidence for a role for 
STAT3 fibrosis as seen in a number of disease models linked with fibrosis such as diabetic 
nephropathy, unilateral ureteral obstruction and anti-Thy1 glomerulonephritis (Yanagita et 
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al., 2001; Chuang and He, 2010; Pang et al., 2010). The pathway is involved in renal 
ischaemia/reperfusion injury as JAK2 blockade reduced disease by reducing macrophage 
accumulation and tubular epithelial cell apoptosis (Yang et al., 2008) as well as in a mouse 
model of lupus nephritis where its inhibition reduced disease (Dong et al., 2007; Wang et al., 
2010). Activation of STAT3 has also been identified in a number of types of human 
glomerulonephritis including lupus nephritis, IgA nephropathy and vasculitis (Arakawa et al., 
2008).  
 
Along with the investigation of the effect of the Crgn2 locus on the NTN phenotype and 
macrophage activation, the AP-1 transcription factor Jund was associated with 
glomerulonephritis susceptibility at the locus and was a direct determinant of macrophage 
activation (Behmoaras et al., 2008). Therefore, as well as demonstrating the effect of Crgn2 
on the BMDM transcriptome over the eight hour LPS timecourse, it was essential to 
demonstrate similar effects when the expression level of Jund was altered in isolation acutely 
rather than due to a chronic genetically determined change. The result of siRNA knockdown 
of Jund compared to transfection with scrambled control siRNA was to cause major changes 
in the BMDM transcriptome in both unstimulated and eight hour LPS stimulated BMDMs 
(Table 4.24).  Whilst a number of genes showed extremely robust fold differences between 
the two siRNA groups (Table 4.25), it is notable that the majority of genes showed only 
moderate changes in gene expression, particularly less than 1.5-fold suggesting that the action 
of Jund was fine-tuned gene expression responses after LPS stimulation. In unstimulated 
BMDMs, genes with higher expression in the scrambled control siRNA transfected group, i.e. 
with higher Jund expression, were associated with responses to LPS and regulation of cell 
activation showing that the ability of the cell to respond to stimulation was fundamentally 
altered by changing the level of Jund expression (Table 4.26). Pathway analysis was in line 
with this (Table 4.27) with enrichment seen in scrambled control siRNA transfected BMDMs 
for the NOD-like receptor signalling pathway and apoptosis along with cytokine-cytokine 
receptor interaction, chemokine signalling pathway and cell adhesion molecules suggesting 
that the BMDM in this state was poised and more able to respond to inflammatory stimuli.  
 
In the timecourse analysis between WKY and WKY.LCrgn2 BMDMs, 830 genes were 
identified that significantly changed over the eight hours of LPS stimulation. The analysis of 
unstimulated BMDMs following siRNA knockdown of Jund identified 1,672 genes that were 
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differentially expressed compared to scrambled control siRNA and that 1,476 genes were 
differentially expressed following Jund knockdown after eight hours of LPS stimulation. 
These differences suggest that adaptation to the chronic reduction in Jund level had occurred 
in WKY.LCrgn2 BMDMs and that functional redundancy with other AP-1 transcription 
factor proteins could be occurring. In addition, adaptation to the effects of the other genes 
located within the Crgn2 congenic interval could also be a factor in the differences seen.  
 
An overlap between the set of genes differentially expressed in the timecourse between WKY 
and WKY.LCrgn2 BMDMs and the siRNA knockdown datasets identified that 201 genes 
were directly controlled by alterations in Jund expression and were differentially expressed 
between WKY and WKY.LCrgn2 BMDMs. Seven genes were identified that had greater 
than two-fold differences in expression between scrambled control and Jund siRNA 
transfected BMDMs (Table 4.35). All were present in the unstimulated dataset between 
scrambled control and Jund siRNA transfected BMDMs. Cdo1, as well as Arginase (Arg1) 
had been identified already as prominent effector candidates mediating Jund function. 
Metallothionein 2A (Mt2A) demonstrated 4.58-fold higher expression in scrambled control 
siRNA transfected WKY BMDMs compared to Jund siRNA transfected BMDMs. Mt2a is an 
intracellular metal-binding protein whose overexpression is frequently observed in invasive 
human breast cancers and  AP-1 along with NF-κB is required for this process (Kim et al., 
2011b). Mt2a has been linked with protective roles again oxidative stress and protection 
against apoptosis in multiple different cell types (Kang et al., 2003; Reinecke et al., 2006; 
Yamasaki et al., 2007; Yang and Chitambar, 2008; Xue et al., 2009). Jund has previously 
been associated with protective roles against oxidative stress (Gerald et al., 2004) and the 
findings that Jund can directly alter the expression of Mt2a identifies it as a potential key 
effector gene in the WKY BMDM overactivation phenotype mediating the protective effects 
of Jund against oxidative stress. 
 
A major theme identified by the analysis was the differences that were occurring in the 
regulation of cell death and apoptosis between the WKY and LEW strains. These terms were 
prominent in the functional enrichment analyses, especially linked with genes demonstrating 
significantly higher expression in LEW BMDMs. A number of QTL candidate genes, such as 
Cyp2j4, and effector genes, such as Cdo1, are also associated with such functions. The  
progression of innate immune responses may be regulated at the level of macrophage survival 
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(Park et al., 2005) and these findings suggest that an important difference between the 
BMDMs from the WKY and LEW strains that is influenced by the Crgn2 congenic interval 
and within that QTL, Jund, might be their ability to survive in the inflamed glomeruli of the 
NTN model and prolonged survival by WKY BMDMs could lead to enhanced activation and 
increased inflammatory damage.   
 
The transcriptional drivers of the LPS response were observed to be very similar in the 
individual responses of the WKY and LEW and WKY.LCrgn2 strains. By two hours of LPS 
stimulation, there was enrichment for NF-κB and IRF transcription factors in genes with 
increased expression in WKY, LEW and WKY.LCrgn2 BMDMs (Table 3.7, 4.5). In WKY 
and LEW BMDMs there was also enrichment in downregulated genes for the transcription 
factor CREB which plays major roles in immune responses including inhibiting NF-κB 
activation (Wen et al., 2010). Whilst the main drivers were shared in common, their 
contribution to the LPS response was different. Motif enrichment analysis of the 
differentially expressed gene sets found a positive enrichment of IRF binding sites with a 
higher contribution to the increased expression of genes in basal WKY BMDMs compared to 
LEW BMDMs (Table 3.32). This suggests that genetic factors could alter the IRF driven 
transcriptional response after LPS stimulation in WKY BMDMs compared to LEW BMDMs. 
IRF transcription factors regulate the expression of proinflammatory cytokines and have 
associations with inflammatory renal disease. Polymorphisms in IRF5 are associated with 
susceptibility to SLE in humans (Hom et al., 2008; Han et al., 2009; Chung et al., 2011) and, 
along with Irf1, mediate development of lupus in murine models (Reilly et al., 2006; Tamura 
et al., 2008; Tada et al., 2011). In basal WKY BMDMs, IRF-7 demonstrates significantly 
higher expression in WKY BMMDs compared to LEW BMDMs and, as it functions as a 
master regulator for IFN-α proinflammatory cytokines (Tamura et al., 2008; Santana-de Anda 
et al., 2011), if this translated to differences in its expression at the protein level, this could be 
a major factor contributing to the differences in the overall LPS response in the WKY strain 
compared to the LEW strain. Motif enrichment analysis also identified enrichment for AP-1 
transcription factor motifs within the genes upregulated in basal WKY BMDMs compared to 
LEW BMDMs (Table 3.26) and this was also evident after two hours of LPS stimulation 
(Appendix A, Table A.6). This demonstrates that AP-1 transcription factor does contribute 
to the LPS response in this strain. This is highly relevant as JunD is part of the Jun family of 
proteins which are the major constituent members of the AP-1 family.  
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As a constitutive transcription factor, JunD would be expected to bind widely in the genome 
of the rat BMDM and the evidence gathered from the phenotype of the Jund
-/-
 mouse and the 
data in the NTN model would suggest that a range of genes involved in developmental 
processes along with genes involved in the innate immune response would be influenced by 
JunD. In addition the marked changes in expression of the transcription factor between WKY 
and WKY.LCrgn2 BMDMs would also be expected to alter its overall binding profile. The 
advances in high throughput sequencing technology allow for the genome wide binding 
profiles of transcription factors to be identified using ChIP-Seq. Chapter 5 detailed the 
results of the ChIP-Seq based approach that was used to map the genome wide binding 
profile of JunD in basal and LPS stimulated WKY and WKY.LCrgn2 BMDMs. The 
experiment aimed to gain insights on how the genetically determined differences in JunD 
expression alters its set of cis-acting targets at the genome scale level (Lupien et al., 2008; 
Lupien and Brown, 2009). The main effect of altering JunD expression was to significantly 
alter the amount of JunD-binding events within the genome. JunD-binding peaks were 
distributed throughout the genome and were similar between the strains and conditions. The 
relatively large proportion of intergenic peaks, between 35% of peaks in WKY LPS-
stimulated BMDMs and 44% of peaks in WKY.LCrgn2 basal BMDMs was comparable to 
other data sets (Barish et al., 2010; Ghisletti et al., 2010). A substantial proportion, however, 
were located in the promoter region of the gene and within the gene body itself (Figure 5.3). 
The association of peaks with the nearest gene identified that 5.339 unique transcripts were 
associated with a peak in WKY basal BMDMs and 7,612 transcripts in WKY LPS stimulated 
BMDMs. In contrast there were considerably fewer genes in WKY.LCrgn2 BMDMs that 
were linked with 2,606 linked transcripts in the basal state and 1,022 in the LPS stimulated 
state. Putting this into context with the transcriptomic data, after two hours of LPS 
stimulation in WKY BMDMs, 7509 transcripts were differentially expressed rising to 11,616 
at four hours of LPS stimulation and 9,807 after eight hours (Table 4.1). This shows that in 
comparison to the overall numbers of genes responding to LPS, JunD, even in WKY 
BMDMs, only binds to a proportion of transcripts showing that it has specific functions and 
not a global role as seen for factors such as PU.1 (Ghisletti et al., 2010).  
 
The genes associated with peaks in all the strains demonstrated core functions for JunD in the 
macrophage with enrichment seen for antigen processing and presentation (Table 5.4, 5.5, 
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5.8 and 5.9). Regardless of the stimulation or activation state, JunD peaks were associated in 
WKY BMDMs with multiple developmental functions fitting with its role as a constitutive 
transcription factor including ectoderm and epithelium development, cardiac and 
reproductive developmental processes (Table 5.12) which are highly relevant because of the 
impaired fertility and cardiac abnormalities observed in the Jund
-/-
 knockout mouse (Thepot 
et al., 2000; Hilfiker-Kleiner et al., 2005). In WKY BMDMs, this suggests JunD functions 
not just to increase macrophage activation but could also act as a determinant of more 
fundamental cellular phenotypes (Table 5.12). The cistrome evidence presented suggests that 
the overexpression of JunD in WKY rats enables it to bind to an increased number of genes 
with the potential to influence multiple processes.  
 
The analysis of the JunD cistrome ultimately aimed to understand how the binding pattern of 
JunD in the WKY and WKY.LCrgn2 resulted in the differences seen in the LPS response 
over an eight hour timecourse between WKY and WKY.LCrgn2 BMDMs. The analysis of 
the effect of siRNA knockdown of Jund in WKY BMDMs confirmed that JunD is able to 
alter the expression of genes in BMDMs both in the unstimulated and LPS stimulated state 
(Table 4.20). Whilst multiple genes are present in the Crgn2 congenic interval, the fact that 
Jund, as a major determinant of macrophage activation and the positional candidate within 
the Crgn2 QTL (Behmoaras et al., 2008), is a transcription factor suggests that JunD-bound 
genes could underlie the differences in gene expression seen between WKY and 
WKY.LCrgn2 BMDMs in the stimulation time course. There were 6,976 unique JunD-bound 
genes in LPS stimulated WKY BMDMs compared to only 386 in LPS stimulated BMDMs 
from the WKY.LCrgn2 strain. The JunD-bound genes in the LPS-stimulated WKY BMDMs 
associated with multiple immune processes including the protein kinase cascade, cell 
activation and the regulation of responses to external stimulus and the MAPK signalling 
pathway (Table 5.10). This demonstrates that the increased expression of JunD in WKY 
BMDMs compared to WKY.LCrgn2 BMDMs results in JunD interacting with multiple genes 
that determine how the macrophage responds to the LPS stimulus.  
 
In this ChIP-Seq study, an early timepoint (two hours of LPS stimulation) in the LPS 
response was analysed in order to understand how interactions of JunD with the genome at 
this timepoint could lead on to the differences seen in gene expression after this time. Such a 
view has been used in other studies linking the two hour timepoint with gene expression 
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changes at eight hours of LPS stimulation in mice macrophages stimulated with LPS 
(Ghisletti et al., 2010). It is, therefore, pertinent that the major transcriptomic differences 
between WKY and WKY.LCrgn2 BMDMs occurred later in the timecourse, mostly at eight 
hours of stimulation (see Chapter 4). Whilst these changes in effector gene expression may 
not be the same as the genes bound by JunD earlier in the timecourse, genes that were bound 
by JunD and were differentially expressed could be some of the main mediators through 
which JunD is able to alter macrophage activation. Of the 830 genes that showed differential 
expression over the timecourse of LPS stimulation between WKY and WKY.LCrgn2 
BMDMs, 112 genes were JunD-bound and of this, 76 were also differentially expressed 
between WKY BMDMs and LEW BMDMs, relevant as the Crgn2 from the NTN-resistant 
LEW strain is introgressed onto the WKY background in the WKY.LCrgn2 congenic strain. 
These genes showed enrichment for functions linked to the response to molecules of bacterial 
origin, organic substances and LPS (Table 5.14). These results demonstrate that JunD 
interacts with genes that determine how BMDMs are able to respond to LPS. 
 
These findings between the WKY and WKY.LCrgn2 strains reflect how the chronic 
difference in JunD expression could alter the LPS response and by inference how the WKY 
BMDMs in the NTN-model could respond differently when infiltrating the inflammatory 
glomeruli. In this chronic setting, redundancy within the AP-1 transcription factor could limit 
the effect the difference in Jund expression had on macrophage behaviour. An acute change 
in Jund expression was examined by siRNA knockdown. There were 343 genes that were 
differentially expressed between scrambled control and Jund siRNA transfected WKY 
BMDMs in either the unstimulated or LPS stimulated state that had JunD-binding peaks. 
Confirming the findings observed between the WKY and WKY.LCrgn2 BMDMs, these 343 
genes were functionally associated to the response to organic substance, intracellular 
signalling cascades and cell activation showing that Jund could be a determinant of 
macrophage activation by altering how the BMDMs are able to respond to stimulation.  
 
Combining these sets of genes identified 35 different genes, apart from Jund itself that had a 
LPS-inducible JunD-peak, were differentially expressed between WKY and WKY.LCrgn2 
BMDMs and were directly influenced by siRNA knockdown of Jund in either the 
unstimulated or LPS stimulated states (Table 5.16). Within this set of genes could lie some of 
the key mediators of how Jund functions to determine macrophage activation. For example, 
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tumour necrosis factor receptor superfamily, member 1A (Tnfrsf1a) is one of the main 
receptors mediating TNF-α signalling and can activate NF-κB as well as mediate apoptosis 
and regulate inflammation. Mutations in the gene cause the autosomal dominant multisystem 
auto-inflammatory disorder tumour necrosis factor receptor (TNFR) associated periodic 
syndrome (TRAPS) (Stojanov and McDermott, 2005). Blockade of TNF-α has been shown 
previously to reduce inflammation and scarring in the NTN model (Khan et al., 2005). 
Mitogen-activated protein kinase kinase 3 (Map2k3) participates in the MAP kinase-mediated 
signalling pathway to activate p38-MAPK and blockade of p38-MAPK has been shown 
previously to reduce Crgn in the NTN model (Sheryanna et al., 2007).  
 
The work presented in Chapter 6 aimed was to investigate JUND expression in human renal 
biopsy sections to investigate if the expression pattern of JUND was linked to the severity of 
glomerular inflammation and whether the overall pattern of AP-1 transcription factor binding 
and activity in glomerular disease was linked to glomerular inflammation. In addition two 
different approaches were used to investigate whether any genetic polymorphisms at the 
JUND locus were associated with the risk of developing ANCA-associated vasculitis and 
Crgn.  
 
The first investigation in human renal biopsy sections used standard immunohistochemical 
techniques to identify the pattern of JUND staining in biopsy sections and the degree of 
macrophage infiltration seen. Staining for macrophage infiltration confirmed that infiltration 
of macrophages occurs in glomerular inflammation as shown by the increased numbers of 
macrophages in the cases of systemic lupus erythematosus (SLE) in comparison to the 
minimal change disease (MCD) and thin basement nephropathy (TBM) groups where very 
few macrophages were seen. The work also found that, as a constitutive transcription factor, 
JUND is expressed widely within cells of both the glomerulus and the tubulo-interstitial 
compartment in both nephritic kidneys as demonstrated by the widespread staining in cases 
of SLE nephritis and in renal disorders without inflammation as demonstrated by the MCD 
and TBM groups. Whilst double staining for macrophage markers and JUND was not 
performed, examination of the renal biopsy sections confirmed that JUND was expressed in 
human macrophages infiltrating nephritic glomeruli. 
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Southwestern histochemistry was used as a technique to probe for active AP-1 transcription 
factor binding in the nephritic glomeruli of the WKY rat following NTN induction. A change 
in AP-1 binding was evident between day 0 of the model and day 8 showing that AP-1 is 
activated after NTN induction fitting with previous findings for a role of JunD and AP-1 in 
crescentic glomerulonephritis (Sakurai et al., 1997; Sakurai and Sugita, 1998; Behmoaras et 
al., 2008). There were however methodological challenges that resulted in a level of 
reproducibility and consistency of the technique that was not good enough for the method to 
be applied to human renal biopsies. 
 
Two approaches were used in human genetic studies of patients with ANCA-associated 
vasculitis which is the disease that most commonly causes Crgn. The first approach involved 
sequencing the JUND locus in 99 French patients with ANCA vasculitis. Analysis of the 
sequencing results identified that two novel polymorphisms not contained within the dbSNP 
database (Sherry et al., 2001) were located within the proximal promoter region of the gene. 
No differences in the frequency of three recognised SNPs in the single exon coding region of 
the gene were identified. A weak association between a haplotype involving SNPs in the 
promoter region of the gene was found with a P-value of 0.037 but the size of the cohorts 
used means that greater significance could not be reached as the power to detect small effects 
was low. It did however highlight the potential for studying genetic variation in more detail at 
this locus. A tagging SNP study was performed that surveyed a wider region around the 
JUND locus. Whilst 275 cases and 959 controls were successfully genotyped, there were only 
minimal differences observed between the two groups for the frequencies of any of the alleles 
and none met any threshold for statistical significance. Whilst not excluding a functional role 
for JUND in signalling in macrophage activation in humans it does suggest that cis-acting 
genetic polymorphisms at the JUND locus do not contribute to disease risk in patients with 
ANCA vasculitis. One can speculate that as JUND is a constitutively expressed transcription 
factor, in evolutionary terms there would be a selection pressure against genetic variation 
affecting such an important gene for development as demonstrated by the abnormalities 
demonstrated by the Jund
-/-
 knockout mouse (Thepot et al., 2000). 
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7.1 Concluding remarks 
The work presented in this thesis used a number of different genomic approaches including 
microarray analyses, RNA interference and ChIP-Seq to investigate how Jund might 
influence macrophage activation and glomerulonephritis susceptibility. The approach 
identified the sets of genes moderated by the Crgn2 QTL during the LPS response as well as 
the effect acute changes in Jund expression had on the WKY BMDM transcriptome. The 
JunD cistrome analysis identified the genome-wide pattern of JunD binding in WKY and 
WKY.LCrgn2 BMDMs and integration of this data set with the transcriptome data identified 
some of the key effector genes and pathways that could underlie the WKY overactivation 
phenotype. This provides the basis for their prioritisation and further investigation of their 
role in macrophage activation and their potential function in the NTN model. In addition, the 
work was extended to investigate the transcriptomes of NTN-susceptible WKY BMDMs 
compared to NTN-resistant LEW BMDMs which allowed the identification of new candidate 
genes for the Crgn3-7 QTLs and effector genes for macrophage activation which are 
potential targets through which macrophage behaviour could be modulated. Southwestern 
histochemistry confirmed that AP-1 transcription factor is indeed activated in the NTN model 
and that JUND expression is prominent in macrophages and the glomeruli of human patients. 
Whilst no genetic polymorphisms in JUND were associated with susceptibility to disease, the 
data from the investigations in the rat BMDMs gives support to the need to develop strategies 
through which JunD can be inhibited in vivo in both the rat model and human patients in 
order to modulate macrophage behaviour and treat severe inflammatory renal disease. 
 
 
 
 
 
 
 
 
 
 
428 
 
References 
 
 
ABI (2011). Ambion® WT Expression Kit Product Bulletin (Applied Biosystems). 
Aitman, T.J., Boone, C., Churchill, G.A., Hengartner, M.O., Mackay, T.F.C., and Stemple, 
D.L. (2011). The future of model organisms in human disease research. Nat Rev Genet 12, 
575-582. 
Aitman, T.J., Critser, J.K., Cuppen, E., Dominiczak, A., Fernandez-Suarez, X.M., Flint, J., 
Gauguier, D., Geurts, A.M., Gould, M., Harris, P.C., et al. (2008). Progress and prospects in 
rat genetics: a community view. Nat Genet 40, 516-522. 
Aitman, T.J., Dong, R., Vyse, T.J., Norsworthy, P.J., Johnson, M.D., Smith, J., Mangion, J., 
Roberton-Lowe, C., Marshall, A.J., Petretto, E., et al. (2006). Copy number polymorphism in 
Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 439, 851-855. 
Aitman, T.J., Glazier, A.M., Wallace, C.A., Cooper, L.D., Norsworthy, P.J., Wahid, F.N., Al-
Majali, K.M., Trembling, P.M., Mann, C.J., Shoulders, C.C., et al. (1999). Identification of 
Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism 
in hypertensive rats. Nat Genet 21, 76-83. 
Aitman, T.J., Petretto, E., and Behmoaras, J. (2010). Genetic mapping and positional cloning. 
Methods Mol Biol 597, 13-32. 
Akbulut, T., Regner, K.R., Roman, R.J., Avner, E.D., Falck, J.R., and Park, F. (2009). 20-
HETE activates the Raf/MEK/ERK pathway in renal epithelial cells through an EGFR- and 
c-Src-dependent mechanism. American Journal of Physiology - Renal Physiology 297, F662-
F670. 
Aki, K., Shimizu, A., Masuda, Y., Kuwahara, N., Arai, T., Ishikawa, A., Fujita, E., Mii, A., 
Natori, Y., Fukunaga, Y., et al. (2010). ANG II receptor blockade enhances anti-
inflammatory macrophages in anti-glomerular basement membrane glomerulonephritis. 
American Journal of Physiology - Renal Physiology 298, F870-F882. 
429 
 
Allen, A.R., McHale, J., Smith, J., Cook, H.T., Karkar, A., Haskard, D.O., Lobb, R.R., and 
Pusey, C.D. (1999). Endothelial expression of VCAM-1 in experimental crescentic nephritis 
and effect of antibodies to very late antigen-4 or VCAM-1 on glomerular injury. J Immunol 
162, 5519-5527. 
Altschul, S.F., Gish, W., Miller, W., Myers, E.W., and Lipman, D.J. (1990). Basic local 
alignment search tool. Journal of Molecular Biology 215, 403-410. 
Altshuler, D., Daly, M.J., and Lander, E.S. (2008). Genetic Mapping in Human Disease. 
Science 322, 881-888. 
Anderson, C.A., Boucher, G., Lees, C.W., Franke, A., D'Amato, M., Taylor, K.D., Lee, J.C., 
Goyette, P., Imielinski, M., Latiano, A., et al. (2011). Meta-analysis identifies 29 additional 
ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nature 
genetics 43, 246-252. 
Angel, P., Imagawa, M., Chiu, R., Stein, B., Imbra, R.J., Rahmsdorf, H.J., Jonat, C., Herrlich, 
P., and Karin, M. (1987). Phorbol ester-inducible genes contain a common cis element 
recognized by a TPA-modulated trans-acting factor. Cell 49, 729-739. 
Angel, P., and Karin, M. (1991). The role of Jun, Fos and the AP-1 complex in cell-
proliferation and transformation. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 
1072, 129-157. 
Appel, A.S., and Appel, G.B. (2009). An update on the use of mycophenolate mofetil in 
lupus nephritis and other primary glomerular diseases. Nat Clin Pract Neph 5, 132-142. 
Appel, G.B., Contreras, G., Dooley, M.A., Ginzler, E.M., Isenberg, D., Jayne, D., Li, L.-S., 
Mysler, E., Sanchez-Guerrero, J., Solomons, N., et al. (2009). Mycophenolate Mofetil versus 
Cyclophosphamide for Induction Treatment of Lupus Nephritis. J Am Soc Nephrol, 
ASN.2008101028. 
Arakawa, T., Masaki, T., Hirai, T., Doi, S., Kuratsune, M., Arihiro, K., Kohno, N., and 
Yorioka, N. (2008). Activation of signal transducer and activator of transcription 3 correlates 
430 
 
with cell proliferation and renal injury in human glomerulonephritis. Nephrology Dialysis 
Transplantation 23, 3418-3426. 
Ashizawa, M., Miyazaki, M., Abe, K., Furusu, A., Isomoto, H., Harada, T., Ozono, Y., Sakai, 
H., Koji, T., and Kohno, S. (2003). Detection of nuclear factor-[kappa]B in IgA nephropathy 
using Southwestern histochemistry. American Journal of Kidney Diseases 42, 76-86. 
Aslam, A., Mittal, S., Koch, F., Andrau, J.-C., and Winkler, G.S. (2009). The Ccr4-Not 
Deadenylase Subunits CNOT7 and CNOT8 Have Overlapping Roles and Modulate Cell 
Proliferation. Mol Biol Cell 20, 3840-3850. 
Atanur, S.S., Birol, I., Guryev, V., Hirst, M., Hummel, O., Morrissey, C., Behmoaras, J., 
Fernandez-Suarez, X.M., Johnson, M.D., McLaren, W.M., et al. (2010). The genome 
sequence of the spontaneously hypertensive rat: Analysis and functional significance. 
Genome Research 20, 791-803. 
Atkins, R., Glasgow, E., Holdsworth, S., and Matthews, F. (1976). THE MACROPHAGE IN 
HUMAN RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS. The Lancet 307, 830-
832. 
Atkins, R.C. (1998). Macrophages in renal injury. American journal of kidney diseases 31, 
xlv-xlvii. 
Avery, S.V. (2011). Molecular targets of oxidative stress. Biochemical Journal 434, 201-210. 
Baba, T., Ishizu, A., Iwasaki, S., Suzuki, A., Tomaru, U., Ikeda, H., Yoshiki, T., and 
Kasahara, M. (2006). CD4+/CD8+ macrophages infiltrating at inflammatory sites: a 
population of monocytes/macrophages with a cytotoxic phenotype. Blood 107, 2004-2012. 
Baba, T., Iwasaki, S., Maruoka, T., Suzuki, A., Tomaru, U., Ikeda, H., Yoshiki, T., Kasahara, 
M., and Ishizu, A. (2008). Rat CD4+CD8+ Macrophages Kill Tumor Cells through an 
NKG2D- and Granzyme/Perforin-Dependent Mechanism. J Immunol 180, 2999-3006. 
431 
 
Badis, G., Berger, M.F., Philippakis, A.A., Talukder, S., Gehrke, A.R., Jaeger, S.A., Chan, 
E.T., Metzler, G., Vedenko, A., Chen, X., et al. (2009). Diversity and Complexity in DNA 
Recognition by Transcription Factors. Science 324, 1720-1723. 
Bakri, Y., Sarrazin, S., Mayer, U.P., Tillmanns, S., Nerlov, C., Boned, A., and Sieweke, M.H. 
(2005). Balance of MafB and PU.1 specifies alternative macrophage or dendritic cell fate. 
Blood 105, 2707-2716. 
Barish, G.D., Yu, R.T., Karunasiri, M., Ocampo, C.B., Dixon, J., Benner, C., Dent, A.L., 
Tangirala, R.K., and Evans, R.M. (2010). Bcl-6 and NF-kappaB cistromes mediate opposing 
regulation of the innate immune response. Genes Dev 24, 2760-2765. 
Barrett, J.C., Fry, B., Maller, J., and Daly, M.J. (2005). Haploview: analysis and visualization 
of LD and haplotype maps. Bioinformatics 21, 263-265. 
Barski, A., Cuddapah, S., Cui, K., Roh, T.-Y., Schones, D.E., Wang, Z., Wei, G., Chepelev, 
I., and Zhao, K. (2007). High-Resolution Profiling of Histone Methylations in the Human 
Genome. Cell 129, 823-837. 
Behmoaras, J., Bhangal, G., Smith, J., McDonald, K., Mutch, B., Lai, P.C., Domin, J., Game, 
L., Salama, A., Foxwell, B.M., et al. (2008). Jund is a determinant of macrophage activation 
and is associated with glomerulonephritis susceptibility. Nat Genet 40, 553-559. 
Behmoaras, J., Smith, J., D'Souza, Z., Bhangal, G., Chawanasuntoropoj, R., Tam, F.W., 
Pusey, C.D., Aitman, T.J., and Cook, H.T. (2010). Genetic loci modulate macrophage activity 
and glomerular damage in experimental glomerulonephritis. J Am Soc Nephrol 21, 1136-
1144. 
Bellyei, S., Szigeti, A., Boronkai, A., Pozsgai, E., Gomori, E., Melegh, B., Janaky, T., 
Bognar, Z., Hocsak, E., Sumegi, B., et al. (2007a). Inhibition of cell death by a novel 16.2 kD 
heat shock protein predominantly &lt;i&gt;via&lt;/i&gt; Hsp90 mediated lipid rafts 
stabilization and Akt activation pathway. Apoptosis 12, 97-112. 
432 
 
Bellyei, S., Szigeti, A., Pozsgai, E., Boronkai, A., Gomori, E., Hocsak, E., Farkas, R., 
Sumegi, B., and Gallyas, J.F. (2007b). Preventing apoptotic cell death by a novel small heat 
shock protein. European Journal of Cell Biology 86, 161-171. 
Bentley, D.R., Balasubramanian, S., Swerdlow, H.P., Smith, G.P., Milton, J., Brown, C.G., 
Hall, K.P., Evers, D.J., Barnes, C.L., Bignell, H.R., et al. (2008). Accurate whole human 
genome sequencing using reversible terminator chemistry. Nature 456, 53-59. 
Berden, A.E., Ferrario, F., Hagen, E.C., Jayne, D.R., Jennette, J.C., Joh, K., Neumann, I., 
Noel, L.H., Pusey, C.D., Waldherr, R., et al. (2010). Histopathologic classification of ANCA-
associated glomerulonephritis. Journal of the American Society of Nephrology : JASN 21, 
1628-1636. 
Birney, E., Stamatoyannopoulos, J.A., Dutta, A., Guigo, R., Gingeras, T.R., Margulies, E.H., 
Weng, Z., Snyder, M., Dermitzakis, E.T., Thurman, R.E., et al. (2007). Identification and 
analysis of functional elements in 1% of the human genome by the ENCODE pilot project. 
Nature 447, 799-816. 
Blat, Y., and Kleckner, N. (1999). Cohesins bind to preferential sites along yeast 
chromosome III, with differential regulation along arms versus the centric region. Cell 98, 
249-259. 
Bochukova, E.G., Huang, N., Keogh, J., Henning, E., Purmann, C., Blaszczyk, K., Saeed, S., 
Hamilton-Shield, J., Clayton-Smith, J., O'Rahilly, S., et al. (2010). Large, rare chromosomal 
deletions associated with severe early-onset obesity. Nature 463, 666-670. 
Bolstad, B.M., Irizarry, R.A., Åstrand, M., and Speed, T.P. (2003). A comparison of 
normalization methods for high density oligonucleotide array data based on variance and 
bias. Bioinformatics 19, 185-193. 
Bomback, A.S., and Appel, G.B. (2010). Updates on the Treatment of Lupus Nephritis. 
Journal of the American Society of Nephrology 21, 2028-2035. 
Booth, A.D., Almond, M.K., Burns, A., Ellis, P., Gaskin, G., Neild, G.H., Plaisance, M., 
Pusey, C.D., and Jayne, D.R. (2003). Outcome of ANCA-associated renal vasculitis: a 5-year 
433 
 
retrospective study. American journal of kidney diseases : the official journal of the National 
Kidney Foundation 41, 776-784. 
Bosch, X. (2010). Inflammation: Rituximab in ANCA vasculitis and lupus: bittersweet 
results. Nat Rev Nephrol 6, 137-139. 
Bosch, X., and Pomares, M. (1998). Familial Mediterranean fever. The Lancet 351, 1658. 
Boyce, N.W., Tipping, P.G., and Holdsworth, S.R. (1989). Glomerular macrophages produce 
reactive oxygen species in experimental glomerulonephritis. Kidney Int 35, 778-782. 
Brazma, A., Hingamp, P., Quackenbush, J., Sherlock, G., Spellman, P., Stoeckert, C., Aach, 
J., Ansorge, W., Ball, C.A., Causton, H.C., et al. (2001). Minimum information about a 
microarray experiment (MIAME)[mdash]toward standards for microarray data. Nat Genet 
29, 365-371. 
Brenner, D.A., O'Hara, M., Angel, P., Chojkier, M., and Karin, M. (1989). Prolonged 
activation of jun and collagenase genes by tumour necrosis factor-α. Nature 337, 661-663. 
Brown, H.J., Lock, H.R., Wolfs, T.G.A.M., Buurman, W.A., Sacks, S.H., and Robson, M.G. 
(2007). Toll-Like Receptor 4 Ligation on Intrinsic Renal Cells Contributes to the Induction of 
Antibody-Mediated Glomerulonephritis via CXCL1 and CXCL2. Journal of the American 
Society of Nephrology 18, 1732-1739. 
Buttke, T.M., and Sandstrom, P.A. (1994). Oxidative stress as a mediator of apoptosis. 
Immunology Today 15, 7-10. 
Cairns, J., Spyrou, C., Stark, R., Smith, M.L., Lynch, A.G., and Tavaré, S. (2011). 
BayesPeak—an R package for analysing ChIP-seq data. Bioinformatics 27, 713-714. 
Cao, Z., Sun, X., Icli, B., Wara, A.K., and Feinberg, M.W. (2010). Role of Krüppel-like 
factors in leukocyte development, function, and disease. Blood 116, 4404-4414. 
Caplen, N.J., Parrish, S., Imani, F., Fire, A., and Morgan, R.A. (2001). Specific inhibition of 
gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. 
434 
 
Proceedings of the National Academy of Sciences of the United States of America 98, 9742-
9747. 
Cesaroni, M., Cittaro, D., Brozzi, A., Pelicci, P.G., and Luzi, L. (2008). CARPET: a web-
based package for the analysis of ChIP-chip and expression tiling data. Bioinformatics 24, 
2918-2920. 
Chadban, S.J., Wu, H., and Hughes, J. (2010). Macrophages and Kidney Transplantation. 
Seminars in nephrology 30, 278-289. 
Chae, J.J., Komarow, H.D., Cheng, J., Wood, G., Raben, N., Liu, P.P., and Kastner, D.L. 
(2003). Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to 
endotoxin and a defect in macrophage apoptosis. Molecular Cell 11, 591-604. 
Chae, J.J., Wood, G., Masters, S.L., Richard, K., Park, G., Smith, B.J., and Kastner, D.L. 
(2006). The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts 
directly with caspase-1 to modulate IL-1β production. Proceedings of the National Academy 
of Sciences 103, 9982-9987. 
Chandra, J., Samali, A., and Orrenius, S. (2000). Triggering and modulation of apoptosis by 
oxidative stress. Free Radical Biology and Medicine 29, 323-333. 
Chandra, S., Romero, M.J., Shatanawi, A., Alkilany, A.M., Caldwell, R.B., and Caldwell, 
R.W. (2011). Oxidative Species Increase Arginase Activity in Endothelial Cells through 
RhoA/Rho Kinase Pathway. British Journal of Pharmacology, no-no. 
Chavele, K.-M., Martinez-Pomares, L., Domin, J., Pemberton, S., Haslam, S.M., Dell, A., 
Cook, H.T., Pusey, C.D., Gordon, S., and Salama, A.D. (2010). Mannose receptor interacts 
with Fc receptors and is critical for the development of crescentic glomerulonephritis in mice. 
The Journal of Clinical Investigation 120, 1469-1478. 
Chen, C., Wei, X., Rao, X., Wu, J., Yang, S., Chen, F., Ma, D., Zhou, J., Dackor, R.T., 
Zeldin, D.C., et al. (2011a). Cytochrome P450 2J2 Is Highly Expressed in Hematologic 
Malignant Diseases and Promotes Tumor Cell Growth. Journal of Pharmacology and 
Experimental Therapeutics 336, 344-355. 
435 
 
Chen, G., Wang, P., Zhao, G., Xu, G., Gruzdev, A., Zeldin, D.C., and Wang, D.W. (2011b). 
Cytochrome P450 epoxygenase CYP2J2 attenuates nephropathy in streptozotocin-induced 
diabetic mice. Prostaglandins & Other Lipid Mediators In Press, Corrected Proof. 
Chinenov, Y., and Kerppola, T.K. (2001). Close encounters of many kinds: Fos-Jun 
interactions that mediate transcription regulatory specificity. Oncogene 20, 2438-2452. 
Chuang, P.Y., and He, J.C. (2010). JAK/STAT signaling in renal diseases. Kidney Int 78, 
231-234. 
Chung, S.A., Taylor, K.E., Graham, R.R., Nititham, J., Lee, A.T., Ortmann, W.A., Jacob, 
C.O., Alarcón-Riquelme, M.E., Tsao, B.P., Harley, J.B., et al. (2011). Differential Genetic 
Associations for Systemic Lupus Erythematosus Based on Anti–dsDNA Autoantibody 
Production. PLoS Genet 7, e1001323. 
Consortium, I.H. (2005). A haplotype map of the human genome. Nature 437, 1299-1320. 
Consortium, I.H. (2007). A second generation human haplotype map of over 3.1 million 
SNPs. Nature 449, 851-861. 
Consortium, T.G.P. (2010). A map of human genome variation from population-scale 
sequencing. Nature 467, 1061-1073. 
Cook-Mills, J.M. (2002). VCAM-1 signals during lymphocyte migration: role of reactive 
oxygen species. Molecular Immunology 39, 499-508. 
Cook, H.T., Singh, S.J., Wembridge, D.E., Smith, J., Tam, F.W.K., and Pusey, C.D. (1999). 
Interleukin-4 ameliorates crescentic glomerulonephritis in Wistar Kyoto rats. Kidney Int 55, 
1319-1326. 
Cook, H.T., Smith, J., Salmon, J.A., and Cattell, V. (1989). Functional characteristics of 
macrophages in glomerulonephritis in the rat. O2- generation, MHC class II expression, and 
eicosanoid synthesis. Am J Pathol 134, 431-437. 
436 
 
Cook, H.T., Tarzi, R., D'Souza, Z., Laurent, G., Lin, W.-C., Aitman, T.J., Mechta-Grigoriou, 
F., and Behmoaras, J. (2011). AP-1 Transcription Factor JunD Confers Protection from 
Accelerated Nephrotoxic Nephritis and Control Podocyte-Specific Vegfa Expression. The 
American Journal of Pathology 179, 134-140. 
Corrotte, M., Chasserot-Golaz, S., Huang, P., Du, G., Ktistakis, N.T., Frohman, M.A., Vitale, 
N., Bader, M.-F., and Grant, N.J. (2006). Dynamics and Function of Phospholipase D and 
Phosphatidic Acid During Phagocytosis. Traffic 7, 365-377. 
Corrotte, M., Tran Nyguyen, A.P., Harlay, M.L., Vitale, N., Bader, M.-F., and Grant, N.J. 
(2010). Ral Isoforms Are Implicated in FcγR-Mediated Phagocytosis: Activation of 
Phospholipase D by RalA. The Journal of Immunology 185, 2942-2950. 
Crowley, M.T., Costello, P.S., Fitzer-Attas, C.J., Turner, M., Meng, F., Lowell, C., 
Tybulewicz, V.L.J., and DeFranco, A.L. (1997). A Critical Role for Syk in Signal 
Transduction and Phagocytosis Mediated by Fcγ Receptors on Macrophages. J Exp Med 186, 
1027-1039. 
Cui, Z., and Zhao, M.-H. (2011). Advances in human antiglomerular basement membrane 
disease. Nat Rev Nephrol advance online publication. 
Dai, M., Wang, P., Boyd, A.D., Kostov, G., Athey, B., Jones, E.G., Bunney, W.E., Myers, 
R.M., Speed, T.P., Akil, H., et al. (2005). Evolving gene/transcript definitions significantly 
alter the interpretation of GeneChip data. Nucleic acids research 33, e175. 
de Bakker, P.I.W., Yelensky, R., Pe'er, I., Gabriel, S.B., Daly, M.J., and Altshuler, D. (2005). 
Efficiency and power in genetic association studies. Nat Genet 37, 1217-1223. 
de Groot, R.P., Karperien, M., Pals, C., and Kruijer, W. (1991). Characterization of the 
mouse junD promoter - high basal activity due to an octamer motif. The EMBO Journal 10, 
2523-2532. 
De Santa, F., Narang, V., Yap, Z.H., Tusi, B.K., Burgold, T., Austenaa, L., Bucci, G., 
Caganova, M., Notarbartolo, S., Casola, S., et al. (2009). Jmjd3 contributes to the control of 
gene expression in LPS-activated macrophages. EMBO J 28, 3341-3352. 
437 
 
Degrandi, D., Hoffmann, R., Beuter-Gunia, C., and Pfeffer, K. (2009). The Proinflammatory 
Cytokine-Induced IRG1 Protein Associates with Mitochondria. Journal of Interferon & 
Cytokine Research 29, 55-68. 
del Rio, M.L., Lucas, C.L., Buhler, L., Rayat, G., and Rodriguez-Barbosa, J.I. (2010). 
HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation. 
Journal of Leukocyte Biology 87, 223-235. 
Devireddy, L.R., Gazin, C., Zhu, X., and Green, M.R. (2005). A Cell-Surface Receptor for 
Lipocalin 24p3 Selectively Mediates Apoptosis and Iron Uptake. Cell 123, 1293-1305. 
Di, A., Nelson, D.J., Bindokas, V., Brown, M.E., Libunao, F., and Palfrey, H.C. (2003). 
Dynamin Regulates Focal Exocytosis in Phagocytosing Macrophages. Mol Biol Cell 14, 
2016-2028. 
Dietrich, D., Krispin, M., Dietrich, J., Fassbender, A., Lewin, J., Harbeck, N., Schmitt, M., 
Eppenberger-Castori, S., Vuaroqueaux, V., Spyratos, F., et al. (2010). CDO1 Promoter 
Methylation is a Biomarker for Outcome Prediction of Anthracycline Treated, Estrogen 
Receptor-Positive, Lymph Node-Positive Breast Cancer Patients. BMC Cancer 10, 247. 
Dionisio, N., Albarran, L., Berna-Erro, A., Hernandez-Cruz, J.M., Salido, G.M., and Rosado, 
J.A. (2011). Functional role of the calmodulin- and inositol 1,4,5-trisphosphate receptor-
binding (CIRB) site of TRPC6 in human platelet activation. Cellular Signalling 23, 1850-
1856. 
Dong, J., Wang, Q.-X., Zhou, C.-Y., Ma, X.-F., and Zhang, Y.-C. (2007). Activation of the 
STAT1 signalling pathway in lupus nephritis in MRL/lpr mice. Lupus 16, 101-109. 
Duffield, J.S., Tipping, P.G., Kipari, T., Cailhier, J.-F., Clay, S., Lang, R., Bonventre, J.V., 
and Hughes, J. (2005). Conditional Ablation of Macrophages Halts Progression of Crescentic 
Glomerulonephritis. Am J Pathol 167, 1207-1219. 
Echeverri, C.J., and Perrimon, N. (2006). High-throughput RNAi screening in cultured cells: 
a user's guide. Nat Rev Genet 7, 373-384. 
438 
 
Edwards, J.P., Zhang, X., Frauwirth, K.A., and Mosser, D.M. (2006). Biochemical and 
functional characterization of three activated macrophage populations. J Leukoc Biol 80, 
1298-1307. 
Eferl, R., and Wagner, E.F. (2003). AP-1: a double-edged sword in tumorigenesis. Nat Rev 
Cancer 3, 859-868. 
El Kasmi, K.C., Qualls, J.E., Pesce, J.T., Smith, A.M., Thompson, R.W., Henao-Tamayo, M., 
Basaraba, R.J., Konig, T., Schleicher, U., Koo, M.-S., et al. (2008). Toll-like receptor-
induced arginase 1 in macrophages thwarts effective immunity against intracellular 
pathogens. Nat Immunol 9, 1399-1406. 
Elbashir, S.M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., and Tuschl, T. (2001a). 
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. 
Nature 411, 494-498. 
Elbashir, S.M., Lendeckel, W., and Tuschl, T. (2001b). RNA interference is mediated by 21- 
and 22-nucleotide RNAs. Genes Dev 15, 188-200. 
Falschlehner, C., Schaefer, U., and Walczak, H. (2009). Following TRAIL’s path in the 
immune system. Immunology 127, 145-154. 
Fanciulli, M., Norsworthy, P.J., Petretto, E., Dong, R., Harper, L., Kamesh, L., Heward, J.M., 
Gough, S.C.L., de Smith, A., Blakemore, A.I.F., et al. (2007). FCGR3B copy number 
variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. 
Nat Genet 39, 721-723. 
Farnham, P.J. (2009). Insights from genomic profiling of transcription factors. Nat Rev Genet 
10, 605-616. 
Fauci, A.S., and Wolff, S.M. (1973). Wegener's granulomatosis: studies in eighteen patients 
and a review of the literature. Medicine (Baltimore) 52, 535-561. 
Fearnhead, N., Winney, B., and Bodmer, W.F. (2005). Rare Variant Hypothesis for 
Multifactorial Inheritance. Cell Cycle 4, 521-525. 
439 
 
Feinberg, M.W., Cao, Z., Wara, A.K., Lebedeva, M.A., SenBanerjee, S., and Jain, M.K. 
(2005). Kruppel-like Factor 4 Is a Mediator of Proinflammatory Signaling in Macrophages. 
Journal of Biological Chemistry 280, 38247-38258. 
Ferenbach, D., and Kluth, D. (2010). Macrophage Cell Therapy in Renal Disease. Seminars 
in nephrology 30, 345-353. 
Ferrario, F., Castiglione, A., Colasanti, G., Barbiano di Belgioioso, G., Bertoli, S., D'Amico, 
G., and Nava, S. (1985). The detection of monocytes in human glomerulonephritis. Kidney 
Int 28, 513-519. 
Ferrario, F., and Rastaldi, M. (1999). Necrotizing-crescentic glomerulonephritis in ANCA-
associated vasculitis: the role of monocytes. Nephrol Dial Transplant 14, 1627-1631. 
Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., and Mello, C.C. (1998). 
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. 
Nature 391, 806-811. 
Foster, S.L., Hargreaves, D.C., and Medzhitov, R. (2007). Gene-specific control of 
inflammation by TLR-induced chromatin modifications. Nature 447, 972-978. 
Fujita, E., Shimizu, A., Masuda, Y., Kuwahara, N., Arai, T., Nagasaka, S., Aki, K., Mii, A., 
Natori, Y., Iino, Y., et al. (2010). Statin Attenuates Experimental Anti-Glomerular Basement 
Membrane Glomerulonephritis Together with the Augmentation of Alternatively Activated 
Macrophages. The American Journal of Pathology 177, 1143-1154. 
Gabriel, S.B., Schaffner, S.F., Nguyen, H., Moore, J.M., Roy, J., Blumenstiel, B., Higgins, J., 
DeFelice, M., Lochner, A., Faggart, M., et al. (2002). The structure of haplotype blocks in the 
human genome. Science 296, 2225-2229. 
Gargalovic, P., and Dory, L. (2003). Cellular apoptosis is associated with increased caveolin-
1 expression in macrophages. Journal of Lipid Research 44, 1622-1632. 
Geissmann, F., Manz, M.G., Jung, S., Sieweke, M.H., Merad, M., and Ley, K. (2010). 
Development of Monocytes, Macrophages, and Dendritic Cells. Science 327, 656-661. 
440 
 
Gerald, D., Berra, E., Frapart, Y.M., Chan, D.A., Giaccia, A.J., Mansuy, D., Pouysségur, J., 
Yaniv, M., and Mechta-Grigoriou, F. (2004). JunD Reduces Tumor Angiogenesis by 
Protecting Cells from Oxidative Stress. Cell 118, 781-794. 
Geurts, A.M., Cost, G.J., Freyvert, Y., Zeitler, B., Miller, J.C., Choi, V.M., Jenkins, S.S., 
Wood, A., Cui, X., Meng, X., et al. (2009). Knockout Rats via Embryo Microinjection of 
Zinc-Finger Nucleases. Science 325, 433. 
Ghisletti, S., Barozzi, I., Mietton, F., Polletti, S., De Santa, F., Venturini, E., Gregory, L., 
Lonie, L., Chew, A., Wei, C.L., et al. (2010). Identification and characterization of enhancers 
controlling the inflammatory gene expression program in macrophages. Immunity 32, 317-
328. 
Gibbs, R.A., Weinstock, G.M., Metzker, M.L., Muzny, D.M., Sodergren, E.J., Scherer, S., 
Scott, G., Steffen, D., Worley, K.C., Burch, P.E., et al. (2004). Genome sequence of the 
Brown Norway rat yields insights into mammalian evolution. Nature 428, 493-521. 
Gilchrist, M., Thorsson, V., Li, B., Rust, A.G., Korb, M., Roach, J.C., Kennedy, K., Hai, T., 
Bolouri, H., and Aderem, A. (2006). Systems biology approaches identify ATF3 as a 
negative regulator of Toll-like receptor 4. Nature 441, 173-178. 
Giorgini, A., Brown, H.J., Sacks, S.H., and Robson, M.G. (2010). Toll-Like Receptor 4 
Stimulation Triggers Crescentic Glomerulonephritis by Multiple Mechanisms Including a 
Direct Effect on Renal Cells. The American Journal of Pathology 177, 644-653. 
Goldstein, D.B. (2009). Common Genetic Variation and Human Traits. New England Journal 
of Medicine 360, 1696-1698. 
Gómez-Martín, D., Díaz-Zamudio, M., Galindo-Campos, M., and Alcocer-Varela, J. (2010). 
Early growth response transcription factors and the modulation of immune response: 
Implications towards autoimmunity. Autoimmunity Reviews 9, 454-458. 
Gordon, S. (2003). Alternative activation of macrophages. Nature reviews Immunology 3, 
23-35. 
441 
 
Gordon, S., and Martinez, F.O. (2010). Alternative Activation of Macrophages: Mechanism 
and Functions. Immunity 32, 593-604. 
Gordon, S., and Taylor, P.R. (2005). Monocyte and macrophage heterogeneity. Nat Rev 
Immunol 5, 953-964. 
Graham, R.R., Cotsapas, C., Davies, L., Hackett, R., Lessard, C.J., Leon, J.M., Burtt, N.P., 
Guiducci, C., Parkin, M., Gates, C., et al. (2008). Genetic variants near TNFAIP3 on 6q23 
are associated with systemic lupus erythematosus. Nat Genet 40, 1059-1061. 
Guerry, M.-J.C.J., Brogan, P., Bruce, I.N., D'Cruz, D.P., Harper, L., Luqmani, R., Pusey, 
C.D., Salama, A.D., Scott, D.G.I., Savage, C.O.S., et al. (2011). Recommendations for the 
use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology. 
Gupta, S., Stamatoyannopoulos, J., Bailey, T., and Noble, W. (2007). Quantifying similarity 
between motifs. Genome biology 8, R24. 
Hambleton, J., Weinstein, S.L., Lem, L., and DeFranco, A.L. (1996). Activation of c-Jun N-
terminal kinase in bacterial lipopolysaccharide-stimulated macrophages. Proceedings of the 
National Academy of Sciences 93, 2774-2778. 
Han, J.-W., Zheng, H.-F., Cui, Y., Sun, L.-D., Ye, D.-Q., Hu, Z., Xu, J.-H., Cai, Z.-M., 
Huang, W., Zhao, G.-P., et al. (2009). Genome-wide association study in a Chinese Han 
population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat 
Genet 41, 1234-1237. 
Han, Y., Ma, F.Y., Tesch, G.H., Manthey, C.L., and Nikolic-Paterson, D.J. (2011). c-fms 
blockade reverses glomerular macrophage infiltration and halts development of crescentic 
anti-GBM glomerulonephritis in the rat. Lab Invest 91, 978-991. 
Hancock, W.W., and Atkins, R.C. (1984). Cellular Composition of Crescents in Human 
Rapidly Progressive Glomerulonephritis Identified Using Monoclonal Antibodies. American 
Journal of Nephrology 4, 177-181. 
442 
 
Hao, X., Wang, Y., Ren, F., Zhu, S., Ren, Y., Jia, B., Li, Y.-P., Shi, Y., and Chang, Z. (2011). 
SNX25 regulates TGF-[beta] signaling by enhancing the receptor degradation. Cellular 
Signalling 23, 935-946. 
Hargreaves, D.C., Horng, T., and Medzhitov, R. (2009). Control of Inducible Gene 
Expression by Signal-Dependent Transcriptional Elongation. Cell 138, 129-145. 
Harley, J.B., Alarcon-Riquelme, M.E., Criswell, L.A., Jacob, C.O., Kimberly, R.P., Moser, 
K.L., Tsao, B.P., Vyse, T.J., and Langefeld, C.D. (2008). Genome-wide association scan in 
women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, 
KIAA1542 and other loci. Nat Genet 40, 204-210. 
Harper, L., and Savage, C.O. (2005). ANCA-associated renal vasculitis at the end of the 
twentieth century--a disease of older patients. Rheumatology 44, 495-501. 
Hata, M., Takahara, S., Tsuzaki, H., Ishii, Y., Nakata, K., Akagawa, K.S., and Satoh, K. 
(2009). Expression of Th2-skewed pathology mediators in monocyte-derived type 2 of 
dendritic cells (DC2). Immunology Letters 126, 29-36. 
Hatsuzawa, K., Tamura, T., Hashimoto, H., Hashimoto, H., Yokoya, S., Miura, M., Nagaya, 
H., and Wada, I. (2006). Involvement of Syntaxin 18, an Endoplasmic Reticulum (ER)-
localized SNARE Protein, in ER-mediated Phagocytosis. Mol Biol Cell 17, 3964-3977. 
Heckmann, M., Holle, J.U., Arning, L., Knaup, S., Hellmich, B., Nothnagel, M., Jagiello, P., 
Gross, W.L., Epplen, J.T., and Wieczorek, S. (2008). The Wegener's granulomatosis 
quantitative trait locus on chromosome 6p21.3 as characterised by tagSNP genotyping. Ann 
Rheum Dis 67, 972-979. 
Heinig, M., Petretto, E., Wallace, C., Bottolo, L., Rotival, M., Lu, H., Li, Y., Sarwar, R., 
Langley, S.R., Bauerfeind, A., et al. (2010). A trans-acting locus regulates an anti-viral 
expression network and type 1 diabetes risk. Nature 467, 460-464. 
Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y.C., Laslo, P., Cheng, J.X., Murre, C., 
Singh, H., and Glass, C.K. (2010). Simple Combinations of Lineage-Determining 
443 
 
Transcription Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell 
Identities. Molecular Cell 38, 576-589. 
Hernandez-Presa, M.A., Bustos, C., Ortego, M., Tunon, J., Ortega, L., and Egido, J. (1998). 
ACE Inhibitor Quinapril Reduces the Arterial Expression of NF-{kappa}B-Dependent 
Proinflammatory Factors but not of Collagen I in a Rabbit Model of Atherosclerosis. Am J 
Pathol 153, 1825-1837. 
Hernandez-Presa, M.A., GoMez-Guerrero, C., and Egido, J. (1999). In situ non-radioactive 
detection of nuclear factors in paraffin sections by Southwestern histochemistry. Kidney Int 
55, 209-214. 
Hernandez, J.M., Floyd, D.H., Weilbaecher, K.N., Green, P.L., and Boris-Lawrie, K. (2008). 
Multiple facets of junD gene expression are atypical among AP-1 family members. 
Oncogene. 
Hess, J., Angel, P., and Schorpp-Kistner, M. (2004). AP-1 subunits: quarrel and harmony 
among siblings. J Cell Sci 117, 5965-5973. 
Hilfiker-Kleiner, D., Hilfiker, A., Kaminski, K., Schaefer, A., Park, J.-K., Michel, K., Quint, 
A., Yaniv, M., Weitzman, J.B., and Drexler, H. (2005). Lack of JunD Promotes Pressure 
Overload-Induced Apoptosis, Hypertrophic Growth, and Angiogenesis in the Heart. 
Circulation 112, 1470-1477. 
Hindorff, L.A., Junkins, H.A., Mehta, J., and Manolio, T.A. (2011). A catalog of published 
genome-wide association studies. Available at http://www.genome.gov/26525384. Accessed 
9th September 2011  
Hindorff, L.A., Sethupathy, P., Junkins, H.A., Ramos, E.M., Mehta, J.P., Collins, F.S., and 
Manolio, T.A. (2009). Potential etiologic and functional implications of genome-wide 
association loci for human diseases and traits. Proc Natl Acad Sci U S A 106, 9362-9367. 
Hirai, S., Ryseck, R., Mechta, F., Bravo, R., and Yaniv, M. (1989). Characterization of junD: 
a new member of the jun proto-oncogene family. The EMBO Journal 8, 1433-1439. 
444 
 
Hirschhorn, J.N. (2009). Genomewide Association Studies -- Illuminating Biologic 
Pathways. N Engl J Med 360, 1699-1701. 
Hoffman, G.S., Kerr, G.S., Leavitt, R.Y., Hallahan, C.W., Lebovics, R.S., Travis, W.D., 
Rottem, M., and Fauci, A.S. (1992). Wegener granulomatosis: an analysis of 158 patients. 
Ann Intern Med 116, 488-498. 
Holdsworth, S. (2007). Leukocytes in glomerular injury. Seminars in Immunopathology 29, 
355-374. 
Holdsworth, S.R., Neale, T.J., and Wilson, C.B. (1981). Abrogation of macrophage-
dependent injury in experimental glomerulonephritis in the rabbit. Use of an antimacrophage 
serum. J Clin Invest 68, 686-698. 
Hom, G., Graham, R.R., Modrek, B., Taylor, K.E., Ortmann, W., Garnier, S., Lee, A.T., 
Chung, S.A., Ferreira, R.C., Pant, P.V.K., et al. (2008). Association of Systemic Lupus 
Erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 358, 900-909. 
Hu, X., Chen, J., Wang, L., and Ivashkiv, L.B. (2007). Crosstalk among Jak-STAT, Toll-like 
receptor, and ITAM-dependent pathways in macrophage activation. J Leukoc Biol 82, 237-
243. 
Huang, D.W., Sherman, B.T., and Lempicki, R.A. (2009a). Bioinformatics enrichment tools: 
paths toward the comprehensive functional analysis of large gene lists. Nucleic acids research 
37, 1-13. 
Huang, D.W., Sherman, B.T., and Lempicki, R.A. (2009b). Systematic and integrative 
analysis of large gene lists using DAVID bioinformatics resources. Nat Protocols 4, 44-57. 
Hubner, N., Wallace, C.A., Zimdahl, H., Petretto, E., Schulz, H., Maciver, F., Mueller, M., 
Hummel, O., Monti, J., Zidek, V., et al. (2005). Integrated transcriptional profiling and 
linkage analysis for identification of genes underlying disease. Nat Genet 37, 243-253. 
445 
 
Hull, R.P., and Aitman, T. (2012). The Discovery of RNA Interference - Gene silencing by 
double-stranded RNA. In Nobel Prizes that Changed Medicine, G. Thompson, ed. (Imperial 
College Press), p. 250. 
Hull, R.P., and Goldsmith, D.J.A. (2008). Nephrotic syndrome in adults. BMJ 336, 1185-
1189. 
Hume, D.A., Ross, I.L., Himes, S.R., Sasmono, R.T., Wells, C.A., and Ravasi, T. (2002). The 
mononuclear phagocyte system revisited. Journal of Leukocyte Biology 72, 621-627. 
Ikezumi, Y., Hurst, L.A., Masaki, T., Atkins, R.C., and Nikolic-Paterson, D.J. (2003). 
Adoptive transfer studies demonstrate that macrophages can induce proteinuria and 
mesangial cell proliferation. Kidney Int 63, 83-95. 
Intlekofer, A.M., Takemoto, N., Wherry, E.J., Longworth, S.A., Northrup, J.T., Palanivel, 
V.R., Mullen, A.C., Gasink, C.R., Kaech, S.M., Miller, J.D., et al. (2005). Effector and 
memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat Immunol 6, 1236-1244. 
Irizarry, R.A., Hobbs, B., Collin, F., Beazer-Barclay, Y.D., Antonellis, K.J., Scherf, U., and 
Speed, T.P. (2003). Exploration, normalization, and summaries of high density 
oligonucleotide array probe level data. Biostatistics 4, 249-264. 
Isome, M., Fujinaka, H., Adhikary, L.P., Kovalenko, P., El-Shemi, A.G.A., Yoshida, Y., 
Yaoita, E., Takeishi, T., Takeya, M., Naito, M., et al. (2004). Important role for macrophages 
in induction of crescentic anti-GBM glomerulonephritis in WKY rats. Nephrol Dial 
Transplant 19, 2997-3004. 
Iversen, P., and Brun, C. (1951). Aspiration biopsy of the kidney. Am J Med 11, 324-330. 
Iwasaki, A., and Medzhitov, R. (2010). Regulation of Adaptive Immunity by the Innate 
Immune System. Science 327, 291-295. 
Iyer, S.S., Agrawal, R.S., Thompson, C.R., Thompson, S., Barton, J.A., and Kusner, D.J. 
(2006). Phospholipase D1 Regulates Phagocyte Adhesion. The Journal of Immunology 176, 
3686-3696. 
446 
 
Iyer, S.S., Barton, J.A., Bourgoin§, S., and Kusner, D.J. (2004). Phospholipases D1 and D2 
Coordinately Regulate Macrophage Phagocytosis. The Journal of Immunology 173, 2615-
2623. 
Iyoda, M., Shibata, T., Kawaguchi, M., Yamaoka, T., and Akizawa, T. (2009). Preventive 
and therapeutic effects of imatinib in Wistar-Kyoto rats with anti-glomerular basement 
membrane glomerulonephritis. Kidney Int 75, 1060-1070. 
Jacob, H.J. (1999). Functional genomics and rat models. Genome Research 9, 1013-1016. 
Jacob, H.J., Lazar, J., Dwinell, M.R., Moreno, C., and Geurts, A.M. (2010). Gene targeting in 
the rat: advances and opportunities. Trends in Genetics 26, 510-518. 
Janeway, C.A., and Medzhitov, R. (2002). INNATE IMMUNE RECOGNITION. Annual 
Review of Immunology 20, 197-216. 
Jayne, D., Rasmussen, N., Andrassy, K., Bacon, P., Tervaert, J.W.C., Dadoniene, J., 
Ekstrand, A., Gaskin, G., Gregorini, G., de Groot, K., et al. (2003). A Randomized Trial of 
Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic 
Autoantibodies. N Engl J Med 349, 36-44. 
Jayne, D.R.W., Gaskin, G., Rasmussen, N., Abramowicz, D., Ferrario, F., Guillevin, L., 
Mirapeix, E., Savage, C.O.S., Sinico, R.A., Stegeman, C.A., et al. (2007). Randomized Trial 
of Plasma Exchange or High-Dosage Methylprednisolone as Adjunctive Therapy for Severe 
Renal Vasculitis. J Am Soc Nephrol 18, 2180-2188. 
Johnson, D.S., Mortazavi, A., Myers, R.M., and Wold, B. (2007). Genome-Wide Mapping of 
in Vivo Protein-DNA Interactions. Science 316, 1497-1502. 
Johnson, G.C., Esposito, L., Barratt, B.J., Smith, A.N., Heward, J., Di Genova, G., Ueda, H., 
Cordell, H.J., Eaves, I.A., Dudbridge, F., et al. (2001). Haplotype tagging for the 
identification of common disease genes. Nature genetics 29, 233-237. 
Jones, R.B., Cohen Tervaert, J.W., Hauser, T., Luqmani, R., Morgan, M.D., Peh, C.A., 
Savage, C.O., Segelmark, M., Tesar, V., van Paassen, P., et al. (2010). Rituximab versus 
447 
 
Cyclophosphamide in ANCA-Associated Renal Vasculitis. New England Journal of 
Medicine 363, 211-220. 
Jubb, A.M., Chalasani, S., Frantz, G.D., Smits, R., Grabsch, H.I., Kavi, V., Maughan, N.J., 
Hillan, K.J., Quirke, P., and Koeppen, H. (2006). Achaete-scute like 2 (ascl2) is a target of 
Wnt signalling and is upregulated in intestinal neoplasia. Oncogene 25, 3445-3457. 
Kadonaga, J.T. (2004). Regulation of RNA Polymerase II Transcription by Sequence-
Specific DNA Binding Factors. Cell 116, 247-257. 
Kanehisa, M., and Goto, S. (2000). KEGG: Kyoto Encyclopedia of Genes and Genomes. 
Nucleic acids research 28, 27-30. 
Kanehisa, M., Goto, S., Furumichi, M., Tanabe, M., and Hirakawa, M. (2010). KEGG for 
representation and analysis of molecular networks involving diseases and drugs. Nucleic 
acids research 38, D355-D360. 
Kanehisa, M., Goto, S., Hattori, M., Aoki-Kinoshita, K.F., Itoh, M., Kawashima, S., 
Katayama, T., Araki, M., and Hirakawa, M. (2006). From genomics to chemical genomics: 
new developments in KEGG. Nucleic acids research 34, D354-D357. 
Kanellis, J., Garcia, G.E., Li, P., Parra, G., Wilson, C.B., Rao, Y., Han, S., Smith, C.W., 
Johnson, R.J., Wu, J.Y., et al. (2004). Modulation of Inflammation by Slit Protein In Vivo in 
Experimental Crescentic Glomerulonephritis. The American Journal of Pathology 165, 341-
352. 
Kang, B., Hao, C., Wang, H., Zhang, J., Xing, R., Shao, J., Li, W., Xu, N., Lu, Y., and Liu, S. 
(2008). Evaluation of Hepatic-Metastasis Risk of Colorectal Cancer upon the Protein 
Signature of PI3K/AKT Pathway. Journal of Proteome Research 7, 3507-3515. 
Kang, Y.J., Li, Y., Sun, X., and Sun, X. (2003). Antiapoptotic Effect and Inhibition of 
Ischemia/Reperfusion-Induced Myocardial Injury in Metallothionein-Overexpressing 
Transgenic Mice. The American Journal of Pathology 163, 1579-1586. 
448 
 
Kawai, T., and Akira, S. (2010). The role of pattern-recognition receptors in innate immunity: 
update on Toll-like receptors. Nat Immunol 11, 373-384. 
Kawai, T., and Akira, S. (2011). Toll-like Receptors and Their Crosstalk with Other Innate 
Receptors in Infection and Immunity. Immunity 34, 637-650. 
Kawasaki, K., Yaoita, E., Yamamoto, T., and Kihara, I. (1992). Depletion of CD8 positive 
cells in nephrotoxic serum nephritis of WKY rats. Kidney Int 41, 1517-1526. 
Keane, T.M., Goodstadt, L., Danecek, P., White, M.A., Wong, K., Yalcin, B., Heger, A., 
Agam, A., Slater, G., Goodson, M., et al. (2011). Mouse genomic variation and its effect on 
phenotypes and gene regulation. Nature 477, 289-294. 
Kelly, L.M., Englmeier, U., Lafon, I., Sieweke, M.H., and Graf, T. (2000). MafB is an 
inducer of monocytic differentiation. EMBO J 19, 1987-1997. 
Kent, W.J., Sugnet, C.W., Furey, T.S., Roskin, K.M., Pringle, T.H., Zahler, A.M., and 
Haussler, D. (2002). The human genome browser at UCSC. Genome Res 12, 996-1006. 
Khan, S.B., Allen, A.R., Bhangal, G., Smith, J., Lobb, R.R., Cook, H.T., and Pusey, C.D. 
(2003). Blocking VLA-4 Prevents Progression of Experimental Crescentic 
Glomerulonephritis. Nephron Experimental Nephrology 95, e100-e110. 
Khan, S.B., Cook, H.T., Bhangal, G., Smith, J., Tam, F.W.K., and Pusey, C.D. (2005). 
Antibody blockade of TNF-α reduces inflammation and scarring in experimental crescentic 
glomerulonephritis. Kidney Int 67, 1812-1820. 
Kiefer, F., Brumell, J., Al-Alawi, N., Latour, S., Cheng, A., Veillette, A., Grinstein, S., and 
Pawson, T. (1998). The Syk Protein Tyrosine Kinase Is Essential for Fcgamma Receptor 
Signaling in Macrophages and Neutrophils. Mol Cell Biol 18, 4209-4220. 
Kiełbasa, S.M., Klein, H., Roider, H.G., Vingron, M., and Blüthgen, N. (2010). TransFind—
predicting transcriptional regulators for gene sets. Nucleic acids research 38, W275-W280. 
449 
 
Kim, B.-H., Shenoy, A.R., Kumar, P., Das, R., Tiwari, S., and MacMicking, J.D. (2011a). A 
Family of IFN-γ–Inducible 65-kD GTPases Protects Against Bacterial Infection. Science 332, 
717-721. 
Kim, H.G., Kim, J.Y., Han, E.H., Hwang, Y.P., Choi, J.H., Park, B.H., and Jeong, H.G. 
(2011b). Metallothionein-2A overexpression increases the expression of matrix 
metalloproteinase-9 and invasion of breast cancer cells. FEBS Letters 585, 421-428. 
Kim, J.H., Bugaj, L.J., Oh, Y.J., Bivalacqua, T.J., Ryoo, S., Soucy, K.G., Santhanam, L., 
Webb, A., Camara, A., Sikka, G., et al. (2009). Arginase inhibition restores NOS coupling 
and reverses endothelial dysfunction and vascular stiffness in old rats. Journal of Applied 
Physiology 107, 1249-1257. 
Kim, Y.-M., Kim, E.-C., and Kim, Y. (2011c). The human lysyl oxidase-like 2 protein 
functions as an amine oxidase toward collagen and elastin. Molecular Biology Reports 38, 
145-149. 
Kimbrell, D.A., and Beutler, B. (2001). The evolution and genetics of innate immunity. Nat 
Rev Genet 2, 256-267. 
Kinjyo, I., Gordon, S.M., Intlekofer, A.M., Dowdell, K., Mooney, E.C., Caricchio, R., Grupp, 
S.A., Teachey, D.T., Rao, V.K., Lindsten, T., et al. (2010). Cutting Edge: 
Lymphoproliferation Caused by Fas Deficiency Is Dependent on the Transcription Factor 
Eomesodermin. The Journal of Immunology 185, 7151-7155. 
Kluth, D.C. (2007). Pro-resolution properties of macrophages in renal injury. Kidney Int 72, 
234-236. 
Kluth, D.C., Ainslie, C.V., Pearce, W.P., Finlay, S., Clarke, D., Anegon, I., and Rees, A.J. 
(2001). Macrophages transfected with adenovirus to express IL-4 reduce inflammation in 
experimental glomerulonephritis. Journal of immunology 166, 4728-4736. 
Kluth, D.C., Erwig, L.-P., and Rees, A.J. (2004). Multiple facets of macrophages in renal 
injury. Kidney Int 66, 542-557. 
450 
 
Knight, A., Sandin, S., and Askling, J. (2008). Risks and relative risks of Wegener's 
granulomatosis among close relatives of patients with the disease. Arthritis & Rheumatism 
58, 302-307. 
Konopatskaya, O., and Poole, A.W. (2010). Protein kinase C[alpha]: disease regulator and 
therapeutic target. Trends in Pharmacological Sciences 31, 8-14. 
Kovary, K., and Bravo, R. (1991). Expression of different Jun and Fos proteins during the 
G0-to-G1 transition in mouse fibroblasts: in vitro and in vivo associations. Mol Cell Biol 11, 
2451-2459. 
Ku, C.S., Loy, E.Y., Pawitan, Y., and Chia, K.S. (2010). The pursuit of genome-wide 
association studies: where are we now? J Hum Genet 55, 195-206. 
Kuhlmann, A.-S., Villaudy, J., Gazzolo, L., Castellazzi, M., Mesnard, J.-M., and Duc Dodon, 
M. (2007). HTLV-1 HBZ cooperates with JunD to enhance transcription of the human 
telomerase reverse transcriptase gene (hTERT). Retrovirology 4, 92. 
Kurschus, F.C., and Jenne, D.E. (2010). Delivery and therapeutic potential of human 
granzyme B. Immunological Reviews 235, 159-171. 
Lai-Cheong, J.E., Parsons, M., and McGrath, J.A. (2010). The role of kindlins in cell biology 
and relevance to human disease. The International Journal of Biochemistry & Cell Biology 
42, 595-603. 
Lai, P.-C., Cook, H.T., Smith, J., Keith, J.C.J., Pusey, C.D., and Tam, F.W.K. (2001). 
Interleukin-11 Attenuates Nephrotoxic Nephritis in Wistar Kyoto Rats. J Am Soc Nephrol 12, 
2310-2320. 
Laird, P.W. (2010). Principles and challenges of genome-wide DNA methylation analysis. 
Nat Rev Genet 11, 191-203. 
Lamb, J.A., Ventura, J.-J., Hess, P., Flavell, R.A., and Davis, R.J. (2003). JunD Mediates 
Survival Signaling by the JNK Signal Transduction Pathway. Molecular Cell 11, 1479-1489. 
451 
 
Lamkanfi, M. (2011). Emerging inflammasome effector mechanisms. Nat Rev Immunol 11, 
213-220. 
Lan, H.Y., Nikolic-Paterson, D.J., Zarama, M., Vannice, J.L., and Atkins, R.C. (1993). 
Suppression of experimental crescentic glomerulonephritis by the interleukin-1 receptor 
antagonist. Kidney international 43, 479-485. 
Lapucci, A., Lulli, M., Amedei, A., Papucci, L., Witort, E., Di Gesualdo, F., Bertolini, F., 
Brewer, G., Nicolin, A., Bevilacqua, A., et al. (2010). ζ-Crystallin is a bcl-2 mRNA binding 
protein involved in bcl-2 overexpression in T-cell acute lymphocytic leukemia. The FASEB 
Journal 24, 1852-1865. 
Lashkari, D.A., DeRisi, J.L., McCusker, J.H., Namath, A.F., Gentile, C., Hwang, S.Y., 
Brown, P.O., and Davis, R.W. (1997). Yeast microarrays for genome wide parallel genetic 
and gene expression analysis. Proceedings of the National Academy of Sciences 94, 13057-
13062. 
Leavy, O. (2011). Innate immunity: GBPs coordinate vesicular trafficking for host defence. 
Nat Rev Immunol 11, 372-373. 
Lee, J.A., Cochran, B.J., Lobov, S., and Ranson, M. (2011). Forty Years Later and the Role 
of Plasminogen Activator Inhibitor Type 2/SERPINB2 Is Still an Enigma. Semin Thromb 
Hemost 37, 395-407. 
Lee, W.-H., Kim, S.-H., Lee, Y., Lee, B.B., Kwon, B., Song, H., Kwon, B.S., and Park, J.-E. 
(2001). Tumor Necrosis Factor Receptor Superfamily 14 Is Involved in Atherogenesis by 
Inducing Proinflammatory Cytokines and Matrix Metalloproteinases. Arteriosclerosis, 
Thrombosis, and Vascular Biology 21, 2004-2010. 
Lee, W., Mitchell, P., and Tjian, R. (1987). Purified transcription factor AP-1 interacts with 
TPA-inducible enhancer elements. Cell 49, 741-752. 
Leek, J.T., Monsen, E., Dabney, A.R., and Storey, J.D. (2006). EDGE: extraction and 
analysis of differential gene expression. Bioinformatics 22, 507-508. 
452 
 
Lerner, R.A., Glassock, R.J., and Dixon, F.J. (1967). The role of anti-glomerular basement 
membrane antibody in the pathogenesis of human glomerulonephritis. J Exp Med 126, 989-
1004. 
Levy, J.B., Turner, A.N., Rees, A.J., and Pusey, C.D. (2001). Long-Term Outcome of Anti–
Glomerular Basement Membrane Antibody Disease Treated with Plasma Exchange and 
Immunosuppression. Ann Intern Med 134, 1033-1042. 
Li, H.-H., Cheng, H.-H., Sun, K.-H., Wei, C.-C., Li, C.-F., Chen, W.-C., Wu, W.-M., and 
Chang, M.-S. (2008). Interleukin-20 targets renal mesangial cells and is associated with lupus 
nephritis. Clinical Immunology 129, 277-285. 
Li, H., and Durbin, R. (2009). Fast and accurate short read alignment with Burrows-Wheeler 
transform. Bioinformatics 25, 1754-1760. 
Li, L., and Okusa, M.D. (2010). Macrophages, Dendritic Cells, and Kidney Ischemia-
Reperfusion Injury. Seminars in nephrology 30, 268-277. 
Li, M., Ge, Q., Wang, W., Wang, J., and Lu, Z. (2011). c-Jun binding site identification in 
K562 cells. Journal of Genetics and Genomics 38, 235-242. 
Li, Q., Subbulakshmi, V., Fields, A.P., Murray, N.R., and Cathcart, M.K. (1999). Protein 
Kinase Cα Regulates Human Monocyte O  2Production and Low Density Lipoprotein Lipid 
Oxidation. Journal of Biological Chemistry 274, 3764-3771. 
Li, R., Fan, W., Tian, G., Zhu, H., He, L., Cai, J., Huang, Q., Cai, Q., Li, B., Bai, Y., et al. 
(2010). The sequence and de novo assembly of the giant panda genome. Nature 463, 311-
317. 
Li, R., Yang, N., Zhang, L., Huang, Y., Zhang, R., Wang, F., Luo, M., Liang, Y., and Yu, X. 
(2007). Inhibition of JAK/STAT Signaling Ameliorates Mice Experimental Nephrotic 
Syndrome. American Journal of Nephrology 27, 580-589. 
Li, W.X. (2008). Canonical and non-canonical JAK-STAT signaling. Trends in Cell Biology 
18, 545-551. 
453 
 
Little, M.A., and Pusey, C.D. (2005). Glomerulonephritis due to antineutrophil cytoplasm 
antibody-associated vasculitis: an update on approaches to management. Nephrology 
(Carlton) 10, 368-376. 
Litvak, V., Ramsey, S.A., Rust, A.G., Zak, D.E., Kennedy, K.A., Lampano, A.E., Nykter, M., 
Shmulevich, I., and Aderem, A. (2009). Function of C/EBPdelta in a regulatory circuit that 
discriminates between transient and persistent TLR4-induced signals. Nature immunology 
10, 437-443. 
Liu, D., Evans, I., Britton, G., and Zachary, I. (2007). The zinc-finger transcription factor, 
early growth response 3, mediates VEGF-induced angiogenesis. Oncogene 27, 2989-2998. 
Liu, Y., Taylor, M.W., and Edenberg, H.J. (2006). Model-based identification of cis-acting 
elements from microarray data. Genomics 88, 452-461. 
Lockhart, D.J., Dong, H., Byrne, M.C., Follettie, M.T., Gallo, M.V., Chee, M.S., Mittmann, 
M., Wang, C., Kobayashi, M., Horton, H., et al. (1996). Expression monitoring by 
hybridization to high-density oligonucleotide arrays. Nat Biotechnol 14, 1675-1680. 
Lu, S.-C., Wu, H.-W., Lin, Y.-J., and Chang, S.-F. (2009). The essential role of Oct-2 in LPS-
induced expression of iNOS in RAW 264.7 macrophages and its regulation by trichostatin A. 
American Journal of Physiology - Cell Physiology 296, C1133-C1139. 
Lucas, M., Stuart, L.M., Savill, J., and Lacy-Hulbert, A. (2003). Apoptotic Cells and Innate 
Immune Stimuli Combine to Regulate Macrophage Cytokine Secretion. The Journal of 
Immunology 171, 2610-2615. 
Lucas, M., Stuart, L.M., Zhang, A., Hodivala-Dilke, K., Febbraio, M., Silverstein, R., Savill, 
J., and Lacy-Hulbert, A. (2006). Requirements for Apoptotic Cell Contact in Regulation of 
Macrophage Responses. The Journal of Immunology 177, 4047-4054. 
Lupien, M., and Brown, M. (2009). Cistromics of hormone-dependent cancer. Endocrine-
Related Cancer 16, 381-389. 
454 
 
Lupien, M., Eeckhoute, J., Meyer, C.A., Wang, Q., Zhang, Y., Li, W., Carroll, J.S., Liu, X.S., 
and Brown, M. (2008). FoxA1 Translates Epigenetic Signatures into Enhancer-Driven 
Lineage-Specific Transcription. Cell 132, 958-970. 
Ma, F.Y., Flanc, R.S., Tesch, G.H., Bennett, B.L., Friedman, G.C., and Nikolic-Paterson, D.J. 
(2009). Blockade of the c-Jun amino terminal kinase prevents crescent formation and halts 
established anti-GBM glomerulonephritis in the rat. Lab Invest. 
Machiya, J.-i., Shibata, Y., Yamauchi, K., Hirama, N., Wada, T., Inoue, S., Abe, S., 
Takabatake, N., Sata, M., and Kubota, I. (2007). Enhanced Expression of MafB Inhibits 
Macrophage Apoptosis Induced by Cigarette Smoke Exposure. Am J Respir Cell Mol Biol 
36, 418-426. 
Mackaness, G.B. (1964). THE IMMUNOLOGICAL BASIS OF ACQUIRED CELLULAR 
RESISTANCE. J Exp Med 120, 105-120. 
Magil, A.B. (2009). Monocytes/macrophages in renal allograft rejection. Transplantation 
Reviews 23, 199-208. 
Majumader, S. (2006). REST In Good Times and Bad: Roles In Tumor Suppressor and 
Oncogenic Activities. Cell Cycle 5, 1929-1935. 
Manolio, T.A., Collins, F.S., Cox, N.J., Goldstein, D.B., Hindorff, L.A., Hunter, D.J., 
McCarthy, M.I., Ramos, E.M., Cardon, L.R., Chakravarti, A., et al. (2009). Finding the 
missing heritability of complex diseases. Nature 461, 747-753. 
Mansfield, N., Hamour, S., Marie-Habib, A., Tarzi, R., Levy, J., Griffith, M., Cairns, T., 
Cook, H.T., Pusey, C.D., and Salama, A.D. (2011). Prolonged disease-free remission 
following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated 
vasculitis. Nephrology Dialysis Transplantation. 
Mantovani, A., Sica, A., Sozzani, S., Allavena, P., Vecchi, A., and Locati, M. (2004). The 
chemokine system in diverse forms of macrophage activation and polarization. Trends 
Immunol 25, 677-686. 
455 
 
Maratou, K., Behmoaras, J., Fewings, C., Srivastava, P., D'Souza, Z., Smith, J., Game, L., 
Cook, T., and Aitman, T. (2010). Characterization of the macrophage transcriptome in 
glomerulonephritis-susceptible and -resistant rat strains. Genes Immun 12, 78-89. 
Mardis, E.R. (2007). ChIP-seq: welcome to the new frontier. Nat Meth 4, 613-614. 
Mardis, E.R. (2008). Next-Generation DNA Sequencing Methods. Annual Review of 
Genomics and Human Genetics 9, 387-402. 
Marks-Konczalik, J., Chu, S.C., and Moss, J. (1998). Cytokine-mediated Transcriptional 
Induction of the Human Inducible Nitric Oxide Synthase Gene Requires Both Activator 
Protein 1 and Nuclear Factor kappa B-binding Sites. J Biol Chem 273, 22201-22208. 
Mathieson, P. (2007). Minimal change nephropathy and focal segmental glomerulosclerosis. 
Seminars in Immunopathology 29, 415-426. 
McConnell, B.B., and Yang, V.W. (2010). Mammalian Krüppel-Like Factors in Health and 
Diseases. Physiological Reviews 90, 1337-1381. 
McDermott, J.E., Archuleta, M., Thrall, B.D., Adkins, J.N., and Waters, K.M. (2011). 
Controlling the Response: Predictive Modeling of a Highly Central, Pathogen-Targeted Core 
Response Module in Macrophage Activation. PLoS ONE 6, e14673. 
Mechta-Grigoriou, F., Gerald, D., and Yaniv, M. (2001). The mammalian Jun proteins: 
redundancy and specificity. Oncogene 20, 2378-2389. 
Medzhitov, R., and Horng, T. (2009). Transcriptional control of the inflammatory response. 
Nat Rev Immunol 9, 692-703. 
Mehraein-Ghomi, F., Lee, E., Church, D.R., Thompson, T.A., Basu, H.S., and Wilding, G. 
(2008). JunD mediates androgen-induced oxidative stress in androgen dependent LNCaP 
human prostate cancer cells. The Prostate 68, 924-934. 
Meixner, A., Karreth, F., Kenner, L., Penninger, J.M., and Wagner, E.F. (2010). Jun and 
JunD-dependent functions in cell proliferation and stress response. Cell Death Differ. 
456 
 
Meixner, A., Karreth, F., Kenner, L., and Wagner, E.F. (2004). JunD regulates lymphocyte 
proliferation and T helper cell cytokine expression. The EMBO Journal 23, 1325-1335. 
Metzker, M.L. (2010). Sequencing technologies - the next generation. Nat Rev Genet 11, 31-
46. 
Mezzano, S., Aros, C., Droguett, A., Burgos, M.E., Ardiles, L., Flores, C., Schneider, H., 
Ruiz-Ortega, M., and Egido, J. (2004). NF-{kappa}B activation and overexpression of 
regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 19, 2505-2512. 
Mezzano, S., Droguett, A., Eugenia Burgos, M., Aros, C., Ardiles, L., Flores, C., Carpio, D., 
Carvajal, G., Ruiz-Ortega, M., and Egido, J. (2007). Expression of gremlin, a bone 
morphogenetic protein antagonist, in glomerular crescents of pauci-immune 
glomerulonephritis. Nephrol Dial Transplant 22, 1882-1890. 
Mezzano, S.A., Barria, M., Droguett, M.A., Burgos, M.E., Ardiles, L.G., Flores, C., and 
Egido, J. (2001). Tubular NF-κB and AP-1 activation in human proteinuric renal disease. 
Kidney Int 60, 1366-1377. 
Mizuki, N., Meguro, A., Ota, M., Ohno, S., Shiota, T., Kawagoe, T., Ito, N., Kera, J., Okada, 
E., Yatsu, K., et al. (2010). Genome-wide association studies identify IL23R-IL12RB2 and 
IL10 as Behcet's disease susceptibility loci. Nat Genet 42, 703-706. 
Mohr, S., Bakal, C., and Perrimon, N. (2010). Genomic Screening with RNAi: Results and 
Challenges. Annual Review of Biochemistry 79, 37-64. 
Monach, P.A., and Merkel, P.A. (2010). Genetics of vasculitis. Current Opinion in 
Rheumatology 22, 157-163. 
Monti, J., Fischer, J., Paskas, S., Heinig, M., Schulz, H., Gosele, C., Heuser, A., Fischer, R., 
Schmidt, C., Schirdewan, A., et al. (2008). Soluble epoxide hydrolase is a susceptibility 
factor for heart failure in a rat model of human disease. Nature genetics 40, 529-537. 
457 
 
Moreno, C., Hoffman, M., Stodola, T.J., Didier, D.N., Lazar, J., Geurts, A.M., North, P.E., 
Jacob, H.J., and Greene, A.S. (2011). Creation and Characterization of a Renin Knockout 
Rat. Hypertension 57, 614-619. 
Morgan, M.D., Harper, L., Williams, J., and Savage, C. (2006). Anti-Neutrophil Cytoplasm-
Associated Glomerulonephritis. J Am Soc Nephrol 17, 1224-1234. 
Moriwaki, K., Kiyomoto, H., Hitomi, H., Ihara, G., Kaifu, K., Matsubara, K., Hara, T., 
Kondo, N., Ohmori, K., Nishiyama, A., et al. (2006). Interferon-[gamma] enhances 
superoxide production in human mesangial cells via the JAK-STAT pathway. Kidney Int 70, 
788-793. 
Mosser, D.M. (2003). The many faces of macrophage activation. J Leukoc Biol 73, 209-212. 
Mosser, D.M., and Edwards, J.P. (2008). Exploring the full spectrum of macrophage 
activation. Nat Rev Immunol 8, 958-969. 
Mukhtyar, C., Flossmann, O., Hellmich, B., Bacon, P.A., Cid, M.C., Cohen Tervaert, J.W., 
Gross, W.L., Guillevin, L., Jayne, D.R.W., Mahr, A., et al. (2007). Outcomes from studies of 
Antineutrophil Cytoplasm Antibody Associated Vasculitis: a systematic review by the 
EULAR Systemic Vasculitis Task Force. Ann Rheum Dis 67, 1004-1010. 
Muller, W.A. (2011). Mechanisms of Leukocyte Transendothelial Migration. Annual Review 
of Pathology: Mechanisms of Disease 6, 323-344. 
Murray, P.J. (2007). The JAK-STAT Signaling Pathway: Input and Output Integration. The 
Journal of Immunology 178, 2623-2629. 
Myers, R.M., Stamatoyannopoulos, J., Snyder, M., Dunham, I., Hardison, R.C., Bernstein, 
B.E., Gingeras, T.R., Kent, W.J., Birney, E., Wold, B., et al. (2011). A user's guide to the 
encyclopedia of DNA elements (ENCODE). PLoS Biol 9, e1001046. 
Nakabeppu, Y., Ryder, K., and Nathans, D. (1988). DNA binding activities of three murine 
Jun proteins: Stimulation by Fos. Cell 55, 907-915. 
458 
 
Nakashima, S. (2002). Protein Kinase Cα (PKCα): Regulation and Biological Function. 
Journal of Biochemistry 132, 669-675. 
Nakayama, K., Nitto, T., Inoue, T., and Node, K. (2008). Expression of the cytochrome P450 
epoxygenase CYP2J2 in human monocytic leukocytes. Life Sciences 83, 339-345. 
Natoli, G., Ghisletti, S., and Barozzi, I. (2011). The genomic landscapes of inflammation. 
Genes & Development 25, 101-106. 
Nau, G.J., Richmond, J.F.L., Schlesinger, A., Jennings, E.G., Lander, E.S., and Young, R.A. 
(2002). Human macrophage activation programs induced by bacterial pathogens. Proceedings 
of the National Academy of Sciences 99, 1503-1508. 
Nawa, Y., Kawahara, K.-i., Tancharoen, S., Meng, X., Sameshima, H., Ito, T., Masuda, Y., 
Imaizumi, H., Hashiguchi, T., and Maruyama, I. (2009). Nucleophosmin may act as an 
alarmin: implications for severe sepsis. Journal of Leukocyte Biology 86, 645-653. 
Nejentsev, S., Walker, N., Riches, D., Egholm, M., and Todd, J.A. (2009). Rare variants of 
IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science 324, 
387-389. 
Newell, C.L., Deisseroth, A.B., and Lopez-Berestein, G. (1994). Interaction of nuclear 
proteins with an AP-1/CRE-like promoter sequence in the human TNF-alpha gene. J Leukoc 
Biol 56, 27-35. 
Ng, S.B., Buckingham, K.J., Lee, C., Bigham, A.W., Tabor, H.K., Dent, K.M., Huff, C.D., 
Shannon, P.T., Jabs, E.W., Nickerson, D.A., et al. (2010a). Exome sequencing identifies the 
cause of a mendelian disorder. Nat Genet 42, 30-35. 
Ng, S.B., Nickerson, D.A., Bamshad, M.J., and Shendure, J. (2010b). Massively parallel 
sequencing and rare disease. Human Molecular Genetics 19, R119-R124. 
Ng, S.B., Turner, E.H., Robertson, P.D., Flygare, S.D., Bigham, A.W., Lee, C., Shaffer, T., 
Wong, M., Bhattacharjee, A., Eichler, E.E., et al. (2009). Targeted capture and massively 
parallel sequencing of 12 human exomes. Nature 461, 272-276. 
459 
 
Nguyen, D.U.Y., Ping, F.U., Mu, W.E.I., Hill, P., Atkins, R.C., and Chadban, S.J. (2006). 
Macrophage accumulation in human progressive diabetic nephropathy. Nephrology 11, 226-
231. 
Nguyen, V., Cudrici, C., Zernetkina, V., Niculescu, F., Rus, H., Drachenberg, C., and Rus, V. 
(2009). TRAIL, DR4 and DR5 are upregulated in kidneys from patients with lupus nephritis 
and exert proliferative and proinflammatory effects. Clinical Immunology 132, 32-42. 
Nilsson, R., Bajic, V.B., Suzuki, H., di Bernardo, D., Björkegren, J., Katayama, S., Reid, J.F., 
Sweet, M.J., Gariboldi, M., Carninci, P., et al. (2006). Transcriptional network dynamics in 
macrophage activation. Genomics 88, 133-142. 
Node, K., Huo, Y., Ruan, X., Yang, B., Spiecker, M., Ley, K., Zeldin, D.C., and Liao, J.K. 
(1999). Anti-inflammatory Properties of Cytochrome P450 Epoxygenase-Derived 
Eicosanoids. Science 285, 1276-1279. 
North, R.J. (1978). Opinions. The Journal of Immunology 121, 806-809. 
Northrup, Daniel L., and Zhao, K. (2011). Application of ChIP-Seq and Related Techniques 
to the Study of Immune Function. Immunity 34, 830-842. 
Oien, D., and Moskovitz, J. (2007). Ablation of the mammalian methionine sulfoxide 
reductase A affects the expression level of cysteine deoxygenase. Biochem Biophys Res 
Commun 352, 556 - 559. 
Okada, S., Obata, S., Hatano, M., and Tokuhisa, T. (2003). Dominant-negative effect of the 
c-fos family gene products on inducible NO synthase expression in macrophages. Int 
Immunol 15, 1275-1282. 
Opar, A. (2010). Kinase inhibitors attract attention as oral rheumatoid arthritis drugs. Nat Rev 
Drug Discov 9, 257-258. 
Ozsolak, F., and Milos, P.M. (2011). RNA sequencing: advances, challenges and 
opportunities. Nat Rev Genet 12, 87-98. 
460 
 
Pallan, L., Savage, C.O., and Harper, L. (2009). ANCA-associated vasculitis: from bench 
research to novel treatments. Nat Rev Nephrol 5, 278-286. 
Palumbo, K., Zerr, P., Tomcik, M., Vollath, S., Dees, C., Akhmetshina, A., Avouac, J., 
Yaniv, M., Distler, O., Schett, G., et al. (2011). The transcription factor JunD mediates 
transforming growth factor β-induced fibroblast activation and fibrosis in systemic sclerosis. 
Annals of the Rheumatic Diseases. 
Pang, M., Ma, L., Gong, R., Tolbert, E., Mao, H., Ponnusamy, M., Chin, Y.E., Yan, H., 
Dworkin, L.D., and Zhuang, S. (2010). A novel STAT3 inhibitor, S3I-201, attenuates renal 
interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. Kidney Int 
78, 257-268. 
Papin, S., Cuenin, S., Agostini, L., Martinon, F., Werner, S., Beer, H.D., Grutter, C., Grutter, 
M., and Tschopp, J. (2007). The SPRY domain of Pyrin, mutated in familial Mediterranean 
fever patients, interacts with inflammasome components and inhibits proIL-1[beta] 
processing. Cell Death Differ 14, 1457-1466. 
Park, J.M., Greten, F.R., Wong, A., Westrick, R.J., Arthur, J.S.C., Otsu, K., Hoffmann, A., 
Montminy, M., and Karin, M. (2005). Signaling Pathways and Genes that Inhibit Pathogen-
Induced Macrophage Apoptosis-- CREB and NF-[kappa]B as Key Regulators. Immunity 23, 
319-329. 
Park, P.J. (2009). ChIP-seq: advantages and challenges of a maturing technology. Nat Rev 
Genet 10, 669-680. 
Patil, N., Berno, A.J., Hinds, D.A., Barrett, W.A., Doshi, J.M., Hacker, C.R., Kautzer, C.R., 
Lee, D.H., Marjoribanks, C., McDonough, D.P., et al. (2001). Blocks of limited haplotype 
diversity revealed by high-resolution scanning of human chromosome 21. Science 294, 1719-
1723. 
Pease, A.C., Solas, D., Sullivan, E.J., Cronin, M.T., Holmes, C.P., and Fodor, S.P. (1994). 
Light-generated oligonucleotide arrays for rapid DNA sequence analysis. Proceedings of the 
National Academy of Sciences of the United States of America 91, 5022-5026. 
461 
 
Pepke, S., Wold, B., and Mortazavi, A. (2009). Computation for ChIP-seq and RNA-seq 
studies. Nat Meth 6, S22-S32. 
Pesce, J.T., Ramalingam, T.R., Mentink-Kane, M.M., Wilson, M.S., El Kasmi, K.C., Smith, 
A.M., Thompson, R.W., Cheever, A.W., Murray, P.J., and Wynn, T.A. (2009). Arginase-1–
Expressing Macrophages Suppress Th2 Cytokine–Driven Inflammation and Fibrosis. PLoS 
Pathog 5, e1000371. 
Petretto, E., Mangion, J., Dickens, N.J., Cook, S.A., Kumaran, M.K., Lu, H., Fischer, J., 
Maatz, H., Kren, V., Pravenec, M., et al. (2006). Heritability and Tissue Specificity of 
Expression Quantitative Trait Loci. PLoS Genetics 2, e172. 
Petretto, E., Sarwar, R., Grieve, I., Lu, H., Kumaran, M.K., Muckett, P.J., Mangion, J., 
Schroen, B., Benson, M., Punjabi, P.P., et al. (2008). Integrated genomic approaches 
implicate osteoglycin (Ogn) in the regulation of left ventricular mass. Nature genetics 40, 
546-552. 
Pirkmajer, S., and Chibalin, A.V. (2011). Serum starvation: caveat emptor. American Journal 
of Physiology - Cell Physiology 301, C272-C279. 
Plüddemann, A., Mukhopadhyay, S., and Gordon, S. (2011). Innate immunity to intracellular 
pathogens: macrophage receptors and responses to microbial entry. Immunological Reviews 
240, 11-24. 
Polager, S., and Ginsberg, D. (2009). p53 and E2f: partners in life and death. Nat Rev Cancer 
9, 738-748. 
Pravenec, M., Churchill, P.C., Churchill, M.C., Viklicky, O., Kazdova, L., Aitman, T.J., 
Petretto, E., Hubner, N., Wallace, C.A., Zimdahl, H., et al. (2008). Identification of renal 
Cd36 as a determinant of blood pressure and risk for hypertension. Nat Genet 40, 952-954. 
Puente, X.S., Pinyol, M., Quesada, V., Conde, L., Ordonez, G.R., Villamor, N., Escaramis, 
G., Jares, P., Bea, S., Gonzalez-Diaz, M., et al. (2011). Whole-genome sequencing identifies 
recurrent mutations in chronic lymphocytic leukaemia. Nature 475, 101-105. 
462 
 
Rabinovich, A., Jin, V.X., Rabinovich, R., Xu, X., and Farnham, P.J. (2008). E2F in vivo 
binding specificity: Comparison of consensus versus nonconsensus binding sites. Genome 
Research 18, 1763-1777. 
Radhakrishnan, J., Moutzouris, D.-A., Ginzler, E.M., Solomons, N., Siempos, I.I., and Appel, 
G.B. (2009). Mycophenolate mofetil and intravenous cyclophosphamide are similar as 
induction therapy for class V lupus nephritis. Kidney Int 77, 152-160. 
Ramirez-Carrozzi, V.R., Braas, D., Bhatt, D.M., Cheng, C.S., Hong, C., Doty, K.R., Black, 
J.C., Hoffmann, A., Carey, M., and Smale, S.T. (2009). A Unifying Model for the Selective 
Regulation of Inducible Transcription by CpG Islands and Nucleosome Remodeling. Cell 
138, 114-128. 
Ramirez-Carrozzi, V.R., Nazarian, A.A., Li, C.C., Gore, S.L., Sridharan, R., Imbalzano, 
A.N., and Smale, S.T. (2006). Selective and antagonistic functions of SWI/SNF and Mi-2Î² 
nucleosome remodeling complexes during an inflammatory response. Genes & Development 
20, 282-296. 
Ramsey, S.A., Klemm, S.L., Zak, D.E., Kennedy, K.A., Thorsson, V., Li, B., Gilchrist, M., 
Gold, E.S., Johnson, C.D., Litvak, V., et al. (2008). Uncovering a Macrophage 
Transcriptional Program by Integrating Evidence from Motif Scanning and Expression 
Dynamics. PLoS Comput Biol 4, e1000021. 
Rauscher, F.J., Voulalas, P.J., Franza, B.R., and Curran, T. (1988). Fos and Jun bind 
cooperatively to the AP-1 site: reconstitution in vitro. Genes & Development 2, 1687-1699. 
Ravasi, T., Wells, C.A., and Hume, D.A. (2007). Systems biology of transcription control in 
macrophages. BioEssays 29, 1215-1226. 
Ravetch, J.V., and Bolland, S. (2001). IGG FC RECEPTORS. Annual Review of 
Immunology 19, 275-290. 
Raychaudhuri, S., Remmers, E.F., Lee, A.T., Hackett, R., Guiducci, C., Burtt, N.P., 
Gianniny, L., Korman, B.D., Padyukov, L., Kurreeman, F.A.S., et al. (2008). Common 
variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet 40, 1216-1223. 
463 
 
Rees, A.J. (2010). Monocyte and Macrophage Biology: An Overview. Seminars in 
nephrology 30, 216-233. 
Reilly, C.M., Olgun, S., Goodwin, D., Gogal, R.M., Santo, A., Romesburg, J.W., 
Ansar Ahmed, S., and Gilkeson, G.S. (2006). Interferon regulatory factor-1 gene deletion 
decreases glomerulonephritis in MRL/lpr mice. European Journal of Immunology 36, 1296-
1308. 
Reinecke, F., Levanets, O., Olivier, Y., Louw, R., Semete, B., Grobler, A., Hidalgo, J., 
Smeitink, J., Olckers, A., and Van der westhuizen, F.H. (2006). Metallothionein isoform 2A 
expression is inducible and protects against ROS-mediated cell death in rotenone-treated 
HeLa cells. Biochem J 395, 405-415. 
Remmers, E.F., Cosan, F., Kirino, Y., Ombrello, M.J., Abaci, N., Satorius, C., Le, J.M., 
Yang, B., Korman, B.D., Cakiris, A., et al. (2010). Genome-wide association study identifies 
variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet's 
disease. Nat Genet 42, 698-702. 
Ren, B., Robert, F., Wyrick, J.J., Aparicio, O., Jennings, E.G., Simon, I., Zeitlinger, J., 
Schreiber, J., Hannett, N., Kanin, E., et al. (2000). Genome-wide location and function of 
DNA binding proteins. Science 290, 2306-2309. 
Reynolds, J., Haxby, J., Juggapah, J.K., Evans, D.J., and Pusey, C.D. (2009). Identification of 
a nephritogenic immunodominant B and T cell epitope in experimental autoimmune 
glomerulonephritis. Clinical & Experimental Immunology 155, 311-319. 
Reynolds, J., Mavromatidis, K., Cashman, S.J., Evans, D.J., and Pusey, C.D. (1998). 
Experimental autoimmune glomerulonephritis (EAG) induced by homologous and 
heterologous glomerular basement membrane in two substrains of Wistar-Kyoto rat. 
Nephrology Dialysis Transplantation 13, 44-52. 
Reynolds, J., Tam, F.W.K., Chandraker, A., Smith, J., Karkar, A.M., Cross, J., Peach, R., 
Sayegh, M.H., and Pusey, C.D. (2000). CD28-B7 blockade prevents the development of 
464 
 
experimental autoimmune glomerulonephritis. The Journal of Clinical Investigation 105, 
643-651. 
Risch, N., and Merikangas, K. (1996). The future of genetic studies of complex human 
diseases. Science 273, 1516-1517. 
Roberts, I.S.D., Cook, H.T., Troyanov, S., Alpers, C.E., Amore, A., Barratt, J., Berthoux, F., 
Bonsib, S., Bruijn, J.A., Cattran, D.C., et al. (2009). The Oxford classification of IgA 
nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 
Robertson, A.G., Bilenky, M., Tam, A., Zhao, Y., Zeng, T., Thiessen, N., Cezard, T., Fejes, 
A.P., Wederell, E.D., Cullum, R., et al. (2008). Genome-wide relationship between histone 
H3 lysine 4 mono- and tri-methylation and transcription factor binding. Genome Research 18, 
1906-1917. 
Robertson, G., Hirst, M., Bainbridge, M., Bilenky, M., Zhao, Y., Zeng, T., Euskirchen, G., 
Bernier, B., Varhol, R., Delaney, A., et al. (2007). Genome-wide profiles of STAT1 DNA 
association using chromatin immunoprecipitation and massively parallel sequencing. Nat 
Meth 4, 651-657. 
Robson, M.G. (2009). Toll-like receptors and renal disease. Nephron 113, e1-7. 
Rodriguez, H.M., Vaysberg, M., Mikels, A., McCauley, S., Velayo, A.C., Garcia, C., and 
Smith, V. (2010). Modulation of Lysyl Oxidase-like 2 Enzymatic Activity by an Allosteric 
Antibody Inhibitor. Journal of Biological Chemistry 285, 20964-20974. 
Roider, H.G., Kanhere, A., Manke, T., and Vingron, M. (2007). Predicting transcription 
factor affinities to DNA from a biophysical model. Bioinformatics 23, 134-141. 
Rosin, D.L., and Okusa, M.D. (2011). Dangers Within: DAMP Responses to Damage and 
Cell Death in Kidney Disease. Journal of the American Society of Nephrology 22, 416-425. 
Rozen, S., and Skaletsky, H. (2000). Primer3 on the WWW for general users and for 
biologist programmers. Methods in molecular biology 132, 365-386. 
465 
 
Russell, L., and Garrett-Sinha, L.A. (2010). Transcription factor Ets-1 in cytokine and 
chemokine gene regulation. Cytokine 51, 217-226. 
Ryder, K., Lanahan, A., Perez-Albuerne, E., and Nathans, D. (1989). jun-D: a third member 
of the jun gene family. Proceedings of the National Academy of Sciences of the United States 
of America 86, 1500-1503. 
Sakurai, H., Shigemori, N., Hisada, Y., Ishizuka, T., Kawashima, K., and Sugita, T. (1997). 
Suppression of NF-[kappa]B and AP-1 activation by glucocorticoids in experimental 
glomerulonephritis in rats: molecular mechanisms of anti-nephritic action. Biochimica et 
Biophysica Acta (BBA) - Molecular Basis of Disease 1362, 252-262. 
Sakurai, H., and Sugita, T. (1998). c-Jun N-terminal kinase-mediated AP-1 activation in 
experimental glomerulonephritis in rats. Biochem Mol Biol Int 45, 831-839. 
Sandelin, A., Carninci, P., Lenhard, B., Ponjavic, J., Hayashizaki, Y., and Hume, D.A. 
(2007). Mammalian RNA polymerase II core promoters: insights from genome-wide studies. 
Nature reviews Genetics 8, 424-436. 
Santana-de Anda, K., Gómez-Martín, D., Díaz-Zamudio, M., and Alcocer-Varela, J. (2011). 
Interferon regulatory factors: Beyond the antiviral response and their link to the development 
of autoimmune pathology. Autoimmunity Reviews. 
Satsu, H., Terasawa, E., Hosokawa, Y., and Shimizu, M. (2003). Functional characterization 
and regulation of the taurine transporter and cysteine dioxygenase in human hepatoblastoma 
HepG2 cells. Biochem J 375, 441 - 447. 
Schonermarck, U., and de Groot, K. (2011). Vasculitis: Rituximab: effective in ANCA-
associated vasculitis? Nat Rev Nephrol 7, 6-8. 
Schonthaler, H.B., Guinea-Viniegra, J., and Wagner, E.F. (2011). Targeting inflammation by 
modulating the Jun/AP-1 pathway. Annals of the Rheumatic Diseases 70, i109-i112. 
Schroder, W.A., Le, T.T.T., Major, L., Street, S., Gardner, J., Lambley, E., Markey, K., 
MacDonald, K.P., Fish, R.J., Thomas, R., et al. (2010). A Physiological Function of 
466 
 
Inflammation-Associated SerpinB2 Is Regulation of Adaptive Immunity. The Journal of 
Immunology 184, 2663-2670. 
Schuh, N.R., Guerrero, M.S., Schrecengost, R.S., and Bouton, A.H. (2010). BCAR3 
Regulates Src/p130Cas Association, Src Kinase Activity, and Breast Cancer Adhesion 
Signaling. Journal of Biological Chemistry 285, 2309-2317. 
Seshadri, S., Duncan, M.D., Hart, J.M., Gavrilin, M.A., and Wewers, M.D. (2007). Pyrin 
Levels in Human Monocytes and Monocyte-Derived Macrophages Regulate IL-1β 
Processing and Release. The Journal of Immunology 179, 1274-1281. 
Sethu, S., Mendez-Corao, G., and Melendez, A.J. (2008). Phospholipase D1 Plays a Key 
Role in TNF-α Signaling. The Journal of Immunology 180, 6027-6034. 
Sharda, D.R., Yu, S., Ray, M., Squadrito, M.L., De Palma, M., Wynn, T.A., Morris, S.M., 
and Hankey, P.A. (2011). Regulation of Macrophage Arginase Expression and Tumor 
Growth by the Ron Receptor Tyrosine Kinase. The Journal of Immunology. 
Shaulian, E. (2010). AP-1 -- The Jun proteins: Oncogenes or tumor suppressors in disguise? 
Cellular Signalling 22, 894-899. 
Shaulian, E., and Karin, M. (2001). AP-1 in cell proliferation and survival. Oncogene 20, 
2390-2400. 
Shaulian, E., and Karin, M. (2002). AP-1 as a regulator of cell life and death. Nat Cell Biol 4, 
E131-E136. 
Sheedy, F.J., Palsson-McDermott, E., Hennessy, E.J., Martin, C., O'Leary, J.J., Ruan, Q., 
Johnson, D.S., Chen, Y., and O'Neill, L.A.J. (2010). Negative regulation of TLR4 via 
targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat 
Immunol 11, 141-147. 
Sherry, S.T., Ward, M.H., Kholodov, M., Baker, J., Phan, L., Smigielski, E.M., and Sirotkin, 
K. (2001). dbSNP: the NCBI database of genetic variation. Nucleic acids research 29, 308-
311. 
467 
 
Sheryanna, A., Bhangal, G., McDaid, J., Smith, J., Manning, A., Foxwell, B.M.J., Feldmann, 
M., Cook, H.T., Pusey, C.D., and Tam, F.W.K. (2007). Inhibition of p38 Mitogen-Activated 
Protein Kinase Is Effective in the Treatment of Experimental Crescentic Glomerulonephritis 
and Suppresses Monocyte Chemoattractant Protein-1 but Not IL-1beta or IL-6. J Am Soc 
Nephrol 18, 1167-1179. 
Shui, J.-W., Steinberg, M.W., and Kronenberg, M. (2011). Regulation of inflammation, 
autoimmunity, and infection immunity by HVEM-BTLA signaling. Journal of Leukocyte 
Biology 89, 517-523. 
Silva, F.G., Hoyer, J.R., and Pirani, C.L. (1984). Sequential studies of glomerular crescent 
formation in rats with antiglomerular basement membrane-induced glomerulonephritis and 
the role of coagulation factors. Laboratory investigation; a journal of technical methods and 
pathology 51, 404-415. 
Simon, A.R., Rai, U., Fanburg, B.L., and Cochran, B.H. (1998). Activation of the JAK-STAT 
pathway by reactive oxygen species. Am J Physiol 275, C1640-1652. 
Sjöbring, U., Björck, L., and Kastern, W. (1991). Streptococcal protein G. Gene structure and 
protein binding properties. Journal of Biological Chemistry 266, 399-405. 
Skol, A.D., Scott, L.J., Abecasis, G.R., and Boehnke, M. (2006). Joint analysis is more 
efficient than replication-based analysis for two-stage genome-wide association studies. Nat 
Genet 38, 209-213. 
Smith, J., Lai, P.-C., Behmoaras, J., Roufosse, C., Bhangal, G., McDaid, J.P., Aitman, T., 
Tam, F.W.K., Pusey, C.D., and Cook, H.T. (2007). Genes Expressed by Both Mesangial 
Cells and Bone Marrow-Derived Cells Underlie Genetic Susceptibility to Crescentic 
Glomerulonephritis in the Rat. J Am Soc Nephrol 18, 1816-1823. 
Smith, J., McDaid, J.P., Bhangal, G., Chawanasuntorapoj, R., Masuda, E.S., Cook, H.T., 
Pusey, C.D., and Tam, F.W.K. (2010). A Spleen Tyrosine Kinase Inhibitor Reduces the 
Severity of Established Glomerulonephritis. Journal of the American Society of Nephrology 
21, 231-236. 
468 
 
Solomon, M.J., Larsen, P.L., and Varshavsky, A. (1988). Mapping proteinDNA interactions 
in vivo with formaldehyde: Evidence that histone H4 is retained on a highly transcribed gene. 
Cell 53, 937-947. 
Spyrou, C., Stark, R., Lynch, A.G., and Tavare, S. (2009). BayesPeak: Bayesian analysis of 
ChIP-seq data. BMC Bioinformatics 10, 299. 
Stahl, E.A., Raychaudhuri, S., Remmers, E.F., Xie, G., Eyre, S., Thomson, B.P., Li, Y., 
Kurreeman, F.A., Zhernakova, A., Hinks, A., et al. (2010). Genome-wide association study 
meta-analysis identifies seven new rheumatoid arthritis risk loci. Nature genetics 42, 508-
514. 
Stassen, P.M., Cohen-Tervaert, J.W., Lems, S.P., Hepkema, B.G., Kallenberg, C.G., and 
Stegeman, C.A. (2009). HLA-DR4, DR13(6) and the ancestral haplotype A1B8DR3 are 
associated with ANCA-associated vasculitis and Wegener's granulomatosis. Rheumatology 
48, 622-625. 
Stojanov, S., and McDermott, M.F. (2005). The tumour necrosis factor receptor-associated 
periodic syndrome: current concepts. Expert Reviews in Molecular Medicine 7, 1-18. 
Storey, J.D., Dai, J.Y., and Leek, J.T. (2007). The optimal discovery procedure for large-
scale significance testing, with applications to comparative microarray experiments. 
Biostatistics 8, 414-432. 
Storey, J.D., and Tibshirani, R. (2003). Statistical significance for genomewide studies. 
Proceedings of the National Academy of Sciences 100, 9440-9445. 
Storey, J.D., Xiao, W., Leek, J.T., Tompkins, R.G., and Davis, R.W. (2005). Significance 
analysis of time course microarray experiments. Proceedings of the National Academy of 
Sciences of the United States of America 102, 12837-12842. 
Subramanian, A., Kuehn, H., Gould, J., Tamayo, P., and Mesirov, J.P. (2007). GSEA-P: a 
desktop application for Gene Set Enrichment Analysis. Bioinformatics 23, 3251-3253. 
469 
 
Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., 
Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., et al. (2005). Gene set enrichment 
analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc 
Natl Acad Sci U S A 102, 15545-15550. 
Summers, S.A., Hoi, A., Steinmetz, O.M., O'Sullivan, K.M., Ooi, J.D., Odobasic, D., Akira, 
S., Kitching, A.R., and Holdsworth, S.R. (2010a). TLR9 and TLR4 are required for the 
development of autoimmunity and lupus nephritis in pristane nephropathy. Journal of 
Autoimmunity 35, 291-298. 
Summers, S.A., van der Veen, B.S., O'Sullivan, K.M., Gan, P.-Y., Ooi, J.D., Heeringa, P., 
Satchell, S.C., Mathieson, P.W., Saleem, M.A., Visvanathan, K., et al. (2010b). Intrinsic 
renal cell and leukocyte-derived TLR4 aggravate experimental anti-MPO glomerulonephritis. 
Kidney Int 78, 1263-1274. 
Swanberg, M., Lidman, O., Padyukov, L., Eriksson, P., Akesson, E., Jagodic, M., Lobell, A., 
Khademi, M., Borjesson, O., Lindgren, C.M., et al. (2005). MHC2TA is associated with 
differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple 
sclerosis and myocardial infarction. Nat Genet 37, 486-494. 
Tada, Y., Kondo, S., Aoki, S., Koarada, S., Inoue, H., Suematsu, R., Ohta, A., Mak, T.W., 
and Nagasawa, K. (2011). Interferon regulatory factor 5 is critical for the development of 
lupus in MRL/lpr mice. Arthritis & Rheumatism 63, 738-748. 
Takatani, T., Takahashi, K., Uozumi, Y., Shikata, E., Yamamoto, Y., Ito, T., Matsuda, T., 
Schaffer, S., Fujio, Y., and Azuma, J. (2004). Taurine inhibits apoptosis by preventing 
formation of the Apaf-1/caspase-9 apoptosome. Am J Physiol 287, C949 - 953. 
Talotta, F., Cimmino, A., Matarazzo, M.R., Casalino, L., De Vita, G., D'Esposito, M., Di 
Lauro, R., and Verde, P. (2008). An autoregulatory loop mediated by miR-21 and PDCD4 
controls the AP-1 activity in RAS transformation. Oncogene 28, 73-84. 
470 
 
Tam, F., Smith, J., Morel, D., Karkar, A., Thompson, E., Cook, H., and Pusey, C. (1999). 
Development of scarring and renal failure in a rat model of crescentic glomerulonephritis. 
Nephrol Dial Transplant 14, 1658-1666. 
Tamura, T., Yanai, H., Savitsky, D., and Taniguchi, T. (2008). The IRF Family Transcription 
Factors in Immunity and Oncogenesis. Annual Review of Immunology 26, 535-584. 
Tang, W.W., Qi, M., and Warren, J.S. (1996). Monocyte chemoattractant protein 1 mediates 
glomerular macrophage infiltration in anti-GBM Ab GN. Kidney Int 50, 665-671. 
Tarzi, R.M., Cook, H.T., Jackson, I., Pusey, C.D., and Lord, G.M. (2004). Leptin-Deficient 
Mice Are Protected from Accelerated Nephrotoxic Nephritis. The American Journal of 
Pathology 164, 385-390. 
Tarzi, R.M., Cook, H.T., and Pusey, C.D. (2011). Crescentic Glomerulonephritis: New 
Aspects of Pathogenesis. Seminars in nephrology 31, 361-368. 
Tarzi, R.M., Davies, K.A., Claassens, J.W.C., Verbeek, J.S., Walport, M.J., and Cook, H.T. 
(2003). Both Fc[gamma] Receptor I and Fc[gamma] Receptor III Mediate Disease in 
Accelerated Nephrotoxic Nephritis. The American Journal of Pathology 162, 1677-1683. 
Tarzi, R.M., Davies, K.A., Robson, M.G., Fossati-Jimack, L., Saito, T., Walport, M.J., and 
Cook, H.T. (2002). Nephrotoxic nephritis is mediated by Fc[ggr] receptors on circulating 
leukocytes and not intrinsic renal cells. Kidney Int 62, 2087-2096. 
Taylor, S.R.J., Turner, C.M., Elliott, J.I., McDaid, J., Hewitt, R., Smith, J., Pickering, M.C., 
Whitehouse, D.L., Cook, H.T., Burnstock, G., et al. (2009). P2X7 Deficiency Attenuates 
Renal Injury in Experimental Glomerulonephritis. Journal of the American Society of 
Nephrology 20, 1275-1281. 
Tengku-Muhammad, T.S., Hughes, T.R., Foka, P., Cryer, A., and Ramji, D.P. (2000). 
Cytokine-mediated differential regulation of macrophage activator protein-1 genes. Cytokine 
12, 720-726. 
471 
 
Tesar, V., and Hruskova, Z. (2011). Treatment of proliferative lupus nephritis: a slowly 
changing landscape. Nat Rev Nephrol 7, 96-109. 
Tesch, G.H. (2010). Macrophages and Diabetic Nephropathy. Seminars in nephrology 30, 
290-301. 
The International, F.M.F.C. (1997). Ancient Missense Mutations in a New Member of the 
RoRet Gene Family Are Likely to Cause Familial Mediterranean Fever. Cell 90, 797-807. 
The Wegener's Granulomatosis Etanercept Trial Research, G. (2005). Etanercept plus 
Standard Therapy for Wegener's Granulomatosis. N Engl J Med 352, 351-361. 
Thepot, D., Weitzman, J.B., Barra, J., Segretain, D., Stinnakre, M.G., Babinet, C., and Yaniv, 
M. (2000). Targeted disruption of the murine junD gene results in multiple defects in male 
reproductive function. Development 127, 143-153. 
Thomson, N.M., Holdsworth, S.R., Glasgow, E.F., and Atkins, R.C. (1979). The macrophage 
in the development of experimental crescentic glomerulonephritis. Studies using tissue 
culture and electron microscopy. The American Journal of Pathology 94, 223-240. 
Tipping, P.G., and Holdsworth, S.R. (2006). T Cells in Crescentic Glomerulonephritis. J Am 
Soc Nephrol 17, 1253-1263. 
Toualbi-Abed, K., Daniel, F., Güller, M.C., Legrand, A., Mauriz, J.-L., Mauviel, A., and 
Bernuau, D. (2008). Jun D cooperates with p65 to activate the proximal κB site of the cyclin 
D1 promoter: role of PI3K/PDK-1. Carcinogenesis 29, 536-543. 
Trivedi, S. (2011). 1.3 Clinical Genetics, Epigenetics or Pharmacogenetics. Clinical & 
Experimental Immunology 164, 74-78. 
Tryggvason, K., and Patrakka, J. (2006). Thin Basement Membrane Nephropathy. Journal of 
the American Society of Nephrology 17, 813-822. 
Turner, C.M., Tam, F.W.K., Lai, P.-C., Tarzi, R.M., Burnstock, G., Pusey, C.D., Cook, H.T., 
and Unwin, R.J. (2007). Increased expression of the pro-apoptotic ATP-sensitive P2X7 
472 
 
receptor in experimental and human glomerulonephritis. Nephrology Dialysis 
Transplantation 22, 386-395. 
Tusher, V.G., Tibshirani, R., and Chu, G. (2001). Significance analysis of microarrays 
applied to the ionizing radiation response. Proceedings of the National Academy of Sciences 
98, 5116-5121. 
Untergasser, A., Nijveen, H., Rao, X., Bisseling, T., Geurts, R., and Leunissen, J.A. (2007). 
Primer3Plus, an enhanced web interface to Primer3. Nucleic acids research 35, W71-74. 
Vaquerizas, J.M., Kummerfeld, S.K., Teichmann, S.A., and Luscombe, N.M. (2009). A 
census of human transcription factors: function, expression and evolution. Nat Rev Genet 10, 
252-263. 
Vernon, M.A., Mylonas, K.J., and Hughes, J. (2010). Macrophages and Renal Fibrosis. 
Seminars in nephrology 30, 302-317. 
Vogt, P.K. (2001). Jun, the oncoprotein. Oncogene 20, 2365-2377. 
Wada, T., Yokoyama, H., Furuichi, K., Kobayashi, K.I., Harada, K., Naruto, M., Su, S.B., 
Akiyama, M., Mukaida, N., and Matsushima, K. (1996). Intervention of crescentic 
glomerulonephritis by antibodies to monocyte chemotactic and activating factor 
(MCAF/MCP-1). Faseb J 10, 1418-1425. 
Wagner, E.F., and Eferl, R. (2005). Fos/AP-1 proteins in bone and the immune system. 
Immunological Reviews 208, 126-140. 
Walters, R.G., Jacquemont, S., Valsesia, A., de Smith, A.J., Martinet, D., Andersson, J., 
Falchi, M., Chen, F., Andrieux, J., Lobbens, S., et al. (2010). A new highly penetrant form of 
obesity due to deletions on chromosome 16p11.2. Nature 463, 671-675. 
Wang, S., Yang, N., Zhang, L., Huang, B., Tan, H., Liang, Y., Li, Y., and Yu, X. (2010). 
Jak/STAT signaling is involved in the inflammatory infiltration of the kidneys in MRL/lpr 
mice. Lupus 19, 1171-1180. 
473 
 
Wang, X.M., Kim, H.P., Song, R., and Choi, A.M.K. (2006). Caveolin-1 Confers 
Antiinflammatory Effects in Murine Macrophages via the MKK3/p38 MAPK Pathway. Am J 
Respir Cell Mol Biol 34, 434-442. 
Wang, Y., and Harris, D.C.H. (2011). Macrophages in Renal Disease. Journal of the 
American Society of Nephrology 22, 21-27. 
Weening, J.J., D’Agati, V.D., Schwartz, M.M., Seshan, S.V., Alpers, C.E., Appel, G.B., 
Balow, J.E., Bruijn, J.A., Cook, T., Ferrario, F., et al. (2004). The Classification of 
Glomerulonephritis in Systemic Lupus Erythematosus Revisited. Journal of the American 
Society of Nephrology 15, 241-250. 
Wei, L., Vahedi, G., Sun, H.W., Watford, W.T., Takatori, H., Ramos, H.L., Takahashi, H., 
Liang, J., Gutierrez-Cruz, G., Zang, C., et al. (2010). Discrete roles of STAT4 and STAT6 
transcription factors in tuning epigenetic modifications and transcription during T helper cell 
differentiation. Immunity 32, 840-851. 
Weinblatt, M.E., Kavanaugh, A., Genovese, M.C., Musser, T.K., Grossbard, E.B., and 
Magilavy, D.B. (2010). An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid 
Arthritis. New England Journal of Medicine 363, 1303-1312. 
Weitzman, J.B., Fiette, L., Matsuo, K., and Yaniv, M. (2000). JunD Protects Cells from p53-
Dependent Senescence and Apoptosis. Molecular Cell 6, 1109-1119. 
Wen, A.Y., Sakamoto, K.M., and Miller, L.S. (2010). The Role of the Transcription Factor 
CREB in Immune Function. The Journal of Immunology 185, 6413-6419. 
Westman, K., Bygren, P., Olsson, H., Ranstam, J., and Wieslander, J. (1998). Relapse rate, 
renal survival, and cancer morbidity in patients with Wegener's granulomatosis or 
microscopic polyangiitis with renal involvement. Journal of the American Society of 
Nephrology 9, 842-852. 
Wieczorek, S., Hoffjan, S., Chan, A., Rey, L., Harper, L., Fricke, H., Holle, J.U., Gross, 
W.L., Epplen, J.T., and Lamprecht, P. (2009). Novel association of the CD226 (DNAM-1) 
474 
 
Gly307Ser polymorphism in Wegener's granulomatosis and confirmation for multiple 
sclerosis in German patients. Genes and Immunity 10, 591-595. 
Williams, T.M., Little, M.H., and Ricardo, S.D. (2010). Macrophages in Renal Development, 
Injury, and Repair. Seminars in nephrology 30, 255-267. 
Wilson, H.M., Chettibi, S., Jobin, C., Walbaum, D., Rees, A.J., and Kluth, D.C. (2005). 
Inhibition of macrophage nuclear factor-kappaB leads to a dominant anti-inflammatory 
phenotype that attenuates glomerular inflammation in vivo. The American Journal of 
Pathology 167, 27-37. 
Wilson, H.M., Stewart, K.N., Brown, P.A., Anegon, I., Chettibi, S., Rees, A.J., and Kluth, 
D.C. (2002). Bone-marrow-derived macrophages genetically modified to produce IL-10 
reduce injury in experimental glomerulonephritis. Mol Ther 6, 710-717. 
Winn, M.P., Conlon, P.J., Lynn, K.L., Farrington, M.K., Creazzo, T., Hawkins, A.F., 
Daskalakis, N., Kwan, S.Y., Ebersviller, S., Burchette, J.L., et al. (2005). A Mutation in the 
TRPC6 Cation Channel Causes Familial Focal Segmental Glomerulosclerosis. Science 308, 
1801-1804. 
Wolk, K., Kunz, S., Asadullah, K., and Sabat, R. (2002). Cutting Edge: Immune Cells as 
Sources and Targets of the IL-10 Family Members? The Journal of Immunology 168, 5397-
5402. 
WTCCC (2007). Genome-wide association study of 14,000 cases of seven common diseases 
and 3,000 shared controls. Nature 447, 661-678. 
Wu, S., Moomaw, C.R., Tomer, K.B., Falck, J.R., and Zeldin, D.C. (1996). Molecular 
Cloning and Expression of CYP2J2, a Human Cytochrome P450 Arachidonic Acid 
Epoxygenase Highly Expressed in Heart. Journal of Biological Chemistry 271, 3460-3468. 
Xiao, L., Rao, J.N., Zou, T., Liu, L., Marasa, B.S., Chen, J., Turner, D.J., Passaniti, A., and 
Wang, J.Y. (2007). Induced JunD in intestinal epithelial cells represses CDK4 transcription 
through its proximal promoter region following polyamine depletion. Biochem J 403, 573-
581. 
475 
 
Xu, Y., Ding, H., Peng, J., Cui, G., Liu, L., Cianflone, K., and Wang, D.W. (2011). 
Association between polymorphisms of CYP2J2 and EPHX2 genes and risk of coronary 
artery disease. Pharmacogenet Genomics 21, 489-494. 
Xue, W., Liu, Q., Cai, L., Wang, Z., and Feng, W. (2009). Stable overexpression of human 
metallothionein-IIA in a heart-derived cell line confers oxidative protection. Toxicology 
Letters 188, 70-76. 
Yaghi, A., Bradbury, J.A., Zeldin, D.C., Mehta, S., Bend, J.R., and McCormack, D.G. 
(2003). Pulmonary cytochrome P-450 2J4 is reduced in a rat model of acute Pseudomonas 
pneumonia. American Journal of Physiology - Lung Cellular and Molecular Physiology 285, 
L1099-L1105. 
Yamasaki, M., Nomura, T., Sato, F., and Mimata, H. (2007). Metallothionein is up-regulated 
under hypoxia and promotes the survival of human prostate cancer cells. Oncol Rep 18, 
1145-1153. 
Yamasaki, S., Ishikawa, E., Sakuma, M., Hara, H., Ogata, K., and Saito, T. (2008). Mincle is 
an ITAM-coupled activating receptor that senses damaged cells. Nat Immunol 9, 1179-1188. 
Yanagita, M., Arai, H., Nakano, T., Ohashi, K., Mizuno, K., Fukatsu, A., Doi, T., and Kita, 
T. (2001). Gas6 Induces Mesangial Cell Proliferation via Latent Transcription Factor STAT3. 
Journal of Biological Chemistry 276, 42364-42369. 
Yang, J., Yang, W., Hirankarn, N., Ye, D.Q., Zhang, Y., Pan, H.-F., Mok, C.C., Chan, T.M., 
Wong, R.W.S., Mok, M.Y., et al. (2011). ELF1 is associated with systemic lupus 
erythematosus in Asian populations. Human Molecular Genetics 20, 601-607. 
Yang, M., and Chitambar, C.R. (2008). Role of oxidative stress in the induction of 
metallothionein-2A and heme oxygenase-1 gene expression by the antineoplastic agent 
gallium nitrate in human lymphoma cells. Free Radical Biology and Medicine 45, 763-772. 
Yang, N., Luo, M., Li, R., Huang, Y., Zhang, R., Wu, Q., Wang, F., Li, Y., and Yu, X. 
(2008). Blockage of JAK/STAT signalling attenuates renal ischaemia-reperfusion injury in 
rats. Nephrology Dialysis Transplantation 23, 91-100. 
476 
 
Yang, W., Shen, N., Ye, D.-Q., Liu, Q., Zhang, Y., Qian, X.-X., Hirankarn, N., Ying, D., 
Pan, H.-F., Mok, C.C., et al. (2010). Genome-Wide Association Study in Asian Populations 
Identifies Variants in ETS1 and WDFY4 Associated with Systemic Lupus Erythematosus. 
PLoS Genet 6, e1000841. 
Young, M.R., Santhanam, A.N., Yoshikawa, N., and Colburn, N.H. (2010). Have Tumor 
Suppressor PDCD4 and its Counteragent Oncogenic miR-21 Gone Rogue? Molecular 
Interventions 10, 76-79. 
Yu, J.W., Wu, J., Zhang, Z., Datta, P., Ibrahimi, I., Taniguchi, S., Sagara, J., Fernandes-
Alnemri, T., and Alnemri, E.S. (2005). Cryopyrin and pyrin activate caspase-1, but not NF-
[kappa]B, via ASC oligomerization. Cell Death Differ 13, 236-249. 
Zenz, R., Eferl, R., Scheinecker, C., Redlich, K., Smolen, J., Schonthaler, H., Kenner, L., 
Tschachler, E., and Wagner, E. (2008). Activator protein 1 (Fos/Jun) functions in 
inflammatory bone and skin disease. Arthritis Research & Therapy 10, 201. 
Zenz, R., and Wagner, E.F. (2006). Jun signalling in the epidermis: From developmental 
defects to psoriasis and skin tumors. The International Journal of Biochemistry & Cell 
Biology 38, 1043-1049. 
Zhang, Q.-Y., Ding, X., and Kaminsky, L.S. (1997). cDNA Cloning, Heterologous 
Expression, and Characterization of Rat Intestinal CYP2J4. Archives of Biochemistry and 
Biophysics 340, 270-278. 
Zhang, Y., Liu, T., Meyer, C.A., Eeckhoute, J., Johnson, D.S., Bernstein, B.E., Nussbaum, 
C., Myers, R.M., Brown, M., Li, W., et al. (2008). Model-based analysis of ChIP-Seq 
(MACS). Genome biology 9, R137. 
Zheng, L., Sinniah, R., and Hsu, S.I.H. (2008). Pathogenic Role of NF-{kappa}B Activation 
in Tubulointerstitial Inflammatory Lesions in Human Lupus Nephritis. J Histochem 
Cytochem 56, 517-529. 
477 
 
Zheng, L.L. (2006). In situ glomerular expression of activated NF-κB in human lupus 
nephritis and other non-proliferative proteinuric glomerulopathy. Virchows Archiv 448, 172-
183. 
Zhou, H., Zarubin, T., Ji, Z., Min, Z., Zhu, W., Downey, J.S., Lin, S., and Han, J. (2005). 
Frequency and Distribution of AP-1 Sites in the Human Genome. DNA Research 12, 139-
150. 
Zimin, A.V., Delcher, A.L., Florea, L., Kelley, D.R., Schatz, M.C., Puiu, D., Hanrahan, F., 
Pertea, G., Van Tassell, C.P., Sonstegard, T.S., et al. (2009). A whole-genome assembly of 
the domestic cow, Bos taurus. Genome biology 10, R42. 
Zordoky, B.N.M., and El-Kadi, A.O.S. (2010). Effect of cytochrome P450 polymorphism on 
arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacology & 
Therapeutics 125, 446-463. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
478 
 
Appendix A: Additional results from Chapter 3 
Table A. 1 Gene ontology analysis using DAVID for genes demonstrating differential 
expression between WKY and LEW basal BMDMs 
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Table A.1 continued 
 
Enrichment for biological process functional annotation terms used a threshold of <5% FDR 
and fold enrichment >1.5.  
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Table A. 2 Gene ontology analysis using DAVID for genes demonstrating increased 
expression in LEW BMDMs compared to WKY BMDMs following two hours of LPS 
stimulation. 
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Table A.2 continued 
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Table A.2 continued 
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Table A.2 continued 
 
Enrichment for biological process functional annotation terms used a threshold of <5% FDR 
and fold enrichment >1.5 
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Table A. 3  Gene ontology analysis using DAVID for genes demonstrating increased 
expression in WKY BMDMs compared to LEW BMDMs following four hours of LPS 
stimulation 
Enrichment for biological process functional annotation terms used a threshold of <5% FDR 
and fold enrichment >1.5 
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Table A. 4 Gene ontology analysis using DAVID for genes demonstrating 
increased expression in LEW BMDMs compared to WKY BMDMs following 
four hours of LPS stimulation 
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Table A.4 continued 
 
Enrichment for biological process functional annotation terms used a threshold of <5% FDR 
and fold enrichment >1.5 
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Table A. 5 Gene ontology analysis using DAVID for genes demonstrating increased 
expression in LEW BMDMs compared to WKY BMDMs following eight hours of LPS 
stimulation 
 
Enrichment for biological process functional annotation terms and KEGG canonical 
pathways used a threshold of <5% FDR and fold enrichment >1.5. 
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Table A. 6 Motif enrichment analysis of genes demonstrating differential expression 
between WKY and LEW BMDMs following two hours LPS stimulation 
 
Enriched TRANSFAC vertebrate transcription factor binding sites (TFBS) in genes 
differentially expressed between WKY and LEW BMDMs. Genes with higher expression in 
WKY BMDMs were given a positive fold change whilst genes with LEW BMDMs were 
given a negative fold change. MotifModeler Xm score is the estimated functional level of the 
transcription factor. A positive Xm score indicates increased expression in favour of WKY 
BMDMs. Enriched TFBS from MotifModeler selected on basis of a transcriptional 
contribution (TCS) score two standard deviations above the mean value for all the TFBS 
identified. A higher TCS score indicates a stronger contribution. The transcription factor 
binding site ID given is the enriched TRANSFAC vertebrate motif identified. 
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Table A. 7 Motif enrichment analysis of genes demonstrating differential expression 
between WKY and LEW BMDMs following four hours LPS stimulation 
 
Enriched TRANSFAC vertebrate transcription factor binding sites (TFBS) in genes 
differentially expressed between WKY and LEW BMDMs. Genes with higher expression in 
WKY BMDMs were given a positive fold change whilst genes with LEW BMDMs were 
given a negative fold change. MotifModeler Xm score is the estimated functional level of the 
transcription factor. A positive Xm score indicates increased expression in favour of WKY 
BMDMs. Enriched TFBS from MotifModeler selected on basis of a transcriptional 
contribution (TCS) score two standard deviations above the mean value for all the TFBS 
identified. A higher TCS score indicates a stronger contribution. The transcription factor 
binding site ID given is the enriched TRANSFAC vertebrate motif identified. 
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Table A. 8 Motif enrichment analysis of genes demonstrating differential expression 
between WKY and LEW BMDMs following eight hours LPS stimulation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enriched TRANSFAC vertebrate transcription factor binding sites (TFBS) in genes 
differentially expressed between WKY and LEW BMDMs. Genes with higher expression in 
WKY BMDMs were given a positive fold change whilst genes with LEW BMDMs were 
given a negative fold change. MotifModeler Xm score is the estimated functional level of the 
transcription factor. A positive Xm score indicates increased expression in favour of WKY 
BMDMs. Enriched TFBS from MotifModeler selected on basis of a transcriptional 
contribution (TCS) score two standard deviations above the mean value for all the TFBS 
identified. A higher TCS score indicates a stronger contribution. The transcription factor 
binding site ID given is the enriched TRANSFAC vertebrate motif identified. 
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Figure A. 1 Validation of the microarray data for Il1rn, interleukin 1 receptor 
antagonist, by qRT-PCR 
Validation of microarray data by qRT-PCR. (A) Microarray expression values (log2 
transformed). (B) Samples were amplified using a set of four biological replicates with three 
technical replicates per sample. Relative gene expression was measured by qRT-PCR and 
normalised with Hprt for WKY and LEW BMDMs. *P<0.05; **P<0.01;***P<0.001 
statistically significantly different to WKY using a two way ANOVA to compare the overall 
timecourse with Bonferonni’s post-tests to compare individual time points. (C) Two way 
ANOVA results of the overall timecourse indicating contribution of different factors to the 
variation seen in graph B. Error bars represent standard error of the mean. 
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Figure A. 2 Validation of the microarray data for Arg1, arginase 1, by qRT-
PCR 
Validation of microarray data by qRT-PCR. (A) Microarray expression values (log2 
transformed). (B) Samples were amplified using a set of four biological replicates with three 
technical replicates per sample. Relative gene expression was measured by qRT-PCR and 
normalised with Hprt for WKY and LEW BMDMs. *P<0.05; **P<0.01;***P<0.001 
statistically significantly different to WKY using a two way ANOVA to compare the overall 
timecourse with Bonferonni’s post-tests to compare individual time points. (C) Two way 
ANOVA results of the overall timecourse indicating contribution of different factors to the 
variation seen in graph B. Error bars represent standard error of the mean. 
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Figure A. 3 Validation of the microarray data for Serpinb2, serpin peptidase 
inhibitor, clade B (ovalbumin), member 2, by qRT-PCR 
Validation of microarray data by qRT-PCR. (A) Microarray expression values (log2 
transformed). (B) Samples were amplified using a set of four biological replicates with three 
technical replicates per sample. Relative gene expression was measured by qRT-PCR and 
normalised with Hprt for WKY and LEW BMDMs. *P<0.05; **P<0.01;***P<0.001 
statistically significantly different to WKY using a two way ANOVA to compare the overall 
timecourse with Bonferonni’s post-tests to compare individual time points. (C) Two way 
ANOVA results of the overall timecourse indicating contribution of different factors to the 
variation seen in graph B. Error bars represent standard error of the mean. 
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Figure A. 4 Validation of the microarray data for Tnfsrf14, tumour necrosis 
factor receptor superfamily, member 14 (herpesvirus entry mediator), by qRT-
PCR 
Validation of microarray data by qRT-PCR. (A) Microarray expression values (log2 
transformed). (B) Samples were amplified using a set of four biological replicates with three 
technical replicates per sample. Relative gene expression was measured by qRT-PCR and 
normalised with Hprt for WKY and LEW BMDMs. *P<0.05; **P<0.01;***P<0.001 
statistically significantly different to WKY using a two way ANOVA to compare the overall 
timecourse with Bonferonni’s post-tests to compare individual time points. (C) Two way 
ANOVA results of the overall timecourse indicating contribution of different factors to the 
variation seen in graph B. Error bars represent standard error of the mean. 
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Figure A. 5 Validation of the microarray data for Mcoln2, mucolipin 2, by 
qRT-PCR 
Validation of microarray data by qRT-PCR. (A) Microarray expression values (log2 
transformed). (B) Samples were amplified using a set of four biological replicates with three 
technical replicates per sample. Relative gene expression was measured by qRT-PCR and 
normalised with Hprt for WKY and LEW BMDMs. *P<0.05; **P<0.01;***P<0.001 
statistically significantly different to WKY using a two way ANOVA to compare the overall 
timecourse with Bonferonni’s post-tests to compare individual time points. (C) Two way 
ANOVA results of the overall timecourse indicating contribution of different factors to the 
variation seen in graph B. Error bars represent standard error of the mean. 
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Figure A. 6 Validation of the microarray data for Gzmb, granzyme B, by qRT-
PCR 
Validation of microarray data by qRT-PCR. (A) Microarray expression values (log2 
transformed). (B) Samples were amplified using a set of four biological replicates with three 
technical replicates per sample. Relative gene expression was measured by qRT-PCR and 
normalised with Hprt for WKY and LEW BMDMs. *P<0.05; **P<0.01;***P<0.001 
statistically significantly different to WKY using a two way ANOVA to compare the overall 
timecourse with Bonferonni’s post-tests to compare individual time points. (C) Two way 
ANOVA results of the overall timecourse indicating contribution of different factors to the 
variation seen in graph B. Error bars represent standard error of the mean. 
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Figure A. 7 Validation of the microarray data for Ccr2, chemokine (C-C motif) 
receptor 2, by qRT-PCR 
Validation of microarray data by qRT-PCR. (A) Microarray expression values (log2 
transformed). (B) Samples were amplified using a set of four biological replicates with three 
technical replicates per sample. Relative gene expression was measured by qRT-PCR and 
normalised with Hprt for WKY and LEW BMDMs. *P<0.05; **P<0.01;***P<0.001 
statistically significantly different to WKY using a two way ANOVA to compare the overall 
timecourse with Bonferonni’s post-tests to compare individual time points. (C) Two way 
ANOVA results of the overall timecourse indicating contribution of different factors to the 
variation seen in graph B. Error bars represent standard error of the mean. 
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Figure A. 8 Validation of the microarray data for Ube2v1, ubiquitin-
conjugating enzyme E2 variant 1, by qRT-PCR 
Validation of microarray data by qRT-PCR. (A) Microarray expression values (log2 
transformed). (B) Samples were amplified using a set of four biological replicates with three 
technical replicates per sample. Relative gene expression was measured by qRT-PCR and 
normalised with Hprt for WKY and LEW BMDMs. *P<0.05; **P<0.01;***P<0.001 
statistically significantly different to WKY using a two way ANOVA to compare the overall 
timecourse with Bonferonni’s post-tests to compare individual time points. (C) Two way 
ANOVA results of the overall timecourse indicating contribution of different factors to the 
variation seen in graph B. Error bars represent standard error of the mean. 
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Figure A. 9 Validation of the microarray data for Cdo1, cysteine dioxygenase, 
type 1, by qRT-PCR 
Validation of microarray data by qRT-PCR. (A) Microarray expression values (log2 
transformed). (B) Samples were amplified using a set of four biological replicates with three 
technical replicates per sample. Relative gene expression was measured by qRT-PCR and 
normalised with Hprt for WKY and LEW BMDMs. *P<0.05; **P<0.01;***P<0.001 
statistically significantly different to WKY using a two way ANOVA to compare the overall 
timecourse with Bonferonni’s post-tests to compare individual time points. (C) Two way 
ANOVA results of the overall timecourse indicating contribution of different factors to the 
variation seen in graph B. Error bars represent standard error of the mean. 
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Figure A. 10    Validation of the microarray data for Mafb, v-maf 
musculoaponeurotic fibrosarcoma oncogene homology B (avian) , by qRT-PCR 
 
Validation of microarray data by qRT-PCR. (A) Microarray expression values (log2 
transformed). (B) Samples were amplified using a set of four biological replicates with three 
technical replicates per sample. Relative gene expression was measured by qRT-PCR and 
normalised with Hprt for WKY and LEW BMDMs. *P<0.05; **P<0.01;***P<0.001 
statistically significantly different to WKY using a two way ANOVA to compare the overall 
timecourse with Bonferonni’s post-tests to compare individual time points. (C) Two way 
ANOVA results of the overall timecourse indicating contribution of different factors to the 
variation seen in graph B. Error bars represent standard error of the mean. 
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Figure A. 11 Validation of the microarray data for Mmp7, matrix 
metallopeptidase 7, by qRT-PCR 
Validation of microarray data by qRT-PCR. (A) Microarray expression values (log2 
transformed). (B) Samples were amplified using a set of four biological replicates with three 
technical replicates per sample. Relative gene expression was measured by qRT-PCR and 
normalised with Hprt for WKY and LEW BMDMs. *P<0.05; **P<0.01;***P<0.001 
statistically significantly different to WKY using a two way ANOVA to compare the overall 
timecourse with Bonferonni’s post-tests to compare individual time points. (C) Two way 
ANOVA results of the overall timecourse indicating contribution of different factors to the 
variation seen in graph B. Error bars represent standard error of the mean. 
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Figure A. 12 Validation of the microarray data for Tgfb2, transforming growth 
factor, beta 2, by qRT-PCR 
Validation of microarray data by qRT-PCR. (A) Microarray expression values (log2 
transformed). (B) Samples were amplified using a set of four biological replicates with three 
technical replicates per sample. Relative gene expression was measured by qRT-PCR and 
normalised with Hprt for WKY and LEW BMDMs. *P<0.05; **P<0.01;***P<0.001 
statistically significantly different to WKY using a two way ANOVA to compare the overall 
timecourse with Bonferonni’s post-tests to compare individual time points. (C) Two way 
ANOVA results of the overall timecourse indicating contribution of different factors to the 
variation seen in graph B. Error bars represent standard error of the mean. 
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Figure A. 13  Validation of the microarray data for Ccl22, chemokine (C-C 
motif) ligand 22, by qRT-PCR 
Validation of microarray data by qRT-PCR. (A) Microarray expression values (log2 
transformed). (B) Samples were amplified using a set of four biological replicates with three 
technical replicates per sample. Relative gene expression was measured by qRT-PCR and 
normalised with Hprt for WKY and LEW BMDMs. *P<0.05; **P<0.01;***P<0.001 
statistically significantly different to WKY using a two way ANOVA to compare the overall 
timecourse with Bonferonni’s post-tests to compare individual time points. (C) Two way 
ANOVA results of the overall timecourse indicating contribution of different factors to the 
variation seen in graph B. Error bars represent standard error of the mean. 
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Figure A. 14   Validation of the microarray data for Plac8, placenta-specific 8, 
by qRT-PCR 
Validation of microarray data by qRT-PCR. (A) Microarray expression values (log2 
transformed). (B) Samples were amplified using a set of four biological replicates with three 
technical replicates per sample. Relative gene expression was measured by qRT-PCR and 
normalised with Hprt for WKY and LEW BMDMs. *P<0.05; **P<0.01;***P<0.001 
statistically significantly different to WKY using a two way ANOVA to compare the overall 
timecourse with Bonferonni’s post-tests to compare individual time points. (C) Two way 
ANOVA results of the overall timecourse indicating contribution of different factors to the 
variation seen in graph B. Error bars represent standard error of the mean. 
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Appendix B: Additional results from Chapter 4 
Table B. 1 Gene ontology analysis for genes demonstrating differential expression 
over the LPS timecourse between WKY and WKY.LCrgn2 BMDMs 
506 
 
Table B.1 continued 
 
507 
 
Table B.1 continued 
 
Genes demonstrating differential expression over time identified using EDGE 1.1.291 (Leek 
et al., 2006). Enrichment for biological process functional annotation terms used a threshold 
of <5% FDR and fold enrichment >1.5 
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Table B. 2 Gene ontology analysis using DAVID for genes demonstrating differential 
expression over the LPS timecourse between WKY and WKY.LCrgn2 BMDMs and 
between WKY and LEW BMDMs T 
509 
 
Table  B.2 continued 
 
 
510 
 
Table B.2 continued 
 
 
Genes demonstrating differential expression over time identified using EDGE 1.1.291 (Leek 
et al., 2006). Enrichment for biological process functional annotation terms used a threshold 
of <5% FDR and fold enrichment >1.5. 
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Figure B. 1 Validation of microarray data for Serpinb2, serpin peptidase 
inhibitor, clade B (ovalbumin), member 2, by qRT-PCR  
Validation of microarray data by qRT-PCR. (A) Microarray expression values (log2 
transformed). (B) Samples were amplified using a set of four biological replicates with three 
technical replicates per sample. Relative gene expression was measured by qRT-PCR and 
normalised with Hprt for WKY and WKY.LCrgn2 BMDMs. *P<0.05; 
**P<0.01;***P<0.001 statistically significantly different to WKY using a two way ANOVA 
to compare the overall timecourse with Bonferonni’s post-tests to compare individual time 
points. (C) Two way ANOVA results of the overall timecourse indicating contribution of 
different factors to the variation seen in graph B. Error bars represent standard error of the 
mean 
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Figure B. 2 Validation of microarray data for Arg1, arginase 1, by qRT-PCR 
Validation of microarray data by qRT-PCR. (A) Microarray expression values (log2 
transformed). (B) Samples were amplified using a set of four biological replicates with three 
technical replicates per sample. Relative gene expression was measured by qRT-PCR and 
normalised with Hprt for WKY and WKY.LCrgn2 BMDMs. *P<0.05; 
**P<0.01;***P<0.001 statistically significantly different to WKY using a two way ANOVA 
to compare the overall timecourse with Bonferonni’s post-tests to compare individual time 
points. (C) Two way ANOVA results of the overall timecourse indicating contribution of 
different factors to the variation seen in graph B. Error bars represent standard error of the 
mean 
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Figure B. 3 Validation of microarray data for Vcam1, vascular cell adhesion 
molecule 1, by qRT-PCR 
Validation of microarray data by qRT-PCR. (A) Microarray expression values (log2 
transformed). (B) Samples were amplified using a set of four biological replicates with three 
technical replicates per sample. Relative gene expression was measured by qRT-PCR and 
normalised with Hprt for WKY and WKY.LCrgn2 BMDMs. *P<0.05; 
**P<0.01;***P<0.001 statistically significantly different to WKY using a two way ANOVA 
to compare the overall timecourse with Bonferonni’s post-tests to compare individual time 
points. (C) Two way ANOVA results of the overall timecourse indicating contribution of 
different factors to the variation seen in graph B. Error bars represent standard error of the 
mean 
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Figure B. 4 Validation of microarray data with qRT-PCR for Vegfa 
Validation of microarray data by qRT-PCR. (A) Microarray expression values (log2 
transformed). (B) Samples were amplified using a set of four biological replicates with three 
technical replicates per sample. Relative gene expression was measured by qRT-PCR and 
normalised with Hprt for WKY and WKY.LCrgn2 BMDMs. *P<0.05; 
**P<0.01;***P<0.001 statistically significantly different to WKY using a two way ANOVA 
to compare the overall timecourse with Bonferonni’s post-tests to compare individual time 
points. (C) Two way ANOVA results of the overall timecourse indicating contribution of 
different factors to the variation seen in graph B. Error bars represent standard error of the 
mean 
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Figure B. 5 Validation of microarray data with qRT-PCR for Il-10 
Validation of microarray data by qRT-PCR. (A) Microarray expression values (log2 
transformed). (B) Samples were amplified using a set of four biological replicates with three 
technical replicates per sample. Relative gene expression was measured by qRT-PCR and 
normalised with Hprt for WKY and WKY.LCrgn2 BMDMs. *P<0.05; 
**P<0.01;***P<0.001 statistically significantly different to WKY using a two way ANOVA 
to compare the overall timecourse with Bonferonni’s post-tests to compare individual time 
points. (C) Two way ANOVA results of the overall timecourse indicating contribution of 
different factors to the variation seen in graph B. Error bars represent standard error of the 
mean 
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Figure B. 6 Validation of microarray data with qRT-PCR for Mfap3l 
Validation of microarray data by qRT-PCR. (A) Microarray expression values (log2 
transformed). (B) Samples were amplified using a set of four biological replicates with three 
technical replicates per sample. Relative gene expression was measured by qRT-PCR and 
normalised with Hprt for WKY and WKY.LCrgn2 BMDMs. *P<0.05; 
**P<0.01;***P<0.001 statistically significantly different to WKY using a two way ANOVA 
to compare the overall timecourse with Bonferonni’s post-tests to compare individual time 
points. (C) Two way ANOVA results of the overall timecourse indicating contribution of 
different factors to the variation seen in graph B. Error bars represent standard error of the 
mean 
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Figure B. 7 Validation of microarray data with qRT-PCR for Crtc1 
Validation of microarray data by qRT-PCR. (A) Microarray expression values (log2 
transformed). (B) Samples were amplified using a set of four biological replicates with three 
technical replicates per sample. Relative gene expression was measured by qRT-PCR and 
normalised with Hprt for WKY and WKY.LCrgn2 BMDMs. *P<0.05; 
**P<0.01;***P<0.001 statistically significantly different to WKY using a two way ANOVA 
to compare the overall timecourse with Bonferonni’s post-tests to compare individual time 
points. (C) Two way ANOVA results of the overall timecourse indicating contribution of 
different factors to the variation seen in graph B. Error bars represent standard error of the 
mean 
 
 
 
0 2 4 6 8
8
9
10
11
12
WKY
WKY.LCrgn2
Time of LPS stimulation (hours)
C
rt
c1
 e
x
p
re
ss
io
n
 (
lo
g
2
 v
a
lu
es
)
A 
C 
B 
0 2 4 6 8
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
WKY
WKY.LCrgn2
Time of LPS stimulation (hrs)
C
rt
c
1
/H
p
rt
m
R
N
A
(r
e
la
ti
v
e
 e
x
p
r
e
ss
io
n
)
*** 
** 
518 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B. 8 Validation of microarray data with qRT-PCR for Crim1 
Validation of microarray data by qRT-PCR. (A) Microarray expression values (log2 
transformed). (B) Samples were amplified using a set of four biological replicates with three 
technical replicates per sample. Relative gene expression was measured by qRT-PCR and 
normalised with Hprt for WKY and WKY.LCrgn2 BMDMs. *P<0.05; 
**P<0.01;***P<0.001 statistically significantly different to WKY using a two way ANOVA 
to compare the overall timecourse with Bonferonni’s post-tests to compare individual time 
points. (C) Two way ANOVA results of the overall timecourse indicating contribution of 
different factors to the variation seen in graph B. Error bars represent standard error of the 
mean 
 
 
 
0 2 4 6 8
0.0
0.5
1.0
1.5
2.0
2.5
3.0
WKY
WKY.LCrgn2
Time of LPS stimulation (hrs)
C
ri
m
1
/H
p
rt
m
R
N
A
(r
el
a
ti
v
e 
ex
p
re
ss
io
n
)
* 
0 2 4 6 8
7.5
8.0
8.5
9.0
9.5
WKY
WKY.LCrgn2
Time of LPS stimulation (hours)
C
ri
m
1
 e
x
p
re
ss
io
n
 (
lo
g
2
 v
a
lu
es
)
A 
C 
B 
519 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B. 9 Validation of microarray data with qRT-PCR for Slit2  
Validation of microarray data by qRT-PCR. (A) Microarray expression values (log2 
transformed). (B) Samples were amplified using a set of four biological replicates with three 
technical replicates per sample. Relative gene expression was measured by qRT-PCR and 
normalised with Hprt for WKY and WKY.LCrgn2 BMDMs. *P<0.05; 
**P<0.01;***P<0.001 statistically significantly different to WKY using a two way ANOVA 
to compare the overall timecourse with Bonferonni’s post-tests to compare individual time 
points. (C) Two way ANOVA results of the overall timecourse indicating contribution of 
different factors to the variation seen in graph B. Error bars represent standard error of the 
mean 
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Figure B. 10     Validation of microarray data with qRT-PCR for Cables2 
Validation of microarray data by qRT-PCR. (A) Microarray expression values (log2 
transformed). (B) Samples were amplified using a set of four biological replicates with three 
technical replicates per sample. Relative gene expression was measured by qRT-PCR and 
normalised with Hprt for WKY and WKY.LCrgn2 BMDMs. *P<0.05; 
**P<0.01;***P<0.001 statistically significantly different to WKY using a two way ANOVA 
to compare the overall timecourse with Bonferonni’s post-tests to compare individual time 
points. (C) Two way ANOVA results of the overall timecourse indicating contribution of 
different factors to the variation seen in graph B. Error bars represent standard error of the 
mean 
 
 
 
0 2 4 6 8
0
1
2
3
4
WKY
WKY.LCrgn2
Time of LPS stimulation (hrs)
C
a
b
le
s2
/H
p
rt
m
R
N
A
(r
el
a
ti
v
e 
ex
p
re
ss
io
n
)
0 2 4 6 8
8.5
9.0
9.5
10.0
10.5
11.0
11.5
WKY
WKY.LCrgn2
Time of LPS stimulation (hours)
C
a
b
le
s2
 e
x
p
re
ss
io
n
 (
lo
g
2
 v
a
lu
es
)
A 
C 
B 
521 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B. 11        Validation of microarray data with qRT-PCR for Tlr5 
Validation of microarray data by qRT-PCR. (A) Microarray expression values (log2 
transformed). (B) Samples were amplified using a set of four biological replicates with three 
technical replicates per sample. Relative gene expression was measured by qRT-PCR and 
normalised with Hprt for WKY and WKY.LCrgn2 BMDMs. *P<0.05; 
**P<0.01;***P<0.001 statistically significantly different to WKY using a two way ANOVA 
to compare the overall timecourse with Bonferonni’s post-tests to compare individual time 
points. (C) Two way ANOVA results of the overall timecourse indicating contribution of 
different factors to the variation seen in graph B. Error bars represent standard error of the 
mean 
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Table B. 3 Gene ontology analysis using DAVID for genes demonstrating increased 
expression following eight hours LPS stimulation compared to baseline in scrambled 
control siRNA transfected BMDMs  
 
 
Enrichment for biological process functional annotation terms and KEGG canonical pathway 
analysis used a threshold of <5% FDR and fold enrichment >1.5. The top 20 enriched 
biological processes and top 10 KEGG pathway terms are displayed in this table. 
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Table B. 4 Gene ontology analysis for genes demonstrating increased expression 
following eight hours LPS stimulation compared to baseline in Jund siRNA transfected 
BMDMs 
 
Enrichment for biological process functional annotation terms and KEGG canonical pathway 
analysis used a threshold of <5% FDR and fold enrichment >1.5. The top 20 enriched 
biological processes and top 10 KEGG pathway terms are displayed in this table. 
524 
 
Table B. 5 Gene ontology analysis using DAVID for genes demonstrating decreased 
expression following LPS stimulation in control siRNA transfected WKY BMDMs  
 
Enrichment for biological process functional annotation terms and KEGG canonical pathway 
analysis used a threshold of <5% FDR and fold enrichment >1.5. The top 20 enriched 
biological processes and top 10 KEGG pathway terms are displayed in this table. 
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Table B. 6 Gene ontology analysis using DAVID for genes demonstrating decreased 
expression following LPS stimulation in Jund siRNA transfected WKY BMDMs  
 
Enrichment for biological process functional annotation terms and KEGG canonical pathway 
analysis used a threshold of <5% FDR and fold enrichment >1.5. The top 20 enriched 
biological processes terms are displayed in this table. 
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Appendix C: Additional results from Chapter 5 
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Table C. 1  Functional annotation analysis of JunD-bound genes in two hour LPS-
stimulated WKY BMDMs 
This table details the significantly enriched biological process functional annotation terms 
from DAVID for JunD-bound genes in two hour LPS-stimulated WKY  BMDMs. 
Enrichment for biological process functional annotation terms used a threshold of <5% FDR 
and fold enrichment >1.5.  
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Table C. 2 Functional annotation analysis of the unique JunD-bound genes in WKY 
BMDMs compared to WKY.LCrgn2 BMDMs following two hour of LPS stimulation 
 
This table details the significantly enriched biological process functional annotation terms 
from DAVID for JunD-bound genes in two hour LPS-stimulated WKY  BMDMs. 
Enrichment for biological process functional annotation terms used a threshold of <5% FDR 
and fold enrichment >1.5.  
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Table C. 3  Functional annotation analysis of JunD-bound genes common between  
WKY basal and WKY LPS-stimulated BMDMs 
This table details the significantly enriched biological process functional annotation terms 
from DAVID for JunD-bound genes common between basal and two hour LPS-stimulated 
WKY BMDMs. Enrichment for biological process functional annotation terms used a 
threshold of <5% FDR and fold enrichment >1.5.  
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Table C. 4 Functional annotation analysis of JunD-bound genes unique to LPS-
stimulated WKY BMDMs in comparison with basal WKY BMDMs 
This table details the significantly enriched biological process functional annotation terms 
from DAVID for JunD-bound genes unique to LPS-stimulated WKY BMDMs compared to  
basal WKY BMDMs. Enrichment for biological process functional annotation used a 
threshold of <5% FDR and fold enrichment >1.5.  
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Table C. 5 Gene ontology analysis of unique core JunD-bound genes in WKY 
BMDMs 
 
This table details the significantly enriched biological process functional annotation terms 
and KEGG pathway terms from DAVID for unique core JunD-bound genes in WKY 
BMDMs compared to basal WKY BMDMs and basal and LPS-stimulated WKY.LCrgn2 
BMDMs. Enrichment for biological process functional annotation terms and KEGG 
canonical pathways used a threshold of <5% FDR and fold enrichment >1.5.  
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Table C. 6 Gene ontology analysis of unique LPS-inducible JunD-bound genes in 
WKY BMDMs 
This table details the significantly enriched biological process functional annotation terms 
and KEGG pathway terms from DAVID for unique LPS-inducible JunD-bound genes in 
WKY BMDMs compared to basal WKY BMDMs and basal and LPS-stimulated 
WKY.LCrgn2 BMDMs. Enrichment for biological process functional annotation terms and 
KEGG canonical pathways used a threshold of <5% FDR and fold enrichment >1.5.  
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Appendix D: Primer sequences used for qPCR validation of 
microarray data 
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Appendix E: Primer sequences used for qPCR validation of 
ChIP-Seq data 
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Appendix F: Primer sequences used for PCR and sequencing of 
the human JUND locus 
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Appendix G: Guide to data stored on DVD 
The enclosed DVD contains the data files from microarray and ChIP-Seq experiments 
 
Microarray folder: 
 
 
 
ChIP-Seq folder: 
 
Lists of peaks 
Lists of gene associated peaks 
